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ABSTRACT 
 
 
Opioids have been used to produce analgesia, euphoria, sleep, and relief from diarrhea 
and cough. However, opioid use is associated with several negative neurochemical adaptions 
including tolerance, dependence, and respiratory depression. Studies have shown that selective 
delta-opioid receptor (DOR) antagonism in the presence of a mu-opioid receptor (MOR) agonist 
greatly reduces the development of MOR-mediated morphine tolerance and dependence. 
Unfortunately, multi-drug regimens have complicated pharmacokinetics (PK) and are often 
impractical to implement in clinical practice due decreased patient compliance stemming from 
these PK issues. 
This work describes the design and synthesis of a peptidomimetic series of bi-functional 
ligands with a mixed-efficacy profile that display MOR agonism and DOR antagonism. These 
ligands retain the analgesic effect (mediated via MOR agonism) while reducing side effects 
(mediated via DOR antagonism). In particular, three parallel series of peptidomimetics series 
were synthesized that retain the key opioid binding elements and orientation of lead peptides, but 
that eliminate the metabolically labile moieties of the lead peptides, thereby creating more 
bioavailable ligands. The three parallel series of ligands utilized a tetrahydroquinoline (THQ) 
core, a tetrahydronaphthalene (THN) core, or an N-acetylated THQ core. N-acetylation increased 
the affinity of the peptidomimetics for DOR, without significantly altering the subnanomolar 
affinity and efficacy at MOR, and improved selectivity over the κ-opioid receptor (KOR). Using 
computational modeling, it was determined that the increase in DOR affinity could be through an 
interaction between the carbonyl moiety of N-acetylated group and a tyrosine residue in DOR. 
Additional analogue series were synthesized, including series with 1) various N-substitutions, all 
of which contain a carbonyl to maintain DOR affinity, 2) several methoxy and hydroxyl moieties 
to explore SAR, 3) stereochemistry around the THQ and THN core to explore SAR, and 4.) 
 
 
xv 
 
fluorine incorporated to increase bioavailabilty. Of all analogues synthesized and screened for in 
vivo activity, 54 emerged as having in vivo activity in the Warm Water Tail Withdrawal assay 
after intraperitoneal administration at 10 mg/kg.  Importantly, this compound had a similar 
duration of action to morphine at the same 10 mg/kg dose and, however unlike morphine, 54 did 
not produce tolerance upon chronic administration. 
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CHAPTER 1 
Introduction 
 
 
1.1 Opioid receptors: structure and function 
 
Opioids have been used recreationally and medically for thousands of years for a variety of 
ailments including headache, coughs, shortness of breath, insomnia, antidiarrheal, euphoric 
properties and analgesic properties. Morphine and codeine, the two principal active ingredients 
of opium that produce the characteristic euphoria and analgesia, along with thebaine (which is 
not itself used therapeutically, but can be converted to other clinically useful agents such as: 
oxycodone, oxymorphone, and naloxone) were isolated and characterized in the 18th and 19th 
centuries (Figure 1.1).  
 
 
Figure 1.1. Chemical structures of the opiates found in the opium extract. Structural differences highlighted in blue. 
 
Since its isolation and characterization, morphine has been used as the premier treatment for 
severe pain. Although opioids are irreplaceable as pain-relieving agents, their use is often 
associated with several side effects including constipation and respiratory depression, which can 
limit their clinical utility. Furthermore, both acute and chronic use of opioids can result in 
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neurochemical adaptations that result in physiological tolerance and dependence.1-4 While there 
are many theories as to how tolerance develops including theories concerning receptor down 
regulation and desensitization mechanisms,1-4 these all most likely reflect a common adaptive 
response to increased levels of opioid ligand in the body. When sustained administration of 
opioid drug leads to a decrease in effect or analgesia in the case of opioids, then tolerance has 
developed. Essentially, in order to achieve the same effect (or level of analgesia in the case of 
opioids) an escalating drug dosage needs to be administered. On the other hand, dependence is 
the result of an altered state of biology induced by a drug. In other words, continued use of a 
drug results in a new “normal” state of cellular functioning, where drug is necessary to maintain 
the new state of homeostasis, and removal of drug results in withdrawal symptoms. With these 
side effects in mind, the development of clinically effective opioid analgesics devoid of abuse 
potential is a critical goal. However, in order to achieve this goal, an understanding of how 
opioid analgesics exert their analgesic effects through interactions with opioid receptors (ORs) 
located in the brain and spinal cord is necessary.  
Opioid receptors belong to the large family of class A, rhodopsin-like G protein-coupled 
receptors (GPCRs) and are comprised of seven transmembrane (7TM) spanning alpha helices 
connected by three extracellular and three intracellular loops with an extracellular N-terminus 
and an intracellular C-terminus.5 All GPCRs couple with heterotrimeric guanine nucleotide 
binding proteins (G proteins) which are composed of an α, and a dimeric βγ subunit. Upon ligand 
binding to a GPCR, specific conformations of the receptor are stabilized, a signal is transmitted 
from extracellular space to the intracellular space and second messengers are activated to initiate 
downstream signaling. When an agonist binds, a conformational change in the transmembrane 
helices occurs which in turn favors the exchange of a guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP). This exchange allows for the dissociation of the G protein from 
the receptor as well as the dissociation of the α subunit from the βγ subunit. These subunits go on 
to effect downstream signaling partners and alter cell signaling. Eventually the signal is 
terminated and the receptor is reset for subsequent signaling by hydrolysis of GTP to GDP 
allowing for the re-association of the α and βγ subunits with each other and the receptor.5  
There are three classical types of opioid receptors, µ (MOR), δ (DOR) and ĸ (KOR), each of 
which is coupled to an inhibitory G protein, Gαi/o, which when dissociated from the receptor via 
the aforementioned process can: (1) inhibit the conversion of adenosine triphosphate (ATP) to 
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cyclic adenosine monophosphate (cAMP) via adenylyl cyclase, (2) shut down voltage-gated Ca2+  
channels, and (3) open K+ channels via G protein inwardly rectifying potassium channels 
(GIRKs). The overall effects on nerve cell function when an agonist binds to an opioid receptor 
includes the reduction of membrane excitability and subsequent decrease in cell firing 
culminating in the inhibition of neurotransmitter release.5 
Despite all opioid receptors being coupled to the same G protein, Gαi/o, each displays unique 
physiological effects upon agonist binding. For example, the treatment of severe pain relies on µ-
opioid receptor (MOR) agonists, such as morphine, which also produce most of the undesired 
side effects limiting their use in pain treatment.6 Despite their ability to also produce analgesia, 
KOR agonists produce dysphoric and psychomimetic effects, thus their use as pain relievers has 
been discouraged.6 While DOR agonists have also been shown to produce analgesia with a lesser 
risk of dependence, they are less efficacious than the commonly used analgesics, and can 
produce seizures.6 
While MOR agonists, like morphine, are the gold standard in the treatment of severe pain, 
their therapeutic use is often limited due to unfortunate side effects including tolerance, 
dependence, respiratory depression, and constipation. However, several studies have explored 
the simultaneous administration of a δ-opioid receptor (DOR) ligands as a means to mitigate the 
negative side effects of purely MOR selective compounds. Recently there has been a shift in 
drug design methodology that has moved from administering “cocktails” with multiple drug 
components, each component with a different therapeutic target, to designing a single compound 
that hits multiple targets. In the opioid community, this paradigm has prompted the design and 
synthesis of ligands with varying mixed-efficacy profiles. 
While several mixed-efficacy profiles exist, of particular interest to our lab is the design and 
synthesis of ligands showing MOR agonism and DOR antagonism, a profile that has been shown 
to elicit the desired analgesia of a pure MOR agonist but with reduced risk of tolerance and 
dependence in a number of preclinical models of analgesia. 
 
1.2 Opioid receptor ligands 
In order to design and tailor ligands that specifically bind to opioid receptors, it is necessary 
to understand the structural motifs present in the natural opiates and in the endogenous opioid 
ligands that are responsible for facilitating certain interactions with the GPCR that result in 
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ligand binding. There is a set of endogenous opioid peptides that preferentially binds to each of 
the opioid receptor subtypes: endorphins and endomorphins for MOR, dynorphins for KOR, and 
enkephalins for DOR. All of these ligands are peptides of varying length that incorporate a 
Tyrosine (Tyr) residue in the first position and a phenylalanine (Phe) in the fourth position when 
going from N to C terminus (Figure 1.2). The conservation of these amino acids across the 
endogenous peptides highlights the importance of these moieties in the binding of the ligand to 
each of the opioid receptor types.  
 
Endogenous Opioid Receptor Ligands 
 
MOR 
endorphins: Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr (α-endorphin) 
endomorphins: Tyr-Pro-Phe-Phe-NH2 (endomorphin-1) 
 
DOR 
enkephalins: Tyr-Gly-Gly-Phe-Met (met-enkephalin) 
 
KOR 
dynorphins:  Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asn-Asn-Gln (dynorphin A) 
 
Figure 1.2. Structures of the endogenous opioid receptor ligands. Examples of endogenous peptide in parentheses. 
Common structural motif highlighted in blue. 
 
1.3 Development of mixed-efficacy opioid ligands 
The first reported MOR agonist/DOR antagonist mixed-efficacy ligand for the opioid 
receptors was a tetrapeptide containing Tyr in the first position and Phe in the fourth position, 
reported by Schiller in 1992.7 This peptide, H-Tyr-Tic-Phe-Phe-NH2 (TIPP-NH2; Tic = 
tetrahydroisoquinoline-3-carboxylic acid, Figure 1.3), produced moderate MOR agonist activity 
and potent DOR antagonist activity. 7 Shortly after the discovery of TIPP-NH2, several other 
mixed-efficacy peptides were synthesized from various groups, all producing various degrees of 
MOR agonism/DOR antagonism.8-18 Particularly noteworthy was the synthesis and evaluation of 
DIPP-NH2[Ψ] (H-Dmt-TicΨ[CH2NH]-Phe-Phe-NH2) in 19959 (Figure 1.3), which incorporated 
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a reduced peptide bond between the Tic and Phe residues and is the 2,6 –dimethyltyrosine 
analogue (Dmt) of TIPP-NH2. DIPP-NH2[Ψ] displayed balanced subnanomolar affinity at MOR 
and DOR and produced no physical dependence and less acute tolerance than morphine upon 
chronic administration of high doses when given intracerebroventricularly (i.c.v.).10 However, 
DIPP-NH2[Ψ] displayed restricted blood brain barrier (BBB) permeability which severely 
limited its therapeutic potential.10 Therefore, in an attempt to develop a MOR agonist/DOR 
antagonist capable of crossing the BBB, the bifunctional ligand consisting of the highly potent 
MOR agonist [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2) and the potent and selective DOR 
antagonistTICP[Ψ] (H-Tyr-TicΨ[CH2NH]-Cha-Phe-OH; Cha = cyclohexylalanine) was 
synthesized in 2004.14 It was hypothesized that this compound, 
[Dmt1]DALDACH2CH2NHTICP[Ψ] , would cross the BBB through conferred permeability 
via the [Dmt1]DALDA portion, which alone is capable of penetrating the BBB. As expected, this 
bifunctional ligand displayed the desired MOR agonist/DOR antagonist profile in vitro. 
Additionally, this compound produced analgesic potency similar to that of morphine in the 
mouse tail-flick assay after subcutaneous (s.c.) administration, displayed a longer duration of 
action than morphine, and elicited less analgesic tolerance than morphine, suggesting that this 
compound is capable of crossing the BBB. Although [Dmt1]DALDACH2CH2NHTICP[Ψ]  
(Figure 1.3) displayed favorable in vitro and in vivo profiles, one potential drawback of this 
compound is that the [Dmt1]DALDA portion, when administered to animals alone, it produced 
profound tolerance after chronic intrathecal (i.th.) administration.19 Thus, while this compound is 
one of the first MOR agonists/DOR antagonists that is suggested to cross the BBB, it is not the 
ideal drug candidate due to the potential to risk of tolerance via the [Dmt1]DALDA portion. 
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H-Tyr-Tic-Phe-Phe-NH2 TIPP-NH2 
Schiller 
1992 
 
 
 
H-Dmt-TicΨ[CH2NH]-Phe-Phe-NH2, DIPP-NH2[Ψ] 
Schiller 
1995 
 
 
[Dmt1]DALDACH2CH2NHTICP[Ψ] 
Weltrowska 
2004 
Figure 1.3 Structures of select MOR agonist/DOR antagonist ligands 
To summarize, small opioid receptor peptides displaying mixed-efficacy MOR agonist/DOR 
antagonist profiles have been developed. Unfortunately, although the in vitro profiles for all of 
these mixed-efficacy ligands produce the desired MOR agonism/DOR antagonism profile, many 
of these compounds have difficulty crossing the BBB in vivo, and if and when they do cross the 
BBB these compounds still produce tolerance. Thus, there remains an unmet need of opioid 
analgesics devoid of tolerance and dependence liability that have the potential to be formulated 
for therapeutic use.  
 
1.4 Development of mixed-efficacy opioid peptidomimetics 
The majority of the mixed-efficacy MOR agonist/DOR antagonist ligands that have been 
synthesized are either peptide mimics of the endogenous ligands or modified morphine-like 
compounds. Two additional approaches that have been taken in order to create mixed-efficacy 
opioid ligands that cross the BBB include glycosylating lead peptides and generating 
peptidomimetics.  
For the latter approach, a former member of the Mosberg lab synthesized one of the first sets 
of peptidomimetic ligands that displayed a MOR agonist/DOR antagonist profile in vitro. This 
peptidomimetic (synthesized as a mixture of diastereomers) was designed using computational 
modeling of the high affinity cyclic tetrapeptide JOM-13(Tyr-c(S-S)[D-Cys-Phe-D-Pen]OH) and 
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structurally-related compounds (Figure 1.4). Peptidomimetic 1 utilizes a tetrahydroquinoline 
(THQ) core to eliminate the peptidic, disulfide-containing cycle of JOM-13, while retaining the 
key binding elements including a dimethyl tyrosine (Dmt mimics the Tyr of JOM-13 and has 
been empirically shown to increase binding affinity across all three opioid receptors), and a 
benzyl side chain (mimics Phe of JOM-13).20 The pharmacological results for both diastereomers 
of 1 indicate that the stereochemistry at position 4 (Figure 1.4) plays an important role in the 
orientation of the ligand in the receptors, as the in vitro profiles for both diastereomers are quite 
disparate, with one diastereomer showing tighter binding (Ki = 0.22 nM at MOR, 9.4 nM at 
DOR, 68 nM at KOR) across all three receptors relative to the other diastereomer (Ki = 2.6 nM 
at MOR, 56 nM at DOR, 220 nM at KOR).21 However, one drawback seen with the “good” 
diastereomer of 1, is that it still displays nanomolar binding affinity at KOR, which is 
problematic when trying to design MOR agonist/DOR antagonist ligands. In a subsequent study, 
it was determined that the stereochemistry at position 4 that resulted in tighter binding across the 
opioid receptors is R.21 However, despite the unequal binding profiles of both diastereomers of 1, 
both of these ligands had binding affinity profiles similar to that of JOM-13 and other related 
compounds indicating that the THQ core was a good mimic for the cyclic peptide JOM-13. 
Futhermore, conformational analysis of both diastereomers of the peptidomimetic display good 
superposition with JOM-6 (a structurally-related peptide to JOM-13).  The in vitro results along 
with the computational analysis indicate that 1 serves as a “proof of concept” that key binding 
elements seen in opioid peptide ligands can be transferred onto a more bioavailable scaffold. 
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Figure 1.4 Evolution of the peptiomimetic 
 
1.5 Objectives 
Despite all of the advances in the design and synthesis of mixed-efficacy MOR agonist/DOR 
antagonist ligands, there remains an unmet need for opioid analgesics that cross the BBB and are 
devoid of tolerance, dependence, and other undesirable side effects. For my thesis project, I 
designed, synthesized, and modified our peptidomimetic scaffold in order to: 1) balance affinities 
between MOR and DOR while reducing affinity and efficacy at KOR to create a more selective 
MOR agonist/DOR antagonist profile, 2) probe bioavailability and improve metabolic stability, 
and 3) penetrate the BBB and improve in vivo efficacy. Chapter 2, discusses the results from 
three parallel series of peptidomimetics that led to the discovery of an N-acetylated 
tetrahydroquinoline core-containing compound with more balanced MOR and DOR affinities 
(relative to 1, Figure 1.4), that acts as an agonist at MOR and an antagonist at DOR and produces 
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antinociception for longer than 3 h after intraperitoneal (ip) administration. Chapter 3, explores 
the effects of additional N-substitutions on the THQ core in an attempt to probe the effect of 
various modifications on the binding affinity and efficacy at DOR. Chapter 4 describes the 
incorporation of methoxy and hydroxyl moieties at various positions around the core and 
pendant region to probe steric and electronic requirements and limitations across the opioid 
receptors and to potentially expose key differences that confer selectivity to one receptor type 
over the others. Chapter 5 describes efforts to synthesize compounds that probe the effects of 
different stereochemistry on ligand binding. Chapter 6 highlights efforts to increase metabolic 
stability through incorporation of a fluorine moiety at various locations on the peptidomimetic 
core. Finally, Chapter 7 summarizes all the studies and SAR campaigns completed and offers 
future directions.  
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CHAPTER 2 
 
Structure-activity relationship studies on three parallel series of mixed-efficacy µ-opioid 
receptor agonist/δ-opioid receptor antagonist peptidomimetics 
 
 
 
 2.1 Introduction 
 The successful transfer of key binding elements from a peptide scaffold to 1 expanded the 
chemical space that could be altered and modified in order to tailor ligands to specific opioid 
receptors. While 1 was designed from the tetrapeptide JOM-13, a parallel cyclic pentapeptide 
series also revealed promising leads toward bifunctional MOR agonist/DOR antagonist ligands. 
The subsequent series of peptidomimetics are based on a series of cyclic, mixed-efficacy MOR 
agonist/DOR antagonist pentapeptides with the general formula Tyr-c[D-Cys-X3-X4-Cys]NH2,
22 
where cyclization occurs through either a disulfide bond or an methylene dithioether bond and 
X3 or X4 represents phenylalanine (Phe), 3-(1-Naphtyhl)alanine (1-Nal), or a 3-(2-
Naphtyhl)alanine (2-Nal) amino acids. Briefly, using Tyr-c[D-Cys-Phe-Phe-Cys]NH2 as the 
parent compound, it was shown that peptides substituting either a 1-Nal or a 2-Nal in the X3 
position decreased DOR binding, while the same substitutions in position X4 displayed increased 
affinity binding at DOR, when compared to the parent compound. Additionally, the compounds 
containing 1-Nal or 2-Nal in the X4 position were fully efficacious at MOR and displayed 
Synthesis of 1 was originally synthesized by Dr. Yafei Jin of the Vahlteich Medicinal Chemistry Core at the University of Michigan and Dr. Kate 
Kojiro of the Mosberg Lab at the University of Michigan. The original synthesis was not asymmetric. Dr. Aaron Bender also of the Mosberg Lab 
completed the synthesis of 1 asymmetrically and is responsible for determining the desired R-stereochemistry at the 4 position of the THQ core. 
Compounds 56, 57, and 68 were synthesized by Dr. Larisa Yeomans of the Mosberg lab. The in vitro data was acquired chiefly by Nicholas 
Griggs and Mary Clark of the Traynor Lab at the University of Michigan (Table 2.1). In addition, Tyler Trask, Evan Schramm, Aaron 
Chadderdon and Chao Gao also of the Traynor Lab made significant contributions to collecting the in vitro pharmacology data (Table 2.1).  Dr. 
Jessica Anand of the Jutkiewicz Lab at the University of Michigan is responsible for performing all of the in vivo assays (Figure 2.3-2.6) and 
James Hallahan performed the icv injections for the data shown in Figure 2.5. Dr. Irina Pogozheva of the Mosberg Lab completed the 
computational modeling (Figure 2.7).  The syntheses, in vitro data (Table 2.1), and in vivo data (Figure 2.3) for 1, 9, 9’, 56, and 57 were 
originally published in reference 21. The syntheses, in vitro data (Table 2.1, 2.2, and 2.3). and in vivo data (Figure 2.3 and 2.4) for the remaining 
compounds included in this chapter were originally published in reference 23.  The in vivo data in Figures 2.5 and 2.6 has not yet been published. 
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reduced efficacy at DOR,22 thus fitting the desired MOR agonist/DOR antagonist profile. 
Furthermore, in the case of the peptides containing of the formula Tyr-c[D-Cys-Phe-2-Nal-
Cys]NH2, DOR efficacy was essentially eliminated.
22 The finding that bulkier aromatics can 
potentially enhance our desired MOR agonist/DOR antagonist profile served as the foundation 
for the initial SAR study of our peptidomimetics which included substitution of the benzyl 
pendant with 1- and 2- methylnapthyl pendants, among other pendants.  
 
2.2 Design and synthesis of the three parallel peptidomimetic series 
The first series of peptidomimetics (which includes 1) utilized a THQ core and incorporated 
Dmt and various aromatic moieties (benzyl, phenethyl, 1-naphthyl, 2-naphthyl, and 2-indanyl) 
that mimic the Tyr1 and Phe4 residues seen in the peptide series and also in the endogenous 
ligands, respectively (Figure 2.1, Panel A). Additionally, this first peptidomimetic series was not 
synthesized asymmetrically, unlike subsequent series, resulting in a set of diastereomers for final 
products. Later, it was determined that stereochemistry that resulted in a higher affinity binding 
profile had R-stereochemistry at position 4 (Refer to Figure 1.4, structure of 1 for numbering 
system)21 and thus after this finding, the synthesis of the peptidomimetics was completed 
asymmetrically to yield compounds with the desired R-stereochemistry at position 4. This 
original opioid peptidomimetic series displayed the desired profile (as seen in Table 2.1)21 and 
confirmed that the THQ scaffold is a suitable and bioavailable template, but there remained 
opportunity to improve in vitro and in vivo properties. For example, compounds in the original 
THQ series displayed 10-130-fold binding affinity preference for MOR over DOR (Table 2.2), 
and many also exhibited considerable affinity and efficacy at KOR (Table 2.1).  Additionally, 1 
was submitted to the Pharmacokinetics Core at the University of Michigan to determine the 
metabolic stability of THQ peptidomimetic series and to provide some insight into possible 
metabolic routes. Through this study, it was discovered that there were three likely metabolism 
routes for our peptidomimetics, one of which was oxidation of the THQ core (Figure 2.1, Panel 
B). Using SMARTCyp, an online metabolic site predictor, the top 10 metabolic labilities were 
determined and four were predicted to be on the THQ core (Figure 2.1, Panel C). In the 
subsequent generation of two parallel series of compounds, two different modifications to the 
THQ series were explored. These modifications included the replacement of the THQ scaffold 
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with a tetrahydronaphthalene (THN) scaffold or N-acetylation of the nitrogen in the THQ core of 
the original series (Figure 2.1). These modifications were designed to 1) probe and improve 
bioavailability and metabolic stability, 2) balance the affinity at MOR and DOR while reducing 
KOR affinity and efficacy, and 3) increase in vivo efficacy and duration of action.23 
 
  
Figure 2.1 Structures and potential metabolism routes for peptidomimetics. A. Structures of the three parallel series 
of peptidomimetics. B. Metabolic routes determined by the PK Core at the Univeristy of Michigan. C. Metabolic 
liabilities as predicted by SMARTCyp. Red indicates highly labile, pink indicates moderately labile, orange fairly 
labile 
 
Through both of these modifications, the goal was to reduce the metabolic lability associated 
with the nitrogen heteroatom in the THQ ring, as two common metabolic concerns associated 
with a nitrogen heteroatom include N-oxidation and oxidation α to a heteroatom.24-28 
Furthermore, the amine in the THQ core is also part of an aniline system, which is susceptible to 
aromatization, not only in vivo, but potentially in ambient atmosphere with trace acid present.29  
Through acetylation of the THQ nitrogen, N-oxidation would be blocked, however oxidation 
α to a heteroatom was still of concern. Incorporating a THN scaffold would eliminate both the N-
B 
C 
A 
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oxidation and oxidation α to a heteroatom completely, by eliminating the problematic nitrogen 
atom from the scaffold all together. Additionally, it was observed that N-acetylation of the parent 
compound 1 to form 52 improved DOR affinity (DOR Ki = 9.4 nM vs. 1.8 nM, respectively), 
without altering MOR affinity (MOR Ki = 0.22 nM vs. 0.13 nM, respectively), resulting in an 
overall better balance of MOR and DOR binding. Consequently, two parallel series, with 
variable pendant R (Figure 2.1) and an N-acetylated THQ core or THN core were explored to 
examine effects on bioavailability and relative MOR and DOR affinities.  
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2.2.1 Synthesis of the 2-methylindanyl THQ analogue 
The 2-methylindanyl analogue was one of the first analogues of the THQ series to be 
synthesized. As such, this synthesis was not completed asymmetrically, unlike other analogues in 
the subsequent parallel series.21 The core THQ intermediate 6 (Scheme 2.1) was synthesized 
using the methodology developed by Schmidt et al and described in ref, 21 and 30. In this 
synthesis, the pendant moiety is incorporated in the first step through an aldol condensation 
between 1-indanone and p-nitrobenzaldeyde to yield 2 which was hydrogenated to yield the 
aniline 3. The amine in 3 was acylated with 3-bromopropionyl chloride to give 4, cyclized to 
form lactam 5, and then treated with trifluoromethanesulfonic acid (TfOH) to promote a Fries-
Rearrangement and yield 6. Treatment of 6 with hydroxylamine yielded 7, which was 
hydrogenated to form the racemic amine 8. Amine 8 was coupled to di-Boc protected 2,6-
dimethyl-L-tyrosine (diBoc-Dmt) and deprotected to yield diastereomers 9 and 9’(Scheme 2.1).   
 
Scheme 2.1 Synthesis of the 2-methylindanyl THQ analogue 
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2.2.2  Synthesis of the 1-methylindanyl THQ analogue 
Like the 2-methylindanyl analogue, the 1-methylindanyl analogue incorporated the pendant 
diversity in the first step and was synthesized as a racemic mixture using a slight modification of 
methodology originally developed by Kolanos et al.31 The synthesis began with a condensation 
reaction between indene and 4-acetamidobenzaldehyde, to form 10, which was hydrogenated to 
form a racemic mixture of 11, then deprotected to yield aniline 12. Intermediate 12 was acylated 
with 3-bromopropionyl chloride to give 13, cyclized to form lactam 14, and then treated with 
TfOH to promote a Fries-Rearrangement and yield 15. Intermediate 15 was Boc-protected using 
di-tert-butyl dicarbonate to yield 16. Instead of using hydroxylamine like in the synthesis of the 
2-indanyl analogue, the 1-methylindanyl analogue was synthesiszed asymmetrically utilizing 
chemistry developed by the Ellman group.32-34 For the asymmetric synthesis, 16 was treated with 
(R)-t-butanesulfinamide and Ti(OEt)4 to form a chiral imine in situ which was reduced with 
NaBH4 to form the desired R-stereochemistry for intermediate 17. The Ellman auxillary was 
cleaved using concentrated hydrochloric acid (HCl) forming primary amine 18 which was then 
coupled to diBoc-Dmt and deprotected to yield compound 19 as an inseparable mixture of 
diastereomers (Scheme 2.2). 
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Scheme 2.2 Synthesis of the 1-methylindanyl THQ analogue 
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2.2.3  Synthesis of the methylcyclohexyl THQ analogue 
The synthesis of the methylcyclohexyl THQ analogue began with the acylation of p-
bromoaniline using 3-bromopropionyl chloride to yield 20. Intermediate 20 is cyclized under 
basic conditions to form lactam 21, and is then treated with TfOH to form intermediate 22.30 The 
nitrogen of 22 was protected with a tert-butyloxycarbonyl (Boc) group forming 23, which was 
subjected to Suzuki cross-coupling35 to incorporate the methylcyclohexyl moiety and yield 24.  
Intermediate 24 was treated with (R)-t-butanesulfinamide and Ti(OEt)4 to form a chiral imine in 
situ which was reduced with NaBH4 to form the desired R-stereochemistry for intermediate 25.
32-
34 The Ellman auxillary was cleaved using concentrated HCl forming primary amine 26 which 
was then coupled to diBoc-Dmt and deprotected to yield compound 27 (Scheme 2.3). 
 
Scheme 2.3 Synthesis of the methylcyclohexyl THQ analogue 
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2.2.4 Forming the N-acetylated dihydroquinolinone intermediates 
The synthesis of the N-acetylated analogue of 1 began with acylation of the commercially 
available benzyl aniline with 3-bromopropionyl chloride to give 28, followed by cyclization in 
the presence of base to form lactam 29. Treatment of 29 with TfOH promoted a Fries-
Rearrangement and yielded 3030 (Scheme 2.4, A). With the dihydroquinolinone core constructed, 
intermediates 6, 15, and 30, were treated with acetic anhydride (Ac2O) to form the N-acetylated 
intermediates, 31-33 (Scheme 2.4, B) 
 
Scheme 2.4. A. Synthesis of the benzyl dihydroquinolinone core B. Acetylation of the benzyl, 1- and 2- 
methylindanyl analogues 
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In order to synthesize the N-acetylated dihydroquinolinone intermediates with the 
methylcyclohexyl-, 1-methylnaphthyl-, and 2-methylnaphthyl- pendants, 22 was acetylated using 
Ac2O to form 34 which was then subjected to Suzuki coupling to form intermediates 35-37 
(Scheme 2.5).23,36 
 
Scheme 2.5 Synthesis of the N-acetylated dihyroquinolinone intermediates containing the methylcyclohexyl, 
2-methylnapthyl, and 1-methylnaphthyl pendants 
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2.2.5 Completing the synthesis of the N-acetylated THQ Series 
Once all of the desired pendants were incorporated onto the N-acetylated dihydroquinolinone 
core, the syntheses converged. Intermediates 31-33 and 35-37 were treated with (R)-t-
butanesulfinamide and Ti(OEt)4 to form imines in situ, which were reduced in situ with NaBH4 
to form the desired R-stereochemistry of intermediates 38-43.32-34 The Ellman auxiliary was 
cleaved using concentrated HCl forming primary amines 44-49, which were then coupled to 
diBoc-Dmt and deprotected to yield final compounds 50-55 (Scheme 2.6).23 
 
Scheme 2.6 Completion of the N-acetylated analogues 
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2.2.6 Synthesis of the THN Series 
Synthesis of THN compounds 65-67 began by converting the ketone of commercially 
available 7-bromo-dihydronaphthalenone to the chiral imine using (R)-t-butanesulfinamide and 
Ti(OEt)4 followed by in situ reduction to form 58 using NaBH4 to afford the desired R-
stereochemistry of the sulfonamide. Next, the pendant substituents were incorporated via Suzuki 
coupling35,36 to form intermediates 59-61.  Intermediates 59-61 were then treated with 
concentrated HCl to cleave the Ellman auxiliary affording primary amines 62-64.31-33 In the final 
step, the amines 19m-p were coupled to diBoc-Dmt and deprotected to yield compounds 65-67 
(Scheme 2.7). 23 
 
Scheme 2.7 Synthesis of the THN analogues 
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2.3 Results 
Binding and Efficacy Assays. 
Binding affinities (Ki) for the final compounds were determined from competitive 
displacement of radiolabeled [3H]diprenorphine in membrane preparations from C6 cells stably 
expressing MOR  (C6-MOR) or DOR (C6-DOR) or CHO cells stably expressing KOR (CHO-
KOR), as previously described37,38(Table 2.1). Efficacy of the compounds was assessed by 
agonist-stimulated [35S]GTPγS binding to G protein39 in cell membrane preparations of C6-
MOR, C6-DOR, and CHO-KOR (Table 2.1). These assays are described in full in 8.2. In order to 
determine the effects of the modifications on MOR and DOR selectivity, the DOR Ki value was 
divided by the MOR Ki value resulting in a relative selectivity for a peptidomimetic to bind to 
MOR over DOR (Table 2.2). As the relative fold data suggests, the N-acetylated series appeared 
to bring the ratio of MOR to DOR binding closer to 1:1, when compared to the THQ series. In 
contrast, the THN series created a larger disparity between MOR and DOR binding, with most 
THN-containing peptidomimetics significantly preferring MOR over DOR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Table 2.1  Opioid Receptor Binding Affinities and Efficacies of Peptidomimetics21,23 
 
    Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd X R1 R2 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f N H 
 
0.22 
(0.02) 
9.4 
(0.8) 
68 
(2) 
1.6 
(0.3) 
110 
(6) 
540 
(70) 
81 
(2) 
16 
(2) 
22 
(2) 
52 N 
 
0.13 
(0.02) 
1.8 
(0.1) 
87 
(10) 
6.0 
(1) 
68 
(2) 
>1300 
76 
(4) 
26 
(3) 
29 
(5) 
68e CH2 -- 
0.045 
(0.03) 
4.0 
(1) 
19  
(7) 
2.9 
(0.6) 
dns dns 
64 
(9) 
dns dns 
27 N H 
 
0.043 
(0.005) 
3.4  
(1) 
6.2 
(1) 
2.6 
(1) 
dns 
97 
(30) 
57 
(5) 
dns 
36 
(4) 
53 N 
 
0.03 
(0.01) 
0.32 
(0.1) 
8.4 
(2) 
0.61 
(0.2) 
14 
(8) 
240 
(70) 
70 
(6) 
26 
(5) 
33 
(6) 
65 CH2 -- 
0.12 
(0.02) 
14 
(6) 
20 
(5) 
dns dns 
350 
(80) 
dns dns 
25 
(6) 
56e N H 
 
0.078 
(0.007) 
10 
(2) 
54 
(7) 
0.53 
(0.08) 
dns dns 
96 
(3) 
dns dns 
54 N 
 
0.04 
(0.01) 
0.23 
(0.02) 
48 
(20) 
0.93 
(0.2) 
dns dnsd 
87 
(3) 
dns dnsd 
66 CH2 -- 
0.06 
(0.01) 
12 
(4) 
92 
(20) 
4.4 
(2) 
dns dns 
72 
(4) 
dns dns 
57e N H 
 
0.76 
(0.1) 
6.0 
(0.7) 
17 
(1) 
0.84 
(0.4) 
69  
(40) 
dns 
93 
(5) 
15 
(1) 
dns 
55 N 
 
0.06 
(0.02) 
1.3 
(0.4) 
4.3 
(2) 
0.48 
(0.2) 
dns dnsd 
70 
(4) 
dns dnsd 
67 CH2 -- 
0.39 
(0.08) 
5.0 
(0.3) 
63 
(20) 
14 
(7) 
dns dnsd 
58 
(2) 
dns dnsd 
9 N H 
 
0.16 
(0.04) 
4.1 
(2) 
1.2 
(0.4) 
0.24 
(0.03) 
dns dns 
86 
(1) 
dns 
38 
(2) 
50 N 
 
0.05 
(0.00) 
0.44 
(0.07) 
12 
(4) 
0.56 
(0.1) 
dns 
610 
(250) 
84 
(2) 
dns 
60 
(10) 
19 N H 
 
0.05 
(0.02) 
6.8 
(2) 
19 
(10) 
9.0 
(6) 
dns 
180 
(80) 
16 
(8) 
dns 
52 
(7) 
51 N 
 
0.03 
(0.00) 
0.84 
(0.13) 
15 
(0.2) 
15 
(10) 
dns >1000 
39 
(10) 
dns 
26 
(8) 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [3H]diprenorphine in 
membrane preparations. bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. 
Efficacy is represented as percent maximal stimulation relative to standard agonist DAMGO (MOR), DPDPE 
(DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the mean with S.E.M. in parentheses for n=3 
independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. dns: does not 
stimulate. esynthesized by Larisa Yeomans. fsynthesized by Kate Kojiro. 
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Table 2.2 Binding Affinity Ratios of Peptidomimetics23 
 
    DOR Ki/MOR Ki Ratio 
Cpd X R1 R2  
1 N H 
 
43 
52 N 
 
14 
68 CH2 -- 89 
27 N H 
 
79 
53 N 
 
11 
65 CH2 -- 117 
56 N H 
 
128 
54 N 
 
6 
66 CH2 -- 140 
57 N H 
 
8 
55 N 
 
22 
67 CH2 -- 13 
9  N H 
 
26 
50 N 
 
9 
19 N H 
 
136 
51 N 
 
28 
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In vivo WWTW Assay. 
     Several compounds were chosen based on in vitro data to be assayed for antinociception 
in the mouse Warm Water Tail Withdrawal (WWTW) assay following intraperitoneal (ip) 
injection (description of assay in 8.3). Of the compounds assayed (Table 2.3, Figure 2.3), only 
three compounds displayed dose-dependent antinociceptive activity. Compounds 50 and 56 
displayed partial antinociception at the maximum dose tested, whereas 54 displayed full 
antinociception with ED50 = 4.72 ± 0.01 mg/kg. By comparison, the ED50 of morphine, under the 
same conditions, was 4.73 ± 0.001 mg/kg.  Because compound 54 displayed full antinociception 
at 10 mg/kg in the initial WWTW assay, a time course study was completed to determine 
duration of action (Figure 2.4, Panel A). As can be seen in Figure 2.4, 54 produced maximal 
antinociception with a rapid on-set which is maintained for approximately 200 min. This 200 
min duration of action is greater than 3 times longer compared to the duration of action of the 
original lead peptidomimetic 121, and similar to that observed for the same dose of morphine 
(Figure 2.4 B)21 suggesting better bioavailability or metabolic stability. Additionally, despite 
being structural isomers with a similar in vitro profile, 54 and 55 displayed drastically different 
in vivo results when administered via ip injection (Figure 2.3). While 54 displayed full 
antinociception after ip administration, 55 displayed no antinociception at the same dose after ip 
administration. To further explore this unexpected result, both 54 and 55 via 
intracerebroventricular (icv) injection, then the WWTW assay was performed. Both 54 and 55 
displayed full antinociception at a dose of 300 ng/3 µL at 5 min and 15 min post icv injection 
(Figure 2.5), indicating that 55 is indeed capable of producing antinociception when 
administered centrally, but not when administered via ip injection, suggesting that subtle 
differences in chemical structure create substantial differences in pharmacokinetics. 
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Table 2.3 In vivo Activity of Select Peptidomimetics 
Cpd Scaffold R2 In vivo Activity following ip administrationb 
1a THQ 
 
Full antinociception at 10 mg/kg with duration of action >1h 
52 N-acetyl THQ No activity up to 10 mg/kg 
68 THN Partial antinociception with latency of 14 sec at 10 mg/kg  
27 THQ 
 
No activity up to 10 mg/kg 
53 N-acetyl THQ No activity up to 10 mg/kg 
56 THQ 
 
Partial antinociception with latency of 10 sec at 10 mg/kg 
54 N-acetyl THQ Full antinociception at 10 mg/kg with duration of action of >3 h 
66 THN No activity up to 10 mg/kg 
55 N-acetyl THQ 
 
No activity up to 10 mg/kg 
67 THN No activity up to 10 mg/kg 
9 THQ 
 
No activity up to 10 mg/kg 
50 N-acetyl THQ Partial antinociception with latency of 11 sec at 10 mg/kg 
Summary of antinociceptive effects of select analogues (n=3 for all analogues, except for 54 n=6) in mouse 
WWTW assay following intraperitoneal (ip) administration, with a cut-off time of 20 sec. asee ref. 21.bFull 
antinociception indicates that the cut-off time was reached. 
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Figure 2.3 Cumulative antinociceptive dose response curves of select analogues 1, 50, 54, 55, and 56 in the mouse 
WWTW assay following ip administration. n=3 for all analogues, except for 54 where n=6.  Plotted as average ± 
S.E.M. ****, p < 0.0001 for 1, 50, 54, 56 for the 10 mg/kg dose when compared to baseline. 21, 23 
 
 
 
Figure 2.4 Time course of antinociception of 1 and 54 in the mouse WWTW assay following ip administration of 
10 mg/kg. n=6 for both peptidomimetics, plotted as average ± S.E.M. 21, 23  
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Figure 2.5 Time course antinociception of 54 and 55 in mouse WWTW assay following intracerebroventricular 
(icv) administration of 300 ng/3 µL. n=2, plotted as average +/- SEM. 
 
 
In Vivo Assay for Chronic Tolerance. 
Peptidomimetic 54 produced a MOR agonist/DOR antagonist profile with selectivity over 
KOR and relatively balanced binding affinities at MOR and DOR in vitro (Table 2.1 and 2.2) 
and produced antinociception for over 3 h after ip administration. Because of these promising 
results, 54 was tested to see if it produced chronic tolerance in mice. In this assay, a dose-
response curve for 54 was determined for all mice described in 8.2. Mice were then separated 
into two groups: one of which was treated twice daily with saline (ip), while the second group 
was treated twice daily with escalating doses of 54 such that the mice received 10 
mg/kg/injection (inj) on day 1, 20 mg/kg/inj on day 2, 30 mg/kg/inj on day 3, 40 mg/kg/inj on 
day 4, and 50 mg/kg/inj on day 5 (ip). On day 6, increasing cumulative doses of 54 was 
administered to all mice and a second dose response-curve was determined for both groups of 
mice (chronic saline or chronic 54). As expected, the dose-response curves on day 1 and day 6 
for mice receiving chronic saline do not shift, which indicates that a 10 mg/kg dose of 54 was 
fully efficacious on day 1 and on day 6. Additionally, in Figure 2.6 Panel A, 54 was fully 
efficacious at a 10 mg/kg dosage both before and after chronic treatment with 54 This was 
demonstrated in no shift in the ED50 values on day 1 and day 6 which were both 4.73±0.001. 
This indicates that under these conditions 54 did not produce antinociceptive tolerance in mice. 
For comparison, the same assay was done with morphine, as expected produced roughly a 4-fold 
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rightward, parallel shift in the dose-response indicating that mice became tolerant to this 
treatment regime.  
 
 
 
Figure 2.6 Determination of chronic tolerance to antinociceptive effect (mouse WWTW assay) of 54 (A) and 
morphine (B). After baseline withdrawal latency was determined, mice were treated with cumulative doses of drug 
(1.0, 3.2, or 10 mg/kg) to determine dose-reponse curves (open circle for saline, closed circle for 54) on day 1. After 
receiving either saline or escalating doses of  for five days, a second dose-response curve was determined on day 6 
(open square for saline, closed square for 54). Plotted as average ± S.E.M, n=4-6 mice for each group.  
 
 
 
 
A 
B 
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2.4 Discussion 
 
The analogues presented above reiterate that it is possible to transfer key pharmacophore 
elements from a MOR agonist/DOR antagonist peptide to a peptidomimetic scaffold, with the 
original parent peptidomimetic, 1, showing antinociceptive activity after peripheral 
administration in mice. While the THQ series of compounds displayed the desired MOR 
agonist/DOR antagonist profile, there remained opportunity to improve the balance of binding 
affinities at MOR and DOR, and reduce any remaining KOR binding and efficacy. Although the 
optimal balance of “MOR agonism” with “DOR antagonism” is yet to be determined, a low 
nanomolar, balanced affinity profile (~1:1 MOR Ki: DOR Ki) was a logical place to start, since 
this would ensure that both MOR agonist and DOR antagonist character would be represented in 
the in vivo outcome and would provide useful information for future studies. The THQ series 
displayed relatively unbalanced MOR and DOR affinities, where compounds were 10- to 130- 
fold selective for MOR over DOR (Table 2.1). In order to optimize the initial compounds, effects 
of N-acetylation of the THQ nitrogen and utilization of THN scaffold instead of a THQ scaffold 
were explored. Through these modifications of the THQ scaffold, the goal was to reduce or 
eliminate metabolic susceptibility associated with the THQ ring nitrogen, while also examining 
the effect of these modifications on binding affinity and efficacy across all three opioid 
receptors. Additionally, we wished to explore the additional effect of modifying the R2 
substituent, in the search for a MOR agonist/DOR antagonist with a better MOR/DOR affinity 
balance. 
While a total of six compound sets were synthesized, (each set defined by the pendant 
substituent), only four of these sets incorporated all three of the different scaffolds; these sets 
include analogues in which the pendant substituent is a benzyl, a 1-methylnaphthyl, a 2- 
methylnaphthyl, or a methylcyclohexyl. The initial in vitro results for the parallel series of 
scaffold modifications yield interesting insight into both the electronic and steric requirements 
for optimal binding. The effects of both scaffold modifications on the binding affinities are 
shown in Table 2.1. The most noticeable trend across these four sets of compounds is seen with 
the N-acetylated THQ series at DOR. This N-acetylated series (regardless of pendant) shows a 
significantly higher affinity at DOR than the unsubstituted THQ counterpart. Additionally, N-
acetylation maintains, and in some cases slightly improves affinity at MOR while slightly 
decreasing affinity at KOR. The effect of the N-acetylated THQ scaffold on efficacy (Table 2.1) 
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across all receptors is minimal, with most compounds retaining similar efficacy as seen with the 
parent THQ series. When considering the effects of the N-acetylation on the THQ scaffold as a 
whole, this modification appears to balance the MOR/DOR binding profile as determined by the 
DOR Ki/MOR Ki ratio (Table 2.2) while maintaining the desired MOR agonist/DOR antagonist 
efficacy profile. The only exception to this trend is in the case of compound 55, where the MOR 
and DOR affinity both increase, with the MOR affinity increasing to a greater extent, resulting in 
a higher preference for MOR over DOR.  
In contrast, the effect of the THN scaffold on binding affinities at all three receptors (Table 
2.1), when compared with the parent THQ scaffold, showed no consistent or advantageous 
trends. The data in Tables 2.1 and 2.2 indicate that the series incorporating the THN scaffold, 
when compared to the unsubstituted THQ scaffold, leads to greater disparity in the binding 
affinities at MOR and DOR. These disparities are caused by either increasing affinity at MOR 
more so than at DOR or by decreasing affinity at DOR more than at MOR, relative to the parallel 
analogue with a THQ core. Both of these effects result in a less desirable affinity profile, and 
sometimes result in a profile with reduced affinity at both MOR and DOR. Furthermore, the 
THN scaffold does not improve selectivity over KOR across all sets of compounds. In addition 
to the effects that the THN scaffold has on the binding affinities at MOR, DOR, and KOR, the 
THN core also results in reduced efficacy at MOR, when compared to our parent THQ series. 
Because the THN scaffold presented no apparent advantage, the 1- and 2-methylindanyl THN 
analogues were not pursued. 
In order to explain the results of the N-acetylated THQ series, computational docking of one 
of the THQ/N-acetylated ligand pairs docked in the binding pocket of the inactive state of DOR 
(DORi) was completed, as previously described. Modeling 54 and 56 in the DORi binding 
pocket (Figure 2.7) as a representative example, it can be seen that the N-acetyl of 54 extends 
further into the DORi binding pocket to create a polar contact with Tyr129 in transmembrane 
helix 3 (TM3) of the receptor (Figure 2.7, Panel B), an interaction that appears to be unavailable 
with the unsubstituted THQ core (Figure 2.7, Panel A).  It seems that the N-acetyl can increase 
DORi binding through three modes: 1) The carbonyl of the N-acetyl forms a hydrogen bond with 
the hydroxyl in Tyr129, and once the hydrogen bond is formed, this could orient the ligand in the 
receptor to form a tighter hydrogen bonding network between 2) the primary amine of the 2,6-L-
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dimethyl tyrosine (Dmt) moiety of the ligand and Asp128 of the receptor, and 3) the Dmt 
hydroxyl moiety of the ligand and His278. It has been previously reported60-66 that ligand 
interaction with His278 and Asp128 are important for opioid ligand binding in all three classical 
receptors. While the DOR Tyr129 residue is conserved in MOR (Tyr148), the N-acetylation does 
not appear to have as profound of an effect in the MOR binding pocket, with the measured 
distance between 56 and 54 to the Tyr residue 4.7 Å to 4.3 Å, respectively (not pictured). When 
both 56 and 54 are overlaid with the crystal structure of the recently reported66 MOR 
agonist/DOR antagonist, DIPP-NH2, (Figure 2.7, Panels C and D, respectively) in DORi, it can 
be seen that 54 aligns better with the Dmt and free amine moiety of DIPP-NH2 than 56. This 
suggests that the N-acetyl moiety has a subtle, yet impactful effect on the orientation of the 
ligand resulting in increased binding affinity at DORi. We hypothesize that the interaction 
between Tyr129 in the binding pocket of DORi and the N-acetylated ligand 54 (and other N-
acetylated analogues) may bring 14a into closer proximity to His279 and Asp128, facilitating a 
better binding network within the DORi binding pocket.  
While the increase in DOR affinity across the N-acetylated analogues is the most apparent 
trend when considering the in vitro data in their entirety, it is clear that some substituents 
displayed superior profiles over others. For example, the methylcyclohexyl (27, 53, 65) and 1- 
and 2-methylindanyl (19, 51, and 9, 50) analogues picked up considerable undesired KOR 
affinity and agonism, while the 1- and 2-methylnaphthyl analogues (57, 55, 67, and 56, 54, 66) 
display agonist activity at MOR, little or no agonist activity at DOR, and significantly reduced 
binding and efficacy at KOR, suggesting that these compounds behaved as functional antagonists 
at DOR. To confirm antagonist activity at DOR, 54 and 55 were tested against DPDPE, and as 
expected from the high binding affinity and lack of stimulation of [
35
S]GTPγS binding  at DOR, 
54 and 55 both antagonized the DOR agonist DPDPE, with  antagonist affinity constants (Ke) of 
1.98 nM and   27.5 nM, respectively (data not shown). Lastly, 54 stood out as a compound with 
one of the best in vitro profiles for the desired MOR agonist/DOR antagonist profile across all 
three series. Analogue 54 displays subnanomolar affinity at both MOR and DOR (Ki = 0.04 nM 
and 0.23 nM, respectively), indicating that there is only a 6-fold selectivity preference for MOR 
over DOR. Additionally, when comparing MOR and DOR binding affinities to KOR binding 
affinity, 54 displayed 200-fold selectivity for DOR and 1200-fold selectively for MOR, relative 
to KOR. Finally, 54 produced 87% stimulation at MOR, acted as an antagonist at DOR, and 
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displayed no efficacy and a lower relative affinity at KOR, indicating that any KOR-mediated 
effects would be minimal.  
 
Because 54 displayed one of the best in vitro profiles, this analogue, along with 11 other 
compounds were tested for in vivo activity in mice using the WWTW assay. As seen in Figures 
2.3 and 2.8, the in vitro results and cLogP calculations were both poor predictors of in vivo 
activity. Surprisingly, 55 displayed no in vivo activity at 10 mg/kg ip while 54, a structural 
isomer of 55, displayed full antinociception at 10 mg/kg ip. Consequently, both 54 and 55 were 
administered centrally via intracerebroventricular (icv) injection, then performed the WWTW 
assay was performed. Both 54 and 55 displayed full antinociception at 300 ng/3 µL at 5 min and 
15 min post icv injection (Figure 2.5). As both 54 and 55 were active after icv administration, 
this indicates that the difference in in vivo activity following ip administration is a matter of 
 
Figure 2.7 Docking of 54, 56 and DIPP-NH2 in DORinactive (DORi). A. 56 (purple) in DORi with key residues 
shown. B. 54 (teal) in DORi with key residues shown. Dashed lines represent calculated distances between ligand 
and receptor residues, indicating a possible interaction between N-acetyl moiety and Tyr129 that may increase 
binding affinity at DORi. (C) overlay of 56 (purple) and DIPP-NH2 (orange) in DORi. (D) Overlay of 54 (teal) and 
DIPP-NH2 (orange) in DORi.  
56 
56 
 
54 
 
54 
 
 
34 
 
pharmacokinetics and not pharmacodynamics. In order to explore this unexpected result, both 54 
and 55 were submitted for plasma stability testing performed by Quintara Discovery (San 
Francisco, CA, U.S.). These results revealed that both analogues tested were fully stable in 
plasma after 30 min, suggesting compound degradation in the plasma does not account for the 
differing activities in vivo. As such, 54 and 55 were both tested to see if they were substrates for 
the P-glycoprotein (Pgp) transporter. The Pgp transporter is a protein located in the capillary 
endothelial cells of BBB, among other locations in the body, and is responsible for pumping 
xenobiotics out of cells. The results from the Pgp assay suggest that neither 54 nor 55 are 
substrates for the Pgp transporter. Additional pharmacokinetic studies on 54 and 55 will be 
helpful for understanding the basis of the disparate in vivo results.  
In order to determine the duration of action for 54, a time course assay was completed. 
Antinociception produced by 54 (10 mg/kg) lasted over 3 h (Figure 2.4) which is a significant 
increase over the original lead, 1, and comparable to morphine at the same 10 mg/kg dose (Data 
not shown). Additionally, 54 was screened to determine if chronic administration would produce 
tolerance. As can be seen in Figure 2.6 Panel A, the dose-response curve following twice daily 
administration of increasing doses of 54 does not produce a rightward-shift and does not differ 
from animals receiving saline over the duration of the experiment. In contrast, morphine 
produces a rightward-shift indicating the development of tolerance because an increased dose on 
day 6 is necessary to produce the same response as seen in day 1 (Figure 2.6, Panel B).  
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Figure 2.8 Summary of in vivo activity following ip administration, cLogP, and molecular weight (MW, g/mol) for 
select compounds. Compounds 9, 27, 52, 53, 66, 67 do not display antinociception following ip administration and 
structures are not shown.  
In summary, three parallel series of peptidomimetics were synthesized. The original THQ 
scaffold was modified to incorporate a THN and an N-acetylated THQ scaffold with the intention 
of 1) probing and improving bioavailability and metabolic stability, 2) balancing further the 
affinity at MOR and DOR while reducing KOR affinity and efficacy, and 3) increasing in vivo 
activity and duration of action. A better balance in affinity at MOR and DOR was achieved 
through maintaining MOR affinity while increasing DOR affinity via N-acetylation. This 
increase in DOR affinity could be due to an interaction between the carbonyl moiety of the acetyl 
group and Tyr129 in DOR. Additionally, N-acetylation decreased binding affinity and efficacy at 
KOR, thereby creating a more selective MOR agonist/DOR antagonist compound profile. 
Furthermore, three of the compounds produced in vivo activity when administered peripherally. 
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Analogue 54 produced one of the more balanced MOR agonist/DOR antagonist profiles in vivo, 
reduced KOR affinity and efficacy, full antinociception in the mouse WWTW assay for >3 h, a 
promising improvement upon the original lead compound, 1,21 and did not produce chronic 
tolerance in the mouse model. Additional in vivo studies for 54 are planned, including studies to 
determine if chronic administration of 54 produces dependence.  
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CHAPTER 3 
 
 
Effects of various N-substitutions on opioid receptor affinity and efficacy 
 
 
 
 
 
3.1 Introduction 
 
As described above, N-acetylation of the THQ core of the mixed-efficacy MOR agonist/DOR 
antagonist peptidomimetics improves DOR affinity, which results in an overall better balance of 
affinities at MOR and DOR and thereby creates a MOR agonist/DOR antagonist profile, more 
selective over KOR. The hypothesis is that an additional polar contact between the carbonyl of 
the N-acetyl moiety and Tyr129 of DOR in transmembrane 3 (TM3) helix could be responsible for 
this increase in affinity (Figure 2.6). In an effort to explore this region of the receptor binding 
pocket and determine the optimal R-group on the THQ nitrogen, a series of N-substituted THQ 
analogues that incorporate various aliphatic, cyclic, aromatic, and acidic functionalities was 
synthesized. Through this synthetic campaign, the goal was to empirically probe and “map” the 
region of the binding pocket where the N-substitutions interact and define the steric and 
electronic requirements and limits. Analogues in the present SAR campaign were therefore 
designed to (1) include a carbonyl moiety in order to try and maintain the high DOR affinity seen 
in the initial compounds, and (2) incorporate various aliphatic, cyclic, aromatic, and heteroatom-
containing functionalities (Figure 3.1) in order to probe the effect of such modifications on the 
binding affinity and efficacy not only at DOR, but also at MOR and KOR. 
 
 
 
Dr. Aaron Bender of the Mosberg Lab completed the synthesis of 116-119. The in vitro data was acquired chiefly by Nicholas Griggs of the 
Traynor Lab at the University of Michigan (Table 3.1-3.3). In addition, Tyler Trask, Evan Schramm, Aaron Chadderdon and Chao Gao also of 
the Traynor Lab made significant contributions to collecting the in vitro pharmacology data (Table 3.1-3.3).  Dr. Jessica Anand of the Jutkiewicz 
Lab at the University of Michigan is responsible for performing all of the in vivo assays (Figure 3.2-3.3). The syntheses, in vitro data, and in vivo 
data for this series of analogues has not yet been published. 
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Figure 3.1 Peptidomimetic scaffold, pendants, and N-substitutions 
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3.2 Design and synthesis 
All the N-substitution moieties shown in Figure 3.1 were incorporated onto the parent 
peptidomimetic, 1, where R1 is a benzyl pendant. The N-substitutions that produced the most 
promising in vitro and in vivo profiles were integrated onto 9, where R1 is a 2-methylindanyl and 
onto 56, where R1 is a 2-methylnaphthyl pendant. Compound 9 was chosen as a candidate for 
additional N-substitutions because it was shown to increase selectivity over KOR with the 
addition of the acetyl group with a Ki = 1.2 nM at KOR for 9 and 12 nM for 50. Additional N-
substitutions on 9 could help elucidate what types of moieties confer selectivity and efficacy to 
either DOR or KOR. Compound 56 was chosen as a candidate for additional N-substitutions 
because 54, the N-acetylated version of 56, displayed one of the best in vitro profiles among the 
N-acetylated series and produced in vivo activity. Incorporation of other carbonyl-containing N-
substitutions might affect the MOR agonist/DOR antagonist profile of an already promising lead 
or how the N-substitutions might influence in vivo duration of action. 
3.2.1 Synthesis of N-acylated Analogues Containing the Benzyl Pendant 
The majority of the peptidomimetics containing the benzyl pendant, 77-80, were prepared in 
four steps starting from the dihydroquinolinone intermediate 30 which was subjected to acylation 
using either an acid anhydride or acyl chloride to form intermediates 69-72. Intermediates 69-72 
were treated with (R)-t-butanesulfinamide and Ti(OEt)4 to yield imines in situ, which were 
reduced with NaBH4 to form the desired R-stereochemistry of intermediates 73-76.
32-34 The 
Ellman auxiliary was cleaved using concentrated HCl, forming primary amine salts, which were 
then coupled to diBoc-Dmt and subsequently deprotected to yield compounds 77-80 (Scheme 
3.1).   
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Scheme 3.1 Synthesis of N-acylated analogues containing the benzyl pendant 
 
3.2.2 Synthesis of additional N-substituted analogues containing the benzyl pendant 
The synthesis of compounds 88-90 began by protecting the nitrogen in 30 with a tert-
butyloxycarbonyl (Boc) group forming 81. Intermediate 81 was treated with (R)-t-
butanesulfinamide and Ti(OEt)4 to yield an imine in situ, which was reduced with NaBH4 to give 
the desired R-stereochemistry of intermediate 82. 32-34 To ensure both the cleavage of the Ellman 
auxiliary and the removal of the Boc group, 82 was treated first with TFA then with conc. HCl in 
dioxane to ultimately yield the hydrochloride salt 83. Intermediate 83 was coupled to diBoc-Dmt 
forming 84. From this intermediate, 84, the syntheses of 88, 89, and 90 diverged.  The synthesis 
of 88 was completed by first performing a Finkelstein reaction on 2-chloroacetamide to form 2-
iodoacetamide which was cannulated into a solution containing 84 and N,N-
diisopropylethylamine (DIPEA) to give 85. Intermediate 85 was treated with TFA to remove the 
Boc groups, yielding 88. To complete the syntheses of 89 and 90, ethyl 2-bromoacetate was 
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added to intermediate 84 in the presence of potassium carbonate to give 86. Intermediate 86 was 
then treated with TFA to remove Boc groups and afford compound 89. Compound 90 was 
completed by saponification of the ester of 86 with lithium hydroxide (LiOH) yielding 87, which 
was subsequently treated with TFA to remove the Boc groups and yield compound 90 (Scheme 
3.2) 
 
Scheme 3.2 Synthesis of additional N-substituted analogues containing the benzyl pendant 
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3.2.3 Synthesis of N-acylated analogues containing the 2-methylindanyl pendant 
Like the benzyl N-acylated series, N-acylated peptidomimetics containing the 2-
methylindanyl pendant, 97-99, were prepared in four steps starting from the dihydroquinolinone 
intermediate 6 which was subjected to acylation using either an acid anhydride or acyl chloride 
to form intermediates 91-93. Intermediates 91-93 were treated with (R)-t-butanesulfinamide and 
Ti(OEt)4 to yield imines in situ, which were reduced with NaBH4 to form the desired R-
stereochemistry of intermediates 94-96.32-34 The Ellman auxiliary was cleaved using 
concentrated HCl, forming primary amine salts, which were then coupled to diBoc-Dmt and 
subsequently deprotected to yield compounds 97-99.  
 
Scheme 3.3 Synthesis of N-acylated analogues containing the 2-methylindanyl pendant 
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3.2.4 Synthesis of N-acylated analogues containing the 2-methylnaphthyl pendant 
The N-acylated peptidomimetics containing the 2-methylnaphthyl pendant, 113-115, were 
prepared starting with the acylation of p-methylaniline using 3-bromopropionyl chloride to yield 
100. Intermediate 100 was cyclized under basic conditions to form lactam 101, and was then 
treated with TfOH to form intermediate 102. The nitrogen of 102 was protected with a tert-
butyloxycarbonyl (Boc) group forming 103. Intermediate 103 was brominated using N-
bromosuccinimide and benzoyl peroxide to yield 104 which was then subjected to Suzuki cross-
coupling to incorporate the 2-methylnaphthyl moiety and yield 105 Intermediate 105 was treated 
with TFA to remove the Boc group forming 106. Intermediate 106 was treated with propionic 
anhydride to yield 107, butyric anhydride to yield 108, or methylchloroformate to yield 109. 
Intermediates 107-109 were treated with (R)-t-butanesulfinamide and Ti(OEt)4 to form a chiral 
imine in situ which was reduced with NaBH4 to form the desired R-stereochemistry for 
intermediate 110-112. 32-34 The Ellman auxillary was cleaved using concentrated HCl forming 
primary amines which were then coupled to diBoc-Dmt and deprotected to yield compound 113-
115 (Scheme 3.4). 
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Scheme 3.4 Synthesis of N-acylated analogues containing the 2-methylnaphthyl pendant 
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3.3 Results 
Peptidomimetics 77-80, 88-90, 97-99, and 113-115 were evaluated in in vitro binding and 
efficacy assays, as described in 8.2. Select analogues were chosen for in vivo evaluation in the 
WWTW assay, as described in 8.3 (Figure 3.2). Additional analogues screened that displayed no 
in vivo activity at 10 mg /kg in the WWTW assay include the 2-methylindanyl compounds 98 
and 99 and the 2-methylnapthyl compounds 113-115. In vivo data for these compounds are not 
shown. 
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Table 3.1 Binding and Efficacy Data for Peptidomimetics with Benzyl Pendants 
 
  Binding, Ki (nM)a,c EC50 (nM)b, c % stimulation b, c 
Cpd R2 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f H 
0.22 
(0.02) 
9.4 
(0.8) 
68 
(2) 
1.6 
(0.3) 
110 
(6) 
540 
(72) 
81 
(2) 
16 
(2) 
22 
(2) 
52g 
 
0.13 
(0.02) 
1.8 
(0.1) 
87 
(11) 
6.0 
(1) 
68 
(2) 
>1300 
76 
(4) 
26 
(3) 
29 
(5) 
116h 
 
0.12 
(0.01) 
0.76 
(0.4) 
28d 
(2) 
5 
(2) 
41 
(20) 
>1300e 
90 
(7) 
58 
(6) 
14e 
117h 
 
0.10 
(0.03) 
0.41e 100e 
18 
(10) 
8.1d 
(0.9) 
>1500d 
53 
(3) 
44d 
(3) 
20d 
(3) 
77 
 
0.27 
(0.1) 
0.32 
(0.2) 
66 
(20) 
9.5 
(3) 
25 
(20) 
>1400 
90 
(6) 
52 
(2) 
35 
(10) 
118h 
 
0.10 
(0.03) 
0.35 
(0.01) 
25 
(5) 
1.8 
(0.3) 
18 
(9) 
dnsd 
82 
(4) 
70 
(10) 
dnsd 
119h 
 
0.14 
(0.09) 
0.15 
(0.07) 
41 
(20) 
2.1 
(0.20) 
5.6 
(3) 
dnsd 
94 
(5) 
66 
(10) 
dnsd 
78 
 
0.19 
(0.05) 
0.51 
(0.2) 
29 
(8) 
0.78 
(0.2) 
14 
(3) 
280 
(40) 
95 
(5) 
40 
(7) 
29 
(4) 
79 
 
0.15 
(0.04) 
2.7 
(0.7) 
34 
(4) 
3.0 
(0.5) 
67 
(20) 
>1700 
91 
(1) 
47 
(8) 
38 
(4) 
80 
 
0.08 
(0.03) 
0.24 
(0.09) 
21 
(10) 
2.6 
(0.6) 
dns 
430 
(170) 
74 
(7) 
dns 
16 
(4) 
88 
 
0.23 
(0.06) 
2.0 
(0.4) 
4.3 
(1) 
1.54 
(0.15) 
560 
(300) 
380 
(60) 
99 
(3) 
29 
(6) 
49 
(8) 
89 
 
0.24 
(0.10) 
0.58 
(0.20) 
31d 
(20) 
5.1 
(2) 
15 
(3) 
>2700d 
79 
(0.4) 
34 
(2) 
31d 
(20) 
90 
 
4.4 
(0.8) 
67 
(8) 
280 
(50) 
78 
(30) 
dns dns 
87 
(2) 
dns dns 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
en=1 independent assay in duplicate. dns: does not stimulate. fpublished in ref. 21.gpublished in ref 23. hSynthesized by Aaron Bender. 
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Table 3.2 Binding and Efficacy Data for Peptidomimetics with 2-methylindanyl Pendants 
 
  Binding, Ki (nM)a, c  EC50 (nM)b,c % stimulation b, c 
Cpd R2 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
9f H 
0.16 
(0.04) 
4.1 
(1.6) 
1.2 
(0.4) 
0.24 
(0.03) 
dns dns 
86 
(1) 
dns 
38 
(2) 
50g 
 
0.05 
(0.00) 
0.44 
(0.07) 
12 
(4) 
0.56 
(0.1) 
dns 
610 
(250) 
84 
(2) 
dns 
60 
(10) 
97 
 
0.06 
(0.01) 
0.30 
(0.1) 
340e 
2.8 
(1.7) 
dnsd 
390 
(30) 
61 
(10) 
dnsd 
27 
(0.50) 
98 
 
0.19 
(0.07) 
0.40 
(0.05) 
22 
(4) 
4.1 
(1.6) 
dnsd 
340d 
(70) 
63 
(10) 
dnsd 
16d 
(1) 
99 
 
0.10 
(0.02) 
0.32 
(0.05) 
7d 
(3) 
0.39 
(0.05) 
dnsd 
170d 
(40) 
94 
(8) 
dnsd 
26d 
(3) 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
en=1 independent assay in duplicate. dns: does not stimulate. fpublished in ref. 21.gpublished in ref 23. 
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Table 3.3 Binding and Efficacy Data for Peptidomimetics with 2-methylnaphthyl Pendants 
 
  Binding, Ki (nM)a, c  EC50 (nM)b,c % stimulation b, c 
Cpd R2 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
56e H 
0.078 
(0.007) 
10 
(2) 
54 
(7) 
0.53 
(0.08) 
dns dns 
96 
(3) 
dns dns 
54f 
 
0.04 
(0.01) 
0.23 
(0.02) 
48 
(20) 
0.93 
(0.2) 
dns dnsd 
87 
(3) 
dns dnsd 
113 
 
0.28 
(0.05) 
0.21 
(0.1) 
58 
(10) 
13 
(2) 
dns >1400 
75 
(0.50) 
dns 
15 
(3) 
114 
 
0.14 
(0.07) 
0.80 
(0.1) 
64 
(30) 
0.90 
(0.3) 
dns dns 
92 
(7) 
dns dns 
115 
 
0.32 
(0.08) 
1.0 
(0.6) 
140d 
(70) 
0.39 
(0.2) 
dnsd dnsd 
110 
(5) 
dnsd dnsd 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
dns: does not stimulate. epublished in ref. 21.fpublished in ref 23 
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Figure 3.2 Cumulative antinociceptive dose response curves of select N-substituted analogues in the mouse warm 
water tail withdrawal (WWTW) assay following ip administration.  n=3 for all analogues, plotted as average +/- 
S.E.M. ****, p < 0.0001 for 1 and 78 for the 10 mg/kg dose when compared to baseline.  
 
 
 
 
 
 
 
 
Figure 3.3  Time course of antinociception of 1 and 78 in the mouse WWTW assay following ip administration of 
10 mg/kg. n=3, plotted as average ± S.E.M 
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3.4 Discussion 
All new compounds, excluding 90, maintained subnanomolar binding affinity at MOR and 
exhibited an increased DOR binding affinity when compared to the unsubstituted parent 
compounds (1, 9, 56), presumably due to the carbonyl moiety incorporated into each of the N-
substitutions. The only exception to this trend, 90, contained a carboxylic acid moiety and had 
significantly decreased affinity across all three receptors, potentially due to electrostatic 
repulsion between the carboxylic acid moiety of the compound and a conserved Asp residue in 
TM3 (Asp128 in DOR) in the three opioid receptors. Based on these initial in vitro results, it 
appears that a carbonyl-containing moiety was beneficial to maintaining higher binding affinity 
at DOR. Conversely, a negatively charged species was not well tolerated. 
An additional trend seen in the benzyl series was that increasing the N-acyl chain length or 
overall bulk increases DOR stimulation with the exception of 80, which contained a benzoyl 
moiety and produced no stimulation at DOR. As seen in Table 3.1, the unsubstituted compound 1 
showed very weak stimulation at DOR (16%) while the N-acetyl analogue 52 increased 
stimulation at DOR to 26% and the N-propionyl (116) and N-butyryl (117) analogues further 
increased DOR stimulation to between 50-60%. Compounds 77, 118, and 119 contained 
branched or cyclic N-substitutions, and in the case of 118 (containing a cyclopropanecarbonyl 
moiety) and 119 (containing a cyclobutanecarbonyl moiety) DOR stimulation increased to 60% 
and 70%, respectively, giving both of these compounds a MOR agonist/DOR agonist in vitro 
profile. While this profile was not our initial focus, the importance of the MOR agonist/DOR 
agonist profile should be mentioned. Several reports have shown that coadministration a DOR 
agonist with a MOR agonist can increase both the potency and efficacy of the MOR agonist.41-42 
In fact, it has been shown that even subantinociceptive doses of a DOR agonist (in this case Leu-
enkephalin) could potentiate the analgesic actions of morphine.41 These findings imply ligands 
producing a mixed-efficacy MOR agonist/DOR agonist profile could allow for the effective 
management of pain with a decrease in side effects seen with the administration of only a MOR 
agonist. 
Furthermore, in the benzyl series, compounds with longer chain lengths (116), increased bulk 
(118, 119, 80), or longer chains incorporating heteroatoms (78, 79, 88, 89) displayed an 
increased affinity at KOR (Ki values ranging from 8 nM to 40 nM) when compared to 1 (Ki = 68 
nM). In particular, 88, containing an amide functionality, not only displayed increased affinity at 
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KOR (8 nM vs 68 nM for 1), it also exhibited significant KOR stimulation (49%), when 
compared to the unsubstituted 1 (22%), suggesting the possibility that hydrogen bond donors in 
this area of the binding pocket might play a role in increasing affinity and efficacy at KOR. One 
potential interaction that could play a role in the increased affinity and stimulation at KOR is 
hydrogen bonding with His54 near the N-terminus of KOR, a residue that is not conserved in 
MOR or DOR. 
Unlike the benzyl series, increasing the N-acyl chain length does not increase DOR 
stimulation in the 2-methylindanyl series. In fact, none of the compounds in the 2-methylindanyl 
series produce agonist activity at DOR. However, all analogues produce agonism at both MOR 
and KOR, as seen in Table 3.2.  As in the benzyl series, additional chain length increased affinity 
at KOR in the 2-methylindanyl series relative to 1. For example, compounds 9 (Ki =1.2 nM) , 50 
(Ki=12 nM), and 99 (Ki=7.3 nM) all have relatively high binding affinities at KOR relative to 1 
(68 nM). As mentioned, all substitutions on the 2-methylindanyl scaffold maintained various 
degrees of efficacy at KOR with 50 producing the largest agonist effect at KOR with 60% 
stimulation. With these in vitro results, the 2-methylindanyl series could serve as a starting point 
for the design and synthesis of compounds producing a MOR agonist/KOR agonist profile or 
MOR antagonist/KOR agonist profile—a profile that has implications in the treatment of cocaine 
addiction.43-46 
As the acyl chain length increases in the 2-methylnaphthyl series, the balanced-affinity MOR 
agonist/DOR antagonist profile seen with 54 remains essentially constant, while KOR affinity 
slightly decreases indicating that increased chain length helps provide MOR and DOR selectivity 
over KOR (Table 3.3). Additionally, all the compounds in the 2-methylnaphthyl series produce 
full agonism at MOR, all higher than the efficacy of morphine. Perhaps the differences in DOR 
efficacy between the benzyl and the 2-methylnaphthyl series imply that the pendant moiety could 
play an important role in orienting and anchoring the ligand in the DOR binding pocket in the 
inactive receptor conformation.  
When looking at the in vitro data as a whole it appears that various N-acyl substitutions on 
the benzyl scaffold start to alter the MOR agonist/DOR antagonist profile to a  
MOR agonist/DOR agonist profile. Additionally, the 2-methylindanyl series does not enhance 
the desired MOR agonist/DOR antagonist profile, but could potentially serve as a starting point 
for the synthesis of a series of compounds that produce a mixed-efficacy MOR agonist/KOR 
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agonist profile or a MORantagonist/KORagonist profile, as long as the MOR efficacy could be 
removed. Lastly, the 2-methylnaphthyl series appears to be the only series that maintains and 
improves the desired MOR agonist/DOR antagonist profile through enhanced selectivity for 
MOR and DOR over KOR. 
In view of the promising in vitro observations seen in the N-substituted series, 13 of the 17 
novel analogues in this series were chosen for in vivo screening (compounds 116, 117, 90, and 
97 were not selected), but only two analogues emerged as having in vivo efficacy.  Analogue 118 
produced partial antinociception with an 11 sec latency to tail flick at the 10 mg/kg dosage in the 
WWTW assay after ip administration while 78 produced full antinoception at the same dosage. 
Interestingly, while 118 (containing a cyclopropanecarbonyl moiety) produced partial 
antinociception in the WWTW assay, neither 77 (containing a isopropanecarbonyl moiety) nor 
119 (containing a cyclobutanecarbonyl moiety) produced antinociception under the same 
conditions. The in vivo results for 118 are particularly encouraging given the implications of a 
mixed-efficacy MOR agonist/DOR agonist ligand in reducing the tolerance potential seen with 
selective MOR agonists.  
Because 78 produced full antinociception at the 10 mg/kg dosage, it was submitted for 
evaluation in the in vivo WWTW time course assay. As can be seen in Figure 3.3, 78 has a 
similar duration of action to that of 1, in that produces maximal antinociception for 
approximately 1 h. This result was interesting because it suggests that the methyl carboxylate 
moiety of 78, despite blocking a potential site of metabolism, does not increase the duration of 
action. As the time course of 78 is so similar to 1, this could potentially mean that 78 is in fact 
inactive in vivo but is quickly metabolized to 1 resulting in the observed in vivo efficacy and 
duration of action of 1 h, similar to that of 1.  
Interestingly, 115, which had the most promising in vitro profile of the 2-methylnapthyl 
series, did not produce any stimulation at the 10 mg/kg dose in the WWTW assay following ip 
administration, despite having the same methyl carboxylate moiety as the fully efficacious 78. 
This particular finding supports the hypothesis that the methyl carboxylate moiety could be 
metabolically labile and might be removed in vivo resulting in the formation of compound 56, a 
compound with minimal activity at the 10 mg/kg dosage following ip administration. 
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CHAPTER 4 
 
 
Probing the steric and electronic requirements and limitations on the THQ core and in the 
pendant region with methyl-, methoxy-, and hydroxyl-containing moieties  
 
 
4.1 Introduction 
 The benzyl and 2-methylindanyl pendants, both containing numerous unsubstituted 
carbon atoms, offered a large amount of chemical space that was easily modified at one or 
multiple carbons for systematic SAR studies. Moreover, the 2-methylindanyl analogues served 
as probes for determining the spatial depth of the receptor. In this series of analogues, methyl, 
methoxy, and hydroxyl moieties were incorporated onto both the benzyl and 2-methylindanyl 
scaffolds in order to probe the area of the binding pocket where the pendant resides with the 
hopes of exploiting minor differences in the MOR, DOR, and KOR binding pockets that could 
help tailor binding and efficacy profiles (Figure 4.1, Panel B). Furthermore, a large portion of the 
N-substituted series of compounds described in Chapter 3 introduced lipophilic moieties that 
increased the cLogP and created solubility issues. An additional goal of this series was to 
improve solubility and lower cLogP to create more “druggable” compounds through 
incorporation of methoxy and hydroxyl moieties in specific locations on the THQ core, notably 
at carbon 7 (C7) and carbon 8 (C8), that did not affect binding affinity and efficacy (Figure 4.1, 
Panel A). 
 
The in vitro data was acquired chiefly by Nicholas Griggs of the Traynor Lab at the University of Michigan (Table 4.1-4.3). In addition, Tyler 
Trask, Evan Schramm, Aaron Chadderdon and Chao Gao also of the Traynor Lab made significant contributions to collecting the in vitro 
pharmacology data (Table 4.1-4.3).  Dr. Jessica Anand of the Jutkiewicz Lab at the University of Michigan is responsible for performing all of 
the in vivo assays (data not shown). The syntheses, in vitro data, and in vivo data for this series of analogues has not yet been published. 
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Figure 4.1 Methyl-, methoxy, and hydroxyl- modifications to peptidomimetics. A. Modifications to the THQ core 
and B. Modifications to the 2-methylindanyl and benzyl pendants. 
 
4.2 Design and Synthesis 
4.2.1 Synthesis of analogues with methoxy and hydroxyl moieties on the THQ core 
Syntheses of analogues containing a methoxy moiety on the THQ were straight-forward 
starting from either 4-bromo-2-methoxyaniline or 4-bromo-3-methoxyaniline. Despite the fact 
that the methoxy moieties are on the 2- or 3- position of the starting material, throughout the 
synthesis the intermediates are referred to as “-7OMe” for the 3-methoxy starting material and “-
8OMe” for the 2-methoxy starting material due to the numbering scheme on the final 
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compounds. The synthesis of analogues 134-137 began with acylation of the aniline starting 
material with 3-bromoproionyl chloride to form intermediates 120 and 121, which were 
subsequently cyclized in the presence of base to form the lactam intermediate, which was then 
treated with TfOH to form the dihydroquinolinone intermediates 124 and 125. Intermediate 124 
was boc-protected forming 126, while boc-protection of 125 was unsuccessful, most likely due 
to sterics. Instead, 125 was N-acetylated forming 127. Intermediates 125-127 were subjected to 
Suzuki coupling to form 128-130. Intermediates 128-130 were treated with (R)-t-
butanesulfinamide and Ti(OEt)4 to yield imines in situ, which were reduced with NaBH4 to form 
the desired R-stereochemistry of intermediates 131-133. The Ellman auxiliary was cleaved using 
concentrated HCl, forming primary amine salts, which were then coupled to diBoc-Dmt and 
subsequently deprotected to yield compounds 134-136 (Scheme 4.1).  
The synthesis of 137 deviated from the synthesis of its 7-methoxy analogue, 134, after 
coupling to the amine formed during the cleavage of the Ellman auxillary to diBoc-Dmt. The 
identity of the diBoc-Dmt-coupled intermediate was confirmed by mass spectrometry, but was 
otherwise not extensively characterized and thus does not have a number assigned to its identity. 
This intermediate was treated with BBr3 then quenched with MeOH to form 137 (Scheme 4.1).   
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Scheme 4.1 Synthesis of analogues containing methoxy moieties on the THQ core 
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4.2.2 Synthesis of substituted 2-methylindanyl analogues 
For the synthesis of the 2-methylindanyl analogues the pendant moiety is incorporated in the 
first step through an aldol condensation between a substituted 1-indanone and p-
nitrobenzaldeyde to yield 138-140 which were hydrogenated to yield the anilines 141-143. The 
amines in 141-143 were acylated with 3-bromopropionyl chloride to give 144-146, cyclized to 
form lactams 147-149, and then treated with TfOH to promote a Fries-Rearrangement and yield 
150-152. Intermediates 150-152 were boc-protected forming intermediates 153-155. 
Additionally, 152 was N-acetylated using Ac2O to form 156. Intermediates 153-156 were treated 
with (R)-t-butanesulfinamide and Ti(OEt)4 to yield imines in situ, which were reduced with 
NaBH4 to form the desired R-stereochemistry of intermediates 157-160. The Ellman auxiliary 
was cleaved using concentrated HCl, forming primary amine salts, which were then coupled to 
diBoc-Dmt and subsequently deprotected to yield compounds 161, 163, 164, and 165. Analogues 
162 and 164 were synthesized by using BBr3 (Scheme 4.2).  
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Scheme 4.2 Synthesis of substituted 2-methylindanyl compounds 
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4.2.3 Synthesis of the substituted benzyl analogues 
Synthesis of the methoxy- and hydroxyl- benzyl analogues began with a Suzuki coupling 
between 104 and the commercially available methoxybenzyl boronic acid to form 167-170. 
Treatment of 167-170 with (R)-t-butanesulfinamide and Ti(OEt)4 yielded imines in situ, which 
were then reduced with NaBH4 to form 171-174 with the desired R-stereochemistry at the C4 
position. The Ellman auxiliary of 171-174 was cleaved using concentrated HCl, forming the 
primary amine salts, which were then coupled to diBoc-Dmt and subsequently deprotected with 
either TFA to yield compounds 175, 177, 179, and 181, or with BBr3 to yield 176, 178, 180, and 
182 (Scheme 4.3) 
 
Scheme 4.3 Synthesis of the substituted benzyl analogues 
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4.3 Results 
Peptidomimetics 134-136, 161-166, and 175-182 were evaluated in in vitro binding and 
efficacy assays, as previously described (Tables 4.1- 4.3). Analogues chosen for in vivo 
evaluation in the WWTW assay include 134, 137, 162, and 165. None of the analogues selected 
produced in vivo activity at 10 mg/kg; data for these compounds are not shown. 
 
Table 4.1 Binding and Efficacy Data for Peptidomimetics with Methoxy and Hydroxyl Moieties on the THQ Core 
 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd R MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f H 
0.22 
(0.02) 
9.4 
(0.8) 
68 
(2) 
1.6 
(0.3) 
110 
(6) 
540 
(70) 
81 
(2) 
16 
(2) 
22 
(2) 
134 7-OMe 
0.26 
(0.09) 
2.8 
(0.8) 
8.5e 
8.0 
(3) 
110d 
(20) 
dnsd 
98 
(3) 
45d 
(10) 
dnsd 
137 7-OH 
0.33 
(0.1) 
2.7 
(0.07) 
35 
(10) 
9.9 
(4) 
680d 
(360) 
dnsd 
95 
(4) 
16 
(4) 
dnsd 
135 8-OMe 
0.24 
(0.11) 
3.1 
(1.0) 
30d 
(10) 
2.5 
(0.5) 
63 
(10) 
dnsd 
84 
(1) 
51 
(10) 
dnsd 
136 
8-OMe; 
N-acetyl 
0.14 
(0.01) 
2.2 
(1.2) 
45 
(17) 
0.78 
(0.20) 
4.6 
(2) 
>1400 
96 
(10) 
45 
(4) 
16 
(6) 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the mean 
with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. dns: does 
not stimulate. en=1 independent assay in duplicate. fpublished in ref. 21 
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Table 4.2 Binding and Efficacy Data for Peptidomimetics with Methoxy and Hydroxyl Moieties on the  
2-Methylindanyl Pendant 
 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd R MOR DOR KOR MOR DOR KOR MOR DOR KOR 
9f 
 
0.16 
(0.04) 
4.1 
(2) 
1.2 
(0.4) 
0.24 
(0.03) 
dns dns 
86 
(1) 
dns 
38 
(2) 
161 
 
0.09 
(0.0) 
4.1 
(2) 
670e 1.4e dnsd dnsd 33e dnsd dnsd 
162 
 
0.18 
(0.03) 
6.0 
(1) 
16 
(10) 
5.0 
(1) 
dnsd 
26d 
(6) 
69 
(6) 
dnsd 
94d 
(4) 
163 
 
0.26 
(0.2) 
6.2 
(2) 
830e 350e dnse nyt 11e dnse nyt 
164 
 
0.73d 
(0.0) 
20d 
(4) 
290d 
(200) 
dns dnse nyt dns dnse nyt 
165 
 
0.43 
(0.2) 
9.5 
(3) 
27 
(19) 
3.2 
(1) 
dnsd 
45d 
(20) 
92 
(8) 
dnsd 
19d 
(0.2) 
166 
 
N-acetyl 
0.03 
(0.1) 
1.0 
(0.37) 
11 
(8) 
2.1 
(2) 
dnse dnsd 
75 
(9) 
dnse dnsd 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in 
duplicate.en=1 independent assay in duplicate. dns: does not stimulate. nyt:not yet tested. fpublished in ref. 21.  
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Table 4.3 Binding and Efficacy Data for Peptidomimetics with Methoxy and Hydroxyl Moieties on the  
Benzyl Pendant 
 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd R MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f 
 
0.22 
(0.02) 
9.4 
(0.8) 
68 
(2) 
1.6 
(0.3) 
110 
(6) 
540 
(70) 
81 
(2) 
16 
(2) 
22 
(2) 
175 
 
0.34 
(0.08) 
6.5 
(2) 
56d 
(20) 
9 
(2) 
>1000e >1500d 
91 
(7) 
18e 
10d 
(1) 
176 
 
0.26 
(0.04) 
5.6 
(2) 
5.5d 
(2) 
9.8 
(4) 
>1500e 
280d 
(7) 
89 
(3) 
23e 
64d 
(2) 
177 
 
0.24 
(0.10) 
5.4 
(1) 
48d 
(20) 
4.4 
(0.6) 
>2700e dnsd 
99 
(2) 
35e dnsd 
178 
 
0.19 
(0.02) 
1.40 
(0.17) 
16d 
(4) 
4.8 
(0.4) 
380d 
(200) 
280d 
(60) 
96 
(5) 
72d 
(6) 
17d 
(2) 
179 
 
0.41 
(0.14) 
16d 
(0.4) 
130d 
(50) 
10d 
(3) 
dnse dnse 
54d 
(4) 
dnse dnse 
180 
 
1.0e 170e 740e dnsd dnse dnse dnsd dnse dnse 
181 
 
1.6d 
(0.3) 
38e 210e dnsd dnse dnse dnsd dnse dnse 
182 
 
1.5d 
(0.1) 
90e 110e dnsd dnse dnse dnsd dnse dnse 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
en=1 independent assay in duplicate. dns: does not stimulate. fpublished in ref. 21. 
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4.4 Discussion 
Of the three subsets of analogues, the methoxy and hydroxyl substitutions on the THQ core 
appeared to affect the affinity and efficacy the least across all three opioid receptors when 
compared to 1. Even in going from the 7-methoxy (134) to 7-hydroxyl analogue (137), when a 
hydrogen bond donor was introduced, the binding and affinity data are very similar (Table 4.1). 
The only minor trend seen was the slight increase in DOR stimulation with the addition of the 
oxygenated substituent at both C7 and C8, with the methoxy-containing analogues 134-136 
increasing stimulation more than the hydroxyl-containing analogue 137 (Table 4.1). As indicated 
in the previous chapter, the high DOR potency of 136 can be attributed to the N-acetyl 
substitution. Since substitutions in these positions did not greatly affect the binding affinity at 
MOR and DOR relative to 1, substitutions at either C7 or C8 could serve as an ideal means to 
incorporate smaller R-groups with the intention of increasing bioavailability through blocking a 
site of metabolism or altering the hydrophilic and hydrophobic balance to help analogues 
penetrate the BBB.  
In the 2-methylindanyl subset, none of the analogues 161-166 significantly altered MOR and 
DOR binding affinity relative to 9, but most of the substituted 2-methylindanyl compounds 
significantly decreased affinity at KOR (Table 4.2), again relative to 9. However, an even more 
striking effect seen with the substituted 2-methylindanyl series was the reduction or elimination 
of efficacy at MOR seen with most of the methoxy- and hydroxyl-containing analogues. When 
compared to 9, 161 decreased efficacy at MOR 3-fold (from 86% to 33%) while 162 (the 
hydroxyl analogue of 161) recovered most of the efficacy lost by 161 with 70% stimulation at 
MOR. Additionally, analogues 163 and 164 completely eliminate MOR efficacy, creating a high 
affinity antagonist profile at MOR. 
The methoxy- and hydroxyl- substituted benzyl subset offers quite a bit of insight into the 
electronic limitations and requirements in the pendant binding region of the receptors. First and 
foremost, binding affinities at MOR and DOR for 175-178 remain unchained with the addition of 
a methoxy or hydroxyl moiety relative to 1 (Table 4.3). Binding affinity at KOR increased for 
both 176 with the o-OH (5.5 nM) and 178 with the m-OH (16.40 nM) relative to 1 (68 nM) and 
their corresponding methoxy analogues, 175 (56 nM) and 177 (48 nM), respectively. This 
observation implicates the importance of a hydrogen bond donor, rather than an acceptor, in this 
area of the binding pocket of KOR. Compounds 175 and 176 with ortho- substituents maintained 
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a similar low efficacy profile at DOR when compared to 1 (16%), while an increase in DOR 
stimulation was seen with 177 (35%) and 178 (72%), both with meta-substituents. Although 175-
178 produced varying levels of agonist activity at DOR, these analogues had low potency at 
DOR as indicated by the high EC50 values. In addition, both 176 and 178 displayed an increase 
in agonist activity at KOR, compared to their methoxy counterparts, with 176 producing 64% 
stimulation at KOR, implicating the role of a hydrogen bond donor in KOR efficacy. Analogues 
179-182 all contain a p-substituent, which appeared to be the primary factor in the noteworthy 
decrease in binding affinity across all three receptors relative to 1 (Table 4.3). Additionally, the 
incorporation of a p-substituent completely abolishes efficacy at MOR, DOR, and KOR, with the 
exception of 179 which maintains 54% stimulation at MOR. This observation with the  
p-methoxy and p-hydroxyl analogues aligns with the results from the 2-methylindanyl subset 
where a 4-methoxy moiety on the 2-methylindanyl pendant significantly decreases MOR 
efficacy while the 5-methoxy and 5-hydroxyl moieties completely eliminate MOR efficacy 
(Table 4.2). Another interesting observation is that both 162 and 176 display relatively high 
binding affinity and efficacy at KOR when compared to 1, most likely due to the fact that the 
hydroxyl moiety on both of these analogues occupies the same area of the KOR receptor.  
Overall, this SAR campaign showed that small modifications on the THQ core are tolerated 
indicating that substitutions at these locations (C7 and C8) could be used as a strategy to 
incorporate small moieties to subtly increase bioavailability or BBB penetration. Additionally, 
hydroxyl and methoxy substituents that extend deep into the pendant binding pocket (like the 5-
substituted 2-methylindanyl and p-substituted benzyl series) are not well tolerated in that they 
either decrease binding affinity or efficacy at MOR or decrease both. Lastly, KOR affinity is 
increased with hydroxyl moieties for the o- and m- hydroxyl substituted analogues as well as the 
4-substituted 2-methylindanyl analogue, while the m-hydroxyl significantly increases KOR 
efficacy. 
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CHAPTER 5 
 
 
Effects of Stereochemistry on Binding Affinity and Efficacy 
 
 
5.1 Introduction 
 It is understood that because nearly all of the opioid receptor ligands from the 
endogenous peptides to the small-molecule peptides to the morphine-like analogues incorporate 
specific stereocenters at multiple locations, that stereochemistry plays an important role on 
binding and efficacy. In fact, multiple reports have shown that switching from an L- to D- amino 
acid in an opioid peptide ligand can drastically alter the binding affinity profiles.47-49 For this 
reason, incorporation of a stereocenter on the aliphatic carbons on the THQ and THN cores was 
pursued to probe the effects that stereochemistry has on the binding and efficacy of the 
peptiomimetic ligands (Figure 5.1).  
 
 
Anthony Nastase of the Mosberg lab synthesized compound 209. The in vitro data was acquired chiefly by Nicholas Griggs of the Traynor Lab at 
the University of Michigan (Table 5.1). In addition, Tyler Trask, Evan Schramm, Aaron Chadderdon and Chao Gao also of the Traynor Lab made 
significant contributions to collecting the in vitro pharmacology data (Table 5.1).  Dr. Jessica Anand of the Jutkiewicz Lab at the University of 
Michigan is responsible for performing all of the in vivo assays (data not shown). The syntheses, in vitro data, and in vivo data for this series of 
analogues has not yet been published. 
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Figure 5.1 Structures of the peptidomimetics containing various stereo-specific moieties 
 
5.2 Design and Synthesis 
First and foremost, it should be noted that when numbering a THQ core, the nitrogen atom is 
designated as atom one (N1) (Figure 5.1), Conversely, in the conventional numbering system for 
a THN core, the carbon atom taking place of N1 is not technically deemed carbon 1 (C1). 
However, for consistency and clarity, the substituted THN analogues discussed are described as 
having “C1”-substitutions (Figure 5.1).  
The synthesis of 191 (with the 2R-methyl) was the only synthesis that was completed 
asymmetrically (Scheme 5.1) and was designed to probe a specific amino acid difference across 
MOR, DOR and KOR (Figure 5.2). The intention was to design a ligand with methyl at the C2 
position that could favorably interact with Trp284 of DOR and potentially with the aliphatic 
portion of Lys303 in MOR, while either not interacting much with Glu297 of KOR or interacting in 
such a way that further reduced binding affinity at KOR. The 2R-methyl was chosen instead of 
the S-methyl for this particular analogue because it was hypothesized that the downward-
pointing S-methyl would be too far away from the specific residues that were being probed. 
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Figure 5.2 Compound 1 docked in MOR with an overlay of non-conserved residues among MOR, DOR, and KOR 
 
The other analogues in this series were not designed to exploit specific amino acid residue 
differences among the three receptors. Instead, they were synthesized with the intention of 
probing whether the stereochemistry at these locations on the ligand produced any significant 
changes in the affinity and efficacy profiles across MOR, DOR, and KOR.  
Although the syntheses of the remaining compounds in the series were not completed 
asymmetrically, diastereomers were separated at a late stage intermediate. Furthermore, the 
amine intermediate 199 (Scheme 5.2.2) in the synthesis of the 3(R/S)-methyl compounds, was 
crystallized to and submitted for X-ray crystallography to determine the stereochemistry of the 
methyl at C3 to be R. Lastly, the stereochemistry of the “C1”-methyl analogues remains 
unknown, however the final diastereomeric mixture was separable by HPLC.  
 
 
 
 
C2 to Lys303 (MOR) = 6.8 Å 
C2 to Trp284 (DOR) = 8.4 Å 
C2 to Glu297 (KOR) = 5.5 Å 
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5.2.1 Synthesis of the 2R-methyl THQ analogue 
The synthesis of 191, began with chemistry developed by the Davies group50 the 
incorporation of a chiral auxiliary in the second step, which will set the R-stereochemistry for the 
2R-methyl (Scheme 5.1). In the first step, p-methoxyphenol was deprotonated in the presence of 
base followed by the addition of the acid chloride to form 183. Additionally, benzyne was 
formed in situ from the silylaryl triflate which then undergoes nucleophilic attack by an aryl 
amine to form 184. Deprotonation of N-substituted aniline intermediate using n-Butyllithium led 
to the formation of the lithium amide which was added to compound 184 to form 185. 
Saponification of 185 leads to the carboxylic acid intermediate which is immediately cyclized 
with polyphosphoric acid (PPA) to form 186. Treatment of 186 with NBS selectively brominates 
in the 6 position to form 187, which is then Boc protected forming 188, and coupled to the 
benzyl boronic pinacol ester to form 189. Treatment of 189 with (R)-t-butanesulfinamide and 
Ti(OEt)4 yields an imine in situ, which is then reduced with NaBH4 to form the desired R-
stereochemistry at position 4 of intermediate 190.32-34 The Ellman auxiliary of 190 is cleaved 
using concentrated HCl, forming the primary amine salt, which is then coupled to diBoc-Dmt 
and subsequently deprotected to yield compound 191, with R-stereochemistry at both C2 and C4. 
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Scheme 5.1 Synthesis of the 2R-methyl, “C2-methyl” THQ analogue 
 
5.2.2 Synthesis of the 3R- and 3S-methyl THQ analogues 
The synthesis of 201 and 202 began with an SN2 reaction between aniline and methyl (R)-3-
bromo-2-methylpropanoate to form 192, which was saponified and cyclized to form racemized 
193. Intermediate 193 was brominated, boc-protected, then coupled to benzyl boronic pinacol 
ester to form 196. Treatment of 196 with (R)-t-butanesulfinamide and Ti(OEt)4 yielded an imine 
in situ, which was then reduced with NaBH4 to form the desired R-stereochemistry at the C4 
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position. The introduction of the chiral Ellman moiety produced a set of diastereomers which 
were separable via flash column chromatography, thus forming 197 and 198. The Ellman 
auxiliary of 197 and 198 was cleaved using concentrated HCl, forming the primary amine salts 
199 and 200, which were then coupled to diBoc-Dmt and subsequently deprotected to yield 
compounds 201 and 202. 
 
Scheme 5.2 Synthesis of the 3R/S-methyl THQ analogues 
 
5.2.3 Synthesis of the “C1”-methyl THN analogues 
The syntheses for the three “C1”-substituted analogues begins with a Friedel crafts acylation 
reaction between benzene and a racemic mixture of valerolactone 203, which was then 
brominated forming 204. Next, Suzuki coupling with the benzyl pinacol boronic ester yielded 
205, which was treated with (R)-t-butanesulfinamide and Ti(OEt)4 to yield an imine in situ, 
which was reduced with NaBH4 to form the desired R-stereochemistry of intermediates 206. The 
introduction of a new chiral moiety produced a set of diastereomers for intermediate 206. 
 
 
71 
 
However, these diastereomers were inseparable via flash column chromatography and also via 
semi-preparative HPLC; Thus, 206 was carried forward as a mixture of diastereomers. The 
Ellman auxiliary on 206 was cleaved using concentrated HCl, forming primary amine salts, 
which were then coupled to diBoc-Dmt and subsequently deprotected to yield compounds 207 
and 208. The previously inseparable diastereomeric mixture (diastereomers of 217) was 
separable by semi-preparative HPLC at this final stage yielding 219 and 220, however the 
stereochemistry remains unknown.  
 
Scheme 5.3 Synthesis of “C1”-methyl THN analogues 
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5.3 Results 
Peptidomimetics 191, 201, 202, 207, and 208 were evaluated in in vitro binding and efficacy 
assays, as described in 8.2. Analogues chosen for in vivo evaluation in the WWTW assay, as 
described in 8.3, include 201 and 208. Neither analogue produced in vivo activity at 10 mg/kg.; 
data for these compounds are not shown. 
Table 5.1 Binding and Efficacy Data for Peptidomimetics with Chiral Moieties 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd Core MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f 
 
0.16 
(0.04) 
4.1 
(2) 
1.2 
(0.4) 
0.24 
(0.03) 
dns dns 
86 
(1) 
dns 
38 
(2) 
191 
 
1.24 
(0.50) 
87d 
(60) 
240d 
(20) 
8.9 
(4) 
630 
(90) 
>4000 
88 
(2) 
45 
(8) 
29 
(10) 
201 
 
0.75 
(0.03) 
2.0 
(0.2) 
13 
(5) 
6.0 
(1) 
15 
(8) 
750 
(280) 
75 
(13) 
16 
(3) 
27 
(4) 
202 
 
270e 390 e 
130d 
(20) 
550e dnse dnse 44e dnse dnse 
68 
 
0.045 
(0.03) 
4.0 
(1) 
19  
(7) 
2.9 
(0.6) 
dns Dns 
64 
(9) 
dns dns 
207 
 
0.08 
(0.02) 
5.9 
(0.6) 
nyt 
16 
(2) 
dns >1300e 
72 
(4) 
dns 60e 
208 
 
0.32 
(0.10) 
16 
(5) 
nyt dnsd 
110 
(80) 
>3100e dnsd 
14 
(4) 
62e 
209g 
 
0.36 
(0.08) 
6.5 
(0.7) 
nyt 
16 
(5) 
>1000 >1700d 
75 
(4) 
16 
(3) 
75d 
(3) 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
en=1 independent assay in duplicate. dns: does not stimulate. nyt: not yet tested. fpublished in ref. 21.gSynthesized by Tony Nastase 
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5.4 Discussion 
As can be seen by the data, stereochemistry at positions 1, 2, and 3 on the THQ or THN core 
appear to significantly affect the binding and efficacy of the peptidomimetics. As mentioned, it 
was reasoned that the upward-pointing R-methyl at the C2 (referred to as 2R-methyl from this 
point forward) position could favorably interact with Trp284 of DOR and potentially with the 
aliphatic portion of Lys303 in MOR, while either not interacting much with Glu297 of KOR or 
interacting in such a way that KOR further reduce binding affinity at KOR. However, as the data 
suggests (Table 5.1), the 2R-methyl moiety (191) decreased affinity across all three receptors 
relative to 1. This decrease in affinity could be due to a conformational change in the aliphatic 
portion of the THQ ring induced by the 2R-methyl that causes clashing between the ligand and 
the receptors. In other words, the 2R-methyl is essentially too close to the residues to form any 
favorable interactions and instead forces the ligand to shift within the receptors, thereby 
disrupting the binding system and decreasing affinity.  While synthesis of the 2S-methyl 
analogue has not yet been completed, this analogue will help determine if small substitutions are 
tolerated at the C2 position, and if tolerated, which stereochemistry, if any, yields tighter 
binding. 
When comparing compounds 201 (3R-methyl) and 202 (3S-methyl) with each other, 201 
displays a significantly better binding affinity profile (Ki = 0.75 nM at MOR, 2.0 nM at DOR, 13 
nM at KOR) than 202 (Ki = 270 nM at MOR, 390 nM at DOR, 130 nM at KOR). Additionally, 
202 reduces MOR efficacy to 44%, whereas MOR efficacy for 201 remains high at 75%. The 
most reasonable explanation for these stark differences is steric clashing between the 3S-methyl 
and residues in MOR, DOR, and KOR. Figure 5.3 shows a representation of potential steric 
clashing that could occur between all three ORs and the C3 methyls of both 201 and 202, where 
the spheres represent the spatial volume of the moieties that might sterically clash. As can be 
seen, the volume sphere of upward-pointing 3S-methyl of 202 overlaps more with residues in 
MOR, DOR, and KOR than the downward-pointing 3R-methyl of 201, suggesting the higher 
probability of the 3S-methyl to clash with receptor residues thus resulting in weaker binding. 
Additionally, 201 and 1 have similar binding profiles at MOR and DOR, indicating that smaller 
substituents at the C3 position with the downward-pointing, R-stereochemistry can be 
accommodated in these receptors. Furthermore, compound 201 showed 10-fold lower binding 
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affinity than 1 at KOR, improving upon the high affinity MOR and DOR binding profile desired 
for MOR agonist/DOR antagonist ligands. 
 
Figure 5.3 Overlay of 201 and 202 in MOR, DOR, and KOR. A. MOR (grey), B. DOR (green) C. KOR (tan). 201  
is magenta and 202 is cyan  in A-C.  
  
Compounds 207-209 represent an interesting subset of analogues. The binding affinities for 
207-209 at MOR and DOR are similar to each other and to 1, indicating that a methyl or gem-
dimethyl substituent at the “C1” position is tolerated in these binding pockets. The most 
remarkable difference seen was that 207 is a full agonist at MOR while 208 was an antagonist at 
MOR. Meanwhile, 209 with the gem-dimethyl moiety maintained MOR efficacy. These data 
have two implications (1) the stereochemistry at “C1” of the mono methyl compounds 207 and 
208 plays a significant role in maintaining MOR efficacy, (2) the gem-dimethyl moiety must 
adjust the conformation of the ligand in the receptor in such a way the MOR efficacy can be 
maintained, despite the presence of both an “R-methyl” and an “S-methyl” component in the 
gem-dimethyl moiety. Computational modeling of the “C1”S-methyl (methyl group pointing 
downward), the “C1”R-methyl  (methyl group pointing upward), and the gem-dimethyl 
compound was completed. To create the images in Figure 5.4, residues within a 5 Å radius of the 
A B C 
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methyl moiety were first selected, then distances between the residues and the methyl moieties 
were measured. For both compounds, the distance between the methyl moiety and Lys303 had the 
shortest measurement ranging between 2.2 Å for the “C1”R-methyl (Figure 5.4, Panel A) and 3.2 
Å for the “C1”S-methyl (Figure 5.4, Panel B). As the modeling depicts, the S-methyl group 
appears to point down and inward, thereby potentially avoiding interaction with Lys303 in MOR 
in both the active and inactive conformations as indicated by the lack of overlap of the spatial 
volume spheres. In contrast, the R-methyl group points upward and might interact with Lys303 in 
MOR, helping to secure the receptor in the inactive conformation, aiding in the elimination of 
MOR efficacy. As for compound 209 with the gem-dimethyl moiety, the modeling does not 
provide enough insight into how or why this compound retains MOR efficacy, as it appears to 
interact with the Lys303 residue (Figure 5.4 C).  However, one potential hypothesis for the 
retained efficacy at MOR for 209 is that the potency of the MOR agonist activity of 207 is high 
enough to overcome the MOR antagonist activity of 208. Specifically, the presence of the 
upward pointing methyl in the gem-dimethyl moiety is sufficient to produce agonist activity at 
MOR despite the presence of a moiety that produces MOR antagonist activity. 
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Figure 5.4 Overlay of MOR in the active (MORa) and inactive (MORi) confirmations with 207, 208, 209 docked. 
A. MORa (grey) and MORi, tan) with the “C1”S-methyl ligand (magenta), B. the “C1”R-methyl ligand (cyan, B), 
and C. 220 (yellow). Spheres represent spatial volume of methyl moieties and the amine moiety of Lys303 in MOR.  
 
 
A 
B 
C 
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In conclusion, stereochemistry of methyl groups around the THQ and THN role play a 
significant role in binding affinity and efficacy at all three opioid receptors. Based on the in vitro 
data from this study and the computational modeling, it seems that “downward-pointing” 
stereochemistry appears to be tolerated more so than “upward-pointing” stereochemistry. 
However, to confirm this hypothesis the 2S-methyl analogue must be synthesized and the 
stereochemistry of the “C1” methyl analogues must be confirmed. 
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CHAPTER 6 
 
Integrating fluorine to increase bioavailability 
 
 
 
6.1 Introduction 
Although fluorine is a small atom with a van der Waals radius of 1.47 Å, which is only 
marginally larger than that of hydrogen (1.2 Å), the high electronegativity (3.98 on the Pauling 
electronegativity scale) creates a highly polarized C-F bond.51 When designing analogues, these 
particular properties of fluorine can be exploited in order to design analogues where a hydrogen 
atom is replaced by a fluorine without considerable consequences. In fact, incorporation of 
fluorine atoms is a common medicinal chemistry practice that often alters the physical properties 
of neighboring substituents such that an increase potency can be observed.52 For example, in the 
case of a fluorine proximal to basic amine, the electronegativity of the fluorine can reduce the 
basicity of the amine ultimately resulting in better permeability and bioavailability.53,54 
Additionally, strategic introduction of fluorine atoms, especially on electron-rich aromatic rings, 
has been shown to block metabolic oxidation processes associated with labile hydrogen 
atoms.51,54 The blocking of sites of metabolic oxidation could ultimately lead to a longer duration 
of action since the compound will not be metabolized and excreted as easily.  In pursuit of more 
bioavailable molecules, a series of fluorine-containing analogues was synthesized (Figure 6.1). 
In each of these analogues, fluorine was introduced on either the pendant benzyl moiety or the 
aromatic portion of the THQ core. In particular, the 8-fluoro compounds were pursued because if 
shown to produce in vivo activity, the fluorinated THQ core could be easily modified during the 
synthesis to incorporate other pendants.  
Dr. Kate Kojiro and Dr. Yafei Jin of the Vahlteich Medicinal Chemistry Core synthesized 227. The in vitro data was acquired chiefly by Nicholas 
Griggs of the Traynor Lab at the University of Michigan (Table 6.1). In addition, Tyler Trask, Evan Schramm, Aaron Chadderdon and Chao Gao 
also of the Traynor Lab made significant contributions to collecting the in vitro pharmacology data (Table 6.1).  Dr. Jessica Anand of the 
Jutkiewicz Lab at the University of Michigan is responsible for performing all of the in vivo assays. The syntheses, in vitro data, and in vivo data 
for this series of analogues has not yet been published. 
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Figure 6.1 Fluorinated peptidomimetics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
6.2 Design and Synthesis 
6.2.1 Synthesis of fluorinated benzyl pendant analogues 
Synthesis of the fluorinated pendant analogues began with a Suzuki coupling between 116 
and the commercially available fluorinated boronic acids to form 222 and 223. Treatment of 222 
and 223 with (R)-t-butanesulfinamide and Ti(OEt)4 yields imines in situ, which are then reduced 
with NaBH4 to form 224 and 225 with the desired R-stereochemistry at the C4 position. The 
Ellman auxiliary of 224 and 225 was cleaved using concentrated HCl, forming the primary 
amine salts, which were then coupled to diBoc-Dmt and subsequently deprotected to yield 
compounds 226 and 227. 
 
Scheme 6.1 Synthesis of fluorinated benzyl pendant analogues 
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6.2.2 Synthesis of 8-fluoro THQ analogues 
Synthesis of the 8-fluoro analogues began with with acylation of the aniline starting material 
with 3-bromoproionyl chloride to form intermediate 216, which was subsequently cyclized in the 
presence of base to form the lactam intermediate 217, which was then treated with TfOH to form 
the dihydroquinolinone intermediate 218. Intermediate 218 was boc-protected forming 219, then 
subjected to Suzuki coupling to form 220. Intermediate 220 was treated with TFA to remove the 
boc group, then treated with Ac2O to form 222. Intermediates 220 and 222 were treated with (R)-
t-butanesulfinamide and Ti(OEt)4 to yield imines in situ, which were reduced with NaBH4 to 
form the desired R-stereochemistry of intermediates 223 and 224. The Ellman auxiliary was 
cleaved using concentrated HCl, forming primary amine salts, which were then coupled to 
diBoc-Dmt and subsequently deprotected to yield compounds 225 and 226 (Scheme 6.2).  
 
Scheme 6.2 Synthesis of 8-fluoro THQ analogues 
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6.3. Results 
Peptidomimetics 214, 215, and 225-226 were evaluated in in vitro binding and efficacy 
assays, as previously described (Tables 4.1- 4.3). All analogues (214, 215, and 225-227) in this 
series were chosen for in vivo evaluation in the WWTW assay (Figure 6.2). Compounds 214, 
215, and 225 produced full antinociception at a 10 mg/kg dosage following ip administration. 
 
Table 6.1 Binding and Efficacy Data for Peptidomimetics with Fluoro Substitutions 
 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd R1 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
1f 
 
0.22 
(0.02) 
9.4 
(0.8) 
68 
(2) 
1.6 
(0.3) 
110 
(6) 
540 
(70) 
81 
(2) 
16 
(2) 
22 
(2) 
214 
 
0.61 
(0.3) 
4.2d 
(2) 
22 
(8) 
3.8d 
(0.60) 
50 
(20) 
240e 
75 
(3) 
33d 
(10) 
22e 
215 
 
1.1 
(0.5) 
2.5d 
(1.2) 
13 
(5) 
3.5d 
(0.8) 
410d 
(150) 
390d 
(30) 
100d 
(2) 
35d 
(1) 
39d 
(2) 
227g 
 
Results pending 
 
  Binding, Ki (nM)a,c EC50 (nM)b,c % stimulationb,c 
Cpd R1 MOR DOR KOR MOR DOR KOR MOR DOR KOR 
225 H 
0.12d 
(0.01) 
3.0d 
(0.5) 
7.5d 
(1) 
1.6 
(0.20) 
340d 
(200) 
370d 
(8) 
94 
(3) 
26d 
(2) 
38d 
(0.2) 
226 
 
0.16d 
(0.02) 
1.1d 
(0.4) 
35d 
(2) 
1.4 
(0.2) 
79d 
(10) 
890d 
(70) 
99 
(3) 
48d 
(6) 
50d 
(1) 
aBinding affinities (Ki (nM)) were obtained by competitive displacement of radiolabeled [
3H]diprenorphine in membrane preparations. 
bEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding. Efficacy is represented as percent maximal 
stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. cAll values are expressed as the 
mean with S.E.M. in parentheses for n=3 independent assays in duplicate, unless otherwise noted. dn=2 independent assays in duplicate. 
en=1 independent assay in duplicate. dns: does not stimulate. fpublished in ref. 21. gSynthesized by Kate Kojiro. 
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Figure 6.2 Cumulative antinociceptive dose response curves of select fluorinated analogues in the mouse WWTW 
assay following ip administration. n=3 for all analogues, plotted as average +/- S.E.M. ****, p < 0.0001 for 1, 214, 
215, and 225 for the 10 mg/kg dose when compared to baseline.  
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6.4 Discussion 
As expected, the fluorinated analogues produced in vitro profiles similar to that of compound 
1. All analogues maintain subnanomolar binding affinity at MOR and nanomolar affinity at 
DOR. However, like 1 which produces 16% stimulation at DOR and 22% stimulation at KOR, 
all fluorinated analogues not only produce full agonism at MOR, but also varying degrees of 
partial agonism at DOR (26-48%) and KOR (22-50%). Preliminary in vivo results show that 
compounds with an o-fluoro and a m-fluoro produce full in vivo activity in the WWTW assay at 
the 10 mg/kg dose, whereas compound 227 with the p-fluoro is inactive in vivo. Moreover, 225 
with an 8-fluoro moiety is active in vivo, but the N-acetylated version (236) is not. Unfortunately, 
the data does not indicate whether the incorporation of a fluorine atom increased the in vivo 
bioavailability because 1 was already shown to produce in vivo activity and the additional non-
acetylated, fluorinated analogues 214, 215, and 225 also produced in vivo activity. Additionally, 
the N-acetylated version of 1 (compound 52) produced no in vivo activity, and nor did 226 (the 
N-acetylated, 8-fluoro compound). Additional, N-acetylated analogues of 214, 215, and 227 
(with the o-, m-, and p-fluoro benzyl pendants, respectively) could aid in understanding whether 
the addition of a fluorine atom could effectively alter the in vivo activity of a compound from 
inactive to active. Furthermore, subtle changes to the basicity of the nitrogen in the THQ core 
and how this basicity might play a role in bioavailability could be explored with an analogue 
incorporating a fluorine in the 7 position on the THQ core, especially when compared to the 8-
fluoro analogue 225. Lastly, time course studies are planned to determine if the addition of a 
fluorine atom in compounds 214, 215, and 225 increases the duration of action of the in vivo 
activity relative to 1.  
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CHAPTER 7 
 
Conclusions 
 
 
 
7.1 Summary 
When considering all the in vitro and in vivo data across the multiple series of 
peptidomimetics, a few general conclusions about the opioid receptor peptidomimetic 
pharmacophore can be made. First and foremost, N-acetylation of the THQ nitrogen results in an 
increase in DOR binding affinity, regardless of pendant moiety. This increase in affinity is likely 
due to an interaction between the carbonyl of the acetyl group and a tyrosine residue in one of 
the transmembrane helices of DOR. In contrast, DOR efficacy does appear to be somewhat 
dependent on the pendant moiety. For example, N-acetylated compounds with larger pendants 
(1- and 2-methylnaphtyhl and 1- and 2-methylindanyl moieties) do not produce any DOR 
stimulation in vitro, whereas N-acetylated compounds with smaller pendants (benzyl and 
methylcyclohexyl) produce partial DOR agonism in vitro. This implies that the pendants might 
play a role in orienting the ligand in the receptor such that DOR is locked in the inactive 
conformation with the larger pendants, resulting in loss of DOR stimulation. Furthermore, all N-
acylated compounds bind to MOR and DOR with subnanomolar binding affinity, excluding the 
carboxylic acid-containing analogue, indicating that this area of the binding pocket across in both 
MOR and DOR is large and accommodating of several different moieties. Most N-acylated 
compounds with the benzyl pendant produce partial DOR stimulation, excluding the benzoyl 
analogue; however, N-acylated analogues with the 2-methylnaphthyl or 2-methylindanyl pendant 
do not produce any DOR stimulation regardless of chain length. This finding further supports the 
hypothesis that the larger pendants could help lock the peptidomimetic in the inactive 
conformation of DOR. KOR affinity and efficacy is more varied across the N-acylated series, 
especially with the analogues containing the benzyl pendant, implying that ligands exhibiting 
 
 
86 
 
KOR affinity and efficacy could be designed and optimized through SAR at this site of the 
peptidomimetic core.   
Another observation is that smaller moieties, such as a methoxy and hydroxyl groups, on C7 
or C8 of the THQ core do not considerably alter the binding and efficacy profiles at MOR, DOR, 
and KOR, relative to the parent peptidomimetic, 1. In contrast, introduction of methoxy and 
hydroxyl groups onto the 2-methylindanyl and benzyl pendants significantly affects binding and 
efficacy profiles. Methoxy and hydroxyl moieties on the 2-methylindanyl pendant tend to 
significantly decrease or eliminate MOR efficacy, with the exception of compound 162. 
Additionally, compounds with o- or m- methoxy or hydroxyl on the benzyl pendant still 
produced high MOR stimulation, but the p-methoxy and hydroxyl analogues eliminated all MOR 
efficacy, with the exception of analogue with the p-methoxy, 179, which reduced MOR efficacy 
to 54% but did not completely eliminate it. Given the methoxy and hydroxyl data, it appears that 
p- methoxy and p-hydroxyl moieties on the benzyl pendant, or analogues containing a methoxy 
or hydroxyl in this same spatial area, are not tolerated and result in elimination of MOR efficacy. 
While chiral moieties around the THQ and THN cores results in disparate binding affinities 
between the resulting diastereomers, chiral groups at the “C1”, C2, and C3 positions are not 
necessary for binding and efficacy or for in vivo activity. However, R-stereochemistry at C4 is 
important and necessary for maintaining high affinity binding for the peptidomimetic series. 
Addtionally, in vitro data for fluorinated peptidomimetics suggests that the integration of a 
fluorine atom into the peptidomimetic scaffold does not significantly alter the in vitro binding 
and efficacy profile, relative to 1. Three of five fluorinated analogues are active in vivo which 
has promising implications. Pending the results of an additional time course assays, the 
fluorinated analogues could have a longer duration of action than 1 in vivo indicating that the 
fluorine atom could be reducing the basicity of the THQ amine or blocking a site of metabolism, 
or both.  
Of all peptidomimetics synthesized, 39 were screened in the in vivo WWTW assay. Of those 
39 analogues screened, five novel analogues were active in vivo (Table 7.1). All compounds 
active in vivo, excluding 54, produce some degree of DOR agonism in vitro, and in the case of 
237, a relatively high affinity for KOR. Additionally, this compound set ranges in molecular 
weights from 430-522 with cLogP values from 3.7-4.5, implying that neither molecular weight 
nor cLogP are good predictors of in vivo activity with these peptidomimetic compounds.  
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Table 7.1 Summary of Data for Compounds that Produce In Vivo Activity 
Cpd Structure MW cLogP 
In Vitro 
profile 
(Ki (nM), % stim) 
In Vivo 
Profile 
1 
 
430 3.7 
MOR: 0.22, 81% 
DOR: 9.4, 16% 
KOR: 68, 22% 
Full antinociception 
1 h 
54 
 
522 4.5 
MOR: 0.04, 87% 
DOR: 0.23, dns 
KOR: 48, dns 
Full antinociception 
>3 h 
no development of 
chronic tolerance 
78 
 
488 3.8 
MOR: 0.19, 95% 
DOR: 0.51, 40% 
KOR: 29, 29% 
Full antinociception 
214 
 
448 3.9 
MOR: 0.61, 75% 
DOR: 4.2, 33% 
KOR: 22, 22% 
Full antinociception 
215 
 
448 3.9 
MOR: 1.1, 100% 
DOR: 2.5, 35% 
KOR: 13, 39% 
Full antinociception 
225 
 
448 4.2 
MOR: 0.12, 95% 
DOR: 3.0, 26% 
KOR: 7.5, 38% 
Full antinociception 
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Figure 7.2 Structure of 54 
 
Finally, out of the set of active compounds, 54 has nearly balanced MOR and DOR affinities 
(Ki = 0.04 nM and 0.23 nM, respectively, resulting in a 6-fold preference for MOR over DOR), 
200-fold selectivity for MOR and DOR over KOR, and superior in vitro MOR agonist/DOR 
antagonist profile as it is the only compound that does not produce any DOR stimulation and in 
fact acts as an antagonist at DOR when screened against DPDPE. Furthermore, 54 has an in vivo 
duration of action for over 3 h following ip administration of a 10 mg/kg dosage, which is similar 
duration of action to that of morphine at the same dosage. However, unlike morphine, 54 does 
not produce tolerance upon chronic administration. With this profile, 54 represents a promising 
lead candidate for the design of bioavailable mixed-efficacy MOR agonist/DOR antagonist 
ligands that provide the desired analgesic effects but with a reduced risk of producing tolerance 
and dependence.  
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7.2 Future directions 
The in vitro and in vivo data for this complete set of peptidomimetics opens several avenues 
for future directions. First, synthesis of the 2S-methyl THQ analogue should be completed in 
addition to determining the stereochemistry of analogues 207 and 208 (Figure 7.1, Panel A). In 
vitro results from the 2S-methyl will elucidate which stereochemistry, if any, is preferred at the 
C2 position. Additionally, determining the stereochemistry of the “C1”-methyl compounds will 
provide additional insight into which stereochemistry results in MOR agonist activity. Based on 
the in vitro data and computational modeling of the incomplete chiral-methyl containing series of 
peptidomimetics, it could be reasoned, that all stereochemistry that results in a “downward-
pointing” methyl group would be better tolerated in the receptors relative to the “upward-
pointing” counterpart.  
Results from the fluorinated compounds are interesting, but this set of compounds is also 
incomplete. Synthesis of the N-acetylated versions of 214, 215, and 227 (Figure 7.1, Panel B) 
should be completed in order to determine whether in vivo activity can be conferred from a 
peptidomimetic that is inactive in vivo, like 52, to a compound that is active in vivo. Moreover, 
synthesis of the both the THQ and N-acetylated THQ analogues with a 7-fluoro could provide 
additional insight into the effects that fluorine has on basicity, metabolism, and overall 
bioavailability (Figure 7.1, Panel C).  
In addition, in vivo studies to test for the development of dependence with chronic 
administration of 54 are planned. Also, time course assays to determine the duration of action for 
compounds 214, 215, and 225 are planned. If the results from these time course assays are 
promising, in that they increase the duration of action relative to 1, then assays to determine 
whether tolerance and dependence develop after chronic administration will be completed. 
Furthermore, if 225 or either of the proposed 7-fluoro analogues (Figure 7.1, Panel C) produce 
antinociception for a longer duration of action than 1, than additional analogues incorporating the 
7- and 8-fluoro THQ core will be synthesized (Figure 7.1, Panel D). 
Furthermore, because in vivo activity is still produced, via MOR agonism, by compounds that 
have varying degrees of affinity and efficacy at both DOR and KOR, this could indicate that the 
idea of synthesizing a MOR agonist/DOR antagonist ligand might not be the full picture in 
creating an opioid analgesic without of risk of tolerance and dependence. Recently, there have 
been two key observations that have pointed towards the relevance of biased agonism at  
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MOR.56-58 In particular, one study showed that administration of morphine produced an increased 
maximal stimulation and duration of action with reduced side effects in β-arrestin knockout mice 
relative to wildtype mice.59 Since this finding, Trevena, Inc. a company specializing in the 
synthesis of biased agonists for opioid receptors has synthesized a compound, TRV130, now in 
phase 2 clinical trials for the treatment of severe acute pain. TRV130 was shown to be a potent 
analgesic in mice and rats while causing less gastrointestinal dysfunction and respiratory 
suppression than morphine at equipotent doses.59 Given the findings from the knockout studies 
and the success of TRV130, it would be of interest to see if the peptidomimetic compounds 
produced biased agonism at both MOR and DOR, given that some of the peptidomimetics still 
produce stimulation at DOR.  
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Figure 7.1 Additional proposed analogues and structure of TRV130 
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In conclusion, out of this peptidomimetic library compound 54 is a promising lead in the 
development of a MOR agonist/DOR antagonist ligand that produces analgesia, and thus far, 
with development of chronic tolerance in the mouse model. However, the disparate in vivo 
results for 54 and 55, and the lack of predictability of in vivo activity for these peptidomimetics 
remains an intellectual challenge. While the ideal profile for an opioid analgesic with reduced 
risk of tolerance and dependence has many leads, that is, ligands with a MOR agonist/DOR 
antagonist, MOR agonist/DOR agonist, or a biased agonism at MOR are all promising, this 
peptidomimetic library serves as one more step made quest toward finding an opioid analgesic 
with reduced abuse liability. 
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CHAPTER 8 
 
Experimentals 
 
 
8.1 Chemistry 
All reagents and solvents were obtained from commercial sources and used without 
additional purification. Suzuki couplings were performed on a Discover S-class (CEM) 
microwave in a closed vessel with maximum power input of 300 W and temperature set at 110°C 
for 10-60 min under the standard method from their Synergy software. Hydrogenations were 
performed on a Parr hydrogenator apparatus from Parr Instrument Company, model 3916EA, at 
the pressures specified using 10% Pd/C as the catalyst. Flash column chromatography was 
carried out using P60 silica gel (230−400 mesh) either manually or with a Biotage Isolera. 
Purification of final compounds was performed using a Waters semipreparative HPLC with a 
Vydac protein and peptide C18 reverse phase column, using a linear gradient of 15% solvent B 
(0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) to 50% solvent B in solvent A at a 
rate of either 0.5% or 1% per minute and monitoring UV absorbance at 230 nm. Purity of 
synthesized compounds was determined on a Waters Alliance 2690 analytical HPLC instrument 
and a Vydac protein and peptide C18 reverse phase column, using a linear gradient of 0% 
solvent B in solvent A to 45%, 70%, or 90% solvent B in solvent A in 45, 70, or 90 min, 
respectively, and UV absorbance at 230 nm (gradient A). Purities of the final compounds used 
for testing were ≥95% as determined by HPLC. 1H NMR and 13C NMR data were obtained on 
either a 400 or 500 MHz Varian spectrometer using CDCl3 or CD3OD solvents. The identity of 
each compound was verified by mass spectrometry using an Agilent 6130 LC−MS mass 
spectrometer in positive mode. 
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General Procedure A for synthesis of aldol adducts.21 To a reaction vessel containing MeOH 
(375 mL) was added KOH. After dissolution, 1-indanone was added and allowed to dissolve. 
Next, p-nitrobenzaldehyde was added to the reaction mixture and allowed to stir for 1 h. Solvent 
was removed under reduced pressure and the residual solid was washed with cold H2O (50 mL) 
and filtered to yield a homogeneous, tan powder as the pure product.  
General Procedure B for synthesis p-substituted anilines.21 To a hydrogenation vessel was 
added 10% Pd/C catalyst (1.5 g) followed by the slow addition of MeOH (120 mL). The aldol 
intermediate was dissolved in minimal MeOH and added to the vessel, followed by concentrated 
HCl (5.8 mL). The reaction vessel was placed on the hydrogenator under 50 psi of H2 gas and 
allowed to shake for 24 h. The reaction mixture was then filtered through a pad of Celite, and 
solvent was removed under reduced pressure. The crude residue was extracted twice with DCM 
(150 mL) from 2 M NaOH (200 mL), and the combined organic layers were subsequently 
washed 2 × NaHCO3 (100 mL), 1 × brine (100 mL), dried under MgSO4, filtered, and 
concentrated. The crude residue was purified using silica gel chromatography to yield the pure 
product. 
General procedure C for the synthesis of the 3-Bromo-N-propanamides.21,30 To a flame-
dried round bottom flask under Ar was added the aniline compound (1.0 eq) and K2CO3 (2.05 
eq). The reaction vessel was placed back under vacuum and anhyd. DCE was added via syringe. 
The reaction solution stirred under vacuum for 5 min. After 5 min, the reaction vessel was then 
flooded with Ar and 3-bromopropionyl chloride (1.02 eq) was added via syringe.  The reaction 
stirred under Ar at RT for 1 h and was monitored by TLC using a ninhydrin stain for 
disappearance of aniline compound. Once the reaction was complete, it was quenched with dI 
H2O and the layers separated. The organic layer was washed with dI H2O (1 x 50 mL) followed 
by brine (1 x 30 mL), then dried over MgSO4, filtered, and concentrated under reduced pressure 
to yield the pure product. 
General procedure D for the synthesis of phenylazetidin-2-ones. 21,30To a round bottom flask 
already containing the dried, desiccated 3-bromo-N-propanamide (1.0 eq) was added NaOtBu 
(1.05 eq). The reaction vessel was placed under vacuum and anhyd. DMF was added via syringe. 
The solution stirred under vacuum for 5 min, and then was flooded with Ar. The reaction stirred 
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under Ar at RT for up to 3 h and was monitored by TLC. Once complete, the solvent was 
removed under reduced pressure and the resulting crude residue was re-suspended in DCM and 
dI H2O, and the layers separated. The organic layer was washed once with dI H2O (1 x 30 mL), 
then brine (1 x 30 mL), then dried over MgSO4, filtered, and concentrated under reduced 
pressure to yield the crude product, which was then purified using silica gel chromatography to 
yield the pure product. 
General procedure E for the synthesis of 2,3-dihydroquinolin-4(1H)-ones.21,30 To the round 
bottom flask already containing the dried, desiccated phenylazetidin-2-ones (1.0 eq) was added 
anhyd. DCE under vacuum. The reaction vessel stirred under vacuum for 5 min then was flooded 
with Ar. Next, triflic acid (TfOH) (3.0 eq) was added via syringe. The reaction stirred under Ar 
at RT for up to 3 h and was monitored by TLC. Once complete, the reaction was quenched with 
dI H2O (20 mL) and solid K2CO3 (one spatula full) and the layers separated. The organic layer 
was washed once with dI H2O (1 x 30 mL), then sat. NaHCO3 (1 x 30 mL), then brine (1 x 30 
mL), then dried over MgSO4, filtered, and concentrated under reduced pressure to yield the crude 
product, which was then purified using silica gel chromatography to yield the pure product. 
General Procedure F for diBoc-Dmt coupling to form final product. The amine intermediate 
and diBoc-Dmt (1.05 eq) and the coupling reagents PyBOP (1.0 eq), HOBt-Cl  (1.0 eq), were 
dissolved in DMF (10-15 mL) followed by the addition of the and DIPEA (10.0 eq). The reaction 
mixture stirred for 18 h at room temperature. After concentration under reduced pressure, the 
crude residue was dissolved in a 1:1 mixture of DCM and TFA (10 mL) and stirred for 1 h. The 
mixture was concentrated and purified by semipreparative HPLC to yield the final compound. 
Note that while other coupling reagents could be used, the coupling reagents used here were 
chosen to minimize racemization. Additionally, diBoc-Dmt was used instead of monoBoc-Dmt 
to prevent any possible ester formation at the phenol of tyrosine that might occur under these 
coupling conditions, especially at longer reaction times. 
General procedure G for the synthesis of tert-butyl 4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylates. To a flame-dried round bottom flask under Ar was added the 2,3-dihydroquinolin-
4(1H)-one (1.0 eq), Boc2O (1.2-2.0 eq), and DMAP (0.1 eq). The reaction vessel was placed 
back under vacuum for 5 min, then anhyd. DCM was added via syringe and the solution stirred 
for 5 min under vacuum. The round bottom flask was flooded with Ar, and DIPEA (1.2-2.0 eq) 
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was added via syringe. The reaction vessel was equipped with a condenser and placed in oil bath 
at 60°C. The reaction stirred at reflux for 12-16 h under Ar and was monitored by TLC. Once 
significant conversion to product was seen, the reaction was quenched using dI H2O (20 mL) and 
the layers were separated. The organic layer was washed with sat. NaHCO3 solution (1 x 20 mL) 
and brine (1 x 20 mL), then dried over MgSO4, filtered, and concentrated under reduced pressure 
to yield a crude yellow oil which was purified using silica gel chromatography to obtain the pure 
product. 
General procedure H for the synthesis of (R, R) THQ and THN sulfinamides.31-33 To a round 
bottom flask already containing dried, desiccated 6-substituted dihydroquinolinone intermediate 
(1.0 eq) was added (R)-2-methylpropane-2-sulfinamide (2.0-3.0 eq), then the round bottom flask 
was placed under vacuum for 10 min. Meanwhile, a reflux condenser was flame-dried under 
vacuum, and then flooded with Ar. Next, anhyd. THF (~20 mL) was added to the reaction vessel 
containing starting reagents via syringe. The reaction solution allowed to stir under vacuum for 
~5 min and then was flooded with Ar. The round bottom flask was placed in ice bath and 
allowed to equilibrate. Next, Ti(OEt)4 (4.0-6.0 eq) was added slowly via syringe. Once addition 
was complete, the reaction vessel was taken out of ice bath and placed in oil bath at 70°C-75°C, 
equipped with condenser, and stirred for 16-40 h under Ar. The reaction was monitored by TLC 
for loss of ketone. Once sufficient conversion to the tert-butanesulfinyl imine was observed, 
reaction vessel was taken out of oil bath and cooled to ambient temperature. Meanwhile, an 
additional round bottom flask containing a stir bar was flame-dried under vacuum, then flooded 
with Ar, then NaBH4 was added quickly, and then reaction vessel was placed back under vacuum 
for 5 min. Minimal anhyd. THF was added (~5 mL) and vessel allowed to stir under vacuum for 
~ 5 min, then was flooded with Ar. The round bottom flask was placed in dry ice/xylenes bath 
and allowed to equilibrate. Contents from the round bottom flask containing the imine 
intermediate were transferred to round bottom flask containing NaBH4 via cannula. Once 
contents completely added, the reaction was taken out of dry ice/xylenes bath and allowed to 
warm to room temperature. The reaction stirred at ambient temperature for 2-3 h.  Once the 
reaction was complete, MeOH was added to quench. The solvent was removed under reduced 
pressure yielding a solid residue. The residue was re-suspended in DCM, solid remained the 
remaining solid was removed by filtration through a cotton plug and the mother liquor was 
concentrated and purified using silica gel chromatography to yield pure sulfinamide. 
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General procedure I for the synthesis of (R)-1,2,3,4-tetrahydroquinolin-4-amines and (R)-
1,2,3,4-tetrahydronaphthalen-1-amines. To a round bottom flask already containing 
sulfinamide intermediate was added 15-20 mL dioxane followed by conc. HCl (6.0 eq). The 
reaction stirred at RT for up to 3 h. Solvent was removed under reduced pressure to yield slightly 
yellow, clear residue. The residue was re-suspended in Et2O. If a white solid precipitated (the 
HCl salt of the amine): solid was removed via filtration as product without any further 
purification necessary.  If a white solid did not precipitate, but residue remains as film on flask: 
residue washed with fresh Et2O (3 x 5 mL) and dried without any further purification necessary.  
General procedure J for Suzuki couplings using an aliphatic boronic acid.  The aromatic 
bromide (1.0 eq), boronic acid (1.1-2.0 eq), K2CO3 (3.0 eq), Ag2O (2.5 eq), and Pd(dppf)Cl2 (0.1 
eq), were added to a microwave tube and the tube was placed under vacuum for 15 min, then 
flooded with Ar. Roughly 1-2 mL of anhyd THF was added to tube via syringe, then tube was 
placed in microwave for 1 h with a maximum power of 300 W and a maximum temperature of 
80°C with the “PowerMax” option enabled. Once the microwave reaction was complete, reaction 
mixture was filtered through a pad of Celite to remove palladium, and solvents were removed 
under reduced pressure to yield a crude brown residue which was purified using silica gel 
chromatography to obtain the pure product. Procedure adapted from ref. 35. 
General Procedure K for the synthesis of 1-acetyl-2,3-dihydroquinolin-4(1H)-ones. To a 
flame-dried round bottom flask under Ar was added the 2,3-dihydroquinolin-4(1H)-one. The 
reaction vessel was placed back under vacuum for 5 min, then excess Ac2O was added via 
syringe and the solution stirred for 5 min. The round bottom flask was flooded with Ar, equipped 
with a condenser, and placed in oil bath at 100°C. The reaction stirred at reflux for 12-20 h under 
Ar and was monitored by TLC. Once the reaction was complete, the solvent was removed under 
reduced pressure yielding a crude yellow oil which was purified using silica gel chromatograph 
to obtain the pure product. 
General procedure L for Suzuki couplings using an aromatic boronic ester or an aromatic 
boronic acid.  A solution of 3:1 acetone:dI H2O was degassed for 1 h, then Ar was bubbled 
through solution for 1 h to ensure removal and displacement of ambient oxygen. When all the 
reagents are solid: aromatic bromide (1.0 eq), boronic ester (2.0 eq), K2CO3 (3.0 eq), and 
Pd(dppf)Cl2 (0.1 eq), were added to a microwave tube and the tube was placed under vacuum for 
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15 min, then flooded with Ar. Roughly 1-2 mL of the 3:1 acetone:dI H2O solution was added to 
tube via syringe, then tube was placed in microwave for 30-60 min with a maximum power of 
300 W and a maximum temperature of 100°C with the “PowerMax” option enabled. When the 
boronic ester is liquid: aromatic bromide (1.0 eq), K2CO3 (3.0 eq), and Pd(dppf)Cl2 (0.1 eq), 
were added to a microwave tube and the tube was placed under vacuum for 15 min, then flooded 
with Ar. Roughly 1-2 mL of the 3:1 acetone:dI H2O solution was added to tube via syringe, 
followed by addition of the boronic ester (2.0 eq) via syringe. The tube was placed in microwave 
for 30-60 min with a maximum power of 300 W and a maximum temperature of 100°C with the 
“PowerMax” option enabled. Once the microwave reaction was complete, reaction mixture was 
filtered through a pad of Celite to remove palladium, and solvents were removed under reduced 
pressure to yield a crude brown residue which was purified using silica gel chromatography to 
obtain the pure product. Procedure adapted from ref. 36. 
General procedure M for the synthesis of N-acylated analogues using an acid chloride. To a 
flame-dried round bottom flask with stir bar under Ar atomosphere, was added 2,3-
dihydroquinolin-4(1H)-one intermediate (1.0 eq). The reaction vessel was re-evacuated, then 
flooded with Ar. Anhydrous DCM was added via a syringe and the starting material dissolved. 
Next, the acid chloride (2.0 eq) was added via syringe. The reaction was monitored by TLC. 
Once reaction was complete, solvent was removed under reduced pressure. The crude mixture 
was purified using column chromatography to yield the pure product.  
General Procedure N for the synthesis of N-acylated analogues using an acid anhydride. To 
a flame-dried round bottom flask under Ar was added the 2,3-dihydroquinolin-4(1H)-one. The 
reaction vessel was placed back under vacuum for 5 min, then excess acid anhydride (propionic 
or butyric) was added via syringe and the solution stirred for 5 min. The round bottom flask was 
flooded with Ar, equipped with a condenser, and placed in oil bath at 100°C. The reaction stirred 
at reflux for 12-20 h under Ar and was monitored by TLC. Once the reaction was complete, the 
solvent was removed under reduced pressure yielding a crude yellow oil which was purified 
using silica gel chromatograph to obtain the pure product. 
 
 
 
 
99 
 
 
2-(4-Nitrobenzylidene)-2,3-dihydro-1H-inden-1-one (2). 2 was synthesized according to 
general procedure A starting from 1-indanone (3.00 g, 22.7 mmol, 1.0 eq) and p-
nitrobenzaldehyde (4.12 g, 27.2 mmol, 1.2 eq) to yield the title compound 2 as a homogeneous, 
tan powder (5.57 g, 93%). 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 8.3, 2H), 7.94 (d, J = 7.7, 
1H), 7.82 (d, J = 8.2, 2H), 7.73−7.63 (m, 2H), 7.59 (d, J = 7.5, 1H), 7.47 (t, J = 7.3, 1H), 4.10 (s, 
2H). 13C NMR (101 MHz, CDCl3) δ 193.63, 149.28, 141.63, 138.43, 137.50, 135.26, 130.95, 
130.81, 128.06, 126.24, 124.74, 124.08, 32.33. 
 
 
4-((2,3-Dihydro-1H-inden-2-yl)methyl)aniline (3). 3 was synthesized according to general 
procedure B starting from 2 (2.13 g, 8.04 mmol, 1.0 eq) to yield the title compound 3 as a brown 
solid (1.70 g, 95%). 1H NMR (400 MHz, CDCl3) δ 7.16 (dd, J = 8.0, 4.5, 2H), 7.14−7.08 (m, 
2H), 7.01 (d, J = 8.2, 2H), 6.67 (d, J = 8.2, 2H), 3.31 (s, 2H), 2.97 (dd, J = 13.7, 5.7, 2H), 
2.75−2.60 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 143.91, 143.34, 131.97, 129.67, 126.04, 
124.48, 115.51, 41.71, 40.73, 38.86. 
 
 
3-Bromo-N-(4-((2,3-dihydro-1H-inden-2-yl)methyl)phenyl)propanamide (4). 4 was 
synthesized according to general procedure C starting from 3 (686 mg, 3.07 mmol, 1.0 eq) to 
yield the title compound 4 as a fluffy, white solid (1.07 g, 98%). 1H NMR (400 MHz, CDCl3) δ 
7.44 (d, J = 8.2, 2H), 7.20−7.06 (m, 6H), 3.71 (t, J = 6.5, 2H), 2.98−2.63 (m, 4H), 2.77−2.60 (m, 
5H). 13C NMR (101 MHz, CDCl3) δ 167.74, 143.10, 137.96, 135.21, 129.39, 126.11, 124.48, 
120.13, 41.46, 40.93, 40.69, 38.81, 27.16. 
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1-(4-((2,3-Dihydro-1H-inden-2-yl)methyl)phenyl)azetidin-2one (5). 5 was synthesized 
according to general procedure D starting from 4 (1.07 g, 3.00 mmol, 1.0 eq) to yield the title 
compound 5 as a light tan powder (811 mg, 98%). 1H NMR (400 MHz, CDCl3) δ 7.31 (d, J = 
8.3, 2H), 7.20−7.09 (m, 6H), 3.62 (t, J = 4.4, 2H), 3.11 (t, J = 4.4, 2H), 2.97 (dd, J = 14.6, 5.4, 
2H), 2.78−2.61 (m, 5H). 13C NMR (400 MHz, CDCl3) δ 164.26, 143.10, 137.03, 136.61, 129.47, 
126.14, 124.49, 116.16, 41.56, 41.00, 38.82, 38.01, 36.07. 
 
 
6-((2,3-Dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin4(1H)-one (6). 6 was synthesized 
according to general procedure E starting from 5 (811 mg, 2.93 mmol, 1.0 eq) to yield the title 
compound 6 as a viscous yellow oil (772 mg, 95%). 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 
1.9, 1H), 7.22− 7.08 (m, 5H), 6.63 (d, J = 8.3, 1H), 4.30 (br s, 1H), 3.57 (t, J = 6.9, 2H), 2.97 
(dd, J = 14.2, 5.9, 2H), 2.78−2.60 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 193.84, 150.42, 
143.12, 136.09, 131.00, 127.12, 126.06, 124.45, 119.30, 115.90, 42.47, 41.42, 40.42, 38.75, 
38.22. 
 
 
(E/Z)-6-((2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one oxime (7). 7 
was synthesized by suspending 6 (772 mg, 2.78 mmol, 1.0 eq) in 1:1 EtOH/H2O followed by the 
addition of NH2OH·HCl (147 mg, 3.05 mmol, 1.1 eq) and NaOAc·H2O (463 mg, 3.05 mmol, 1.1 
eq). The mixture stirred at reflux for 24 h, after which time solvents were condensed and 
redissolved in EA (30 mL). The organic layer was washed with brine (10 mL), dried with 
MgSO4, filtered, concentrated under reduced pressure, and purified using silica gel 
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chromatography to yield the title compound 7 as a yellow solid (662 mg, 81%). 1H NMR (400 
MHz, CDCl3) 7.63 (d, J = 1.8, 1H), 7.19 −7.05 (m, 5H), 6.60 (dd, J = 21.6, 8.3, 1H), 3.30 (t, J = 
6.5, 2H), 2.93 (dt, J = 13.0, 7.6, 3H), 2.76−2.59 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 152.50, 
145.41, 143.38, 131.51, 131.34, 129.41, 126.08, 124.52, 124.23, 115.78, 41.57, 40.78, 40.74, 
38.86, 23.45. 
 
 
6-((2,3-Dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-amine (8). For the 
synthesis of 8, 10% Pd/C (60 mg) was added to a hydrogenation vessel followed by the slow 
addition of MeOH (10 mL). 7 (662 mg, 2.26 mmol, 1.0 eq) was dissolved in minimal MeOH and 
added to the vessel, followed by the addition of glacial AcOH (0.4 mL). The reaction vessel was 
placed on the hydrogenator under 40 psi of H2 gas and allowed to shake for 12 h. The reaction 
mixture was then filtered through a pad of Celite, and solvent was removed under reduced 
pressure. The crude residue was resuspended in 1 M HCl (30 mL) and extracted with 3 × EA (30 
mL). The organic layer was washed with 3 × 2 M NaOH (30 mL), 1 × brine (30 mL), dried under 
MgSO4, filtered, and concentrated to yield the title compound as a tan oil (120 mg, 75%), which 
was carried to the next reaction without further purification to yield the title compound 8 as a 
brown oil (527 mg, 84%). 1H NMR (400 MHz, CDCl3) 7.13 (ddd, J = 8.7, 7.0, 4.2, 5H), 7.05 (s, 
1H), 6.87 (dd, J = 8.1, 1.8, 1H), 6.46 (t, J = 6.8, 1H), 4.00 (t, J = 4.8, 1H), 3.43−3.34 (m, 1H), 
3.29 (dt, J = 11.0, 5.4, 1H), 3.02−2.94 (m, 3H), 2.77−2.59 (m, 6H). 13C NMR (101 MHz, CDCl3) 
δ 157.04, 150.14, 143.38, 130.14, 129.11, 128.42, 125.98, 124.44, 114.50, 46.89, 41.70, 40.74, 
38.88, 37.75, 31.65. ESI-MS 262.1 [M − NH3 + H] +. HPLC (gradient A): retention time = 
31.39 min. 
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(2S)-1-((6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)-3-
(4-hydroxy-2,6-dimethylphenyl)1-oxopropan-2-amide (9, 9’). 9 and 9’ were synthesized 
according to general procedure F from 8 to form a mixture of crude diastereomers which were 
isolated and purified by semipreparative HPLC and lyophilized to yield the diastereomers of the 
title compound, with 9 as a white powder of the early diastereomer and a 9’ as a tan powder of 
the late diastereomer. HPLC (gradient A): retention time = 31.09 min (early), 33.76 min (late). 
ESI-MS 492.2 [M + Na]+ for both diastereomers. No 1H or 13C NMR data acquired. 
 
 
N-(4-((1H-inden-1-ylidene)methyl)phenyl)acetamide (10). 10 was synthesized according to 
published procedure31 starting from commercially available 1-indene and 4-
acetamidobenzaldehyde to yield title compound 10 (94 mg, 59%). NMR data matched previously 
reported literature values.31 
 
 
N-(4-((2,3-dihydro-1H-inden-1-yl)methyl)phenyl)acetamide (11). 31 11 was synthesized 
according to published procedure31 using 10 to yield title compound 11 (80 mg, 84%). NMR data 
matched previously reported literature values.31 
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4-((2,3-Dihydro-1H-inden-1-yl)methyl)aniline (12).  12 was synthesized according to 
published procedure31 using 11 to yield title compound 12 (36 mg, 54%). NMR data matched 
previously reported literature values.31 
 
 
3-Bromo-N-(4-((2,3-dihydro-1H-inden-1-yl)methyl)phenyl)propanamide (13). 13 was 
synthesized following general procedure C using 12 (473 mg, 2.1 mmol, 1.0 eq), K2CO3 (600 
mg, 4.3 mmol, 2.05 eq), and 3-bromopropionyl chloride (220 mL, 2.2 mmol, 1.02 eq) to yield 
title compound as an off-white solid (759 mg, quant.) with no additional purification necessary. 
1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.0 Hz, 2H), 7.34 (s, 1H), 7.26 (d, J = 1.5 Hz, 0H), 
7.22 (d, J = 6.8 Hz, 1H), 7.14 (dd, J = 19.7, 9.8 Hz, 6H), 5.29 (d, J = 1.5 Hz, 2H), 3.71 (t, J = 6.5 
Hz, 2H), 3.41 (p, J = 7.1 Hz, 1H), 3.09 (dd, J = 13.7, 5.6 Hz, 1H), 2.94 (d, J = 6.6 Hz, 1H), 2.90 
– 2.84 (m, 1H), 2.79 (dt, J = 15.7, 7.7 Hz, 1H), 2.66 (dd, J = 13.6, 9.2 Hz, 1H), 2.17 – 2.08 (m, 
1H), 1.74 (dq, J = 15.1, 8.0, 7.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 167.8, 146.7, 144.1, 
137.4, 135.3, 129.6, 126.5, 126.0, 124.5, 123.7, 120.0, 53.4, 46.4, 40.8, 31.8, 31.1, 27.1. 
 
 
1-(4-((2,3-Dihydro-1H-inden-1-yl)methyl)phenyl)azetidin-2-one (14). 14 was synthesized 
following general procedure E using 13 (759 mg, 2.12 mmol, 1.0 eq), NaOtBu (214 mg, 2.22 
mmol, 1.05 eq) to yield the title compound as a light tan solid (512 mg, 87.4%) with no 
additional purification necessary. 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 8.3 Hz, 2H), 7.25 – 
7.05 (m, 8H), 3.60 (t, J = 4.4 Hz, 2H), 3.40 (p, J = 7.1 Hz, 1H), 3.09 (t, J = 4.5 Hz, 3H), 3.06 (d, 
J = 6.0 Hz, 1H), 2.90 – 2.73 (m, 3H), 2.66 (dd, J = 13.6, 9.0 Hz, 1H), 2.11 (ddd, J = 15.9, 7.9, 
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5.4 Hz, 1H), 1.73 (dq, J = 15.1, 7.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 164.2, 146.6, 144.0, 
136.6, 136.4, 129.6, 126.4, 125.9, 124.5, 123.7, 116.0, 46.4, 40.8, 38.0, 36.0, 31.7, 31.1. 
 
 
6-((2,3-Dihydro-1H-inden-1-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (15). 15 was 
synthesized following general procedure E from 14 (512 mg, 1.85 mmol, 1.0 eq) to yield the title 
compound 15 as a yellow oil (459 mg, 89.6%) after purficiation via silica gel chromatography. 
1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 7.19 (s, 1H), 7.11 (d, J = 11.8 Hz, 5H), 6.60 (d, J = 
8.3 Hz, 1H), 3.52 (t, J = 6.5 Hz, 2H), 3.37 – 3.32 (m, 1H), 3.01 (dd, J = 13.7, 5.0 Hz, 1H), 2.85 
(dd, J = 14.6, 6.5 Hz, 5H), 2.80 – 2.74 (m, 1H), 2.70 – 2.64 (m, 2H), 2.63 – 2.50 (m, 1H), 2.11 
(dt, J = 12.3, 6.5 Hz, 1H), 1.72 (dq, J = 13.8, 7.4, 6.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
193.92, 150.52, 146.64, 143.97, 136.20, 130.20, 127.12, 126.34, 125.88, 124.39, 123.59, 119.01, 
115.82, 46.27, 42.28, 40.17, 38.09, 31.54, 30.95. 
 
 
Tert-butyl-6-((2,3-dihydro-1H-inden-1-yl)methyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate (16). 16 was synthesized following general procedure G using 15 (214 mg, 0.77 
mmol, 1.0 eq), Boc2O (337 mg, 1.54 mmol, 2.0 eq), DMAP (9 mg, 0.077 mmol, 0.1 eq), DIPEA 
(0.268 mL, 1.54 mmol, 2.0 eq). The reaction stirred at reflux for 16 h. Once enough starting 
material was converted to product, the crude yellow oil was purified using silica gel 
chromatography (equil in 100% hex, run in 2:3 EA:hex) to yield the title compound 16 as a 
yellow oil (83 mg, 28.5%). Additionally, 122 mg of starting material 15 was recovered, this was 
not considered when calculating percent yield. 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.4 
Hz, 1H), 7.21 (d, J = 5.9 Hz, 2H), 7.15 (d, J = 8.3 Hz, 4H), 4.16 (t, J = 6.3 Hz, 2H), 3.43 (p, J = 
6.9 Hz, 1H), 3.13 (dd, J = 13.7, 5.4 Hz, 1H), 2.88 – 2.83 (m, 1H), 2.83 – 2.78 (m, 1H), 2.78 – 
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2.74 (t, J = 6.3 Hz, 2H), 2.67 (dd, J = 13.6, 9.5 Hz, 1H), 2.13 (dq, J = 13.1, 7.8 Hz, 1H), 1.74 
(dq, J = 13.9, 7.3 Hz, 1H), 1.56 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 194.3, 152.1, 146.4, 
144.0, 142.2, 136.5, 134.8, 127.2, 126.5, 126.0, 124.6, 124.5, 123.6, 123.5, 82.0, 46.2, 44.3, 40.5, 
39.0, 31.6, 31.0, 28.3. 
 
 
Tert-butyl(4R)-4-(((R)-tert-butylsulfinyl)amino)-6-((2,3-dihydro-1H-inden-1-yl)methyl)-3,4-
dihydroquinoline-1(2H)-carboxylate (17). 17 was synthesized as a mixture of diastereomers 
following general procedure H using 16 (83 mg, 0.220 mmol, 1.0 eq), (R)-2-methylpropane-2-
sulfinamide (80 mg, 0.660 mmol, 3.0 eq), and Ti(OEt)4 (0.277 mL, 0.132 mmol, 6.0 eq) to form 
the (R)-tert-butanesulfinyl imine  intermediate in situ. Once sufficient ketone was converted into 
imine intermediate (after 16 h), the reaction mixture was transferred to a round bottom flask 
containing NaBH4 (50 mg, 0.132 mmol, 6.0 eq) and stirred at room temperature for 3 h before 
being quenched with MeOH. Once resultant solid was removed, crude residue was purified using 
silica gel chromatography (equil in 100%, run in 2:3 EA:hex) to yield the title compound 17 as a 
clear, colorless oil of a mixture of diastereomers (27 mg, 25.7% from 16). 1H NMR (500 MHz, 
CDCl3) δ 7.73 (d, J = 8.0 Hz, 1H), 7.31 – 7.03 (m, 7H), 4.55 (s, 1H), 4.00 (d, J = 12.8 Hz, 1H), 
3.58 (t, J = 12.0 Hz, 1H), 3.44 – 3.35 (m, 1H), 3.28 (s, 1H), 3.07 (ddd, J = 29.4, 13.6, 5.2 Hz, 
1H), 2.94 – 2.84 (m, 1H), 2.83 – 2.74 (m, 1H), 2.64 (ddd, J = 19.0, 13.7, 9.6 Hz, 1H), 2.23 – 2.10 
(m, 2H), 1.99 (dd, J = 23.8, 10.6 Hz, 1H), 1.76 (tt, J = 14.4, 7.6 Hz, 2H), 1.53 (s, 9H), 1.44 (bs, 
3H), 1.22 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 153.6, 146.7, 144.1, 136.41, 136.37, 136.3, 
129.22, 129.16, 128.9, 128.8, 128.31, 128.28, 126.5, 126.0, 125.9, 124.49, 124.46, 123.8, 123.72, 
123.69, 81.1, 55.6, 50.3, 46.4, 46.3, 40.6, 40.5, 40.03, 39.99, 31.9, 31.7, 31.06, 31.05, 29.5, 28.4, 
24.2, 22.6. 
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(4R)-1-(tert-butoxycarbonyl)-6-((2,3-dihydro-1H-inden-1-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-aminium chloride (18). 18 was synthesized as a mixture of 
diastereomers following general procedure I using 17 (27 mg 0.0559 mmol, 1.0 eq) and conc. 
HCl (8 µL, 0.336 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and 
solid crashed out. Solid was filtered off and washed 3 x with fresh Et2O and dried to yield title 
compound 18 as a white solid (10 mg, 43.5%). 1H NMR (500 MHz, CD3OD) δ 7.71 (d, J = 8.5 
Hz, 1H), 7.28 (s, 1H), 7.24  – 7.17 (m, 2H), 7.10 (m, 3H), 4.56 (d, J = 4.7 Hz, 1H), 3.95 – 3.78 
(m, 2H), 3.51 – 3.40 (m, 1H), 3.13 (dt, J = 12.8, 6.4 Hz, 1H), 2.95 – 2.74 (m, 2H), 2.68 (dd, J = 
13.5, 9.2 Hz, 1H), 2.39 – 2.30 (d, J = 4.1 Hz, 1H), 2.18 – 2.03 (m, 2H), 1.78 (dp, J = 13.2, 6.5 
Hz, 1H), 1.54 (d, J = 1.4 Hz, 9H). 13C NMR (126 MHz, CD3OD) δ 154.8, 147.7, 145.1, 138.41, 
138.37, 138.0, 131.0, 130.9, 129.5, 129.4, 127.7, 127.1, 127.0, 125.7, 125.5, 124.7, 83.0,  47.6, 
41.9, 41.7, 32.8, 31.9, 29.2, 28.5. 
 
 
(S)-2-amino-N-((R)-6-(((R/S)-2,3-dihydro-1H-inden-1-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (19). 19 was 
synthesized following general procedure F starting from the (R) amine intermediate 18 (10 mg, 
0.0241 mmol, 1.0 eq) as a mixture of enantiomers to yield crude product as a mixture of 
diastereomers which was purified by semipreparative HPLC then lyophilized to yield the title 
compound 19 as the TFA salt of a mixture of inseparable diastereomers (5 mg, 35.7%). 1H NMR 
(500 MHz, CD3OD) δ 7.18 – 7.14 (m, 1H), 7.12 – 7.06 (m, 2H), 7.05 – 7.00 (m, 1H), 6.97 – 6.91 
(m, 2H), 6.62 (dd, J = 8.4, 3.4 Hz, 1H), 6.49 (s, 2H), 4.97 (t, J = 4.7 Hz, 1H), 3.86 (dt, J = 11.7, 
4.8 Hz, 1H), 3.38 -3.31 (m, 1H) 3.29 – 3.22 (m, 1H), 3.09 – 2.97 (m, 3H), 2.88 – 2.79 (m, 1H), 
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2.78 – 2.69 (m, 1H), 2.64 – 2.43 (m, 3H), 2.28 (s, 6H), 2.13 – 1.98 (m, 1H), 1.79 (t, J = 12.6 Hz, 
1H), 1.69 (ddd, J = 15.1, 13.0, 7.0 Hz, 1H), 1.58 – 1.49 (m, 1H). No 13C NMR spectrum 
acquired. HPLC (gradient A): retention time 30.7. ESI-MS 492.2 [M+Na]+. 
 
 
 
3-Bromo-N-(4-bromophenyl)propanamide (20). 20 was synthesized following general 
procedure C starting from commercially available p-nitrobenzaldehyde (2.0 g, 11.6 mmol, 1.0 
eq), K2CO3 (3.29 g, 23.8 mmol, 2.05 eq), and 3-bromopropionyl chloride (1.20 mL, 11.9 mmol, 
1.02 eq) to yield title compound 20 as an off-white solid (3.53 g, 98.9%) with no additional 
purification necessary after quench and work-up. 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.39 (m, 
4H), 3.70 (t, J = 6.5 Hz, 2H), 2.94 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 167.9, 
136.4, 132.0, 128.3, 121.6, 40.7, 26.8. 
 
 
1-(4-Bromophenyl)azetidin-2-one (21). 21 was synthesized following general procedure D 
starting with 20 (3.53 g, 11.5 mmol, 1.0 eq) and NaOtBu (1.16 g, 12.1 mmol, 1.05 eq). 
Following solvent removal and work-up, the crude product was chromatographed on silica gel 
(equil in 100% hex, run in 1:4 EA:hex) to yield title compound 21 as a pure white, flaky solid 
(1.36 g, 52.1%). 1H NMR (500 MHz, CDCl3) δ 7.46 – 7.42 (m, 2H), 7.27 – 7.22 (m, 2H), 3.62 
(td, J = 4.6, 2.0 Hz, 2H), 3.13 (td, J = 4.6, 1.9 Hz, 2H). No 13C data acquired. 
 
 
6-Bromo-2,3-dihydroquinolin-4(1H)-one (22). 22 was synthesized following general procedure 
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E starting with 21 (1.36 g, 6 mmol, 1.0 eq) and TfOH (1.60 mL, 18.0 mmol, 3.0 eq) to yield a 
crude yellow oil. Following work-up, the crude material was chromatographed on silica gel 
(equil in 100% hex, run in 2:3 EA:hex) to yield title compound 22 as a pure yellow powder (739 
mg, 54.5%). 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.7, 2.4 Hz, 
1H), 6.58 (d, J = 8.7 Hz, 1H), 4.43 (s, 1H), 3.58 (t, 2H), 2.69 (t, 2H). 13C NMR (126 MHz, 
CDCl3) δ 192.3, 150.6, 137.6, 130.0, 120.5, 117.7, 110.2, 42.0, 37.6. 
 
 
Tert-butyl 6-bromo-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (23). 23 was synthesized 
following general procedure G using 22 (300 mg, 1.33 mmol, 1.0 eq), Boc2O (348 mg, 1.59 
mmol, 1.2 eq), DMAP (16.2 mg, 0.13 mmol, 0.1 eq) and DIPEA (0.277 mL, 1.59 mmol, 1.2 eq). 
Following the quench and work-up, the crude product was chromatographed on silica gel (equil 
in 100% hex, run in 2:3 EA:hex) to yield the title compound 23 as a white solid (380 mg, 
87.8%). 1H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 2.4 Hz, 1H), 7.70 (d, J = 8.9 Hz, 1H), 7.57 
(dd, J = 9.0, 2.4 Hz, 1H), 4.15 (t, J = 6.3 Hz, 2H), 2.77 (t, J = 6.3 Hz, 2H), 1.55 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 192.8, 152.4, 143.1, 136.6, 129.9, 126.1, 125.5, 117.1, 82.6, 44.2, 
38.7, 28.3. 
 
 
Tert-butyl 6-(cyclohexylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (24). 24 was 
synthesized following general procedure J using 23 (100 mg, 0.31 mmol, 1.0 eq), 
(cyclohexylmethyl)boronic acid (87 mg, 0.61 mmol, 2.0 eq), K2CO3 (127 mg, 0.92 mmol, 3.0 
eq), Ag2O (178 mg, 0.77 mmol, 2.5 eq), and Pd(dppf)Cl2 (22 mg, 0.031 mmol, 0.1 eq). The 
contents were placed microwave tube and reacted in microwave with max temp of 80°C, max 
power of 300 W for 60 min, with the “Powermax” option disabled. Once filtered through Celite, 
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the solvent was removed and the crude residue purified via silica gel chromatography (equil in 
100% pet. ether, run in 5:1 pet ether:Et2O) to yield title compound 24 as clear, colorless oil (81 
mg, 77.1%). 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 2.2 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 
7.28 (d, J = 2.3 Hz, 1H), 4.19 – 4.08 (m, 2H), 2.82 – 2.71 (m, 2H), 2.47 (d, J = 7.1 Hz, 2H), 1.77 
– 1.59 (m, 5H), 1.55 (s, 9H), 1.51 (s, 1H), 1.18 – 1.12 (m, 2H), 0.97  – 0.90 (m, 3H). 13C NMR 
(126 MHz, CDCl3) δ 194.5, 152.8, 137.1, 135.0, 133.9, 125.5, 124.6, 123.3, 82.0, 44.3, 43.2, 
39.6, 39.1, 36.0, 33.0, 28.3, 26.2. 
 
 
Tert-butyl(R)-4-(((R)-tert-butylsulfinyl)amino)-6-(cyclohexylmethyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (25). 25 was synthesized following general procedure H using 24 (78 mg, 
0.227 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (55 mg, 0.454 mmol, 2.0 eq), and 
Ti(OEt)4 (0.191 mL, 0.909 mmol, 4.0 eq) to form the  (R)-tert-butanesulfinyl imine  intermediate 
in situ. Once sufficient ketone was converted into imine intermediate (after 40 h), the reaction 
mixture was transferred to a round bottom flask containing NaBH4 (34 mg, 0.909 mmol, 4.0 eq) 
and stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid 
was removed, crude residue was purified using silica gel chromatography (equil in 100% hex, 
run in 1:3 EA:hex ) to yield the title compound 25 as a dark, yellow oil (102 mg, 23.5% from 
24). 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 8.6 Hz, 1H), 7.10 (s, 1H), 7.02 (d, J = 8.5 Hz, 
1H), 4.55 (s, 1H), 3.99 (d, J = 12.8 Hz, 1H), 3.55 (t, J = 12.1 Hz, 1H), 3.27 (s, 1H), 2.46 – 2.37 
(m, 2H), 2.17 (d, J = 13.3 Hz, 1H), 1.97 (t, J = 12.8 Hz, 1H), 1.71 - 1.59 (m, 5H), 1.52 (s, 9H), 
1.46 (d, J = 7.5 Hz, 1H), 1.22 (s, 9H), 1.17 – 1.12 (m, 2H), 0.99 – 0.87 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 153.6, 136.9, 136.1, 129.3, 128.9, 128.0, 123.5, 81.0, 55.6, 50.3, 43.2, 40.0, 
39.6, 33.1, 33.0, 29.6, 28.3, 26.5, 26.2, 22.6. 
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(R)-1-(tert-butoxycarbonyl)-6-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-4-aminium 
chloride (26). 26 was synthesized following general procedure I using 25 (22 mg, 0.0490 mmol, 
1.0 eq). After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After 
washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding the title 
compound 26 as an off-white solid (10 mg, 53.5%). 1H NMR (500 MHz, CDCl3) δ 8.79 (s, 3H), 
7.70 (d, J = 8.4 Hz, 1H), 7.32 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 4.39 (s, 1H), 4.08 (d, J = 13.5 Hz, 
1H), 3.64 – 3.54 (m, 1H), 2.40 (d, J = 7.0 Hz, 2H), 2.19 (s, 2H), 1.70 – 1.56 (m , 5H), 1.51 (s, 
10H), 1.19 – 1.08 (m, 3H), 0.98 - 0.85 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 153.1, 137.1, 
136.3, 130.0, 129.4, 123.9, 122.1, 81.4, 47.6, 43.2, 39.9, 39.5, 33.1, 33.0, 28.3, 27.8, 26.5, 26.3, 
26.3. 
 
 
(S)-2-amino-N-((R)-6-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (27). 27 was synthesized following general procedure F starting 
from the (R) amine intermediate 26 (10 mg, 0.0262 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC then lyophilized to yield the title compound 27 as a TFA 
salt (9 mg, 63.2%). 1H NMR (500 MHz, CD3OD) δ 8.09 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 2.0 Hz, 
1H), 6.83 (s, 1H), 6.61 (d, J = 8.1 Hz, 1H), 6.39 (s, 2H), 4.89 (q, J = 5.0 Hz, 1H), 3.78 (dd, J = 
11.6, 5.1 Hz, 1H), 3.16 (dd, J = 13.6, 11.6 Hz, 1H), 2.99 (dt, J = 12.5, 4.3 Hz, 1H), 2.93 (dd, J = 
13.7, 5.1 Hz, 1H), 2.52 (td, J = 11.7, 2.6 Hz, 1H), 2.31 – 2.22 (m, 2H), 2.18 (s, 6H), 1.77 – 1.67 
(m, 1H), 1.61 – 1.48 (m, 5H), 1.47 – 1.40 (m, 1H), 1.37 – 1.27 (m, 1H), 1.12 - 1.02 (m, 3H), 0.87 
– 0.74 (m, 2H). 13C NMR (126 MHz, CD3OD) δ 168.6, 157.4, 140.0, 136.3, 131.8, 131.0, 123.3, 
118.9, 116.4, 53.4, 45.8, 44.3, 41.2, 39.0, 34.3, 34.1, 31.9, 28.7, 27.6, 27.38, 27.36, 20.5. HPLC 
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(gradient A): retention time = 31.0. ESI-MS 458.2 [M+Na]+. 
 
 
N-(4-benzylphenyl)-3-bromopropanamide (28). 28 was synthesized according to general 
procedure C using commercially available benzylaniline (2.15 g, 11.7 mmol, 1.0 eq) to yield title 
compound 28 as tan solid (2.63 g, 98.0%) with no additional purification necessary. 1H NMR 
(500 MHz, CDCl3) δ 7.43 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 7.4 Hz, 2H), 7.22 – 7.12 (5H, m), 3.95 
(s, 2H), 3.71 (t, J = 6.6 Hz, 2H), 2.92 (t, J = 6.6 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 167.7, 
141.9, 137.7, 135.4, 129.5, 128.9, 128.5, 126.1, 120.3, 41.3, 40.7, 27.1. 
 
 
1-(4-Benzylphenyl)azetidin-2-one (29). 29 was synthesized following general procedure D 
using 28 (3.63 g, 1.1 mmol, 1.0 eq) and NaOtBu (1.15 g, 1.2 mmol, 1.05 eq) in anhyd. DMF. 
Following aqueous washes, the title compound 29 was isolated as a tan solid (2.70 g, quant.) and 
was taken ahead to next step (formation of 30) without purification, isolation, or characterization. 
No 1H or 13C data acquired. 
 
 
6-Benzyl-2,3-dihydroquinolin-4(1H)-one (30). 30 was synthesized following general procedure 
E using 29 (2.70 g, 1.1 mmol, 1.0 eq) and TfOH (3.0 mL, 3.4 mmol, 3.0 eq). Following column 
purification (equil in 100% hex, run in 2:3 EA:hex) title compound 30 was isolated as a yellow 
solid (1.91 g, 70.7%).  1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 1.6, 1H), 7.69 (d, J = 1.6, 1H), 
7.29 (dd, J = 8.6, 1.9, 1H), 7.26−7.19 (m, 2H), 7.18− 7.10 (m, 3H), 4.08 (t, J = 6.2, 2H), 3.90 (s, 
2H), 2.68 (t, J = 6.3, 2H); 13C NMR (101 MHz, CDCl3) δ 194.23, 142.37, 140.39, 134.61, 
128.80, 128.54, 127.14, 126.26, 124.78, 123.81, 44.26, 41.14, 38.97. 
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1-Acetyl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (31). 31 was 
synthesized following general procedure K using 6 (55 mg, 0.24 mmol, 1.0 eq). The reaction 
stirred at reflux for 20 h. Once the reaction was complete, solvent was removed and the crude 
residue was purified using silica gel chromatography (equil in 100% hex, run in 2:3 EA:hex) to 
yield title compound 31 as a clear oil (39 mg, 50.4%). 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 
1H), 7.41 (d, J = 6.7 Hz, 2H), 7.20 – 7.07 (m, 4H), 4.24 (t, J = 6.3 Hz, 2H), 3.00 (dd, J = 15.3, 
6.3 Hz, 2H), 2.87 - 2.76 (m, 5H), 2.67 (dd, J = 15.4, 6.2 Hz, 2H), 2.35 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 194.2, 169.4, 142.7, 141.9, 139.0, 134.7, 127.5, 126.2, 125.9, 124.4, 124.0, 43.9, 
41.1, 40.7, 39.4, 38.7, 23.1. 
 
 
1-Acetyl-6-((2,3-dihydro-1H-inden-1-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (32). 32 was 
synthesized following general procedure K using 15 (245 mg, 0.88 mmol, 1.0 eq). The reaction 
stirred at reflux for 16 h. Once the reaction was complete, the solvent was removed and the crude 
residue was purified using silica gel chromatography (equil in 100% hex, run in 2:3 EA:hex) to 
yield the title compound 32 as a clear, colorless oil (190 mg, 67.4%). 1H NMR (500 MHz, 
CDCl3) δ 7.88 (s, 1H), 7.36 (d, J = 6.2 Hz, 1H), 7.21 (d, J = 5.7 Hz, 1H), 7.18 – 7.09 (m, 4H), 
4.23 (s, 2H), 3.44 (p, J = 7.0 Hz, 1H), 3.15 (dd, J = 13.7, 5.5 Hz, 1H), 2.88 (ddd, J = 14.1, 8.2, 
5.5 Hz, 2H), 2.84 – 2.75 (m, 4H), 2.69 (dd, J = 13.7, 9.5 Hz, 1H), 2.34 (s, 3H), 2.13 (ddd, J = 
13.0, 10.4, 6.7 Hz, 1H), 1.81 – 1.67 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 194.0, 169.1, 146.1, 
143.8, 141.9, 138.3, 134.7, 127.5, 126.5, 125.9, 125.7, 124.5, 123.9, 123.5, 46.0, 43.8, 40.4, 39.4, 
31.5, 30.9, 23.0. 
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1-Acetyl-6-benzyl-2,3-dihydroquinolin-4(1H)-one (33). 33 was synthesized following general 
procedure K using 30 (170 mg, 0.72 mmol, 1.0 eq). The reaction stirred at reflux for 16 h. Once 
the reaction was complete solvent was removed under reduced pressure and the crude product 
was chromatographed on silica gel (equil in 100% hex, run in 3:2 EA:hex) to yield the title 
compound as a clear, colorless oil (168 mg, 84.0%). 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.84 
(bs, 1H), 7.37 – 7.33 (m, 2H), 7.31 – 7.24 (m, 2H), 7.23 – 7.15 (m, 3H), 4.20 (t, J = 6.2 Hz, 2H), 
3.98 (s, 2H), 2.76 (t, J = 6.2 Hz, 2H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 194.0, 169.3, 
142.1, 140.0, 138.9, 134.6, 128.8, 128.7, 127.6, 126.4, 126.0, 124.2, 43.9, 41.2, 39.5, 23.1. 
 
 
1-Acetyl-6-bromo-2,3-dihydroquinolin-4(1H)-one (34). 34 was synthesized following general 
procedure K starting with 22 (739 mg, 3.27 mmol, 1.0 eq) fo 16 h. Following removal of solvent, 
the resulting crude yellow oil was purified using silica gel chromatography (equil in 100%,  run 
in 1:3 EA:hex) to yield title compound 33 as a white, waxy solid (704 mg, 80.4%). 1H NMR 
(500 MHz, CDCl3) δ 8.10 (d, J = 2.4 Hz, 1H), 7.64 (dd, J = 8.7, 2.5 Hz, 1H), 7.47 (s, 1H), 4.21 
(t, J = 6.3 Hz, 2H), 2.81 (t, J = 6.3 Hz, 2H), 2.35 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 192.4, 
169.0, 142.6, 136.6, 130.3, 127.0, 125.8, 118.7, 44.2, 39.1, 23.1. 
 
 
1-Acetyl-6-(cyclohexylmethyl)-2,3-dihydroquinolin-4(1H)-one (35). 35 was synthesized 
following general procedure J using 34 (100 mg, 0.37 mmol, 1.0 eq), (cyclohexylmethyl)boronic 
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acid (58 mg, 0.41 mmol, 1.1 eq), K2CO3 (155 mg, 1.12 mmol, 3.0 eq), Ag2O (216 mg, 0.93 
mmol, 2.5 eq), and Pd(dppf)Cl2 (27 mg, 0.37 mmol, 0.1 eq). The contents were placed 
microwave tube and reacted in microwave with max temp of 80°C, max power of 300 W for 60 
min, with the “Powermax” option disabled. Once filtered through Celite, crude residue purified 
via silica gel chromatography (equil in 100% hex, run in 1:3 EA:hex) to yield title compound 35 
as clear, colorless oil (30 mg, 28.3%). Additionally, 51 mg of 34 was recovered; this was not 
considered when calculating percent yield. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.33 (d, J 
= 6.8 Hz, 1H), 4.29 – 4.19 (m, 2H), 2.79 (t, J = 6.2 Hz, 2H), 2.50 (d, J = 7.1 Hz, 2H), 2.33 (s, 
3H), 1.73 – 1.59 (m, 5H), 1.52 (m, 1H), 1.19 – 1.14 (m, 3H), 0.99 – 0.90 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 194.4, 169.3, 141.7, 139.1, 135.0, 127.8, 125.7, 123.8, 43.2, 39.6, 35.3, 34.1, 
33.0, 26.4, 26.2, 23.1. 
 
 
1-Acetyl-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one (36). 36 was synthesized 
following general procedure L using 34 (50 mg, 0.19 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-
(naphthalen-2-ylmethyl)-1,3,2-dioxaborolane (100 mg, 0.37 mmol, 2.0 eq), K2CO3 (78 mg, 0.56 
mmol, 3.0 eq), and Pd(dppf)Cl2 (14 mg, 0.019 mmol, 0.1 eq). The contents were placed 
microwave tube and reacted in microwave with max temp of 110°C, max power of 250 W for 30 
min, with the “Powermax” option enabled. Once crude mixture was filtered through Celite, the 
solvent was removed and the residue was purified via silica gel chromatography (equil in 100% 
hex, run in 1:1 EA:hex) to yield title compound 36 (51 mg, 83.6%)  as clear, colorless oil. 1H 
NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.80 - 7.74 (m, , 3H), 7.63 (s, 1H), 7.48 – 7.36 (m, 3H), 
7.31 – 7.26 (m, 1H), 4.24 – 4.15 (m, 2H), 4.13 (s, 2H), 2.80 – 2.69 (m, 2H), 2.29 (s, 3H).  13C 
NMR (126 MHz, CDCl3) δ 194.0, 169.2, 142.1, 138.6, 137.4, 134.6, 133.5, 132.1, 128.3, 127.60, 
127.57, 127.5, 127.3, 127.2, 127.1, 126.1, 125.9, 125.5, 124.2, 43.9, 41.3, 39.4, 23.0. 
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1-Acetyl-6-(naphthalen-1-ylmethyl)-2,3-dihydroquinolin-4(1H)-one (37). 37  was synthesized 
following general procedure L using 34 (50 mg, 0.19 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-
(naphthalen-1-ylmethyl)-1,3,2-dioxaborolane (100 mg, 0.37 mmol, 2.0 eq), K2CO3 (78 mg, 0.56 
mmol, 3.0 eq), and Pd(dppf)Cl2 (14 mg, 0.019 mmol, 0.1 eq). The contents were placed 
microwave tube and reacted in microwave with max temp of 110°C, max power of 250 W for 30 
min with “Powermax” enabled. Once crude mixture was filtered through Celite, the residue was 
purified via silica gel chromatography (equil in 100% hex, run in 9:1 EA:hex) to yield title 
compound 37 as clear, colorless oil (31 mg, 50.8%). 1H NMR (500 MHz, CDCl3) δ 7.96 – 7.90 
(m, 2H), 7.89 – 7.83 (m, 1H), 7.80 – 7.75 (m, 1H), 7.49 – 7.40 (m, 3H), 7.32 (d, J = 7.1 Hz, 2H), 
4.44 (s, 2H), 4.23 - 4.13 (m, 2H), 2.75 (t, J = 6.2 Hz, 2H), 2.28 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 194.0, 169.2, 142.1, 138.3, 135.4, 134.2, 134.0, 133.6, 131.8, 128.8,  127.6, 127.5, 
127.4, 126.1, 125.7, 125.5, 124.2, 124.0, 43.9, 39.5, 38.3, 23.0. 
 
 
(R)-N-((R)-1-acetyl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
2-methylpropane-2-sulfinamide (38). 38 was synthesized following general procedure H using 
31 (39 mg, 0.122 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (30 mg, 0.244 mmol, 2.0 
eq), and Ti(OEt)4 (0.102 mL, 0.488 mmol, 4.0 eq) to form the  (R)-tert-butanesulfinyl imine  
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 24 h), 
the reaction mixture was transferred to a round bottom flask containing NaBH4 (19 mg, 0.488 
mmol, 4.0 eq) and stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography (equil in 
100% hex, run in 9:1 EA:hex) to yield the title compound 38 as a clear, colorless oil (46 mg, 
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88.9% from 31). 1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.29 (s, 1H), 7.21 – 7.15 (m, 2H), 
7.15 – 7.09 (m, 3H), 4.77 – 4.66 (m, 1H), 4.57 (bs, 1H), 3.01 (dd, J = 15.3, 6.0 Hz, 2H), 2.83 – 
2.72 (m, 3H), 2.67 (dd, J = 15.2, 5.7 Hz, 2H), 2.43 – 2.34 (m, 1H), 2.28 – 2.20 (m, 4H), 2.13 – 
2.02 (m, 1H), 1.22 (s, 9H). No 13C data acquired. 
 
 
(R)-N-((4R)-1-acetyl-6-((2,3-dihydro-1H-inden-1-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-
yl)-2-methylpropane-2-sulfinamide (39). 39 was synthesized as a mixture of diastereomers 
following general procedure H using 32 (176 mg, 0.551 mmol, 1.0 eq), (R)-2-methylpropane-2-
sulfinamide (200 mg, 1.65 mmol, 3.0 eq), and Ti(OEt)4 (0.693 mL, 3.31 mmol, 6.0 eq) to form 
the  (R)-tert-butanesulfinyl imine  intermediate in situ. Once sufficient ketone was converted into 
imine intermediate (after 16 h), the reaction mixture was transferred to a round bottom flask 
containing NaBH4 (125 mg, 3.31 mmol, 6.0 eq) and stirred at room temperature for 3 h before 
being quenched with MeOH. Once resultant solid was removed, crude residue was purified using 
silica gel chromatography (equil in and run in 100% EA) to yield the title compound 39 as a 
clear, colorless oil of a mixture of diastereomers (219 mg, 93.6% from 32). 1H NMR (500 MHz, 
CDCl3) δ 7.29 – 7.25 (m, 1H), 7.24 – 7.19 (m, 1H), 7.17 – 7.09 (m, 4H), 7.09 – 7.05 (m, 1H), 
4.54 (bs, 1H), 3.99 – 3.87 (m, 2H), 3.84 – 3.72 (m, 1H), 3.44 (bs, 1H), 3.19 – 3.04 (m, 1H), 2.96 
– 2.75 (m, 2H), 2.68 (q, J = 12.4 Hz, 1H), 2.25 (s, 3H), 2.23 - 2.19 (m, 1H), 2.19 – 2.12 (m, 1H) 
2.12 – 2.05 (m, 1H), 1.84 – 1.71 (m, 1H), 1.24 – 1.14 (s, 9H). 13C NMR (126 MHz, CDCl3 δ 
169.7, 146.3, 143.8, 138.1, 136.4, 128.7, 128.6, 126.4, 125.9, 125.8, 124.4, 124.3, 123.6, 123.5, 
55.6, 55.0, 50.9, 46.1, 46.0, 40.6, 40.5, 31.7, 31.6, 30.9, 30.9, 30.5, 23.2, 22.4, 22.0, 20.9, 14.0. 
 
 
 
117 
 
 
(R)-N-((R)-1-acetyl-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide (40). 40 was synthesized following general procedure H using 33 (168 mg, 0.601 
mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (219 mg, 1.80 mmol, 3.0 eq), and Ti(OEt)4 
(0.757 mL, 3.61 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in situ. 
Once sufficient ketone was converted into imine intermediate (after 40 h), the reaction mixture 
was transferred to a round bottom flask containing NaBH4 (137 mg, 3.61 mmol, 6.0 eq) and 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography (4:1 EA:hex ) to yield the 
title compound 40 as a clear, colorless oil (105 mg, 45.5% from 33), that was taken ahead to the 
next step (formation of 46) without further characterization. No 1H or  13C data acquired. 
 
 
 
(R)-N-((R)-1-acetyl-6-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide (41). 41 was synthesized following general procedure H using 
35 (56 mg, 0.196 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (48 mg, 0.392 mmol, 2.0 
eq), and Ti(OEt)4 (0.165 mL, 0.785 mmol, 4.0 eq) to form the (R)-tert-butanesulfinyl imine  
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 40 h), 
the reaction mixture was transferred to a round bottom flask containing NaBH4 (30 mg, 0.785 
mmol, 4.0 eq) and stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography (equil in 
100% hex, run in 4:1 EA:hex ) to yield the title compound 41 as a clear, yellow oil (20 mg, 
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26.1% from 35) that was taken ahead to the next step (formation of 47) without further 
characterization. No 1H or  13C data acquired. 
 
 
(R)-N-((R)-1-acetyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide (42). 42 was synthesized following general procedure H from 36 
(51 mg, 0.155 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (56 mg, 0.464 mmol, 3.0 eq), 
and Ti(OEt)4 (0.195 mL, 0.929 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine  
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 40 h), 
the reaction mixture was transferred to a round bottom flask containing NaBH4 (35 mg, 0.929 
mmol, 6.0 eq) and stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography (equil in 
100% hex, run in 100% EA) to yield the title compound 42 as a clear, colorless oil (67 mg, 
quant. from 36) which was taken ahead to the next step (formation of 48) without further 
characterization. No 1H or  13C data acquired. 
 
 
(R)-N-((R)-1-acetyl-6-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide (43). 43 was synthesized following general procedure H using 
37 (31 mg, 0.0941 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (34 mg, 0.282 mmol, 3.0 
eq), and Ti(OEt)4 (0.118 mL, 0.565 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine  
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 40 h), 
the reaction mixture was transferred to a round bottom flask containing NaBH4 (21 mg, 0.565 
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mmol, 6.0 eq) and stirred at room temperature for 3 h before being quenched with MeOH. The 
resultant solid was removed, to yield  the crude, clear, colorless title compound 43 (41 mg, 
quant), that was taken ahead to the next step (formation of 49) without further purification, 
isolation, or characterization. No 1H or  13C data acquired. 
 
 
(R)-1-acetyl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-aminium 
chloride (44). 44 was synthesized following general procedure I using 38 (46 mg 0.108 mmol, 
1.0 eq) and conc. HCl (16 µL, 0.650 mmol, 6.0 eq). After removing solvent, residue was re-
suspended in Et2O, and residue crashed out. Residue was gummy and sticky so it was washed 3 x 
with fresh Et2O and dried to yield the title compound 44 as a tan solid (39 mg, quant.). Solid was 
taken ahead to next reaction (formation of 50) without further isolation, purification, or 
characterization. No 1H or  13C data acquired. 
 
 
(4R)-1-acetyl-6-((2,3-dihydro-1H-inden-1-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-aminium 
chloride (45). 45 was synthesized as a mixture of diastereomers following general procedure I 
using 39 (219 mg 0.516 mmol, 1.0 eq) and conc. HCl (76 µL, 3.10 mmol, 6.0 eq). After 
removing solvent, residue was re-suspended in Et2O, and solid crashed out. Solid was filtered off 
and washed 3 x with fresh Et2O and dried to yield title compound 45 as a white solid (135 mg, 
73.4%). 1H NMR (500 MHz, CD3OD) δ 7.46 – 7.38 (1H), 7.27 (bs, 1 H), 7.22 - 7.17 (m, 1H), 
7.16 – 7.08 (m, 3H), 4.60 (s, 1H), 3.93 (qt, J = 8.3, 4.4 Hz, 2H), 3.53 - 3.44 (m, 1H), 3.17 (dt, J = 
13.4, 6.6 Hz, 1H), 2.94 – 2.84 (m, 1H), 2.84 – 2.74 (m, 1H), 2.74 – 2.67 (m, 1H), 2.46 (dq, J = 
11.5, 4.7 Hz, 1H), 2.30 (s, 3H), 2.18 -2.05 (m, 2H), 1.78 (dp, J = 13.2, 6.6 Hz, 1H). 13C NMR 
(126 MHz, CD3OD) δ 172.43, 172.41, 147.7, 147.6, 145.11, 145.08, 138.1, 131.0, 129.44, 
 
 
120 
 
129.37, 127.7, 127.10, 127.06, 126.3, 125.48, 125.47, 124.73, 124.70, 48.3, 47.6, 41.8, 41.8, 
32.9, 32.8, 31.9, 30.0, 23.4, 23.3. 
 
 
(R)-1-acetyl-6-benzyl-1,2,3,4-tetrahydroquinolin-4-aminium chloride (46). 46 was 
synthesized following general procedure I using 40 (105 mg 0.273 mmol, 1.0 eq) and conc. HCl 
(40 µL, 1.64 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and solid 
crashed out. Solid was filtered off and washed 3 x with fresh Et2O and dried to yield title 
compound 46 as a white solid (68 mg, 78.2%). 1H NMR (500 MHz, CD3OD) δ 7.43 – 7.37 (m, 
1H), 7.32 – 7.21 (m, 4H), 7.20 – 7.15 (m, 1H), 4.62 – 4.53 (m, 1H), 4.01 (s, 2H), 3.95 – 3.86 (m, 
2H), 2.49 – 2.38 (m, 1H), 2.28 (s, 3H), 2.07 (s, 1H). 13C NMR (126 MHz, CD3OD) δ 172.4, 
142.1, 140.9, 138.1, 130.7, 129.9, 129.6, 129.0, 127.3, 126.5, 48.3, 42.2, 29.9, 23.3. 
 
 
(R)-1-acetyl-6-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-4-aminium chloride (47). 47 
was synthesized following general procedure I using 41 (20 mg, 0.0512 mmol, 1.0 eq) and conc. 
HCl (7.5 µL, 0.31 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and 
solid crashed out. After washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted 
off, yielding the title compound 47 as an off-white solid (12 mg, 72.7%). 1H NMR (500 MHz, 
CD3OD) δ 7.27 (s, 1H), 7.21 (d, J = 8.2 Hz, 1H), 4.58 (t, J = 6.7 Hz, 1H), 3.91 (h, J = 8.3, 7.9 
Hz, 2H), 2.53 (d, J = 7.1 Hz, 2H), 2.48 – 2.39 (m, 1H), 2.28 (s, 3H), 2.10 – 1.99 (m, 1H), 1.75-
1.65 (m, 5H), 1.61-1.53 (m, 1H), 1.26 – 1.19 (m, 3H), 1.02-0.94 (m, 2H). No 13C data acquired. 
 
 
 
121 
 
 
(R)-1-acetyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-aminium chloride 
(48). 48 was synthesized following general procedure I using 42 (56 mg, 0.135  mmol, 1.0 eq). 
After removing solvent, residue was re-suspended in Et2O, and solid did not crash out. Residue 
was washed 3 x with fresh Et2O and dried to yield title compound 48 as a clear, yellow oil (56 
mg, quant.). 1H NMR (500 MHz, CD3OD) δ 7.83 – 7.67 (m, 4H), 7.54 – 7.24 (m, 6H), 4.56 (dd, 
J = 7.7, 4.0 Hz, 1H), 4.16 (s, 2H), 3.96 – 3.81 (m, 2H), 2.46 – 2.35 (m, 1H), 2.26 (s, 3H), 2.13 – 
2.09 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 172.5, 140.8, 139.6, 138.1, 135.1, 133.6, 130.8, 
129.2, 128.6, 128.5, 128.4, 128.1, 127.1, 126.5, 48.2, 42.3, 29.8, 23.3, 21.5. 
 
(R)-1-acetyl-6-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-aminium chloride 
(49). 49 was synthesized following general procedure I using 43 (41 mg (from theoretical yield 
of 43), 0.0943 mmol, 1.0 eq) and conc. HCl (14 µL, 0.566 mmol, 6.0 eq). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. Solid was filtered off and 
washed 3 x with fresh Et2O and dried to yield title compound 49 as a white solid (22 mg, 62.9%). 
1H NMR (500 MHz, CD3OD) δ 8.02 (d, J = 7.1 Hz, 1H), 7.87 (d, J = 8.1, 1H), 7.78 (d, J = 7.1 
Hz, 1H), 7.50 – 7.43 (m, 4H), 7.43 – 7.39 (m, 2H), 7.30 – 7.23 (m, 1H), 4.53 (t, J = 6.7 Hz, 1H), 
4.49 (s, 2H), 3.87 (dtd, J = 8.8, 6.7, 6.2, 3.4 Hz, 2H), 2.39 (dq, J = 12.5, 5.7 Hz, 1H), 2.25 (s, 
3H), 2.04 (dd, J = 14.2, 7.1 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 172.5, 137.3, 135.6, 134.6, 
133.3, 130.5, 129.8, 128.8, 128.7, 128.5, 127.08, 127.07, 126.71, 126.70, 126.6, 126.5, 125.3, 
48.2, 39.4, 29.9, 23.3. 
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(S)-N-((R)-1-acetyl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (50). 50  was synthesized following 
general procedure F starting from the (R) amine intermediate 44 (39 mg, 0.108 mmol, 1.0 eq) to 
yield crude product which was purified by semipreparative HPLC then lyophilized to yield the 
title compound 50 as a TFA salt (14 mg, 20.6%).1H NMR (500 MHz, CD3OD) δ 7.12 (s, 4H), 
7.09 – 7.04 (m, 2H), 6.51 (s, 2H), 4.97 (s, 1H), 3.85 (dd, J = 11.2, 4.3 Hz, 1H), 3.29 – 3.19 (m, 
2H), 3.04 (dd, J = 13.7, 4.1 Hz, 2H), 2.98 – 2.87 (m, 2H), 2.73 (d, J = 10.3 Hz, 3H), 2.62 (d, J = 
15.6 Hz, 2H), 2.28 (s, 6H), 2.21 (s, 3H). No 13C NMR data acquired. HPLC (gradient A): 
retention time = 38.4. ESI-MS 534.3 [M+Na]+. 
 
 
 
(S)-N-((R)-1-acetyl-6-(((R/S)-2,3-dihydro-1H-inden-1-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (51). 51 
was synthesized following general procedure F starting from the (R) amine intermediate 35 (20 
mg, 0.056 mmol, 1.0 eq) to yield crude product which was purified by semipreparative HPLC 
then lyophilized to yield the title compound 51 as the TFA salt of a mixture of diastereomers (8 
mg, 22.9%). Starting material 45 was recovered, but not considered when calculating percent 
yield. 1H NMR (500 MHz, CD3OD) δ 7.21 – 6.98 (m, 7H), 6.52 (s, 2H), 5.03 – 4.93 (1, 2H), 
3.87 (dt, J = 10.5, 4.9 Hz, 1H), 3.81 (s, 1H), 3.40 (q, J = 7.3 Hz, 1H), 3.30 - 3.21 (m, 1H), 3.08 – 
3.00 (m, 2H), 2.90 - 2.81 (m, 1H), 2.80 – 2.70 (m, 1H), 2.67 – 2.55 (m, 1H), 2.28 (s, 6H), 2.21 (s, 
3H), 2.15 – 2.03 (m, 1H), 1.94 – 1.82 (m, 1H), 1.71 (dq, J = 14.3, 7.4 Hz, 1H), 1.45 (s, 1H). No 
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13C NMR spectrum acquired. HPLC (gradient A): retention time = 38.4. ESI-MS 534.3 
[M+Na]+. 
 
 
(S)-N-((R)-1-acetyl-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (52). 52 was synthesized following general procedure F starting 
from the (R) amine intermediate 46 (68 mg, 0.215 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC then lyophilized to yield the title compound 52 as a TFA 
salt (16 mg, 12.7%). Starting material 46 was recovered, but not considered when calculating 
percent yield. 1H NMR (500 MHz, CD3OD) δ 7.26 – 7.20 (m, 2H), 7.18 – 7.12 (m, 4H), 7.06 (d, 
J = 8.3 Hz, 1H), 6.51 (s, 2H), 4.94 (t, J = 6.0 Hz, 1H), 3.94 – 3.83 (m, 3H), 3.27 – 3.22 (m, 2H), 
3.16 (m, 1H), 3.05 (dd, J = 13.8, 5.0 Hz, 1H), 2.27 (s, 6H), 2.18 (s, 3H). No 13C NMR spectrum 
acquired. HPLC (gradient A): retention time = 32.7. ESI-MS 494.3 [M+Na]+. 
 
 
(S)-N-((R)-1-acetyl-6-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (53). 53 was synthesized following general 
procedure F starting from the (R) amine intermediate 47 (12 mg, 0.0372 mmol, 1.0 eq) to yield 
crude product which was purified by semipreparative HPLC then lyophilized to yield the title 
compound 53 as a TFA salt (12 mg, 55.5%). 1H NMR (500 MHz, CD3OD) δ 8.15 (d, J = 8.1 Hz, 
1H), 7.06 – 7.00 (m, 2H), 6.51 (s, 2H), 4.99 – 4.93 (m, 1H), 3.88 (dd, J = 11.5, 5.0 Hz, 1H), 3.79 
(s, 1H), 3.26 (dd, J = 13.6, 11.5 Hz, 1H), 3.22 – 3.10 (m, 1H), 3.05 (dd, J = 13.7, 5.0 Hz, 1H), 
2.48 – 2.38 (m, 2H), 2.28 (s, 6H), 2.19 (s, 3H), 1.90 – 1.82 (m, 1H), 1.74 – 1.59 (m, 5H), 1.53 – 
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1.37 (m, 2H), 1.26 – 1.12 (m, 3H), 0.99 – 0.87 (m, 2H). 13C NMR (126 MHz, CD3OD) δ 172.5, 
169.2, 157.5, 140.1, 129.5, 125.4, 123.3, 116.5, 53.5, 47.0, 44.4, 41.0, 34.3, 34.2, 32.0, 31.3, 
27.6, 27.36, 27.35, 23.33, 20.44. HPLC (gradient A): retention time = 39.5. ESI-MS 478.3 
[M+Na]+. 
 
 
(S)-N-((R)-1-acetyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-
(4-hydroxy-2,6-dimethylphenyl)propanamide (54). 54 was synthesized following general 
procedure F starting from the (R) amine intermediate 48 (56 mg, 0.153 mmol, 1.0 eq) to yield 
crude product which was purified by semipreparative HPLC then lyophilized to yield the title 
compound 54 as a TFA salt (17 mg, 30.4%). Starting material 48 was recovered, but not 
considered when calculating percent yield. 1H NMR (500 MHz, CD3OD) δ 7.80 – 7.71 (m, 4H), 
7.60 (s, 1H), 7.47 – 7.36 (m, 2H), 7.28 (dd, J = 8.6, 1.8 Hz, 1H), 7.19 (s, 1H), 7.12 (dd, J = 8.6, 
2.1 Hz, 1H), 6.51 (s, 2H), 4.94 (q, J = 6.8 Hz, 1H), 4.07 (s, 2H), 3.87 (dd, J = 11.5, 5.0 Hz, 1H), 
3.24 (dd, J = 13.7, 11.5 Hz, 1H), 3.04 (dd, J = 13.7, 5.0 Hz, 1H), 2.26 (s, 6H), 2.17 (s, 3H), 1.89 
– 1.79 (m, 1H), 1.51 - 1.41 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 172.5, 169.2, 157.4, 151.9, 
140.1, 139.8, 135.1, 133.6, 129.5, 129.1, 128.6, 128.5, 128.4, 127.9, 127.1, 126.5, 125.8, 123.3, 
116.5, 53.5, 47.2, 47.1, 42.3, 31.9, 31.2, 23.4, 20.4. HPLC (gradient A): retention time = 38.8. 
ESI-MS 522.3 [M+H]+. 
 
 
(S)-N-((R)-1-acetyl-6-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-
(4-hydroxy-2,6-dimethylphenyl)propanamide (55). 55 was synthesized following general 
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procedure F starting from the (R) amine intermediate 49 (22 mg, 0.060 mmol, 1.0 eq) to yield 
crude product which was purified by semipreparative HPLC then lyophilized to yield the title 
compound 55 as a TFA salt (4 mg, 12.9%). Starting material 49 was recovered, but not 
considered when calculating percent yield. 1H NMR (500 MHz, CD3OD) δ 7.99 – 7.95 (m, 1H), 
7.85 (d, J = 7.8 Hz, 1H), 7.78 – 7.74 (m, 1H), 7.48 – 7.37 (m, 4H), 7.27 (d, J = 7.0 Hz, 1H), 7.22 
– 7.17 (m, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 4.93 (bs, 1H) 4.40 (s, 2H), 3.84 (dd, J = 
11.4, 5.0 Hz, 1H), 3.24 (t, J = 12.6 Hz, 1H), 3.05 – 2.98 (m, 1H), 2.27 (d, J = 1.4 Hz, 6H), 2.17 
(s, 3H), 1.86 (dt, J = 11.6, 5.7 Hz, 1H), 1.49 (bs, 1H).  No 13C NMR Spectrum acquired. HPLC 
(gradient A): retention time = 38.3. ESI-MS 544.3 [M+Na]+. 
 
 
Synthesized by Larisa Yeomans. Synthesis and characterization can be found in Ref. 21 
 
Synthesized by Larisa Yeomans. Synthesis and characterization can be found in Ref. 21 
 
 
Synthesized by Larisa Yeomans. Synthesis and characterization herein and in Ref. 23 
(R)-N-((R)-7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)-2-methylpropane-2-sulfinamide 
(58). 58 was synthesized following general procedure H using commercially available 7-bromo-
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3,4-dihydronaphthalen-1(2H)-one (1.0 g, 4.44 mmol, 1 eq), (R)-2-methylpropane-2-sulfinamide 
(1.08 g, 8.88 mmol, 2.0 eq), and Ti(OEt)4 (3.73 mL, 17.8 mmol, 4 eq) to form the  (R)-tert-
butanesulfinyl imine  intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (671.7 mg, 17.76 mmol, 4 eq) and 13 mL of THF in a xylenes dry ice 
bath, after addition, the solution was stirred at room temperature for 3 h before being quenched 
with MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography (1:9 EA:hex) to yield the title compound 58 as a clear, colorless oil (1.13 g, 
77%). 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 1H), 7.24 (dd, J = 8.2, 2.1 Hz, 1H), 
6.93 (d, J = 8.2 Hz, 1H), 4.46 (q, J = 4.4 Hz, 1H), 3.31 (d, J = 4.0 Hz, 1H), 2.72 (dt, J = 17.0, 5.2 
Hz, 1H), 2.61 (ddd, J = 17.0, 8.9, 5.7 Hz, 1H), 2.00 – 1.92 (m, 1H), 1.92 – 1.79 (m, 2H), 1.76 – 
1.67 (m, 1H), 1.18 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 138.9, 138.0, 132.07, 132.06, 130.8, 
130.5, 119.6, 55.4, 52.5, 30.2, 28.4, 22.5, 18.0. 
 
(R)-N-((R)-7-(cyclohexylmethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-2-methylpropane-2-
sulfinamide (59). 59 was synthesized following general procedure J using 58 (100 mg, 0.30 
mmol, 1.0 eq), (cyclohexylmethyl)boronic acid (86 mg, 0.61 mmol, 2.0 eq), K2CO3 (126 mg, 
0.91 mmol, 3.0 eq), Ag2O (175 mg, 0.76 mmol, 2.5 eq), and Pd(dppf)Cl2 (22 mg, 0.031 mmol, 
0.1 eq). The reagents were placed in a microwave tube followed by 1.5 mL anhyd. THF and 
reacted in microwave with max temp of 80°C, max power of 300 W for 60 min, “Powermax” 
option disabled. Once the crude mixture was filtered through Celite, the residue purified via 
silica gel chromatography (equil in 100% hex, run in 2:3 EA:hex) to yield the title compound 59 
as clear, colorless oil (105 mg, quant), which was taken to the next step (formation of 62) 
without further characterization. No 1H or  13C data acquired. 
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(R)-2-methyl-N-((R)-7-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-
yl)propane-2-sulfinamide (60). 60 was synthesized following general procedure L using 58 (49 
mg, 0.15 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(naphthalen-2-ylmethyl)-1,3,2-dioxaborolane (80 
mg, 3.0 mmol, 2.0 eq), K2CO3 (58 mg, 0.42 mmol, 3.0 eq), and Pd(dppf)Cl2 (11 mg, 0.015 
mmol, 0.1 eq). The reagents were placed in a microwave tube followed by 1-2 mL of the 
previously degassed 3:1 acetone/water solvent system and reacted in microwave with max temp 
of 110°C, max power of 300 W for 60 min with “Powermax” enabled. Once crude mixture was 
filtered through Celite, the residue was purified via silica gel chromatography (equil in 100% 
hex, run in 1:1 EA:hex) to yield title compound 60 (32 mg, 55.2%)  as a clear, colorless oil 
which was taken ahead to the next step (formation of 63) without further characterization. No 1H 
or  13C data acquired. 
 
(R)-2-methyl-N-((R)-7-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-
yl)propane-2-sulfinamide (61). 61 was synthesized following general procedure L using 58 (46 
mg, 0.14 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(naphthalen-1-ylmethyl)-1,3,2-dioxaborolane (75 
mg, 0.28 mmol, 2 eq), K2CO3 (58 mg, 0.42 mmol, 3 eq), and Pd(dppf)Cl2 (10 mg, 0.014 mmol, 
0.1 eq). The reagents were placed in a microwave tube followed by the previously degassed 3:1 
acetone/water solvent system and reacted in microwave with max temp of 110°C, max power of 
250 W for 30 min with “Powermax” enabled. Once crude mixture was filtered through Celite, 
the residue was purified via silica gel chromatography (equil in 100% hex, run in 1:4 EA:hex) to 
yield title compound 61 (11 mg, 20.2%)  as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 
8.03 – 7.97 (m, 1H), 7.87 – 7.81 (m, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.48 – 7.38 (m, 3H), 7.37 (s, 
1H), 7.31 (d, J = 6.9 Hz, 1H), 6.96 (s, 2H), 4.53 (q, J = 3.4 Hz, 1H), 4.40 (s, 2H), 3.20 (s, 1H), 
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2.79 -2.71 (m, 1H), 2.70 – 2.60 (m, 1H), 2.05 – 1.97 (m, 1H), 1.94 – 1.79 (m, 2H), 1.77 – 1.65 
(m, 1H), 1.17 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 138.9, 136.8, 136.6, 135.5, 133.9, 132.0, 
129.7, 129.4, 128.6, 127.9, 127.2, 127.1, 125.9, 125.54, 125.47, 124.2, 55.4, 52.4, 38.6, 30.3, 
28.7, 22.6, 18.1. 
 
 
(R)-7-(cyclohexylmethyl)-1,2,3,4-tetrahydronaphthalen-1-aminium chloride (62). 62 was 
synthesized following general procedure I using 59 (100 mg, 0.29 mmol, 1.0 eq) and conc. HCl 
(42 µL, 1.7 mmol, 6.0 eq). After removing solvent, the residue was re-suspended in Et2O and a 
white solid crashed out. The Et2O was filtered off leaving a white, flaky precipitate which was 
washed with cold Et2O, and dried under vacuum without any further purification to yield the title 
compound (45 mg, 55.9%). 1H NMR (500 MHz, CDCl3) δ 8.72 (s, 3H), 7.38 (s, 1H), 7.00 (s, 
2H), 4.40 (q, J = 5.4 Hz, 1H), 2.81 (dt, J = 16.7, 5.4 Hz, 1H), 2.71 – 2.61 (m, 1H), 2.40 (d, J = 
7.1 Hz, 2H), 2.18 – 2.07 (m, 2H), 2.05 – 1.94(m, 1H), 1.79 – 1.69 (m, 1H), 1.68 – 1.55 (m, 5H), 
1.54 – 1.46 m, 1H), 1.22 – 1.08 (m, 3H), 1.01 – 0.84 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
139.7, 134.7, 130.6, 129.7, 129.6, 129.3, 49.7, 43.5, 39.5, 33.11, 33.09, 28.3, 27.93, 27.91, 26.6, 
26.3, 26.3. 
 
 
(R)-7-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-aminium chloride (63). 63 
was synthesized following general procedure I using 60 (30 mg, 0.077 mmol, 1.0 eq) and conc. 
HCl (11 µL, 0.46 mmol, 6.0 eq). After removing solvent, the residue was re-suspended in Et2O, 
and solid did not crash out. Residue was washed 3 x with fresh Et2O then dried to yield the title 
compound 63 as off white, sticky solid (11 mg, 44.3%). 1H NMR (500 MHz, CD3OD) δ 7.83 – 
7.74 (m, 3H), 7.66 (s, 1H), 7.43 (p, J = 7.0 Hz, 2H), 7.35 – 7.29 (m, 2H), 7.23 (d, J = 8.0 Hz, 
1H), 7.16 (d, J = 7.9 Hz, 1H), 4.45 (t, J = 5.6 Hz, 1H), 4.14 (s, 2H), 2.92 – 2.74 (m, 2H), 2.22 – 
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2.11 (m, 1H), 2.04 – 1.82 (m, 3H). 13C NMR (126 MHz, CD3OD) δ 141.2, 140.0, 136.9, 135.1, 
133.6, 133.0, 131.2, 130.9, 129.8, 129.1, 128.6, 128.5, 128.4, 128.0, 127.1, 126.5, 50.3, 42.5, 
29.4, 29.1, 19.6. 
 
(R)-7-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-aminium chloride (64). 64 
was synthesized following general procedure I using 61 (11 mg, 0.028 mmol, 1.0 eq) and conc. 
HCl (4 µL, 0.17 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and 
solid crashed out. After washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted 
off, yielding the title compound 64 as a white solid (7 mg, 77.8%).  1H NMR (400 MHz, 
CD3OD) δ 8.05 – 7.96 (m, 1H), 7.86 (dd, J = 7.0, 2.3 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.47 – 
7.39 (m, 3H), 7.36 (d, J = 7.0 Hz, 1H), 7.30 (s, 1H), 7.17 – 7.07 (m, 2H), 4.47 -3.38 (m, 3H), 
2.90 – 2.69 (m, 2H), 2.14 (ddt, J = 14.5, 9.6, 4.6 Hz, 1H), 1.92 (ddt, J = 43.3, 20.4, 8.1 Hz, 3H). 
No 13C NMR data acquired. 
 
(S)-2-amino-N-((R)-7-(cyclohexylmethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (65). 65 was synthesized following general procedure F 
starting from the (R) amine intermediate 62 (20 mg, 0.0715 mmol, 1.0 eq) to yield crude product 
which was purified by semipreparative HPLC and lyophilized to yield the title compound 65 as a 
TFA salt (35 mg, 89.7%).  1H NMR (500 MHz, CD3OD) δ 8.08 – 8.02 (m, 1H), 6.95 – 6.89 (m, 
3H), 6.49 (s, 2H), 4.98 – 4.93 (m, 1H), 3.92 – 3.81 (m, 1H), 3.25 (d, J = 12.2 Hz, 1H), 3.01 (d, J 
= 14.1 Hz, 1H), 2.60 – 2.54 (bs, 2H), 2.40 – 4.33 (bs, 2H), 2.28 (s, 6H), 1.73 – 1.59 (m, 6H), 
1.58 -1.52 (m, 1H), 1.47 – 1.37 (m, 2H), 1.33 – 1.24 (m, 1H), 1.22- 1.12 (m, 3H), 0.92 (m, 2H). 
13C NMR (126 MHz, CD3OD) δ 168.7, 157.3, 140.1, 139.9, 136.2, 136.0, 130.7, 129.8, 129.5, 
123.2, 116.5, 53.53, 53.49, 48.8, 44.7, 41.1, 34.4, 34.2, 32.0, 30.7, 29.6, 27.7, 27.39, 27.38, 20.5, 
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20.3. HPLC (gradient A): retention time = 47.3. ESI-MS 457.3 [M+H]+. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-7-(naphthalen-2-ylmethyl)-1,2,3,4-
tetrahydronaphthalen-1-yl)propanamide (66). 66 was synthesized following general 
procedure F starting from the (R) amine intermediate 63 (11 mg, 0.034 mmol, 1.0 eq) to yield 
crude product which was purified by semipreparative HPLC and lyophilized to yield the title 
compound 66 as a TFA salt (14 mg, 69.7%).   1H NMR (500 MHz, CD3OD) δ 8.09 (d, J = 8.2 
Hz, 1H), 7.74 (dd, J = 25.4, 7.7 Hz, 4H), 7.56 (s, 1H), 7.40 (p, J = 7.0 Hz, 3H), 7.26 (d, J = 8.3 
Hz, 1H), 7.11 (s, 1H), 7.03 – 6.94 (m, 3H), 6.49 (s, 2H), 5.01 – 4.93 (m, 1H), 4.03 (s, 2H), 3.85 
(dd, J = 11.2, 4.7 Hz, 1H), 3.24 (t, J = 12.5 Hz, 1H), 3.00 (dd, J = 13.5, 4.7 Hz, 1H), 2.65 – 2.55 
(m, 2H), 2.27 (s, 6H), 1.69 – 1.60 (m, 1H), 1.59 – 1.52 (m, 1H), 1.47 – 1.37 (m, 1H), 1.33 – 1.24 
(bs, 1H).  13C NMR (126 MHz, CD3OD) δ 168.8, 157.3, 140.3, 140.0, 139.9, 136.7, 136.6, 135.1, 
133.5, 130.7, 130.4, 129.5, 128.9, 128.6, 128.4, 127.7, 127.0, 126.4, 123.2, 116.5, 111.4, 53.5, 
48.7 , 42.5, 32.0, 30.6, 29.6, 20.5, 20.3. HPLC (gradient A): retention time = 45.6. ESI-MS 479.3 
[M+H]+. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-7-(naphthalen-1-ylmethyl)-1,2,3,4-
tetrahydronaphthalen-1-yl)propanamide (67). 67 was synthesized following general 
procedure F starting from the (R) amine intermediate 64 (7 mg, 0.0216 mmol, 1.0 eq) to yield 
crude product which was purified by semipreparative HPLC and lyophilized to yield the title 
compound 67 as a TFA salt (11 mg, 85.9%).  1H NMR (500 MHz, CD3OD) δ 7.97 (d, J = 8.1 Hz, 
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1H), 7.87 – 7.82 (m, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.49 – 7.34 (m, 3H), 7.22 (d, J = 7.0 Hz, 1H), 
7.13 (s, 1H), 6.95 – 6.84 (m, 2H), 6.49 (d, J = 1.8 Hz, 2H), 4.99 – 4.91 (m, 1H), 4.35 (s, 2H), 
3.84 (ddd, J = 11.5, 5.1, 1.8 Hz, 1H), 3.25 (ddd, J = 13.5, 11.4, 1.9 Hz, 1H), 3.00 (ddd, J = 13.9, 
5.1, 1.7 Hz, 1H), 2.64 – 2.56 (m, 2H), 2.27 (s, 6H), 1.68 -1.59 (m, 1H), 1.59 – 1.51 (m, 1H), 1.46 
– 1.38 (m, 1H), 1.33 – 1.24 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 167.2, 155.9, 138.5, 138.3, 
136.6, 135.2, 135.1, 134.1, 131.9, 129.0, 128.8, 128.2, 127.6, 126.71, 126.69, 125.4, 125.1, 
125.0, 123.8, 121.8, 115.0, 52.1, 47.4, 38.1, 30.6, 29.2, 28.1, 19.1, 18.9. No HPLC retention time 
data. ESI-MS 501.1 [M+Na]+. 
 
 
Synthesized by Larisa Yeomans. Synthesis and characterization can be found in Ref. 23 
 
6-Benzyl-1-isobutyryl-2,3-dihydroquinolin-4(1H)-one (69). 69 was synthesized following 
general procedure M starting from the 30 (100 mg, 0.42 mmol, 1.0 eq), isobutyryl chloride (0.46 
mL, 0.44 mmol, 2.0 eq) and Et3N (0.062 mL, 0.44 mmol, 2.0 eq) to yield crude product which 
was purified to yield the title compound as a clear, colorless oil (105 mg, 80.8%). 1H NMR (500 
MHz, CDCl3) δ 7.87 (d, J = 2.0 Hz, 1H), 7.37 – 7.25 (m, 4H), 7.25 – 7.17 (m, 3H), 4.21 (t, J = 
6.3 Hz, 2H), 3.99 (s, 2H), 3.14 (hept, J = 6.7 Hz, 1H), 2.75 (t, J = 6.2 Hz, 2H), 1.18 (d, J = 6.7 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 194.33, 176.97, 142.29, 140.05, 138.84, 134.59, 128.90, 
128.87, 128.68, 127.64, 126.46, 126.15, 124.22, 43.90, 41.25, 39.79, 31.13, 19.88. 
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Methyl 6-benzyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (70). 70 was synthesized 
following general procedure M starting from the 30 (150 mg, 0.63 mmol, 1.0 eq) and methyl 
chloroformate (0.100 mL, 1.26 mmol, 2.0 eq) yield crude product which was purified to yield the 
title compound as a clear, colorless oil (111 mg, 59.4%). 1H NMR (500 MHz, CDCl3) δ 7.86 (d, 
J = 2.1 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.34 (dd, J = 8.6, 2.2 Hz, 1H), 7.29 (t, J = 7.5 Hz, 2H), 
7.23 – 7.16 (m, 3H), 4.18 (t, J = 6.3 Hz, 2H), 3.97 (s, 2H), 3.84 (s, 3H), 2.76 (t, J = 6.3 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 193.79, 154.23, 141.74, 140.24, 137.32, 134.79, 128.74, 128.51, 
127.13, 126.25, 124.79, 123.58, 53.30, 44.40, 41.09, 38.81.  
 
 
6-Benzyl-1-(2-methoxyacetyl)-2,3-dihydroquinolin-4(1H)-one (71). 71 was synthesized 
following general procedure M starting from the 30 (150 mg, 0.63 mmol, 1.0 eq) and 2-
methoxyacetyl chloride (0.116 mL, 1.26 mmol, 2.0 eq) yield crude product which was purified to 
yield the title compound as a white solid (176 mg, 89.8%). 1H NMR (500 MHz, CDCl3) δ 7.87 
(d, J = 2.2 Hz, 1H), 7.37 (dd, J = 8.4, 2.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.23 – 7.15 (m, 3H), 
4.26 (s, 2H), 4.17 (t, J = 6.3 Hz, 2H), 3.98 (s, 2H), 3.45 (s, 3H), 2.78 (t, J = 6.2 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 193.62, 168.07, 141.25, 139.91, 139.02, 134.72, 128.77, 128.58, 
128.55, 127.56, 126.37, 125.78, 123.66, 76.74, 71.84, 59.24, 43.95, 41.17, 39.41. 
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1-Benzoyl-6-benzyl-2,3-dihydroquinolin-4(1H)-one (72). 72 was synthesized following 
general procedure M starting from the 30 (100 mg, 0.42 mmol, 1.0 eq) and benzoyl chloride (100 
mL, 0.84 mmol, 2.0 eq) to yield crude product which was purified to yield the title compound as 
a clear, slightly yellow oil (139 mg, 96.5%). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 2.1 Hz, 
1H), 7.42 – 7.34 (m, 3H), 7.31 – 7.25 (m, 2H), 7.22 – 7.17 (m, 2H), 7.14 – 7.10 (m, 1H), 7.08 – 
7.04 (m, 2H), 7.01 (dd, J = 8.5, 2.2 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 4.21 (t, J = 6.3 Hz, 2H), 
3.85 (s, 2H), 2.77 (t, J = 6.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 193.73, 170.04, 142.60, 
139.99, 138.06, 135.06, 134.31, 130.99, 128.78, 128.58, 128.47, 128.39, 127.38, 126.36, 124.82, 
124.63, 45.30, 41.10, 39.50. 
 
(R)-N-((R)-6-benzyl-1-isobutyryl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide (73). 73 was synthesized following general procedure H using 69 (105 mg, .34 
mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (124 mg, 1.02 mmol, 3.0 eq), and Ti(OEt)4 
(0.430 mL, 2.05 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in situ. 
Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction mixture 
was transferred via cannula to a round bottom flask containing NaBH4 (77 mg, 2.05 mmol, 6.0 
eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was stirred at room 
temperature for 3 h before being quenched with MeOH. Once resultant solid was removed, crude 
residue was purified using silica gel chromatography to yield the title compound as a clear, 
colorless oil (70 mg, 50%). 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.26 (m, 3H), 7.24 – 7.19 (m, 
3H), 7.10 (dd, J = 8.2, 2.2 Hz, 1H), 4.53 (q, J = 3.9 Hz, 1H), 3.96 (s, 2H), 3.94 – 3.89 (m, 1H), 
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3.75 – 3.67 (m, 1H), 3.30 (bs, 1H), 3.12 (p, J = 6.9 Hz, 1H), 2.24 – 2.15 (m, 1H), 2.08 – 1.98 (m, 
1H), 1.23 – 1.16 (s, 9H), 1.13 (dd, J = 9.0, 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 177.35, 
140.53, 138.70, 136.67, 128.92, 128.67, 128.58, 128.54, 126.28, 124.60, 55.76, 51.04, 41.37, 
40.00, 31.09, 30.96, 22.55, 20.03, 20.01. 
 
 
Methyl(R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-
carboxylate (74). 74 was synthesized following general procedure H using 70 (111 mg, 0.376 
mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (137 mg, 1.13 mmol, 3.0 eq), and Ti(OEt)4 
(0.473 mL, 2.26 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in situ. 
Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction mixture 
was transferred via cannula to a round bottom flask containing NaBH4 (85 mg, 2.26 mmol, 6.0 
eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was stirred at room 
temperature for 3 h before being quenched with MeOH. Once resultant solid was removed, crude 
residue was purified using silica gel chromatography to yield the title compound as a clear, 
colorless oil (124 mg, 82.1%). 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.7 Hz, 1H), 7.27 (t, J 
= 7.8 Hz, 2H), 7.23 – 7.16 (m, 4H), 7.11 – 7.06 (m, 1H), 4.54 (q, J = 3.6 Hz, 1H), 4.01 (dt, J = 
13.0, 4.6 Hz, 1H), 3.93 (s, 2H), 3.78 (d, J = 1.0 Hz, 3H), 3.64 (ddd, J = 12.9, 11.1, 3.8 Hz, 1H), 
3.26 (d, J = 2.7 Hz, 1H), 2.24 – 2.14 (m, 1H), 2.03 – 1.94 (m, 1H), 1.20 (d, J = 1.0 Hz, 9H). 13C 
NMR (126 MHz, CDCl3) δ 154.94, 140.75, 137.11, 136.11, 129.11, 128.79, 128.77, 128.57, 
128.44, 126.09, 126.08, 123.68, 55.59, 52.94, 50.24, 41.15, 40.23, 29.43, 22.51. 
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(R)-N-((R)-6-benzyl-1-(2-methoxyacetyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide (75). 75 was synthesized following general procedure H using 
71 (176 mg, 0.60 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (207 mg, 1.71 mmol, 3.0 
eq), and Ti(OEt)4 (0.716 mL, 3.41 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine  
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 48 h), 
the reaction mixture was transferred via cannula to a round bottom flask containing NaBH4 (129 
mg, 3.41 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution 
was stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid 
was removed, crude residue was purified using silica gel chromatography to yield the title 
compound as a clear, colorless oil (148 mg, 62.7%). 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.24 
(m, 3H), 7.18 (d, J = 7.6 Hz, 3H), 7.09 (dd, J = 8.3, 2.0 Hz, 1H), 4.52 (q, J = 4.3 Hz, 1H), 4.17 
(s, 2H), 3.93 (s, 2H), 3.79 (d, J = 40.2 Hz, 11H), 3.44 (d, J = 3.6 Hz, 1H), 3.39 (s, 3H), 2.20 (dq, 
J = 14.5, 4.9 Hz, 1H), 2.04 (qd, J = 9.2, 8.7, 5.0 Hz, 1H), 1.20 (s, 35H), 1.17 (s, 10H). 13C NMR 
(126 MHz, CDCl3) δ 168.45, 140.40, 135.69, 128.97, 128.82, 128.68, 128.50, 128.46, 128.21, 
126.20, 126.14, 123.95,71.69, 59.16, 55.72, 55.22, 50.80, 41.38, 41.29, 39.90, 30.47, 29.60, 
22.52, 22.21, 22.07. 
 
 
(R)-N-((R)-1-benzoyl-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide (76). 76 was synthesized following general procedure H using 72 (139 mg, 0.41 
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mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (148 mg, 1.22 mmol, 3.0 eq), and Ti(OEt)4 
(0.512 mL, 2.44 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in situ. 
Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction mixture 
was transferred via cannula to a round bottom flask containing NaBH4 (92 mg, 2.44 mmol, 6.0 
eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was stirred at room 
temperature for 3 h before being quenched with MeOH. Once resultant solid was removed, crude 
residue was purified using silica gel chromatography to yield the title compound as an off-white 
solid (127 mg, 69.8%). 1H NMR (500 MHz, CDCl3) δ 7.31 (td, J = 8.0, 1.4 Hz, 3H), 7.27 – 7.15 
(m, 5H), 7.14 – 7.09 (m, 1H), 7.09 – 7.04 (m, 2H), 6.78 (t, J = 9.0 Hz, 2H), 4.54 (q, J = 3.9 Hz, 
1H), 3.93 (dt, J = 12.5, 5.1 Hz, 1H), 3.82 (s, 2H), 3.78 – 3.68 (m, 1H), 3.32 (d, J = 3.1 Hz, 1H), 
2.20 (dq, J = 14.0, 4.7 Hz, 1H), 2.02 (ddt, J = 14.5, 9.9, 5.0 Hz, 1H), 1.13 (d, J = 1.5 Hz, 11H). 
13C NMR (126 MHz, CDCl3) δ 170.22, 140.50, 138.06, 136.69, 135.96, 130.33, 129.87, 128.79, 
128.68, 128.46, 128.34, 128.32, 128.23, 126.15, 125.31, 60.32, 55.72, 50.61, 41.47, 41.19, 30.24, 
22.53, 20.99, 14.15. 
 
 
(S)-2-amino-N-((R)-6-benzyl-1-isobutyryl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (77). 77 was synthesized following general procedure I using 
73 (70 mg, 0.17 mmol, 1.0 eq) and conc. HCl (0.1 mL, 1.0 mmol, 6.0 eq). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (58 mg). Then by following general procedure F with newly formed (R) amine 
intermediate (58 mg, 0.17 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound as a TFA salt (42 mg, 40.7 % 
from 73). Note that not all crude product was purified.  δ 1H NMR (500 MHz, CD3OD) δ 8.18 (d, 
J = 8.2 Hz, 0H), 7.19 (dt, J = 35.4, 7.7 Hz, 6H), 7.04 (d, J = 8.3 Hz, 3H), 6.51 (s, 2H), 3.92 (d, J 
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= 14.2 Hz, 3H), 3.26 (t, J = 12.6 Hz, 1H), 3.12 (ddt, J = 41.3, 13.4, 5.3 Hz, 4H), 2.27 (s, 7H), 
1.86 (dq, J = 12.6, 6.2 Hz, 1H), 1.37 (dd, J = 12.8, 6.4 Hz, 1H), 1.12 (d, J = 6.6 Hz, 5H), 1.05 (d, 
J = 6.9 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 179.32, 169.29, 162.72, 157.37, 142.26, 
140.05, 137.53, 129.77, 129.45, 129.20, 127.13, 125.65, 123.29, 116.40, 53.46, 46.89, 42.12, 
32.38, 31.92, 31.83, 20.44, 20.17, 19.90. HPLC (gradient A): retention time 37.8. ESI-MS 500.3 
[M+H]+ and 522.3 [M+Na]+. 
 
 
Methyl (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-3,4-
dihydroquinoline-1(2H)-carboxylate (78). 78 was synthesized following general procedure I 
using 74 (124 mg, 0.31 mmol, 1.0 eq) and conc. HCl (5 µL, 1.86 mmol, 6.0 eq). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (79 mg). Then by following general procedure F with newly formed (R) amine 
intermediate (40 mg, 0.12 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 78 as a TFA salt (50 mg, 
69.5% from 74).  1H NMR (400 MHz, CD3OD) δ 7.65 (d, J = 8.6 Hz, 1H), 7.26 – 7.20 (m, 2H), 
7.17 – 7.12 (m, 3H), 7.07 (d, J = 2.2 Hz, 1H), 7.03 (dd, J = 8.8, 1.9 Hz, 1H), 6.50 (s, 2H), 4.97 (t, 
J = 5.2 Hz, 1H), 3.87 (s, 2H), 3.86 – 3.81 (m, 1H), 3.75 (d, J = 1.4 Hz, 4H), 3.25 (ddd, J = 13.1, 
11.5, 1.4 Hz, 1H), 3.16 (tdd, J = 6.7, 3.8, 1.4 Hz, 12H), 3.05 – 2.94 (m, 2H), 2.27 (d, J = 1.4 Hz, 
7H), 1.90 – 1.82 (m, 12H), 1.77 (tt, J = 9.7, 4.8 Hz, 1H), 1.54 – 1.45 (m, 1H). No 13C data 
acquired. HPLC (gradient A): retention time 36.6. ESI-MS 488.3 [M+H]+ and 510.3 [M+Na]+. 
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(S)-2-amino-N-((R)-6-benzyl-1-(2-methoxyacetyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (79). 79 was synthesized following general 
procedure I using 75 (148 mg, 0.36 mmol, 1.0 eq) and conc. HCl (5 µL, 2.14 mmol, 6.0 eq). 
After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing 
the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (106 mg). Then by following general procedure F with newly formed (R) 
amine intermediate (55 mg, 0.159 mmol) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound as a TFA salt (79). No yield 
was determined because only a fraction of crude product was purified.  1H NMR (400 MHz, 
CD3OD) δ 7.23 (t, J = 7.8 Hz, 2H), 7.14 (dd, J = 9.3, 2.6 Hz, 4H), 7.07 (dd, J = 8.4, 1.9 Hz, 1H), 
6.51 (s, 2H), 4.96 (t, J = 5.7 Hz, 1H), 4.25 (dd, J = 14.6, 1.1 Hz, 1H), 4.14 (d, J = 14.5 Hz, 1H), 
3.90 (s, 2H), 3.84 (dd, J = 11.5, 5.0 Hz, 1H), 3.40 (s, 3H), 3.25 (t, J = 12.6 Hz, 1H), 3.15 (tdd, J 
= 6.7, 3.7, 1.2 Hz, 7H), 3.02 (dd, J = 13.7, 5.0 Hz, 1H), 2.27 (s, 6H), 1.88 – 1.81 (m, 8H), 1.48 
(s, 1H). No 13C data acquired. HPLC (gradient A): retention time 32.5. ESI-MS 502.3 [M+H]+ 
and 524.3 [M+Na]+. 
 
(S)-2-amino-N-((R)-1-benzoyl-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (80). 80 was synthesized following general procedure I using 76 
(182 mg, 0.41 mmol, 1.0 eq) and conc. HCl (6 µL, 2.45 mmol, 6.0 eq). After removing solvent, 
residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh 
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Et2O, the remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (154 
mg). Then by following general procedure F with newly formed (R) amine intermediate (77 mg, 
0.20 mmol) to yield crude product which was purified by semipreparative HPLC and lyophilized 
to yield the title compound 80 as a TFA salt. No yield was determined because only a fraction of 
crude product was purified  1H NMR (400 MHz, CD3OD) δ 7.47 – 7.42 (m, 1H), 7.37 (d, J = 6.8 
Hz, 4H), 7.25 – 7.20 (m, 2H), 7.15 (d, J = 7.6 Hz, 1H), 7.11 (d, J = 7.6 Hz, 2H), 6.87 – 6.76 (m, 
2H), 6.49 (s, 2H), 5.04 (t, J = 6.0 Hz, 1H), 3.92 – 3.81 (m, 4H), 3.25 (d, J = 12.3 Hz, 1H), 3.06 
(dd, J = 13.8, 5.1 Hz, 1H), 2.28 (s, 6H), 1.94 (t, J = 10.4 Hz, 1H), 1.48 (dd, J = 13.0, 6.3 Hz, 1H). 
13C NMR (126 MHz, CD3OD) δ 172.42, 169.14, 157.49, 142.26, 140.04, 139.67, 137.75, 137.19, 
131.74, 130.37, 129.71, 129.50, 129.45, 129.39, 128.99, 127.15, 126.27, 123.18, 116.45, 53.53, 
49.00, 46.85, 42.06, 31.98, 31.42, 20.44. 
 
 
Tert-butyl 6-benzyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (81). 81 was synthesized 
following general procedure G using 30 (1.1 g, 4.63 mmol, 1.0 eq), Boc2O (1.52 g, 6.95 mmol, 
1.5 eq), DMAP (57 mg, 0.463 mmol, 0.1 eq) and DIPEA (1.21 mL, 6.95 mmol, 1.5 eq). 
Following the quench and work-up, the crude product was chromatographed on silica gel (equil 
in 100% hex, run in 2:3 EA:hex) to yield pure product as a white solid (1.1 g, 70.2%). 1H NMR 
(500 MHz, CDCl3) δ 7.76 (t, J = 2.0 Hz, 1H), 7.60 (dd, J = 8.2, 1.8 Hz, 1H), 7.27 – 7.17 (m, 3H), 
7.15 – 7.07 (m, 3H), 4.08 – 4.02 (m, 2H), 3.88 (s, 2H), 2.66 (td, J = 6.5, 6.0, 1.7 Hz, 2H), 1.47 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 194.22, 152.71, 142.35, 140.37, 136.84, 134.60, 128.78, 
128.53, 127.11, 126.24, 124.76, 123.80, 82.04, 44.23, 41.12, 38.95, 28.25. HPLC (gradient A): 
retention time 39.9. ESI-MS 534.3 [M+H]+ and 556.2 [M+Na]+. 
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Tert-butyl(R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-
carboxylate (82). 82 was synthesized following general procedure H using 81 (1.1g, 4.8 mmol, 
1.0 eq), (R)-2-methylpropane-2-sulfinamide (175 mg, 1.44 mmol, 3.0 eq), and Ti(OEt)4 (0.604 
mL, 2.88 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine  intermediate in situ. Once 
sufficient ketone was converted into imine intermediate (after 48 h), the reaction mixture was 
transferred via cannula to a round bottom flask containing NaBH4 (109 mg, 2.44 mmol, 6.0 eq) 
and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was stirred at room 
temperature for 3 h before being quenched with MeOH. Once resultant solid was removed, crude 
residue was purified using silica gel chromatography to yield the title compound as a clear, 
colorless oil (175 mg, 82.2%). 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 8.2 Hz, 1H), 7.29 – 
7.21 (m, 2H), 7.20 - 7.15 (qd, J = 6.5, 5.4, 1.6 Hz, 4H), 7.06 (dd, J = 8.5, 2.3 Hz, 1H), 4.52 (q, J 
= 3.4 Hz, 1H), 3.97 – 3.87 (m, 3H), 3.57 (tdd, J = 12.9, 4.2, 1.7 Hz, 1H), 3.32 (bs, 1H), 2.20 – 
2.13 (m, 1H), 1.99 – 1.90 (m, 1H), 1.50 (s, 9H), 1.19 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
153.43, 140.77, 136.51, 136.42, 128.88, 128.71, 128.55, 128.47, 128.34, 125.97, 123.89, 80.97, 
55.52, 50.36, 41.08, 40.00, 29.41, 28.22, 22.48. 
 
 
 
 
(R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-aminium chloride (83). 83 was synthesized by first 
treating 82 (400 mg, 0.904 mml, 1.0 eq) with excess 1:1 TFA: DCM. After 1 h, solvent was 
removed under reduced pressure. Next, following general procedure I, the Ellman auxillary was 
cleaved using conc. HCl (0.133 mL, 5.43 mmol, 6.0 eq). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding the title compound as tan solid (110 mg, 44.4% from 
82). 1H NMR (500 MHz, CD3OD) δ 7.68 (d, J = 1.8 Hz, 1H), 7.44 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 
(d, J = 8.3 Hz, 1H), 7.31 – 7.24 (m, 4H), 7.22 – 7.17 (m, 1H), 4.77 (t, J = 6.0 Hz, 1H), 4.06 (s, 
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2H), 3.73 (ddd, J = 12.4, 9.0, 3.1 Hz, 1H), 3.65 (ddd, J = 13.0, 7.8, 3.3 Hz, 1H), 2.61 (dddd, J = 
14.8, 9.0, 5.7, 3.3 Hz, 1H), 2.38 (dddd, J = 14.8, 7.8, 6.4, 3.1 Hz, 1H). No 13C NMR data 
acquired. 
 
 
Tert-butyl((S)-1-(((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)amino)-3-(4-((tert-
butoxycarbonyl)oxy)-2,6-dimethylphenyl)-1-oxopropan-2-yl)carbamate (84). 84 was 
synthesized following a modified version of general procedure F using 83 (110 mg, 0.40 mmol, 
1.0 eq). After coupling to diBoc-Dmt, residue was not deprotected with TFA. Instead, the crude 
residue was purified by semipreparative HPLC and lyophilized to yield the title compound 84 
(287 mg, quant). HPLC (gradient A): retention time = 57.0. ESI-MS 630.3 [M+H]+ and ESI-MS 
652.3 [M+Na]+. No 1H or 13C NMR data acquired. 
 
Tert-butyl((S)-1-(((R)-1-(2-amino-2-oxoethyl)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-
yl)amino)-3-(4-((tert-butoxycarbonyl)oxy)-2,6-dimethylphenyl)-1-oxopropan-2-
yl)carbamate (85). To form 85 from 84, first acetone was degassed for 30 min, then flooded 
with Ar for an additional 30 min. To a flame-dried round bottom flask equipped with a stir bar 
with Ar atmosphere was added sodium iodide (25 mg, 0.16 mmol, 2.0 eq) and 2-chloroacetamide 
(15 mg, 0.16 mmol, 2.0 eq), which was then placed back under vacuum. Next, 10 mL of 
degassed acetone was added to the reaction vessel via cannula, reaction stirred for 10 min. 
Meanwhile, to another flame-dried round bottom flask equipped with a stirbar was added 84, 
degassed acetone, followed by DIPEA (0.021 mL, 0.12 mmol, 1.5 eq) and the solution stirred for 
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10 min. Next, the contents of the round bottom flask containing the sodium iodide and 2-
chloroacetamide was transferred to the flask containing 84 via cannula. The reaction stirred 
stirred at room temp for 24 h. The next day, the solvent was removed under reduced pressure to 
yield the crude product (13 mg) that was taken ahead to next step (formation of 88) without 
further purification, isolation or characterization. HPLC (gradient A): retention time = 60.5. ESI-
MS 687.3 [M+H]+ and ESI-MS 709.3 [M+Na]+. No 1H or 13C NMR data acquired. 
 
 
Ethyl2-((R)-6-benzyl-4-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-((tert-
butoxycarbonyl)oxy)-2,6-dimethylphenyl)propanamido)-3,4-dihydroquinolin-1(2H)-
yl)acetate (86).  To synthesize 86, 84 (214 mg, 0.34 mmol, 1.0 eq) and K2CO3 (94 mg, 0.68 
mmol, 2.0 eq) were placed in a round bottom flask and the atmosphere was evacuated then the 
reaction vessel was flooded with Ar. Anhydrous CH3CN was added via syringe and the solution 
stirred for 15 min. Next, bromo ethylacetate (0.377 mL, 3.4 mmol, 10 eq) was added to the 
reaction vessel, which was equipped with a condenser and placed in an 80˚C oil bath. After 6 h, 
no reaction was taking place (reaction was monitored by TLC). Reaction vessel was taken off 
heat and stirred overnight at RT. After 24 h, the solvent was removed under reduced pressure and 
crude residue was resuspended in DCM and dI H2O and the layers separated. The organic layer 
was washed with 5% citric acid solution (1 x 20 mL) and then with brine (1 x 20 mL), dried over 
MgSO4 to yield the crude residue of 86. HPLC (gradient A): retention time = 72.4. ESI-MS 
716.3 [M+H]+ and ESI-MS 738.3 [M+Na]+. The residue was carried forward (to synthesize 87 
and 89) without further purification, isolation or characterization. No 1H or 13C NMR data 
acquired. 
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2-((R)-6-benzyl-4-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-((tert-butoxycarbonyl)oxy)-2,6-
dimethylphenyl)propanamido)-3,4-dihydroquinolin-1(2H)-yl)acetic acid (87). 87 was 
synthesized by treating crude 86 (107 mg, 0.15 mmol, 1.0 eq) with LiOH (excess) in EtOH at 
60˚C for 2.5 h. Reaction was monitored for loss of starting material by analytical HPLC 
((gradient A): starting material retention time = 72.4). Once starting material was consumed, 
solvent was removed under reduced pressure. HPLC (gradient A): retention time = 49.9. The 
residue was carried forward (90) without further purification, isolation or characterization. No 1H 
or 13C NMR data acquired. 
 
(S)-2-amino-N-((R)-1-(2-amino-2-oxoethyl)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (88). 88 was synthesized from 84 by boc-
deprotection using 1:1 TFA:DCM. After removal of solvent under reduced pressure, the crude 
product was purified by semipreparative HPLC and lyophilized to yield the title compound 88 (2 
mg, 18%). HPLC (gradient A): retention time = 29.8. ESI-MS 509.3 [M+H]+. 1H NMR (500 
MHz, CD3OD) δ 8.33 (d, J = 7.8 Hz, 1H), 7.19 (t, J = 7.4 Hz, 2H), 7.14 – 7.07 (m, 3H), 6.92 (d, 
J = 8.5 Hz, 1H), 6.86 (s, 1H), 6.46 (s, 2H), 6.38 (d, J = 8.5 Hz, 1H), 3.91 (d, J = 17.8 Hz, 1H), 
3.80 (dd, J = 11.8, 5.1 Hz, 1H), 3.76 (s, 2H), 3.66 – 3.59 (m, 1H), 3.25 (t, J = 12.4 Hz, 1H), 3.00 
(dd, J = 13.6, 5.1 Hz, 1H), 2.86 (d, J = 12.1 Hz, 1H), 2.38 (t, J = 12.1 Hz, 1H), 1.81 (t, J = 13.1 
Hz, 1H), 1.52 (d, J = 13.4 Hz, 1H), 1.29 (s, 1H). 13C NMR (126 MHz, CD3OD) δ 175.88, 
157.43, 144.84, 140.04, 131.51, 131.21, 130.86, 129.63, 129.29, 126.85, 123.21, 121.80, 116.48, 
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112.92, 66.62, 55.53, 53.45, 49.00, 47.37, 47.27, 46.62, 41.77, 31.89, 28.93, 20.46. HPLC 
(gradient A): retention time 29.8. ESI-MS 487.3.3 [M+H]+ and 509.3 [M+Na]+. 
 
 
Ethyl 2-((R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-3,4-
dihydroquinolin-1(2H)-yl)acetate (89). 89 was synthesized by treating crude 86 with 3 N HCl 
to remove the remaining boc-groups and yield the crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 89 (44 mg, 41.1%).1H NMR 
(500 MHz, CD3OD) δ 8.17 (d, J = 7.6 Hz, 1H), 7.22 – 7.17 (m, 2H), 7.14 – 7.07 (m, 3H), 6.92 – 
6.85 (m, 2H), 6.43 (s, 2H), 6.39 (d, J = 8.4 Hz, 1H), 4.87 (s, 6H), 4.24 (s, 0H), 4.23 – 4.15 (m, 
2H), 3.81 (q, J = 5.3 Hz, 1H), 3.76 (d, J = 8.6 Hz, 2H), 3.31 (s, 2H), 3.25 (dd, J = 13.5, 11.8 Hz, 
1H), 3.00 (dd, J = 13.6, 5.0 Hz, 1H), 2.85 (dt, J = 11.8, 4.1 Hz, 1H), 2.42 (td, J = 12.3, 3.2 Hz, 
1H), 2.27 (s, 6H), 1.75 (tt, J = 12.8, 4.1 Hz, 1H), 1.57 (dq, J = 13.3, 3.5 Hz, 1H), 1.29 (td, J = 7.1, 
1.0 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 173.03, 168.05, 157.42, 144.44, 143.28, 140.00, 
131.60, 131.03, 130.84, 129.64, 129.29, 126.84, 123.20, 121.53, 116.47, 112.40, 62.35, 53.49, 
53.20, 49.51, 49.34, 49.17, 49.00, 48.83, 48.66, 48.49, 47.56, 46.18, 41.75, 31.87, 28.78, 20.48, 
14.51. HPLC (gradient A): retention time = 41.7. ESI-MS 516.3 [M+H]+ and 538.3 [M+Na]+. 
 
 
2-((R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-3,4-
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dihydroquinolin-1(2H)-yl)acetic acid (90). 90 was formed by treating the crude residue of 87 
with 1:1 TFA:DCM to form crude product which was purified by semipreparative HPLC and 
lyophilized to yield the title compound 90. No yield was determined because only a fraction of 
crude product was purified. HPLC (gradient A): retention time = 26.4. ESI-MS 488.3 [M+H]+ 
and 510.3 [M+Na]+. No 1H or 13C NMR data acquired. Instead, formation of final product 
verified by mass spectrometry. 
 
 
6-((2,3-Dihydro-1H-inden-2-yl)methyl)-1-propionyl-2,3-dihydroquinolin-4(1H)-one (91). 91 
was synthesized according to general procedure N using 6 (155 mg, 0.56 mmol, 1.0 eq) and 
excess propionic anhydride. Once complete, excess anhydride was removed and the crude 
residue was purified using silica gel chromatography to yield the title compound 91 as a clear, 
colorless oil (136 mg, 76.1%) 1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.42 (s, 1H), 7.39 (s, 
1H), 7.16 (q, J = 4.1 Hz, 2H), 7.12 (q, J = 4.5 Hz, 2H), 4.23 (t, J = 6.3 Hz, 2H), 3.00 (dd, J = 
15.3, 6.7 Hz, 2H), 2.85 - 2.74 (m, 5H), 2.69 – 2.57 (m, 4H), 1.23 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 194.25, 172.94, 142.73, 141.93, 138.80, 134.59, 127.42, 126.15, 125.92, 
124.42, 124.12, 43.81, 41.07, 40.65, 39.53, 38.71, 27.88, 9.79. 
 
 
1-Butyryl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (92). 92 
was synthesized according to general procedure N using 6 (320 mg, 1.2 mmol, 1.0 eq) and 
excess butyric anhydride. Once complete, excess anhydride was removed and the crude residue 
was purified using silica gel chromatography to yield the title compound 92 as a clear, colorless 
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oil (152 mg, 37.9%) 1H NMR (500 MHz, CDCl3) δ 7.85 (s, 1H), 7.40 (s, 1H), 7.18 – 7.14 (m, 
2H), 7.13 -7.08 (m, 2H), 4.22 (t, J = 6.4 Hz, 2H), 2.99 (dd, J = 15.4, 6.8 Hz, 2H), 2.82 – 2.71 (m, 
5H), 2.66 (dd, J = 15.4, 6.5 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 1.75 (h, J = 7.4 Hz, 2H), 0.97 (t, J 
= 7.4 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 194.25, 172.14, 142.68, 141.85, 138.74, 134.55, 
127.34, 126.09, 125.83, 124.36, 124.12, 43.80, 41.00, 40.58, 39.55, 38.64, 36.32, 18.99, 13.70. 
 
 
Methyl6-((2,3-dihydro-1H-inden-2-yl)methyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate (93). 93 was synthesized using a modified general procedure N using 6 (250 mg, 
0.90 mmol, 1.0 eq), ethyl methyl dicarbonate (0.150 mL, 1.4 mmol, 1.5 eq), DMAP (11 mg, 0.09 
mmol, 0.1 eq), and DIPEA (235 mL, 1.4 mmol, 1.5 eq). The reaction stirred overnight, once 
complete, solvent was removed and the crude residue was purified using silica gel 
chromatography to yield the title compound 93 as a clear, colorless oil (38 mg, 12.6%). Starting 
material was recovered, but not included in final yield calculation. 1H NMR (500 MHz, CDCl3) δ 
7.85 (d, J = 2.2 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.38 (dd, J = 8.6, 2.3 Hz, 1H), 7.19 – 7.15 (m, 
2H), 7.15 – 7.10 (m, 2H), 4.21 (t, J = 6.3 Hz, 2H), 3.86 (s, 3H), 2.99 (dd, J = 15.5, 6.3 Hz, 2H), 
2.81 – 2.77 (m, 5H), 2.66 (dd, J = 15.2, 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 194.02, 
154.35, 142.90, 141.65, 137.58, 134.94, 127.11, 126.17, 124.79, 124.48, 123.42, 109.98, 53.39, 
44.50, 41.19, 40.64, 38.92, 38.77. 
 
 
(R)-N-((R)-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1-propionyl-1,2,3,4-tetrahydroquinolin-
4-yl)-2-methylpropane-2-sulfinamide (94). 94 was synthesized according to general procedure 
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H using 91 (136 mg, 0.41 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (148 mg, 1.22 
mmol, 3.0 eq), and Ti(OEt)4 (0.51 mL, 2.4 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl 
imine intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 
48 h), the reaction mixture was transferred via cannula to a round bottom flask containing 
NaBH4 (93 mg, 2.4 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the 
solution was stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography to yield 
the title compound 94 as a clear, colorless oil (87 mg, 48.6%). 1H NMR (500 MHz, CDCl3) δ 
7.29 – 7.27 (bs, 1H), 7.19 – 7.15 (m, 2H), 7.15 – 7.10 (m, 3H), 4.56 (q, J = 4.2 Hz, 1H), 3.93 (dt, 
J = 12.7, 5.4 Hz, 1H), 3.76 (ddd, J = 12.7, 9.5, 5.1 Hz, 1H), 3.32 (d, J = 3.5 Hz, 1H), 3.04 – 2.95 
(m, 2H), 2.81 – 2.71 (m, 3H), 2.67 (dd, J = 15.1, 5.5 Hz, 2H), 2.53 (qt, J = 7.2, 1.2 Hz, 2H), 2.27 
- 2.16 (m, 1H), 2.12 – 2.01 (m, 1H), 1.22 (d, J = 1.2 Hz, 9H), 1.18 (td, J = 7.4, 1.2 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 173.44, 142.96, 142.94, 138.73, 136.41, 128.67, 128.61, 126.10, 
124.59, 124.43, 124.42, 55.69, 50.97, 41.23, 40.80, 39.92, 38.82, 38.78, 30.73, 28.07, 22.53, 
9.96. 
 
(R)-N-((R)-1-butyryl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-
yl)-2-methylpropane-2-sulfinamide (95). 95 was synthesized according to general procedure H 
using 92 (152 mg, 0.44 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (159 mg, 1.3 mmol, 
3.0 eq), and Ti(OEt)4 (0.55 mL, 2.6 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine 
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 48 h), 
the reaction mixture was transferred via cannula to a round bottom flask containing NaBH4 (99 
mg, 2.6 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution 
was stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid 
was removed, crude residue was purified using silica gel chromatography to yield the title 
compound as a clear, colorless oil (198 mg, quant). No 1H or 13C NMR spectrum acquired. 
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Instead, product taken ahead to next reaction (formation of 98) without any further isolation, 
purification, or characterization. 
 
 
Methyl(R)-4-(((R)-tert-butylsulfinyl)amino)-6-((2,3-dihydro-1H-inden-2-yl)methyl)-3,4-
dihydroquinoline-1(2H)-carboxylate (96). 96 was synthesized according to general procedure 
H using 93 (94 mg, 0.28 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (102 mg, 0.84 
mmol, 3.0 eq), and Ti(OEt)4 (1.06 mL, 1.7 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl 
imine intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 
48 h), the reaction mixture was transferred via cannula to a round bottom flask containing 
NaBH4 (191 mg, 1.7 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, 
the solution was stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography to yield 
the title compound as a clear, colorless oil (8 mg, 6.5%). 1H NMR (500 MHz, CDCl3) δ 7.80 – 
7.72 (m, 1H), 7.22 (bs, 1H), 7.17 (s, 2H), 7.14 – 7.08 (m, 3H), 4.58 (bs, 1H), 4.05 (dd, J = 11.4, 
5.9 Hz, 1H), 3.81 (d, J = 1.9 Hz, 3H), 3.69 – 3.59 (m, 1H), 3.28 (s, 1H), 2.99 (d, J = 14.9 Hz, 
2H), 2.74 (s, 3H), 2.70 – 2.61 (m, 2H), 2.24 – 2.14 (m, 1H), 2.02 (t, J = 12.7 Hz, 1H), 1.22 (d, J 
= 1.8 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 175.35, 155.02, 143.08, 143.06, 137.41, 136.00, 
129.23, 128.93, 128.42, 126.11, 124.48, 124.45, 123.49, 55.63, 53.02, 50.32, 41.36, 40.67, 40.25, 
38.86, 38.84, 22.57.  
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(S)-2-amino-N-((R)-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1-propionyl-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (97). 97 was 
synthesized following general procedure I using 94 (87 mg, 0.20 mmol, 1.0 eq) and conc. HCl 
(0.029 mL, 1.2 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and 
solid crashed out. After washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted 
off, yielding a white solid amine hydrochloride salt (60 mg). The synthesis was completed by 
following general procedure F with newly formed (R) amine intermediate (18 mg, 0.16 mmol) to 
yield crude product which was purified by semipreparative HPLC and lyophilized to yield the 
title compound as a TFA salt (31 mg, quant.).1H NMR (500 MHz, CD3OD) δ 7.43 (s, 1H), 7.16 – 
7.03 (m, 6H), 6.51 (s, 2H), 4.96 (t, J = 6.3 Hz, 1H), 3.87 (dd, J = 11.4, 4.9 Hz, 1H), 3.81 (s, 1H), 
3.30 – 3.22 (m, 1H), 3.19 (s, 1H), 3.04 (dd, J = 13.7, 5.0 Hz, 1H), 2.98 – 2.85 (m, 2H), 2.77 - 
2.68 (m, 3H), 2.66 – 2.59 (m, 2H), 2.59 – 2.42 (m, 2H), 2.28 (s, 6H), 1.88 (ddt, J = 13.4, 8.0, 5.3 
Hz, 1H), 1.49 – 1.37 (m, 1H), 1.18 – 1.08 (t, 3H). 13C NMR (126 MHz, CD3OD) δ 175.80, 
169.18, 157.46, 144.09, 144.05, 140.07, 137.41, 129.16, 127.21, 125.64, 125.37, 125.35, 123.25, 
116.44, 53.49, 47.02, 42.76, 41.85, 39.88, 39.66, 31.97, 31.47, 28.91, 20.43, 10.12. HPLC 
(gradient A): retention time 40.6. ESI-MS 526.1 [M+H]+ and 548.1 [M+Na]+. 
 
(S)-2-amino-N-((R)-1-butyryl-6-((2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (98). 98 was 
synthesized following general procedure I using 95 (198 mg, 0.44 mmol, 1.0 eq) and conc. HCl 
(0.064 mL, 2.6 mmol, 6.0 eq). After removing solvent, residue was re-suspended in Et2O, and 
solid crashed out. After washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted 
off, yielding a white solid amine hydrochloride salt (168 mg). The synthesis was completed by 
following general procedure F with newly formed (R) amine intermediate (168 mg, 0.44 mmol, 
1.0 eq) to yield crude product which was purified by semipreparative HPLC and lyophilized to 
yield the title compound 98 as a TFA salt (9 mg). No percent yield done because not all crude 
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material was purified. 1H NMR (500 MHz, CD3OD) δ 7.12 (t, J = 5.4 Hz, 7H), 7.07 (dt, J = 5.6, 
2.7 Hz, 2H), 6.51 (s, 2H), 4.95 (s, 1H), 3.92 – 3.78 (m, 2H), 3.18 (bs, 2H), 3.05 (dd, J = 13.5, 5.1 
Hz, 1H), 2.99 – 2.86 (m, 2H), 2.73 (d, J = 14.5 Hz, 3H), 2.66 – 2.57 (m, 2H), 2.49 (q, J = 7.1 Hz, 
2H), 2.28 (s, 6H), 1.88 (dq, J = 12.9, 6.5, 6.0 Hz, 1H), 1.65 (q, J = 7.7 Hz, 2H), 1.41 (s, 1H), 0.95 
(t, J = 7.7 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 174.96, 169.19, 157.46, 144.09, 144.05, 
140.06, 137.40, 129.13, 127.21, 125.68, 125.37, 125.36, 123.25, 116.45, 53.50, 46.97, 42.74, 
41.86, 39.88, 39.66, 37.53, 31.97, 31.63, 27.61, 20.44, 20.07, 14.11. HPLC (gradient A): 
retention time 44.8. ESI-MS 540.3 [M+H]+ and 562.3 [M+Na]+. 
 
 
 
 
Methyl(R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-((2,3-dihydro-
1H-inden-2-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate (99). 99 was synthesized 
following general procedure I using 96 (8 mg, 0.018 mmol, 1.0 eq) and conc. HCl (1 drop). After 
removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the 
solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (6 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (6 mg, 0.0.16 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 99 as a TFA 
salt (7 mg, 70%). 1H NMR (500 MHz, CD3OD) δ 7.66 (d, J = 8.5 Hz, 1H), 7.16 – 7.01 (m, 5H), 
6.50 (s, 2H), 5.00 (t, J = 5.2 Hz, 1H), 3.85 (dd, J = 11.6, 5.0 Hz, 1H), 3.77 (s, 4H), 3.26 (dd, J = 
13.6, 11.6 Hz, 1H), 3.08 – 3.00 (m, 2H), 2.92 (ddd, J = 28.1, 14.9, 5.9 Hz, 2H), 2.74 – 2.57 (m, 
5H), 2.27 (s, 6H), 1.80 (ddt, J = 14.4, 9.6, 4.7 Hz, 1H), 1.52 – 1.44 (m, 1H). 13C NMR (126 
MHz, CD3OD) δ 168.93, 157.49, 156.63, 144.13, 144.08, 140.00, 138.40, 137.28, 130.17, 
129.42, 128.67, 127.20, 125.38, 125.35, 124.47, 123.20, 116.44, 53.54, 53.44, 46.97, 42.82, 
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42.39, 41.71, 39.91, 39.64, 31.95, 30.47, 20.45. HPLC (gradient A): retention time 42.9. ESI-MS 
528.3 [M+H]+ and 550.3 [M+Na]+. 
 
 
3-Bromo-N-(p-tolyl)propanamide (100). 100 was synthesized according to general procedure C 
starting from the commercially available starting material p-toluidine (2.0 g, 18.7 mmol, 1.0 eq), 
K2CO3 (5.29 g, 38.3 mmol, 2.05 eq) and bromopropionyl chloride (3.05 mL, 19.0 mmol, 1.02 
eq) to yield the title compound as an off-white solid (4.52 g, quant.) %) with no additional 
purification necessary. 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.05 (d, J = 8.1 Hz, 
2H), 3.63 (t, J = 6.6 Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 167.85, 134.78, 134.37, 129.49, 120.21, 40.58, 27.17, 20.86. 
 
 
1-(P-tolyl)azetidin-2-one (101). 101 was synthesized according to general procedure D starting 
from 100 (4.5 g, 19 mmol, 1.0 eq) and NaOtBu (1.9 g, 20 mmol, 1.05 eq) to yield the crude 
product which was purified using silica gel chromatography to yield title compound as an off-
white solid (2.8 g, 93.7%). 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 
8.1 Hz, 2H), 3.60 (m, 2H), 3.12 – 3.06 (m, 2H), 2.31 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
164.22, 136.12, 133.36, 129.56, 116.03, 37.95, 35.97, 20.87. 
 
 
6-Methyl-2,3-dihydroquinolin-4(1H)-one (102). 102 was synthesized according to general 
procedure E starting from 101 (2.8 g, 18 mmol, 1.0 eq) and TfOH (4.6 mL, 58 mmol, 3.0 eq) to 
yield the crude product which was then purified using silica gel chromatography to yield title 
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compound as yellow solid (2.1 g, 73.8%). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 2.1 Hz, 
1H), 7.13 (dd, J = 8.3, 2.1 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 3.58 – 3.52 (m, 2H), 2.68 (dd, J = 
7.5, 6.4 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 193.85, 149.95, 136.34, 127.41, 
127.12, 119.34, 115.92, 42.55, 38.22, 20.24. 
 
 
Tert-butyl 6-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (103). 103 was 
synthesized according to general procedure G starting from 102 (1.0 g, 6.2 mmol, 1.0 eq), Boc2O 
(2.0 g, 9.3 mmol, 1.5 eq), DMAP (76 mg, 0.62 mmol, 0.1 eq) and DIPEA (1.6 mL, 9.3 mmol, 1.5 
eq). Following the quench and work-up, the crude product was chromatographed on silica gel 
(equil in 100% hex, run in 2:3 EA:hex) to yield pure product as a white solid (1.4 g, 89.1%). 1H 
NMR (400 MHz, CDCl3) δ 7.78 (d, J = 2.2 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.30 (dd, J = 8.6, 
2.3 Hz, 1H), 4.13 (q, J = 6.3, 4.8 Hz, 2H), 2.74 (t, J = 6.3 Hz, 2H), 2.33 (s, 3H), 1.54 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 194.44, 152.79, 141.79, 134.88, 133.56, 127.11, 124.68, 123.60, 
81.95, 44.29, 39.03, 28.29, 20.60. 
 
 
Tert-butyl 6-(bromomethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (104). 104 was 
synthesized by placing 103 (1.44 g, 5.5 mmol, 1.0 eq), N-bromosuccinimide (1.0 g, 5.6 mmol, 
1.02 eq) and benzoyl peroxide  (40 mg, 0.165 mmol, 0.03 eq) into a round bottom flask which 
was then placed under vaccum for 15 min. Meanwhile, in a separate round bottom flask CCl4 
was degassed for 30 min, then flooded with Ar for 30 min. Then, CCl4 was transferred to 
reaction vessel containing the starting material and reagents via cannula. The reaction vessel was 
then placed in an oil bath at 70oC where it stirred for 4 h. The reaction was monitored by TLC. 
Once complete, solid was filtered off and the mother liquor was concentrated under reduced 
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pressure then purified using silica gel chromatography to yield the title compound as a white 
solid (565 mg, 30%). Note that purification was difficult because starting material and product 
had similar Rf values, thus there is additional impure product not calculated in the yield. 1H 
NMR (400 MHz, CDCl3) δ 7.98 (d, J = 9.1 Hz, 1H), 7.78 (t, J = 9.0 Hz, 1H), 7.51 (t, J = 9.1 Hz, 
1H), 4.46 (d, J = 9.3 Hz, 2H), 4.19 – 4.07 (m, 2H), 2.75 (dt, J = 11.9, 6.5 Hz, 2H), 1.55 (d, J = 
9.4 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 193.50, 152.49, 144.02, 134.53, 133.22, 127.58, 
124.68, 124.12, 82.47, 44.18, 38.72, 32.32, 28.23. 
 
 
Tert-butyl 6-(naphthalen-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (105). 
105 was synthesized following general procedure L starting from 104. 1H NMR (500 MHz, 
CDCl3) δ 7.90 (d, J = 2.2 Hz, 1H), 7.81 – 7.73 (m, 3H), 7.69 (d, J = 8.7 Hz, 1H), 7.63 (s, 1H), 
7.49 – 7.40 (m, 2H), 7.35 (dt, J = 8.6, 1.8 Hz, 1H), 7.30 (dt, J = 8.4, 1.5 Hz, 1H), 4.16 – 4.10 (m, 
4H), 2.78 – 2.71 (m, 2H), 1.54 (d, J = 1.3 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 194.26, 
152.75, 142.47, 137.89, 136.72, 134.71, 133.58, 132.13, 128.24, 127.61, 127.54, 127.35, 127.31, 
127.25, 127.08, 126.78, 126.05, 125.46, 124.82, 123.87, 82.12, 77.25, 77.20, 77.00, 76.75, 44.28, 
41.33, 38.99, 28.29. 
 
 
6-(Naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one (106). 106 was synthesized by 
deprotected 105 with a 1:1 mixture of TFA:DCM. After stirring at RT for 1 h, solvent was 
removed under reduced pressure to yield the title compound 106 as a yellow solid. 1H NMR (500 
MHz, CDCl3) δ 7.84 – 7.72 (m, 2H), 7.68 (s, 0H), 7.62 (s, 1H), 7.49 – 7.38 (m, 1H), 7.33 – 7.24 
(m, 1H), 7.16 (ddd, J = 8.3, 4.8, 1.9 Hz, 1H), 6.65 (ddd, J = 15.4, 8.3, 2.4 Hz, 1H), 4.03 (s, 1H), 
3.59 – 3.53 (m, 2H), 2.77 – 2.66 (m, 2H), 2.25 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 193.66, 
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138.64, 136.34, 136.11, 133.56, 132.05, 130.95, 128.11, 127.58, 127.51, 127.40, 127.36, 127.20, 
126.87, 125.95, 125.31, 119.67, 119.42, 116.41, 116.22, 77.00, 42.57, 42.41, 41.14, 38.08. 
 
 
 
 
6-(Naphthalen-2-ylmethyl)-1-propionyl-2,3-dihydroquinolin-4(1H)-one (107). 107 was 
synthesized according to general procedure N using 106 (150 mg, 0.52 mmol, 1.0 eq) and excess 
propionic anhydride. Once complete, excess anhydride was removed and the crude residue was 
purified using silica gel chromatography to yield the title compound 107 as a clear, pale orange 
oil (156 mg, 87.2%). 1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.81 – 7.73 (m, 3H), 7.63 (s, 
1H), 7.47 – 7.32 (m, 4H), 7.28 (dd, J = 8.4, 1.9 Hz, 1H), 4.22 – 4.15 (m, 2H), 4.12 (s, 2H), 2.74 
(td, J = 6.3, 1.9 Hz, 2H), 2.61 – 2.52 (m, 2H), 1.21 (t, 3H). 13C NMR (126 MHz, CDCl3) δ 
194.08, 172.83, 142.08, 141.47, 138.43, 137.45, 134.74, 134.52, 133.42, 132.01, 128.23, 127.51, 
127.49, 127.41, 127.17, 127.03, 126.03, 125.92, 125.45, 124.30, 123.97, 43.69, 41.27, 39.43, 
27.80, 9.71. 
 
 
1-Butyryl-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one (108). 108 was 
synthesized according to general procedure N using 106 (155 mg, 0.54 mmol, 1.0 eq) and excess 
butyric anhydride. Once complete, excess anhydride was removed and the crude residue was 
purified using silica gel chromatography to yield the title compound 108 as a clear, slightly dark 
red oil (112 mg, 58.0%). 1H NMR (500 MHz, CDCl3) δ 7.94 (s, 1H), 7.85 – 7.76 (m, 3H), 7.66 
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(s, 1H), 7.51 – 7.39 (m, 4H), 7.32 (d, J = 8.5 Hz, 1H), 4.20 (t, J = 6.3 Hz, 2H), 4.15 (s, 2H), 2.76 
(t, J = 5.9 Hz, 2H), 2.60 – 2.49 (m, 2H), 1.75 (h, J = 7.7 Hz, 2H), 0.97 (t, J = 7.6 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 194.00, 171.99, 142.10, 138.38, 137.42, 134.69, 134.47, 133.42, 
132.01, 128.21, 127.49, 127.47, 127.39, 127.16, 127.02, 126.00, 125.90, 125.42, 124.32, 124.00, 
43.71, 41.25, 39.50, 36.28, 18.94, 13.66. 
 
Methyl 6-(naphthalen-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (109). 
109 was synthesized according to general procedure N using 106 (150 mg, 0.52 mmol, 1.0 eq) 
and methylchloroformate (0.200 mL, 2.3 mmol, 2.3 eq). The reaction stirred overnight, once 
complete, solvent was removed and the crude residue was purified using silica gel 
chromatography to yield the title compound 109 as a clear oil (65 mg, 36.1%). Starting material 
was recovered, but not included in final yield calculation. Additionally, not all product was 
purified as the Rf values for the starting material and product were similar and separation was 
difficult.  1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.82 – 7.74 (m, 3H), 7.72 (d, J 
= 8.6 Hz, 1H), 7.64 (s, 1H), 7.48 – 7.41 (m, 2H), 7.38 (dd, J = 8.6, 2.3 Hz, 1H), 7.30 (dd, J = 8.4, 
1.8 Hz, 1H), 4.18 (t, J = 6.3 Hz, 2H), 4.13 (s, 2H), 3.84 (s, 3H), 2.77 (t, J = 6.3 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 193.81, 154.23, 141.81, 137.73, 137.18, 134.88, 133.49, 132.05, 
128.21, 127.55, 127.47, 127.26, 127.23, 127.03, 126.01, 125.42, 124.81, 123.63, 53.32, 44.39, 
41.26, 38.81. 
 
 
(R)-2-methyl-N-((R)-6-(naphthalen-2-ylmethyl)-1-propionyl-1,2,3,4-tetrahydroquinolin-4-
yl)propane-2-sulfinamide (110). 110 was synthesized according to general procedure H using 
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107 (156 mg, 0.45 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (165 mg, 1.36 mmol, 3.0 
eq), and Ti(OEt)4 (0.57 mL, 2.7 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine 
intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 48 h), 
the reaction mixture was transferred via cannula to a round bottom flask containing NaBH4 (103 
mg, 2.7 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution 
was stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid 
was removed, crude residue was purified using silica gel chromatography to yield the title 
compound 110 as a clear, colorless oil (148 mg, 72.5%). No 1H or 13C NMR data acquired. 
Instead, product taken ahead to next reaction (formation of 113) without any further isolation, 
purification, or characterization. 
 
 
(R)-N-((R)-1-butyryl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide (111). 111 was synthesized according to general procedure H 
using 108 (112 mg, 0.31 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (114 mg, 0.94 
mmol, 3.0 eq), and Ti(OEt)4 (0.39 mL, 1.9 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl 
imine intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 
48 h), the reaction mixture was transferred via cannula to a round bottom flask containing 
NaBH4 (71 mg, 1.9 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the 
solution was stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography to yield 
the title compound as a clear, colorless oil (54 mg, 37.21H NMR (500 MHz, CDCl3) δ 7.78 (q, J 
= 7.7 Hz, 3H), 7.66 (s, 1H), 7.44 (pd, J = 7.1, 3.4 Hz, 2H), 7.33 (dd, J = 6.4, 2.1 Hz, 2H), 7.14 
(dt, J = 8.2, 2.0 Hz, 1H), 4.52 (t, J = 4.4 Hz, 1H), 4.11 (s, 2H), 3.89 (dt, J = 12.2, 5.5 Hz, 1H), 
3.74 (ddd, J = 13.6, 9.8, 6.2 Hz, 1H), 3.32 (d, J = 3.3 Hz, 1H), 2.52 – 2.39 (m, 2H), 2.20 (dh, J = 
15.3, 7.4, 5.6 Hz, 1H), 2.04 (dq, J = 12.7, 4.6, 3.9 Hz, 1H), 1.74 – 1.61 (m, 2H), 1.17 (d, J = 1.9 
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Hz, 9H), 0.91 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 187.72, 172.68, 138.03, 
136.64, 133.57, 132.10, 128.79, 128.72, 128.57, 128.21, 127.58, 127.52, 127.46, 127.10, 126.03, 
125.43, 124.85, 124.60, 55.73, 50.96, 41.52, 39.95, 36.69, 30.68, 22.51, 19.14, 13.88. 
 
 
Methyl(R)-4-(((R)-tert-butylsulfinyl)amino)-6-(naphthalen-2-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate (112). 112 was synthesized according to general 
procedure H using 109 (65 mg, 0.19 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (68 mg, 
0.57 mmol, 3.0 eq), and Ti(OEt)4 (0.24 mL, 1.1 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl 
imine intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 
48 h), the reaction mixture was transferred via cannula to a round bottom flask containing 
NaBH4 (43 mg, 1.1 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the 
solution was stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography to yield 
the title compound as a clear, colorless oil (34 mg, 40.0%).  1H NMR (500 MHz, CDCl3) δ 7.81 – 
7.71 (m, 4H), 7.64 (d, J = 5.2 Hz, 1H), 7.48 – 7.39 (m, 2H), 7.34 – 7.26 (m, 2H), 7.13 (ddd, J = 
8.5, 6.0, 2.2 Hz, 1H), 4.55 (h, J = 3.7 Hz, 1H), 4.09 (s, 2H), 4.05 – 3.96 (m, 1H), 3.78 (s, 3H), 
3.69 – 3.59 (m, 1H), 3.33 (q, J = 2.7 Hz, 1H), 2.18 (ddt, J = 12.8, 10.4, 4.3 Hz, 1H), 2.06 – 1.93 
(m, 1H), 1.18 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 154.94, 138.25, 136.95, 136.16, 133.53, 
132.02, 129.23, 128.84, 128.65, 128.08, 127.52, 127.48, 127.43, 126.96, 125.92, 125.30, 123.70, 
55.60, 52.95, 50.35, 41.33, 40.28, 29.49, 22.49. 
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(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(naphthalen-2-ylmethyl)-1-
propionyl-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (113). 113 was synthesized 
following general procedure I using 110 (148 mg, 0.33 mmol, 1.0 eq) and conc. HCl (6 drops). 
After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing 
the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (126 mg). The synthesis was completed by following general procedure F 
with newly formed (R) amine intermediate (60 mg, 0.16 mmol, 1.0 eq) to yield crude product 
which was purified by semipreparative HPLC and lyophilized to yield the title compound 113 as 
a TFA salt (15 mg, 14.7 %). Note that not all crude product was purified. 1H NMR (500 MHz, 
CDCl3) δ 7.76 (ddd, J = 21.9, 8.2, 3.1 Hz, 3H), 7.60 (d, J = 3.2 Hz, 1H), 7.47 – 7.37 (m, 2H), 
7.28 (dt, J = 8.6, 2.2 Hz, 1H), 7.19 (d, J = 3.5 Hz, 1H), 7.15 – 7.09 (m, 1H), 6.51 (d, J = 3.4 Hz, 
2H), 4.93 (p, J = 5.2 Hz, 1H), 4.08 (d, J = 3.4 Hz, 2H), 3.86 (dt, J = 11.2, 4.3 Hz, 1H), 3.78 (s, 
1H), 3.24 (td, J = 12.6, 11.2, 3.5 Hz, 1H), 3.15 (s, 1H), 3.03 (dt, J = 13.9, 4.5 Hz, 1H), 2.58 – 
2.41 (m, 2H), 2.26 (d, J = 3.6 Hz, 6H), 1.85 (dtd, J = 13.5, 8.7, 4.7 Hz, 1H), 1.45 (s, 1H), 1.11 
(td, J = 7.1, 3.2 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 175.85, 169.20, 157.47, 140.07, 
139.86, 137.62, 135.07, 133.59, 129.47, 129.07, 128.58, 128.46, 128.38, 127.87, 127.09, 126.46, 
125.87, 123.24, 116.45, 53.49, 47.11, 42.27, 31.95, 31.29, 28.92, 20.42, 10.06. HPLC (gradient 
A): retention time 41.3. ESI-MS 536.3 [M+H]+ and 558.3 [M+Na]+. 
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(S)-2-amino-N-((R)-1-butyryl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
3-(4-hydroxy-2,6-dimethylphenyl)propanamide (114). 114 was synthesized following general 
procedure I using 112 (34 mg, 0.076 mmol, 1.0 eq) and conc. HCl (3 drops). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (46 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (46 mg, 0.12 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 114 as a TFA 
salt (12 mg, 15.6%). Note that not all crude product was purified. No 1H or 13C data acquired. 
Instead, final product was verified only via mass spectrometry. HPLC (gradient A): retention 
time 44.0. ESI-MS 550.3 [M+H]+ and 572.3 [M+Na]+. 
 
 
Methyl (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-(naphthalen-
2-ylmethyl)-3,4-dihydroquinoline-1(2H)-carboxylate (115). 115 was synthesized following 
general procedure I using 112 (34 mg, 0.076 mmol, 1.0 eq) and conc. HCl (3 drops). After 
removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the 
solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (19 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (19 mg, 0.0.16 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 115 as a TFA 
salt (13 mg, 40.6%). Note that not all crude product was purified. 1H NMR (500 MHz, CD3OD) 
δ 7.78 (d, J = 7.9 Hz, 1H), 7.73 (dd, J = 8.3, 2.9 Hz, 2H), 7.67 (d, J = 8.5 Hz, 1H), 7.59 (s, 1H), 
7.42 (dt, J = 8.9, 6.2 Hz, 2H), 7.27 (dt, J = 8.4, 1.7 Hz, 1H), 7.12 (s, 1H), 7.09 (dt, J = 8.6, 1.8 
Hz, 1H), 6.50 (s, 2H), 4.96 (t, J = 5.1 Hz, 1H), 4.04 (s, 2H), 3.87 – 3.80 (m, 1H), 3.75 (d, J = 1.5 
Hz, 4H), 3.28 – 3.19 (m, 1H), 3.00 (dt, J = 12.6, 8.3 Hz, 2H), 2.26 (d, J = 1.5 Hz, 7H), 1.78 (ddt, 
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J = 14.7, 9.9, 4.7 Hz, 1H), 1.50 (ddd, J = 13.4, 8.6, 4.8 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 
168.96, 157.48, 156.61, 139.99, 138.03, 137.48, 135.07, 133.57, 130.31, 129.72, 129.02, 128.78, 
128.57, 128.46, 128.39, 127.80, 127.05, 126.41, 124.63, 123.19, 116.43, 111.40, 53.54, 53.41, 
47.06, 42.32, 42.14, 31.92, 30.30, 20.44. HPLC (gradient A): retention time 42.7. ESI-MS 538.3 
[M+H]+ and 560.3 [M+Na]+. 
 
 
Synthesized by Dr. Aaron M. Bender. 
 
Synthesized by Dr. Aaron M. Bender. 
 
Synthesized by Dr. Aaron M. Bender. 
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Synthesized by Dr. Aaron M. Bender. 
 
 
3-Bromo-N-(4-bromo-3-methoxyphenyl)propanamide (120). 120 was synthesized according 
to general procedure C starting from the commercially available starting material 4-bromo-3-
methoxyaniline (1.0 g, 5.0 mmol, 1.0 eq), K2CO3 (1.40 g, 10.1 mmol, 2.05 eq) and 
bromopropionyl chloride (0.810 mL, 5.1 mmol, 1.02 eq) to yield the crude product which was 
pure following work-up to yield title compound 120 as a pinkish grey solid (1.67 g, quant.).1H 
NMR (500 MHz, CDCl3) δ 7.54 (dt, J = 5.0, 2.2 Hz, 1H), 7.44 (dd, J = 8.6, 2.6 Hz, 1H), 6.75 (dt, 
J = 8.5, 1.9 Hz, 1H), 3.90 (s, 3H), 3.71 (t, J = 6.6 Hz, 2H), 2.95 (t, J = 6.4 Hz, 2H). 13C NMR 
(126 MHz, CDCl3) δ 167.89, 156.21, 137.93, 133.06, 112.49, 106.47, 104.28, 56.27, 40.74, 
26.69. 
 
 
3-Bromo-N-(4-bromo-2-methoxyphenyl)propanamide (121). 121 was synthesized according 
to general procedure C starting from the commercially available starting material 4-bromo-2-
methoxyaniline (0.50 g, 2.47 mmol, 1.0 eq), K2CO3 (0.701 g, 5.1 mmol, 2.05 eq) and 
bromopropionyl chloride (0.404 mL, 2.5 mmol, 1.02 eq) to yield the title compound as an off-
white solid (834 mg g, quant.) with no additional purification necessary. 1H NMR (500 MHz, 
CDCl3 δ 8.32 – 8.24 (m, 1H), 7.75 (s, 1H), 7.10 (ddd, J = 8.7, 2.2, 1.1 Hz, 1H), 7.00 (q, J = 1.7 
Hz, 1H), 3.89 (t, J = 1.5 Hz, 3H), 3.70 (tt, J = 6.9, 1.5 Hz, 2H), 3.00 – 2.93 (m, 2H).  13C NMR 
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(126 MHz, CDCl3) δ 167.62, 143.55, 133.03, 123.99, 120.90, 116.27, 113.54, 56.04, 40.90, 
26.74. 
 
 
1-(4-Bromo-3-methoxyphenyl)azetidin-2-one (122). 122 was synthesized according to general 
procedure D using 120 (1.70 g, 5.0 mmol, 1.0 eq) and NaOtBu (510 mg, 5.3 mmol, 1.05 eq) to 
yield the crude product which was then purified using silica gel chromatography to yield the title 
compound (122) as an off-white solid (1.14 g, 88.7%) 1H NMR (500 MHz, CDCl3) δ 7.44 (dd, J 
= 8.5, 2.6 Hz, 1H), 7.23 (t, J = 2.3 Hz, 1H), 6.57 (dt, J = 8.6, 2.2 Hz, 1H), 3.90 (s, 3H), 3.62 (dd, 
J = 5.7, 3.3 Hz, 2H), 3.13 (dd, J = 5.8, 3.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 164.50, 
156.35, 138.92, 133.28, 108.33, 105.74, 101.12, 56.29, 38.35, 36.29. 
 
 
1-(4-Bromo-3-methoxyphenyl)azetidin-2-one (123). 123 was synthesized according to general 
procedure D using 120 (860 mg, 2.6 mmol, 1.0 eq) and NaOtBu (257 mg, 2.7 mmol, 1.05 eq) to 
yield the crude product which was then purified using silica gel chromatography to yield the title 
compound (123) as a mauve, waxy solid (631 mg, 94.5%) 1H NMR (500 MHz, CDCl3) δ 7.82 
(dd, J = 8.6, 2.1 Hz, 1H), 7.04 (dt, J = 8.6, 2.3 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 3.91 (t, J = 4.5 
Hz, 2H), 3.81 (d, J = 2.4 Hz, 3H), 3.09 (t, J = 4.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
166.08, 150.53, 126.53, 123.92, 122.65, 117.14, 115.20, 55.86, 43.14, 38.01. 
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6-Bromo-7-methoxy-2,3-dihydroquinolin-4(1H)-one (124). 124 was synthesized according to 
general procedure E using 122 (1.14 g, 4.5 mmol, 1.0 eq) and TfOH (1.2 mL, 13.4 mmol, 3.0 eq) 
to yield the crude product which was then purified using silica gel chromatography to yield the 
title compound (124) as an off-white solid (0.48 g, 59.7%) 1H NMR (500 MHz, CDCl3) δ 8.01 
(s, 1H), 6.11 (s, 1H), 3.87 (s, 3H), 3.57 (t, 2H), 2.65 (t, 2H). 13C NMR (126 MHz, CDCl3) δ 
191.06, 160.83, 152.58, 132.45, 114.48, 109.99, 101.96, 97.59, 56.32, 42.31, 37.28. 
 
 
6-Bromo-8-methoxy-2,3-dihydroquinolin-4(1H)-one (125). 125 was synthesized according to 
general procedure E using 123 (631 mg, 2.5 mmol, 1.0 eq) and TfOH (0.654 mL, 7.4 mmol, 3.0 
eq) to yield the crude product which was then purified using silica gel chromatography to yield 
the title compound (125) as an off-white solid (0.48 g, 59.7%) 1H NMR (500 MHz, CDCl3) δ 
7.59 (t, J = 2.2 Hz, 1H), 6.90 (t, J = 2.2 Hz, 1H), 3.86 (d, J = 1.9 Hz, 3H), 3.62 – 3.55 (m, 2H), 
2.69 (td, J = 7.0, 2.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 192.19, 147.82, 142.20, 121.14, 
119.64, 116.61, 108.76, 56.06, 41.84, 37.69. 
 
 
Tert-butyl 6-bromo-7-methoxy-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (126). 126 
was synthesized according to general procedure G using 124 (0.48 g, 1.9 mmol, 1.0 eq) to yield 
the crude product which was then purified using silica gel chromatography to yield the title 
compound (126) as a viscous yellow oil (0.567 g, 85.1%) 1H NMR (500 MHz, CDCl3) δ 7.93 (s, 
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1H), 7.33 (s, 1H), 4.01 (t, 2H), 3.82 (s, 3H), 2.56 (t, 2H), 1.45 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 191.27, 159.31, 151.96, 144.78, 131.41, 118.86, 106.76, 105.83, 82.13, 56.14, 44.25, 
37.74, 27.96. 
 
 
1-Acetyl-6-bromo-8-methoxy-2,3-dihydroquinolin-4(1H)-one (127). 127 was synthesized 
according to general procedure K using 125 (0.165 mg, 0.64 mmol, 1.0 eq) and excess Ac2O. 
Once the reaction was complete, the solvent was removed under reduced pressure and the crude 
residue was purified using silica gel chromatography to yield the title compound (127) as a 
slightly yellow oil (152 mg, 79.2%) 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 2.2 Hz, 1H), 7.19 
(d, J = 2.1 Hz, 1H), 4.90 (s, 1H), 3.84 (s, 4H), 3.37 (s, 1H), 2.80 (s, 1H), 2.62 (d, J = 18.2 Hz, 
1H), 2.02 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 193.43, 170.71, 153.18, 133.23, 129.03, 
122.05, 120.15, 120.10, 56.31, 44.10, 39.88, 21.93. 
 
 
Tert-butyl 6-benzyl-7-methoxy-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (128). 128 
was synthesized following general procedure L using 126 (142 mg, 0.40 mmol, 1.0 eq), benzyl-
Bpin (0.130 mL, 0.60 mmol, 2.0 eq), K2CO3 (165 mg, 1.2 mmol, 3.0 eq), and Pd(dppf)Cl2 (29 
mg, 0.04 mmol, 0.1 eq). The contents were placed microwave tube and reacted in microwave 
with max temp of 110°C, max power of 250 W for 30 min, with the “Powermax” option enabled. 
Once crude mixture was filtered through Celite, the solvent was removed and the residue was 
purified via silica gel chromatography (equil in 100% hex, run in 1:1 EA:hex) to yield title 
compound (146 mg, 98.9%)  as yellow, clear oil. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 
7.35 (s, 1H), 7.27 – 7.22 (m, 2H), 7.22 – 7.18 (m, 2H), 7.18 – 7.12 (m, 1H), 4.11 (t, 2H), 3.91 (s, 
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2H), 3.86 (s, 3H), 2.67 (t, 2H), 1.57 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 192.72, 161.68, 
152.46, 144.49, 140.05, 128.79, 128.52, 128.05, 126.02, 125.71, 117.94, 104.75, 81.83, 55.47, 
44.54, 38.26, 35.25, 28.14. 
 
 
6-Benzyl-8-methoxy-2,3-dihydroquinolin-4(1H)-one (129). 129 was synthesized following 
general procedure L using 125 (50 mg, 0.20 mmol, 1.0 eq), benzyl-Bpin (0.65 mL, 0.30 mmol, 
2.0 eq), K2CO3 (81 mg, 0.59 mmol, 3.0 eq), and Pd(dppf)Cl2 (14 mg, 0.02 mmol, 0.1 eq). The 
contents were placed microwave tube and reacted in microwave with max temp of 110°C, max 
power of 250 W for 30 min, with the “Powermax” option enabled. Once crude mixture was 
filtered through Celite, the solvent was removed and the residue was purified via silica gel 
chromatography (equil in 100% hex, run in 1:1 EA:hex) to yield title compound (20 mg, 38.5%)  
as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.37 (s, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.21 – 
7.16 (m, 3H), 6.66 (s, 1H), 3.89 (s, 2H), 3.80 (d, J = 1.1 Hz, 3H), 3.57 (t, J = 6.7 Hz, 2H), 2.70 (t, 
J = 6.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 193.68, 147.27, 141.88, 141.18, 129.29, 128.63, 
128.39, 126.00, 118.79, 118.26, 114.64, 55.65, 42.13, 41.49, 38.01. 
 
 
1-Acetyl-6-benzyl-8-methoxy-2,3-dihydroquinolin-4(1H)-one (130). 130 was synthesized 
following general procedure L using 127 (152 mg, 0.51 mmol, 1.0 eq), benzyl-Bpin (0.167 mL, 
0.77 mmol, 2.0 eq), K2CO3 (211 mg, 1.53 mmol, 3.0 eq), and Pd(dppf)Cl2 (37 mg, 0.05 mmol, 
0.1 eq). The contents were placed microwave tube and reacted in microwave with max temp of 
110°C, max power of 250 W for 30 min, with the “Powermax” option enabled. Once crude 
mixture was filtered through Celite, the solvent was removed and the residue was purified via 
silica gel chromatography to yield title compound (112 mg, 70.9%) as clear, colorless oil. 1H 
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NMR (500 MHz, CDCl3) δ δ 7.37 (s, 1H), 7.26 – 7.20 (m, 2H), 7.17 – 7.09 (m, 3H), 6.89 (s, 1H), 
4.93 (s, 1H), 3.92 (s, 2H), 3.76 (s, 3H), 3.32 (t, J = 12.1 Hz, 1H), 2.78 (t, J = 15.6 Hz, 1H), 2.57 
(d, J = 18.4 Hz, 1H), 1.99 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 195.01, 171.07, 152.37, 
140.47, 139.75, 132.19, 128.76, 128.64, 128.19, 126.48, 119.25, 117.67, 55.86, 44.00, 41.72, 
39.97, 21.90. 
 
 
Tert-butyl (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-7-methoxy-3,4-dihydroquinoline-
1(2H)-carboxylate (131). 131 was synthesized according to general procedure H using 128 (200 
mg, 0.54 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (198 mg, 1.63 mmol, 3.0 eq), and 
Ti(OEt)4 (0.685 mL, 3.27 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (124 mg, 3.27 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
as a clear, colorless oil (64 mg, 24.9%). 1H NMR (500 MHz, CDCl3) δ 7.44 (s, 1H), 7.31 – 7.18 
(m, 5H), 7.06 (s, 1H), 4.52 – 4.44 (m, 1H), 3.98 (dt, J = 12.9, 4.3 Hz, 1H), 3.95 – 3.84 (m, 2H), 
3.84 – 3.78 (s, 3H), 3.55 (qd, J = 12.4, 10.9, 3.7 Hz, 1H), 3.21 (s, 1H), 2.17 (dq, J = 14.1, 3.8 Hz, 
1H), 1.95 (dddt, J = 29.9, 15.2, 11.7, 3.6 Hz, 1H), 1.53 (s, 9H), 1.18 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 156.70, 153.40, 140.88, 137.74, 130.25, 128.71, 128.17, 125.72, 125.55, 120.22, 
106.18, 81.07, 55.46, 49.66, 39.96, 35.29, 29.33, 28.36, 22.52. 
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(R)-N-((R)-6-benzyl-8-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide (132). 132 was synthesized according to general procedure H using 130 (112 mg, 
0.36 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (132 mg, 1.1 mmol, 3.0 eq), and 
Ti(OEt)4 (0.455 mL, 2.2 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (82 mg, 2.2 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
as a clear, colorless oil (56 mg, 37.8%). No 1H or 13C data taken. Product was moved on to next 
step. 
 
 
(R)-N-((R)-1-acetyl-6-benzyl-8-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-
2-sulfinamide (133). 133 was synthesized according to general procedure H using 129 (106 mg, 
0.40 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (144 mg, 1.19 mmol, 3.0 eq), and 
Ti(OEt)4 (0.500 mL, 2.4 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (90 mg, 2.4 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the still impure 
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title compound. No 1H or 13C NMR spectrum acquired. Intermediate taken ahead to the next step 
(formation of 136) without any additional isolation, purification, or characterization. 
 
 
(S)-2-amino-N-((R)-6-benzyl-7-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (134). 134 was synthesized following general procedure I using 
131 (56 mg, 0.14 mmol, 1.0 eq) and conc. HCl (4 drops). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (41 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (41 mg, 0.16 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 134 as a TFA salt. Note that 
not all crude product was purified, therefore no yield was calculated. 1H NMR (500 MHz, 
CD3OD) δ 8.15 (d, J = 7.7 Hz, 1H), 7.17 (t, J = 7.5 Hz, 2H), 7.09 (d, J = 7.4 Hz, 3H), 6.89 (s, 
1H), 6.48 (s, 2H), 6.35 (s, 1H), 5.05 (s, 2H), 3.89 – 3.73 (m, 3H), 3.71 (s, 3H), 3.24 (dd, J = 13.6, 
11.6 Hz, 1H), 3.10 – 2.96 (m, 2H), 2.55 (td, J = 12.0, 2.5 Hz, 1H), 2.27 (s, 6H), 1.83 – 1.73 (m, 
1H), 1.55 (tt, J = 10.0, 8.2, 3.2 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 168.56, 168.47, 162.31, 
157.39, 142.68, 140.79, 140.03, 133.12, 129.51, 129.10, 126.67, 124.61, 123.29, 116.41, 115.88, 
101.01, 55.88, 53.32, 49.00, 45.55, 45.46, 38.66, 36.34, 31.88, 28.78, 20.46. HPLC (gradient A): 
retention time 27.8. ESI-MS 482.3 [M+Na]+. 
 
 
(S)-2-amino-N-((R)-6-benzyl-8-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
 
 
169 
 
dimethylphenyl)propanamide (135). 135 was synthesized following general procedure I using 
132 (56 mg, 0.14 mmol, 1.0 eq) and conc. HCl (4 drops). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (41 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (41 mg, 0.14 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 135 as a TFA salt. Note that 
not all crude product was purified, therefore no yield was calculated. No 1H or 13C data was 
collected. Instead, product formation was verified via mass spectrometry. HPLC (gradient A): 
retention time 25.5. ESI-MS 482.3 [M+Na]+. 
 
 
(S)-N-((R)-1-acetyl-6-benzyl-8-methoxy-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (136). 136 was synthesized following general 
procedure I using 133 (150 mg, 0.36 mmol, 1.0 eq) and conc. HCl (4 drops). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (126 mg). The synthesis was completed by following general procedure F 
with newly formed (R) amine intermediate (126 mg, 0.36 mmol, 1.0 eq) to yield crude product 
which was purified by semipreparative HPLC and lyophilized to yield the title compound 136 as 
a TFA salt. Note that not all crude product was purified, therefore no yield was calculated. No 1H 
or 13C data was collected. Instead, product formation was verified via mass spectrometry. HPLC 
(gradient A): retention time: no data collected. ESI-MS 502.2 [M+H]+ and 424.2 [M+Na]+. 
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(S)-2-amino-N-((R)-6-benzyl-7-hydroxy-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (137). 137 was synthesized following general procedure I using 
131 (150 mg, 0.36 mmol, 1.0 eq) and conc. HCl (4 drops). After removing solvent, residue was 
re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (126 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (126 mg, 0.36 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 136 as a TFA salt. Note that 
not all crude product was purified, therefore no yield was calculated. 1H NMR (500 MHz, 
CDCl3) δ 1 8.11 (d, J = 7.6 Hz, 1H), 7.23 – 7.05 (m, 5H), 6.85 (s, 1H), 6.47 (s, 2H), 6.27 (s, 1H), 
3.89 – 3.73 (m, 3H), 3.23 (dd, J = 13.6, 11.7 Hz, 1H), 3.08 – 2.94 (m, 2H), 2.52 (t, J = 11.8 Hz, 
1H), 2.26 (d, J = 1.5 Hz, 6H), 1.77 (d, J = 12.3 Hz, 1H), 1.53 (d, J = 13.7 Hz, 1H). No 13C data 
was collected. HPLC (gradient A): retention time 22.0. ESI-MS 468.3 [M+Na]+. 
 
 
4-Methoxy-2-(4-nitrobenzylidene)-2,3-dihydro-1H-inden-1-one (138). 138 was synthesized 
according to general procedure A starting from commercially available 4-methoxy-2,3-dihydro-
1H-inden-1-one (0.500 g, 3.1 mmol, 1.0 eq) and p-Nitrobenzaldehyde (0.559 g, 3.7 mmol, 1.2 
eq) to yield a mustard yellow powder (0.881 g, 96.8%) No 1H 13C data was collected. Product 
was taken on to the next step (formation of 141) without additional isolation, purification, or 
characterization. 
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5-Methoxy-2-(4-nitrobenzylidene)-2,3-dihydro-1H-inden-1-one (139). 139 was synthesized 
according to general procedure A starting from commercially available 5-methoxy-2,3-dihydro-
1H-inden-1-one (0.500 g, 3.1 mmol, 1.0 eq) and p-Nitrobenzaldehyde (0.559 g, 3.7 mmol, 1.2 
eq) to yield a mustard yellow powder (0.809 g, 88.9%) 1H NMR (500 MHz, CDCl3) δ 8.34 – 
8.28 (m, 2H), 7.88 (d, J = 8.4 Hz, 1H), 7.81 – 7.76 (m, 2H), 7.62 (t, J = 2.3 Hz, 1H), 7.04 – 6.96 
(m, 2H), 4.06 – 4.02 (m, 2H), 3.93 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.91, 165.71, 
152.25, 141.87, 139.09, 130.96, 130.79, 129.61, 126.58, 124.06, 115.69, 109.98, 109.73, 77.00, 
55.78, 32.42. 
 
 
2-(Hydroxy(4-nitrophenyl)methyl)-3-methyl-2,3-dihydro-1H-inden-1-one (140). 140 was 
synthesized according to general procedure A starting from commercially available 3-methyl-
2,3-dihydro-1H-inden-1-one (0.500 g, 3.4 mmol, 1.0 eq) and p-Nitrobenzaldehyde (0.620 g, 4.1 
mmol, 1.2 eq) to yield the title compound (140) as a tan powder (844 mg, 82.7%) 1H NMR (500 
MHz, CDCl3) δ 8.29 – 8.22 (m, 3H), 7.82 – 7.77 (m, 1H), 7.66 (dt, J = 8.7, 2.1 Hz, 5H), 7.44 (td, 
J = 12.6, 12.2, 6.7 Hz, 3H), 5.73 (d, J = 4.7 Hz, 1H), 5.14 (d, J = 1.9 Hz, 1H), 4.97 (d, J = 9.7 
Hz, 1H), 4.46 (d, J = 7.3 Hz, 0H), 3.49 (s, 1H), 3.47 – 3.40 (m, 1H), 2.97 (p, J = 6.6 Hz, 1H), 
2.61 (dd, J = 4.7, 2.6 Hz, 1H), 2.57 – 2.47 (m, 2H), 2.17 (d, J = 1.9 Hz, 5H), 1.58 – 1.51 (m, 3H), 
1.44 – 1.35 (m, 1H), 1.25 (s, 1H), 1.00 – 0.91 (m, 3H), 0.88 (dd, J = 7.1, 1.9 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 208.33, 159.02, 158.35, 136.08, 135.55, 128.11, 127.88, 127.69, 126.38, 
125.14, 125.09, 124.04, 123.85, 123.74, 123.69, 77.26, 77.00, 76.75, 74.82, 71.13, 62.96, 61.34, 
36.14, 33.18, 30.93, 29.74, 20.17, 19.50. 
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4-((4-Methoxy-2,3-dihydro-1H-inden-2-yl)methyl)aniline (141). 141 was synthesized 
according to general procedure B starting from 138 (0.881 g, 2.98 mmol, 1.0 eq) to yield a light 
orange solid (698 mg, 92.3 %). 1H NMR (400 MHz, CDCl3) δ 7.11 (td, J = 7.8, 3.5 Hz, 1H), 
7.03 – 6.97 (m, 2H), 6.80 (dd, J = 7.4, 3.6 Hz, 1H), 6.65 (td, J = 8.6, 2.6 Hz, 3H), 4.12 (qd, J = 
7.1, 3.5 Hz, 1H), 3.84 – 3.78 (m, 3H), 3.02 – 2.93 (m, 2H), 2.76 – 2.62 (m, 4H), 2.58 (ddd, J = 
16.2, 6.4, 4.1 Hz, 1H), 2.05 (d, J = 3.3 Hz, 1H), 1.30 – 1.22 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 156.00, 145.32, 144.23, 144.21, 131.53, 130.79, 129.87, 129.64, 127.48, 127.48, 
116.97, 116.96, 115.28, 115.19, 107.75, 60.38, 55.13, 41.31, 40.88, 39.10, 35.34, 21.04, 14.19. 
 
 
4-((5-Methoxy-2,3-dihydro-1H-inden-2-yl)methyl)aniline (142). 142 was synthesized 
according to general procedure B starting from 139 (809 mg, 0.27 mmol, 1.0 eq) to yield a light 
orange solid (365 mg, 52.6 %). 1H NMR (400 MHz, CDCl3) δ 7.02 (q, J = 7.7 Hz, 1H), 6.95 (t, J 
= 7.6 Hz, 2H), 6.77 – 6.68 (m, 1H), 6.66 (d, J = 9.7 Hz, 1H), 6.58 (dt, J = 8.6, 4.5 Hz, 2H), 3.72 
(d, J = 5.4 Hz, 3H), 3.58 – 3.41 (m, 2H), 2.88 (tt, J = 13.8, 6.5 Hz, 2H), 2.60 (dtq, J = 29.1, 22.1, 
7.2 Hz, 5H). 13C NMR (126 MHz, CDCl3) δ 158.42, 144.75, 144.23, 135.23, 131.31, 129.49, 
124.78, 115.07, 111.71, 110.01, 55.24, 42.11, 40.63, 39.02, 37.87. 
 
 
4-((1-Methyl-2,3-dihydro-1H-inden-2-yl)methyl)aniline (143). 143 was synthesized according 
to general procedure B starting from 140 (844 mg, 0.28 mmol, 1.0 eq) to yield a a crude residue 
that was taken ahead to the next step without further purification (674 mg, quant.). 1H NMR (400 
MHz, CDCl3) δ 7.77 – 7.36 (m, 7H), 7.20 – 7.03 (m, 8H), 3.49 (s, 13H), 3.19 (d, J = 15.4 Hz, 
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1H), 2.99 (q, J = 5.6 Hz, 1H), 2.89 – 2.79 (m, 2H), 2.65 (t, J = 11.0 Hz, 1H), 2.54 (dd, J = 15.3, 
8.0 Hz, 1H), 2.20 (d, J = 14.5 Hz, 2H), 1.41 (d, J = 6.9 Hz, 0H), 1.38 (s, 0H), 1.27 (d, J = 6.5 Hz, 
3H), 1.02 (dd, J = 14.9, 6.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 147.64, 142.66, 141.96, 
140.73, 130.39, 129.04, 128.74, 126.41, 126.35, 126.32, 126.27, 124.44, 124.40, 124.28, 124.18, 
123.60, 123.43, 123.36, 123.28, 123.16, 87.21, 84.87, 77.25, 77.21, 77.00, 76.74, 56.14, 55.00, 
53.93, 50.75, 50.24, 44.85, 43.35, 42.83, 41.12, 39.83, 37.64, 35.28, 34.72, 34.01, 20.64, 19.46, 
19.42, 18.46. 
 
 
3-Bromo-N-(4-((4-methoxy-2,3-dihydro-1H-inden-2-yl)methyl)phenyl)propanamide (144). 
144 was synthesized according to general procedure C starting from 141 (698mg, 2.76 mmol, 1.0 
eq) to yield the title compound as white, waxy solid (997 mg, 93.2%). 1H NMR (400 MHz, 
CDCl3) δ 7.44 (d, J = 8.1 Hz, 2H), 7.22 (s, 1H), 7.18 (d, J = 7.9 Hz, 2H), 7.11 (t, J = 7.8 Hz, 1H), 
6.80 (d, J = 7.4 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 3.80 (d, J = 1.7 Hz, 3H), 3.72 (t, J = 6.8 Hz, 
2H), 3.01 – 2.91 (m, 5H), 2.75 (s, 3H), 2.62 (ddd, J = 40.6, 14.7, 5.0 Hz, 2H). 13C NMR (126 
MHz, CDCl3) δ 179.90, 167.70, 156.01, 155.80, 145.07, 137.98, 135.21, 130.57, 129.42, 127.60, 
120.12, 116.96, 107.83, 55.15, 41.14, 41.05, 40.72, 39.12, 35.33, 27.14. 
 
 
3-Bromo-N-(4-((5-methoxy-2,3-dihydro-1H -inden-2-yl)methyl)phenyl)propanamide (145). 
145 was synthesized according to general procedure C starting from 142 (365 mg, 1.4 mmol, 1.0 
eq) to yield the title compound as a tan solid (554 mg, 99%). 1H NMR (400 MHz, CDCl3) δ 7.45 
(d, J = 8.0 Hz, 2H), 7.28 (d, J = 4.6 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.2 Hz, 1H), 
6.73 (d, J = 2.3 Hz, 1H), 6.70 – 6.66 (m, 1H), 3.77 (d, J = 1.3 Hz, 3H), 3.72 (t, J = 6.4 Hz, 2H), 
2.97 – 2.86 (m, 5H), 2.73 (s, 3H), 2.60 (ddd, J = 21.4, 14.8, 5.2 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 167.76, 158.58, 144.61, 137.97, 135.24, 135.08, 129.38, 124.91, 120.14, 111.90, 
 
 
174 
 
110.10, 55.40, 41.93, 40.98, 40.68, 39.09, 37.95, 27.14. 
 
 
3-Bromo-N-(4-((1-methyl-2,3-dihydro-1H -inden-2-yl)methyl)phenyl)propanamide (146). 
146 was synthesized according to general procedure C starting from 143 (773 mg, 2.8 mmol, 1.0 
eq) to yield the title compound as a tan solid (1.06 g, quant.). 1H NMR (400 MHz, CDCl3) δ 7.60 
– 7.51 (m, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.16 (dd, J = 21.5, 10.6 Hz, 7H), 3.72 (q, J = 6.3 Hz, 
3H), 3.57 (td, J = 6.7, 3.3 Hz, 2H), 3.10 (td, J = 6.6, 1.6 Hz, 1H), 3.01 – 2.90 (m, 5H), 2.91 – 
2.82 (m, 2H), 2.61 (ddd, J = 33.3, 14.9, 9.2 Hz, 2H), 2.24 – 2.16 (m, 1H), 1.27 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 174.76, 167.99, 147.97, 142.35, 137.91, 135.23, 129.45, 
128.34, 128.16, 126.54, 126.27, 126.23, 124.44, 124.26, 123.37, 123.18, 120.25, 119.98, 67.00, 
56.28, 54.80, 50.50, 44.81, 44.28, 43.04, 40.64, 39.74, 38.57, 37.73, 37.33, 36.09, 27.19, 25.29, 
24.01, 19.45, 18.46. 
 
 
1-(4-((4-Methoxy-2,3-dihydro-1H-inden-2-yl)methyl)phenyl)azetidin-2-one (147). 147 was 
synthesized according to general procedure D starting from 144 (997 mg, 2.57 mmol, 1.0 eq) to 
yield the title compound brown oil (789 mg, quant.). 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 
7.31 – 7.27 (m, 2H), 7.20 – 7.16 (m, 2H), 7.11 (t, J = 7.7 Hz, 1H), 6.79 (d, J = 7.5 Hz, 1H), 6.66 
(d, J = 8.1 Hz, 1H), 3.80 (d, J = 1.3 Hz, 4H), 3.61 (dh, J = 4.6, 2.6 Hz, 2H), 3.10 (tt, J = 4.6, 2.2 
Hz, 2H), 2.98 (d, J = 6.4 Hz, 1H), 2.95 (t, J = 1.8 Hz, 6H), 2.88 (q, J = 1.2 Hz, 4H), 2.74 (d, J = 
3.3 Hz, 3H), 2.65 (dd, J = 15.5, 5.6 Hz, 1H), 2.60 – 2.53 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 
164.22, 162.45, 155.93, 144.97, 136.97, 136.49, 130.47, 129.42, 129.23, 127.55, 127.52, 119.93, 
116.89, 116.08, 107.76, 55.07, 41.10, 41.07, 41.02, 39.03, 37.95, 36.41, 35.98, 35.22, 31.36. 
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1-(4-((5-Methoxy-2,3-dihydro-1 H -inden-2-yl)methyl)phenyl)azetidin-2-one (148). 148 was 
synthesized according to general procedure D starting from 145 (544 mg, 1.43 mmol, 1.0 eq) to 
yield the title compound as a solid (439 mg, quant.). 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 0H), 
7.33 – 7.27 (m, 2H), 7.20 – 7.14 (m, 2H), 7.06 (d, J = 8.1 Hz, 1H), 6.76 – 6.72 (m, 1H), 6.71 – 
6.65 (m, 1H), 3.77 (d, J = 1.1 Hz, 3H), 3.62 (td, J = 4.5, 1.2 Hz, 2H), 3.11 (td, J = 4.5, 1.1 Hz, 
2H), 2.95 (d, J = 1.2 Hz, 1H), 2.95 – 2.86 (m, 4H), 2.73 (d, J = 2.7 Hz, 4H), 2.60 (ddd, J = 20.9, 
15.1, 5.7 Hz, 3H) 13C NMR (126 MHz, CDCl3) δ 164.25, 158.57, 144.57, 137.02, 136.55, 
135.04, 129.43, 124.88, 116.11, 111.87, 110.09, 55.37, 42.00, 40.99, 39.05, 37.98, 37.91, 36.03. 
 
 
1-(4-((1-Methyl-2,3-dihydro-1H-inden-2-yl)methyl)phenyl)azetidin-2-one (149). 149 was 
synthesized according to general procedure D starting from 146 (1.06 g, 2.85 mmol, 1.0 eq) to 
yield the title compound as a solid (185 mg, 22.3%). δ 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J 
= 8.2 Hz, 2H), 7.20 – 7.09 (m, 6H), 3.58 (t, J = 4.4 Hz, 2H), 3.07 (t, J = 4.4 Hz, 2H), 2.95 (dd, J 
= 13.5, 5.5 Hz, 1H), 2.89 – 2.82 (m, 2H), 2.60 (ddd, J = 34.2, 14.6, 9.1 Hz, 2H), 2.20 (pd, J = 
8.5, 5.5 Hz, 1H), 1.26 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 164.21, 147.88, 
142.23, 136.83, 136.48, 129.44, 126.18, 126.15, 124.15, 123.08, 116.06, 50.49, 44.69, 39.70, 
37.92, 37.65, 35.95, 18.38. 
 
 
6-((4-Methoxy-2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (150). 
150 was synthesized according to general procedure E starting from 147 (789 mg, 2.57 mmol, 
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1.0 eq) to yield that title compound (205 mg, 25.9%) 1H NMR (400 MHz, CDCl3) δ 7.69 (t, J = 
1.8 Hz, 1H), 7.16 (dt, J = 8.5, 1.8 Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 6.78 (d, J = 7.4 Hz, 1H), 6.66 
– 6.58 (m, 2H), 3.79 (d, J = 1.4 Hz, 3H), 3.57 – 3.48 (m, 2H), 3.01 – 2.92 (m, 2H), 2.76 – 2.60 
(m, 7H), 2.55 (dd, J = 16.0, 6.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 193.89, 155.92, 150.47, 
145.04, 136.10, 130.87, 130.53, 127.51, 127.05, 119.18, 116.92, 115.91, 107.76, 55.06, 42.39, 
40.95, 40.57, 39.02, 38.17, 35.20. 
 
 
6-((5-Methoxy-2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (151). 
151 was synthesized according to general procedure E starting from 148 (514 mg, 1.67 mmol) to 
yield the title compound as a viscous yellow oil (172 mg, 33.4%). 1H NMR (400 MHz, CDCl3) δ 
7.69 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 8.3, 2.1 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.74 – 6.72 (m, 
1H), 6.67 (dd, J = 8.2, 2.5 Hz, 1H), 6.63 (d, J = 8.3 Hz, 1H), 3.77 (s, 3H), 3.57 (t, J = 6.9 Hz, 
2H), 2.92 (td, J = 15.9, 6.9 Hz, 2H), 2.74 – 2.65 (m, 6H), 2.60 (ddd, J = 22.3, 15.1, 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 193.86, 158.57, 150.43, 144.66, 136.12, 135.14, 131.06, 127.15, 
124.90, 119.33, 115.91, 111.90, 110.09, 55.40, 42.51, 41.92, 40.48, 39.04, 38.24, 37.90. 
 
 
6-((1-Methyl-2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one (152). 152 
was synthesized according to general procedure E starting from 149 (185 mg, 0.64 mmol) to 
yield the title compound as a viscous yellow oil (87 mg, 47%). 1H NMR (400 MHz, CDCl3) δ 
7.70 (d, J = 2.3 Hz, 1H), 7.21 – 7.07 (m, 5H), 6.63 (dd, J = 8.3, 2.0 Hz, 1H), 3.56 (td, J = 7.0, 2.2 
Hz, 2H), 2.94 – 2.82 (m, 3H), 2.69 (td, J = 7.1, 6.4, 2.0 Hz, 2H), 2.57 (ddq, J = 13.7, 9.4, 2.9 Hz, 
2H), 2.17 (dddt, J = 14.4, 7.5, 5.2, 2.1 Hz, 1H), 1.28 (dd, J = 6.8, 2.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 193.93, 150.46, 147.99, 142.38, 136.19, 130.80, 127.14, 126.18, 126.16, 126.13, 
 
 
177 
 
124.21, 123.12, 119.23, 115.92, 50.48, 44.63, 42.43, 39.09, 38.18, 37.62, 18.37. 
 
Tert-butyl 6-((4-methoxy-2,3-dihydro-1H-inden-2-yl)methyl)-4-oxo-3,4-dihydroquinoline-
1(2H)-carboxylate (153). 153 was synthesized following general procedure G using 150 (118 
mg, 0.384 mmol, 1.0 eq), Boc2O (101 mg, 0.46 mmol, 2.0 eq), DMAP (5 mg, 0.038 mmol, 0.1 
eq), DIPEA (0.08 mL, 0.46 mmol, 2.0 eq). The reaction stirred at reflux for 16 h. Once enough 
starting material was converted to product, the crude yellow oil was purified using silica gel 
chromatography to yield the title compound as a clear, colorless oil (83 mg, 53.2%). 1H NMR 
(500 MHz, CDCl3) δ 7.84 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.36 (dd, J = 8.3, 2.1 Hz, 
1H), 7.11 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.4 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 4.15 (t, J = 6.3 
Hz, 2H), 3.80 (s, 3H), 2.99 (dt, J = 16.0, 6.4 Hz, 2H), 2.81 – 2.72 (m, 5H), 2.71 – 2.62 (m, 1H), 
2.61 – 2.52 (m, 1H), 1.57 (d, J = 1.4 Hz, 9H), 1.53 (d, J = 4.3 Hz, 1H), 1.47 (d, J = 1.2 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 194.22, 155.91, 152.71, 144.80, 142.14, 137.02, 134.62, 130.34, 
127.57, 126.96, 124.67, 123.56, 116.87, 107.77, 81.92, 80.87, 55.02, 44.24, 40.75, 40.71, 39.04, 
38.95, 35.20, 28.23, 27.81. 
 
 
Tert-butyl 6-((5-methoxy-2,3-dihydro-1H-inden-2-yl)methyl)-4-oxo-3,4-dihydroquinoline-
1(2H)-carboxylate (154). 154 was synthesized following general procedure G using 151 (100 
mg, 0.325 mmol, 1.0 eq), Boc2O (85 mg, 0.39 mmol, 2.0 eq), DMAP (4 mg, 0.033 mmol, 0.1 
eq), DIPEA (0.068 mL, 0.39 mmol, 2.0 eq). The reaction stirred at reflux for 16 h. Once enough 
starting material was converted to product, the crude yellow oil was purified using silica gel 
chromatography to yield the title compound as a clear, colorless oil (47 mg, 35.3%). 1H NMR 
(500 MHz, CDCl3) δ 7.83 (s, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.39 – 7.30 (m, 1H), 7.05 (d, J = 8.1 
Hz, 1H), 6.73 (s, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.15 (t, J = 6.3 Hz, 2H), 3.76 (s, 3H), 2.93 (ddd, J 
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= 18.8, 10.9, 4.1 Hz, 2H), 2.75 (d, J = 6.9 Hz, 6H), 2.60 (ddd, J = 20.8, 14.5, 4.4 Hz, 3H), 1.56 
(s, 11H). 13C NMR (126 MHz, CDCl3) δ 194.28, 158.58, 152.74, 144.39, 142.18, 137.04, 134.86, 
134.64, 126.95, 124.86, 124.68, 123.58, 111.94, 110.05, 81.98, 77.26, 77.00, 76.75, 55.33, 44.27, 
41.64, 40.63, 39.01, 38.97, 37.88, 28.26, 27.84. 
 
 
Tert-butyl 6-((1-methyl-2,3-dihydro-1H-inden-2-yl)methyl)-4-oxo-3,4-dihydroquinoline-
1(2H)-carboxylate (155). 155 was synthesized following general procedure G using 152 (87 mg, 
0.3 mmol, 1.0 eq), Boc2O (78 mg, 0.36 mmol, 2.0 eq), DMAP (4 mg, 0.03 mmol, 0.1 eq), 
DIPEA (0.062 mL, 0.36 mmol, 2.0 eq). The reaction stirred at reflux for 16 h. Once enough 
starting material was converted to product, the crude yellow oil was purified using silica gel 
chromatography to yield the title compound as a clear, colorless oil (51 mg, 43.6%). 1H NMR 
(500 MHz, CDCl3) δ 7.84 (d, J = 2.4 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.36 (dd, J = 8.5, 2.4 Hz, 
1H), 7.19 – 7.09 (m, 6H), 4.15 (t, J = 6.4 Hz, 2H), 3.01 (dd, J = 13.6, 5.2 Hz, 1H), 2.88 (ddd, J = 
11.9, 7.7, 4.4 Hz, 2H), 2.76 (t, J = 6.2 Hz, 3H), 2.67 (dd, J = 13.6, 9.5 Hz, 1H), 2.59 (dd, J = 
15.6, 9.0 Hz, 1H), 2.23 (pd, J = 8.6, 5.3 Hz, 1H), 1.56 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 
194.36, 152.74, 147.79, 142.20, 142.16, 136.95, 134.74, 127.04, 126.27, 126.24, 124.69, 124.22, 
123.60, 123.14, 82.00, 50.22, 44.74, 44.27, 39.34, 38.98, 37.59, 29.66, 28.27, 27.85, 18.37. 
 
 
1-Acetyl-6-((1-methyl-2,3-dihydro-1H-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1H)-one 
(156) 156 was synthesized following general procedure K using 152 (46 mg, 0.158 mmol, 1.0 
eq). Once the reaction was completed, the crude product was purified using silica gel 
chromatography to yield the title comound 156 (49 mg, 92.5%) as a clear, colorless oil.  1H 
NMR (500 MHz, CDCl3) δ 7.87 (s, 1H), 7.44 – 7.39 (m, 1H), 7.20 – 7.07 (m, 5H), 4.30 – 4.19 
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(m, 3H), 3.04 (dd, J = 13.7, 5.1 Hz, 1H), 2.90 (ddd, J = 13.0, 8.0, 4.4 Hz, 2H), 2.80 (t, J = 6.3 
Hz, 3H), 2.71 (dd, J = 13.5, 9.6 Hz, 1H), 2.60 (dd, J = 15.6, 9.1 Hz, 1H), 2.35 (s, 4H), 2.25 (pd, J 
= 8.6, 3.7 Hz, 1H), 1.31 (dd, J = 7.1, 2.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 194.23, 
169.32, 147.70, 142.03, 138.97, 134.81, 134.65, 127.62, 126.38, 126.36, 126.32, 125.94, 124.51, 
124.27, 124.09, 123.53, 123.21, 77.29, 77.23, 77.03, 76.99, 76.78, 50.18, 44.78, 44.69, 41.82, 
39.54, 39.48, 37.61, 36.18, 35.32, 23.13, 18.43, 15.29. 
 
 
Tert-butyl (4R)-4-((( R)-tert-butylsulfinyl)amino)-6-((4-methoxy-2,3-dihydro-1H-inden-2-
yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate (157). 157 was synthesized following 
general procedure H using 153 (83 mg, 0.20 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide 
(74 mg, 0.61 mmol, 3.0 eq), and Ti(OEt)4 (0.325 mL, 1.22 mmol, 6.0 eq) to form the (R)-tert-
butanesulfinyl imine  intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (46 mg, 1.22 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, 
after addition, the solution was stirred at room temperature for 3 h before being quenched with 
MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography to yield the title compound as an off-white solid (43 mg, 41.3%). 1H NMR (500 
MHz, CDCl3) δ 7.71 (d, J = 8.5 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.11 (t, J = 7.9 Hz, 2H), 6.79 
(d, J = 7.5 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 4.57 (q, J = 3.1 Hz, 1H), 4.52 (s, 1H), 4.03 – 3.94 
(m, 1H), 3.80 (d, J = 2.7 Hz, 3H), 3.62 – 3.52 (m, 1H), 3.04 – 2.91 (m, 2H), 2.74 (s, 3H), 2.70 – 
2.62 (m, 1H), 2.61 – 2.52 (m, 1H), 2.19 (dt, J = 13.0, 3.9 Hz, 1H), 2.03 – 1.93 (m, 1H), 1.53 (s, 
10H), 1.44 (s, 3H), 1.22 (s, 11H). 13C NMR (126 MHz, CDCl3) δ 155.95, 153.56, 145.04, 
136.90, 136.34, 130.54, 129.01, 128.68, 128.66, 128.37, 127.54, 123.79, 116.93, 107.77, 81.07, 
77.26, 77.21, 77.00, 76.75, 55.59, 55.10, 55.08, 50.35, 40.91, 40.87, 40.83, 40.03, 40.01, 39.15, 
35.29, 35.27, 29.55, 28.33, 24.16, 22.59. 
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Tert-butyl (4R)-4-(((R)-tert-butylsulfinyl)amino)-6-((5-methoxy-2,3-dihydro-1H-inden-2-
yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate (158). 158 was synthesized following 
general procedure H using 154 (139 mg, 0.41 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide 
(47 mg, 0.12 mmol, 3.0 eq), and Ti(OEt)4 (0.145 mL, 0.69 mmol, 6.0 eq) to form the (R)-tert-
butanesulfinyl imine intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (26 mg, 0.69 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, 
after addition, the solution was stirred at room temperature for 3 h before being quenched with 
MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography to yield the title compound as clear, colorless oil (25 mg, 44.0%). 1H NMR (500 
MHz, CDCl3) δ 7.73 (d, J = 8.5 Hz, 1H), 7.19 (s, 1H), 7.07 (dd, J = 19.0, 8.3 Hz, 2H), 6.73 (s, 
1H), 6.67 (d, J = 7.8 Hz, 1H), 4.62 – 4.49 (m, 1H), 4.12 (q, J = 7.2 Hz, 0H), 3.99 (dt, J = 13.5, 
4.5 Hz, 1H), 3.77 (s, 3H), 3.63 – 3.52 (m, 1H), 3.30 (s, 1H), 3.00 – 2.86 (m, 2H), 2.72 (s, 3H), 
2.67 – 2.52 (m, 2H), 2.18 (dt, J = 13.5, 4.2 Hz, 1H), 2.00 (ddd, J = 20.6, 11.7, 4.1 Hz, 2H), 1.53 
(s, 9H), 1.22 (s, 11H). 13C NMR (126 MHz, CDCl3) δ 158.54, 153.54, 144.58, 144.56, 136.88, 
136.35, 135.07, 135.04, 129.01, 128.65, 128.38, 124.85, 124.84, 123.74, 111.88, 111.86, 110.06, 
81.05, 77.25, 77.00, 76.79, 76.75, 55.58, 55.35, 50.44, 41.81, 40.68, 40.06, 39.11, 39.09, 37.97, 
37.95, 29.65, 28.32, 24.16, 22.57. 
 
 
Tert-butyl (4R)-4-(((R)-tert-butylsulfinyl)amino)-6-((1-methyl-2,3-dihydro-1H-inden-2-
yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate (159). 159 was synthesized following 
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general procedure H using 155 (51 mg, 0.13 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide 
(47 mg, 0.39 mmol, 3.0 eq), and Ti(OEt)4 (0.164 mL, 0.78 mmol, 6.0 eq) to form the (R)-tert-
butanesulfinyl imine intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (30 mg, 0.69 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, 
after addition, the solution was stirred at room temperature for 3 h before being quenched with 
MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography to yield the title compound as clear, colorless oil (19 mg, 29.2%). 1H NMR (500 
MHz, CDCl3) δ 7.74 (d, J = 8.5 Hz, 1H), 7.12 (t, J = 11.3 Hz, 5H), 4.60 – 4.50 (m, 1H), 4.00 (dq, 
J = 13.3, 4.4 Hz, 1H), 3.61 – 3.50 (m, 1H), 3.31 (s, 1H), 3.00 – 2.83 (m, 3H), 2.69 – 2.53 (m, 
2H), 2.20 (dp, J = 12.7, 4.3 Hz, 2H), 2.02 – 1.92 (m, 1H), 1.53 (s, 9H), 1.43 (d, J = 1.9 Hz, 1H), 
1.29 (d, J = 6.8 Hz, 3H), 1.22 (dd, J = 4.8, 2.1 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 153.55, 
153.53, 147.94, 142.37, 142.32, 136.70, 136.38, 136.35, 129.13, 128.78, 128.70, 128.33, 128.31, 
126.20, 126.17, 124.22, 124.20, 123.79, 123.75, 123.14, 123.12, 81.06, 77.25, 77.00, 76.74, 
55.60, 55.59, 50.37, 50.33, 50.31, 50.27, 44.71, 44.69, 39.98, 39.95, 39.31, 39.29, 37.68, 37.66, 
29.47, 28.33, 24.16, 22.57, 18.41, 18.35. 
 
 
(R)-N-((4R)-1-acetyl-6-((1-methyl-2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide (160). 160 was synthesized 
following general procedure H using 156 (49 mg, 0.15 mmol, 1.0 eq), (R)-2-methylpropane-2-
sulfinamide (53 mg, 0.44 mmol, 3.0 eq), and Ti(OEt)4 (0.185 mL, 0.88 mmol, 6.0 eq) to form the 
(R)-tert-butanesulfinyl imine intermediate in situ. Once sufficient ketone was converted into 
imine intermediate (after 48 h), the reaction mixture was transferred via cannula to a round 
bottom flask containing NaBH4 (33 mg, 0.88 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry 
ice bath, after addition, the solution was stirred at room temperature for 3 h before being 
quenched with MeOH. Once resultant solid was removed, crude residue was purified using silica 
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gel chromatography to yield the title compound which was still impure with residual Ellman 
reagent, but was taken ahead to next step. No yield calculated. 1H NMR (500 MHz, CDCl3) δ 
7.26 – 7.18 (m, 2H), 7.11 – 7.00 (m, 5H), 4.50 (d, J = 4.7 Hz, 1H), 3.34 (s, 1H), 2.92 (dt, J = 
13.7, 4.5 Hz, 1H), 2.88 – 2.77 (m, 2H), 2.62 (ddd, J = 13.6, 9.3, 4.0 Hz, 1H), 2.54 (dd, J = 15.6, 
9.0 Hz, 1H), 2.22 – 2.11 (m, 5H), 2.05 – 1.98 (m, 1H), 1.23 (dd, J = 6.8, 1.3 Hz, 3H), 0.85 – 0.78 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 169.90, 147.80, 142.19, 142.15, 128.86, 128.75, 128.68, 
126.23, 124.61, 124.55, 124.20, 124.18, 123.14, 123.12, 77.00, 66.73, 55.71, 50.24, 50.19, 44.68, 
44.66, 39.47, 39.44, 38.66, 37.65, 37.63, 33.93, 30.55, 30.33, 29.63, 28.84, 24.41, 24.18, 23.71, 
23.34, 22.89, 22.55, 21.94, 18.40, 18.36, 13.98, 10.92. 
 
 
(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((4R)-6-((4-methoxy-2,3-dihydro-1H-
inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (161). 161 was synthesized 
following general procedure I using 157 (43 mg, 0.084 mmol, 1.0 eq) and conc. HCl (3 drops). 
After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing 
the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (15 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (25 mg, 0.073 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 161 as a TFA 
salt (35 mg, 79.5%). 1H NMR (500 MHz, CD3OD) δ 7.18 – 7.11 (m, 2H), 7.06 (td, J = 7.8, 4.9 
Hz, 1H), 6.95 (dd, J = 8.2, 4.7 Hz, 1H), 6.76 – 6.71 (m, 1H), 6.67 (dd, J = 8.3, 4.9 Hz, 1H), 6.50 
(d, J = 4.9 Hz, 2H), 5.07 (q, J = 5.0 Hz, 1H), 3.90 (dt, J = 11.1, 5.2 Hz, 1H), 3.76 (d, J = 4.8 Hz, 
3H), 3.31 (s, 2H), 3.28 – 3.18 (m, 2H), 3.06 (dt, J = 13.6, 5.1 Hz, 1H), 2.90 (dddd, J = 32.8, 17.5, 
11.7, 5.8 Hz, 2H), 2.82 – 2.74 (m, 1H), 2.64 (s, 0H), 2.59 (dt, J = 15.3, 5.5 Hz, 1H), 2.48 (dt, J = 
15.9, 5.2 Hz, 1H), 2.28 (d, J = 4.9 Hz, 6H), 1.99 – 1.87 (m, 1H), 1.59 (dq, J = 11.6, 5.8, 5.2 Hz, 
1H). 13C NMR (126 MHz, CD3OD) δ 168.95, 157.37, 145.84, 145.80, 140.07, 134.95, 131.89, 
131.86, 131.25, 131.20, 130.89, 130.85, 128.80, 127.63, 123.34, 121.21, 117.85, 117.83, 116.41, 
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108.96, 108.94, 55.52, 53.39, 49.51, 49.45, 49.34, 49.27, 49.17, 49.00, 48.83, 48.72, 48.66, 
48.49, 45.19, 45.17, 42.33, 42.25, 41.91, 41.89, 40.15, 39.87, 39.59, 39.56, 36.24, 35.96, 31.82, 
28.10, 20.44. HPLC (gradient A): retention time 31.7. ESI-MS 522.1 [M+Na]+. 
 
 
(2S)-2-amino-N-((4R)-6-((4-hydroxy-2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (162). To a round 
bottom flask already containing 161 (25 mg, 0.043 mmol, 1.0 eq) was added anhyd DCM and 
then reaction vessel was placed under vacuum for 10 min, then flooded with Ar. A 1M BBr3 
solution in DCM (0.2 mL, 0.172 mmol, 4.0 eq) was slowly added to the reaction vessel. Once 
completely added, solution stirred for 3 h. After 3 h, solvent was removed under reduced 
pressure and residue was resuspended in MeOH, then solvent was moved. This process was 
repeated 3 x.  The crude mixture was purified using semipreparative HPLC to yield title 
compound 162 (15 mg, 62.5%) as a white fluffy powder. Additional starting material, 161, was 
recoverd but not included in final yield calculation. 1H NMR (500 MHz, CD3OD) δ 8.18 – 8.14 
(m, 0H), 7.05 – 6.98 (m, 2H), 6.94 – 6.88 (m, 1H), 6.72 (d, J = 8.1 Hz, 1H), 6.63 (d, J = 7.3 Hz, 
1H), 6.52 (dd, J = 7.9, 2.7 Hz, 1H), 6.49 (d, J = 1.9 Hz, 2H), 5.01 (q, J = 4.2 Hz, 1H), 3.90 – 3.82 
(m, 1H), 3.28 – 3.21 (m, 1H), 3.15 – 3.07 (m, 1H), 3.02 (ddd, J = 13.8, 5.4, 1.9 Hz, 1H), 2.95 – 
2.78 (m, 2H), 2.62 (dq, J = 27.1, 16.4, 13.4 Hz, 5H), 2.52 – 2.44 (m, 1H), 1.82 (d, J = 12.8 Hz, 
1H), 1.61 – 1.50 (m, 1H). No 13C data acquired. HPLC (gradient A): retention time 25.9. ESI-MS 
508.1 [M+Na]+. 
 
 
 
 
184 
 
(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((4R)-6-((5-methoxy-2,3-dihydro-1H-
inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (163).  163 was synthesized 
following general procedure I using 158 (26 mg, 0.057 mmol, 1.0 eq) and conc. HCl (3 drops). 
After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing 
the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (15 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (15 mg, 0.044 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 163 as a TFA 
salt (19 mg, 70.4%).  No 1H or 13C data acquired. Instead, product formation was verified using 
mass spectrometry. HPLC (gradient A): retention time 30.1. ESI-MS 500.1 [M+H]+ and 522.1 
[M+Na]+. 
 
 
 
(2S)-2-amino-N-((4R)-6-((5-hydroxy-2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (164). To a round 
bottom flask already containing 163 (13 mg, 0.024 mmol, 1.0 eq) was added anhyd DCM and 
then reaction vessel was placed under vacuum for 10 min, then flooded with Ar. A 1M BBr3 
solution in DCM (0.125 mL, 0.090 mmol, 4.0 eq) was slowly added to the reaction vessel. Once 
completely added, solution stirred for 3 h. After 3 h, solvent was removed under reduced 
pressure and residue was resuspended in MeOH, then solvent was moved. This process was 
repeated 3 x.  The crude mixture was purified using semipreparative HPLC to yield title 
compound 164 (1.3 mg, 10%) as a white fluffy powder. Title compound was 80% pure, an 
additional 15% was the methoxy starting material (163), and the entity of remaining 5% impurity 
was undetermined.  Title compound formation was verified by mass spectrometry. No 1H or 13C 
data acquired. Instead, product formation was verified using mass spectrometry. HPLC (gradient 
A): retention time 31.7.  ESI-MS 508.1 [M+Na]+. Retention times of impurities are 24.8 (starting 
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material 163) and 28.1 (unknown impurity).  
 
 
(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((4R)-6-((1-methyl-2,3-dihydro-1H-
inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (165). 165 was synthesized 
following general procedure I using 159 (19 mg, 0.038 mmol, 1.0 eq) and conc. HCl (3 drops). 
After removing solvent, residue was re-suspended in Et2O, and solid crashed out. After washing 
the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (13 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (15 mg, 0.040 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 165 as a TFA 
salt (24 mg, quant.) of two sets of inseparable diastereomers. Title compound formation was 
verified by mass spectrometry as title compound was synthesized as a mixture of two sets of 
diastereomers. No 1H or 13C data acquired. HPLC (gradient A): retention time 34.0. ESI-MS 
506.1 [M+Na]+. 
 
 
(2S)-N-((4R)-1-acetyl-6-((1-methyl-2,3-dihydro-1H-inden-2-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide (166). 
166 was synthesized following general procedure I using 160 (64 mg, 0.15 mmol, 1.0 eq) and 
conc. HCl (3 drops). After removing solvent, residue was re-suspended in Et2O, and solid 
crashed out. After washing the solid 3 x with fresh Et2O, the remaining Et2O was decanted off, 
yielding a white solid amine hydrochloride salt (30 mg). The synthesis was completed by 
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following general procedure F with newly formed (R) amine intermediate (30 mg, 0.081 mmol, 
1.0 eq) to yield crude product which was purified by semipreparative HPLC and lyophilized to 
yield the title compound 166 as a TFA salt of two sets of inseparable diastereomers. No yield 
calculated because only a portion of the crude product was purified. Title compound formation 
was verified by mass spectrometry as title compound was synthesized as a mixture of two sets of 
diastereomers. No 1H or 13C data acquired. HPLC (gradient A): retention time 41.8. ESI-MS 
526.1 [M+H]+ and 548.1 [M+H]+. 
 
 
Tert-butyl 6-(2-methoxybenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (167). 167 
was synthesized following general procedure L using 104 (150 mg, 0.44 mmol, 1.0 eq), (2-
methoxyphenyl)boronic acid (0.134 mg, 0.88 mmol, 2.0 eq), K2CO3 (183 mg, 1.3 mmol, 3.0 eq), 
and Pd(dppf)Cl2 (32 mg, 0.04 mmol, 0.1 eq). The contents were placed microwave tube and 
reacted in microwave with max temp of 110°C, max power of 250 W for 30 min, with the 
“Powermax” option enabled. Once crude mixture was filtered through Celite, the solvent was 
removed and the residue was purified via silica gel chromatography to yield title compound (105 
mg, 64.8%)  as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 2.2 Hz, 1H), 7.55 
(d, J = 8.6 Hz, 1H), 7.26 (dd, J = 8.6, 2.2 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 6.99 (d, J = 7.4 Hz, 
1H), 6.79 – 6.72 (m, 2H), 4.02 (t, J = 6.3 Hz, 2H), 3.85 (s, 2H), 3.70 (s, 3H), 2.63 (t, J = 6.3 Hz, 
2H), 1.45 (d, J = 1.3 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 194.19, 157.11, 152.67, 141.97, 
136.78, 134.63, 130.12, 128.78, 127.55, 127.06, 124.60, 123.45, 120.40, 110.32, 81.82, 55.15, 
44.15, 38.90, 35.13, 28.17. 
 
 
Tert-butyl 6-(3-methoxybenzyl)-4-oxo-3,4-dihydroquinoline-1(2 H)-carboxylate (167). 167 
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was synthesized following general procedure L using 104 (150 mg, 0.44 mmol, 1.0 eq), (e-
methoxyphenyl)boronic acid (0.134 mg, 0.88 mmol, 2.0 eq), K2CO3 (183 mg, 1.3 mmol, 3.0 eq), 
and Pd(dppf)Cl2 (32 mg, 0.04 mmol, 0.1 eq). The contents were placed microwave tube and 
reacted in microwave with max temp of 110°C, max power of 250 W for 30 min, with the 
“Powermax” option enabled. Once crude mixture was filtered through Celite, the solvent was 
removed and the residue was purified via silica gel chromatography to yield title compound (72 
mg, 44.4%)  as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.84 (q, J = 5.9, 4.4 Hz, 1H), 
7.68 (dt, J = 9.6, 4.8 Hz, 1H), 7.32 (dt, J = 8.5, 2.8 Hz, 1H), 7.20 (tq, J = 9.8, 6.3, 4.8 Hz, 1H), 
6.82 – 6.65 (m, 3H), 4.18 – 4.06 (m, 2H), 3.92 (t, J = 5.3 Hz, 2H), 3.82 – 3.69 (m, 3H), 2.80 – 
2.67 (m, 2H), 1.61 – 1.45 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 194.20, 159.68, 152.68, 
142.35, 141.92, 136.63, 134.56, 129.47, 127.08, 124.72, 123.78, 121.18, 114.63, 111.43, 82.02, 
55.08, 44.20, 41.09, 38.92, 28.23. 
 
 
Tert-butyl 6-(4-methoxybenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (167). 167 
was synthesized following general procedure L using 104 (150 mg, 0.44 mmol, 1.0 eq), (4-
methoxyphenyl)boronic acid (0.134 mg, 0.88 mmol, 2.0 eq), K2CO3 (183 mg, 1.3 mmol, 3.0 eq), 
and Pd(dppf)Cl2 (32 mg, 0.04 mmol, 0.1 eq). The contents were placed microwave tube and 
reacted in microwave with max temp of 110°C, max power of 250 W for 30 min, with the 
“Powermax” option enabled. Once crude mixture was filtered through Celite, the solvent was 
removed and the residue was purified via silica gel chromatography to yield title compound (110 
mg, 67.9%)  as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 2.2 Hz, 1H), 7.58 
(d, J = 8.6 Hz, 1H), 7.21 (dd, J = 8.6, 2.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.73 (d, J = 8.3 Hz, 
2H), 4.03 (t, J = 6.3 Hz, 2H), 3.80 (s, 2H), 3.67 (s, 3H), 2.65 (t, J = 6.3 Hz, 2H), 1.45 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 194.23, 157.97, 152.66, 142.20, 137.27, 134.45, 132.41, 129.67, 
126.88, 124.67, 123.72, 115.90, 114.62, 113.88, 81.97, 55.12, 44.16, 40.14, 38.88, 28.18. 
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Tert-butyl6-(4-methoxy-2,6-dimethylbenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
(170). 170 was synthesized following general procedure L using 104 (115 mg, 0.34 mmol, 1.0 
eq), (2,2-dimethyl-4-methoxyphenyl)boronic acid (0.122 mg, 0.68 mmol, 2.0 eq), K2CO3 (140 
mg, 1.0 mmol, 3.0 eq), and Pd(dppf)Cl2 (25 mg, 0.034 mmol, 0.1 eq). The contents were placed 
microwave tube and reacted in microwave with max temp of 110°C, max power of 250 W for 30 
min, with the “Powermax” option enabled. Once crude mixture was filtered through Celite, the 
solvent was removed and the residue was purified via silica gel chromatography to yield title 
compound (108mg, 62.1%)  as clear, colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 2.1 
Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.10 (dd, J = 8.7, 2.1 Hz, 1H), 6.63 (s, 2H), 4.12 (t, J = 6.3 Hz, 
2H), 3.96 (s, 2H), 3.79 (s, 3H), 2.73 (t, J = 6.3 Hz, 2H), 2.21 (s, 6H), 1.54 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 194.20, 157.70, 152.70, 141.97, 139.04, 138.17, 136.00, 133.29, 128.23, 126.14, 
124.69, 123.62, 122.32, 113.48, 111.54, 81.91, 54.96, 44.16, 38.93, 33.52, 28.19, 20.45. 
 
 
Tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(2-methoxybenzyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (171). 171 was synthesized following general procedure H using 167 (105 
mg, 0.28 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (104 mg, 0.86 mmol, 3.0 eq), and 
Ti(OEt)4 (0.359 mL, 1.71 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (65 mg, 1.71 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
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as clear, colorless oil (60 mg, 44.4%). 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.5 Hz, 1H), 
7.22 – 7.14 (m, 2H), 7.13 – 7.05 (m, 2H), 6.90 – 6.81 (m, 2H), 4.52 (bs, 1H), 3.99 – 3.87 (m, 
3H), 3.82 (s, 3H), 3.61 – 3.50 (m, 1H), 3.30 (s, 1H), 2.24 – 2.12 (m, 1H), 1.99 – 1.90 (m, 1H), 
1.50 (s, 9H), 1.20 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 157.19, 153.57, 136.54, 136.24, 
130.21, 129.35, 128.98, 128.68, 128.34, 127.43, 123.79, 120.43, 110.35, 80.99, 55.59, 55.27, 
50.25, 39.95, 35.09, 29.33, 28.31, 22.57. 
 
 
Tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(3-methoxybenzyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (172). 172 was synthesized following general procedure H using 168 (72 mg, 
0.2 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (71 mg, 0.59 mmol, 3.0 eq), and 
Ti(OEt)4 (0.246 mL, 1.18 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (44 mg, 1.18 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
as clear, colorless oil (44 mg, 47.3%). 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.4 Hz, 1H), 
7.22 – 7.16 (m, 2H), 7.07 (dd, J = 8.5, 2.2 Hz, 1H), 6.78 (d, J = 7.7 Hz, 1H), 6.75 – 6.70 (m, 2H), 
4.52 (q, J = 3.5 Hz, 1H), 3.94 (dt, J = 12.9, 4.5 Hz, 1H), 3.88 (s,  2H), 3.77 (s, 3H), 3.61 – 3.53 
(m, 1H), 3.33 (s, 1H), 2.18 (dq, J = 14.1, 4.0 Hz, 1H), 2.02 – 1.90 (m, 1H), 1.50 (s, 9H), 1.20 (s, 
9H).13C NMR (126 MHz, CDCl3) δ 159.63, 153.50, 142.41, 136.50, 136.37, 129.37, 128.93, 
128.54, 128.53, 123.96, 121.23, 114.61, 111.33, 81.05, 55.62, 55.07, 50.41, 41.16, 40.01, 29.41, 
28.28, 22.53. 
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Tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(4-methoxybenzyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (173). 173 was synthesized following general procedure H using 169 (110 
mg, 0.3 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (109 mg, 0.9 mmol, 3.0 eq), and 
Ti(OEt)4 (0.377 mL, 1.80 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (68 mg, 1.8 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
as clear, colorless oil (136 mg, 96.5%). 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.5 Hz, 1H), 
7.16 (d, J = 2.0 Hz, 1H), 7.10 – 7.06 (m, 2H), 7.03 (dd, J = 8.6, 2.2 Hz, 1H), 6.81 – 6.76 (m, 2H), 
4.50 (q, J = 3.6 Hz, 1H), 3.91 (dt, J = 12.9, 4.6 Hz, 1H), 3.83 (s, 2H), 3.74 (s, 3H), 3.62 – 3.51 
(m, 1H), 3.39 (bs, 1H), 2.16 (dq, J = 13.7, 4.3 Hz, 1H), 1.95 – 1.89 (m, 1H), 1.48 (s, 9H), 1.18 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 157.78, 153.40, 136.93, 136.25, 132.88, 129.74, 129.61, 
128.70, 128.46, 128.30, 123.83, 113.75, 113.72, 80.90, 55.54, 55.04, 50.38, 40.11, 39.96, 29.34, 
28.16, 22.43. 
 
 
Tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(4-methoxy-2,6-dimethylbenzyl)-3,4-
dihydroquinoline-1(2H)-carboxylate (174). 174 was synthesized following general procedure 
H using 170 (108 mg, 0.27 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (100 mg, 0.82 
mmol, 3.0 eq), and Ti(OEt)4 (0.343 mL, 1.6 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl 
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imine intermediate in situ. Once sufficient ketone was converted into imine intermediate (after 
48 h), the reaction mixture was transferred via cannula to a round bottom flask containing 
NaBH4 (62 mg, 1.6 mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the 
solution was stirred at room temperature for 3 h before being quenched with MeOH. Once 
resultant solid was removed, crude residue was purified using silica gel chromatography to yield 
the title compound as clear, colorless oil (92 mg, 67.1%). 1H NMR (500 MHz, CDCl3) δ 7.61 (d, 
J = 8.6 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 6.82 (dd, J = 8.6, 2.1 Hz, 1H), 6.61 (s, 2H), 4.49 (q, J = 
3.4 Hz, 1H), 3.97 – 3.85 (m, 3H), 3.78 (s, 3H), 3.63 – 3.53 (m, 1H), 3.33 (s, 1H), 2.20 (s, 6H), 
1.99 – 1.90 (m, 1H), 1.49 (s, 9H), 1.19 (s, 9H).  13C NMR (126 MHz, CDCl3) δ 157.60, 153.54, 
138.20, 136.07, 135.62, 128.76, 128.61, 127.84, 127.32, 123.87, 113.43, 80.96, 55.61, 55.00, 
50.36, 40.05, 33.53, 29.35, 28.27, 22.52, 20.50. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(2-methoxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (175). 175 was synthesized following general procedure 
I using 171 (60 mg, 0.13 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, residue 
was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (51 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (51 mg, 0.13 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 175 as a TFA salt. 1H NMR 
(500 MHz, CD3OD) δ 7.14 (ddd, J = 9.2, 7.5, 1.8 Hz, 1H), 6.97 – 6.93 (m, 2H), 6.88 (ddd, J = 
8.0, 6.0, 1.5 Hz, 2H), 6.80 (td, J = 7.5, 1.1 Hz, 1H), 6.57 (d, J = 8.3 Hz, 1H), 6.48 (s, 2H), 4.92 
(t, J = 4.4 Hz, 1H), 3.85 (dd, J = 11.5, 5.0 Hz, 1H), 3.81 – 3.72 (m, 5H), 3.25 (dd, J = 13.7, 11.5 
Hz, 1H), 3.01 (dt, J = 13.4, 5.1 Hz, 2H), 2.52 (td, J = 11.7, 2.7 Hz, 1H), 2.27 (s, 6H), 1.80 – 1.69 
(m, 1H), 1.54 (dd, J = 12.8, 5.9 Hz, 1H). HPLC (gradient A): retention time 26.5. ESI-MS 482.2 
[M+Na]+. 
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(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(2-hydroxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (176). 176 was synthesized following general procedure 
I using 171 (60 mg, 0.13 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, residue 
was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (38 mg). The 
synthesis was completed by following a modified version general procedure F with newly 
formed (R) amine intermediate (38 mg, 0.13 mmol, 1.0 eq). After coupling to diBoc-Dmt, 
instead of using TFA:DCM to deprotect, .a 1M solution of BBr3 in DCM (0.316 mL, 5.0 eq) was 
slowly added to the reaction vessel to remove the boc groups and cleave the methyl ether. Once 
completely added, solution stirred for 3 h. After 3 h, solvent was removed under reduced 
pressure and residue was resuspended in MeOH, then solvent was moved. This process was 
repeated 3 x to yield crude product which was purified by semipreparative HPLC and lyophilized 
to yield the title compound 176 as a TFA salt. 1H NMR (500 MHz, CD3OD) δ 7.12 (d, J = 2.4 
Hz, 1H), 7.07 (dd, J = 8.1, 2.4 Hz, 1H), 7.02 – 6.97 (m, 1H), 6.96 – 6.92 (m, 1H), 6.81 (dd, J = 
8.3, 2.9 Hz, 1H), 6.76 – 6.67 (m, 2H), 6.49 (d, J = 2.7 Hz, 2H), 4.99 (q, J = 4.3 Hz, 1H), 3.85 
(tdd, J = 14.7, 11.5, 4.3 Hz, 3H), 3.25 (ddd, J = 14.4, 11.5, 3.0 Hz, 1H), 3.07 – 3.00 (m, 1H), 
2.70 – 2.60 (m, 1H), 2.27 (d, J = 2.9 Hz, 6H), 1.87 (ddt, J = 14.3, 10.6, 4.0 Hz, 1H), 1.59 (dd, J = 
12.8, 6.2 Hz, 1H). No 13C data acquired. HPLC (gradient A): retention time 21.3. ESI-MS 468.2 
[M+Na]+. 
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(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(3-methoxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (177). 177 was synthesized following general procedure 
I using 172 (44 mg, 0.093 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, 
residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh 
Et2O, the remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (38 
mg). The synthesis was completed by following general procedure F with newly formed (R) 
amine intermediate (38 mg, 0.13 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 177 as a TFA salt. 1H NMR 
(500 MHz, CD3OD) δ 7.90 (dd, J = 9.0, 1.1 Hz, 0H), 7.76 (d, J = 1.4 Hz, 0H), 7.43 (dt, J = 8.8, 
1.6 Hz, 0H), 7.15 – 7.09 (m, 1H), 6.95 (s, 1H), 6.91 (dd, J = 8.4, 2.0 Hz, 1H), 6.70 (t, J = 6.5 Hz, 
2H), 6.65 (d, J = 2.3 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.48 (s, 2H), 4.96 – 4.91 (m, 1H), 3.85 
(dd, J = 11.6, 5.1 Hz, 1H), 3.77 (s, 2H), 3.72 (d, J = 1.1 Hz, 3H), 3.28 – 3.21 (m, 1H), 3.02 (ddd, 
J = 18.3, 14.0, 4.8 Hz, 2H), 2.55 (td, J = 11.9, 2.4 Hz, 1H), 2.27 (s, 7H), 1.80 – 1.70 (m, 1H), 
1.57 – 1.48 (m, 1H). No 13C data acquired. HPLC (gradient A): retention time 25.6. ESI-MS 
482.2 [M+Na]+. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(3-hydroxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (178). 178 was synthesized following general procedure 
I using 172 (44 mg, 0.093 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, 
residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh 
Et2O, the remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (38 
mg). The synthesis was completed by following a modified version general procedure F with 
newly formed (R) amine intermediate (38 mg, 0.13 mmol, 1.0 eq). After coupling to diBoc-Dmt, 
instead of using TFA:DCM to deprotect, a 1M solution of BBr3 in DCM (0.132 mL, 5.0 eq) was 
slowly added to the reaction vessel to remove the boc groups and cleave the methyl ether. Once 
completely added, solution stirred for 3 h. After 3 h, solvent was removed under reduced 
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pressure and residue was resuspended in MeOH, then solvent was moved. This process was 
repeated 3 x to yield crude product which was purified by semipreparative HPLC and lyophilized 
to yield the title compound 178 as a TFA salt.   1H NMR (500 MHz, CD3OD) δ 7.03 (td, J = 7.8, 
1.3 Hz, 1H), 7.00 (s, 1H), 6.97 (dd, J = 8.3, 1.7 Hz, 1H), 6.69 (dd, J = 8.2, 1.3 Hz, 1H), 6.62 – 
6.55 (m, 2H), 6.54 (d, J = 2.0 Hz, 1H), 6.48 (s, 2H), 4.99 – 4.93 (m, 1H), 3.91 – 3.83 (m, 1H), 
3.75 (s, 2H), 3.29 – 3.22 (m, 1H), 3.08 (dt, J = 12.2, 4.2 Hz, 1H), 3.02 (dd, J = 13.6, 5.1 Hz, 1H), 
2.59 (t, J = 11.3 Hz, 1H), 2.30 – 2.24 (m, 6H), 1.83 – 1.74 (m, 1H), 1.54 (dd, J = 11.5, 4.8 Hz, 
1H). No 13C data acquired. HPLC (gradient A): retention time 20.5. ESI-MS 468.2 [M+Na]+. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(4-methoxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (179). 179 was synthesized following general procedure 
I using 173 (136 mg, 0.29 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, 
residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh 
Et2O, the remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (117 
mg). The synthesis was completed by following general procedure F with newly formed (R) 
amine intermediate (117 mg, 0.13 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 179 as a TFA salt.  1H NMR 
(500 MHz, CD3OD) δ 7.09 (d, J = 2.0 Hz, 1H), 7.05 – 7.01 (m, 3H), 6.86 (dd, J = 8.2, 1.2 Hz, 
1H), 6.80 – 6.76 (m, 2H), 6.49 (s, 2H), 5.00 (t, J = 4.8 Hz, 1H), 3.89 (ddd, J = 11.6, 5.2, 1.2 Hz, 
1H), 3.80 (s, 2H), 3.73 (d, J = 1.3 Hz, 3H), 3.29 – 3.22 (m, 1H), 3.16 (dt, J = 12.8, 4.4 Hz, 1H), 
3.05 (dd, J = 13.6, 5.2 Hz, 1H), 2.72 – 2.65 (m, 1H), 2.27 (s, 6H), 1.87 (ddt, J = 14.7, 10.5, 4.0 
Hz, 1H), 1.63 – 1.54 (m, 1H). No 13C data acquired. HPLC (gradient A): retention time 24.7. 
ESI-MS 482.2 [M+Na]+. 
 
 
195 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(4-hydroxybenzyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide (180). 180 was synthesized following general procedure 
I using 173 (136 mg, 0.029 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, 
residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh 
Et2O, the remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (38 
mg). The synthesis was completed by following a modified version general procedure F with 
newly formed (R) amine intermediate (117 mg, 0.13 mmol, 1.0 eq). After coupling to diBoc-
Dmt, instead of using TFA:DCM to deprotect, a 1M solution of BBr3 in DCM (0.375 mL, 5.0 eq) 
was slowly added to the reaction vessel to remove the boc groups and cleave the methyl ether. 
Once completely added, solution stirred for 3 h. After 3 h, solvent was removed under reduced 
pressure and residue was resuspended in MeOH, then solvent was moved. This process was 
repeated 3 x to yield crude product which was purified by semipreparative HPLC and lyophilized 
to yield the title compound 180 as a TFA salt.  1H NMR (500 MHz, CD3OD) δ 7.05 (s, 1H), 7.01 
(d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.1 Hz, 2H), 6.80 (d, J = 8.2 Hz, 1H), 6.66 (d, J = 8.1 Hz, 2H), 
6.49 (s, 2H), 4.99 (t, J = 4.7 Hz, 1H), 3.88 (dd, J = 11.6, 5.2 Hz, 1H), 3.76 (s, 2H), 3.26 (t, J = 
12.7 Hz, 1H), 3.14 (dt, J = 12.7, 4.2 Hz, 1H), 3.03 (dd, J = 13.7, 5.2 Hz, 1H), 2.69 – 2.61 (m, 
1H), 2.27 (s, 6H), 1.85 (tt, J = 11.0, 4.2 Hz, 1H), 1.56 (d, J = 14.9 Hz, 1H). No 13C data acquired. 
HPLC (gradient A): retention time 18.9. ESI-MS 468.2 [M+Na]+. 
 
 
(S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(4-methoxy-2,6-dimethylbenzyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide (181). 181 was synthesized following general 
procedure I using 174 (92 mg, 0.184 mmol, 1.0 eq) and conc. HCl (5 drops). After removing 
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solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (80 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (80 mg, 0.19 mmol, 1.0 eq) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound 181 (30 mg, 
53.6%) as a TFA salt.  1H NMR (500 MHz, CD3OD) δ 6.97 (d, J = 1.9 Hz, 1H), 6.70 (s, 1H), 
6.67 (d, J = 1.9 Hz, 1H), 6.60 (s, 2H), 6.49 (s, 2H), 4.94 (t, J = 4.6 Hz, 1H), 3.89 (d, J = 6.6 Hz, 
3H), 3.74 (s, 3H), 3.25 (dd, J = 13.7, 11.5 Hz, 1H), 3.10 (ddd, J = 12.4, 5.4, 3.7 Hz, 1H), 3.03 
(dd, J = 13.7, 5.3 Hz, 1H), 2.65 – 2.57 (m, 1H), 2.28 (s, 6H), 2.13 (s, 6H), 1.82 (ddt, J = 14.9, 
11.1, 4.0 Hz, 1H), 1.59 (dtd, J = 13.8, 4.9, 2.7 Hz, 1H). No 13C data acquired. HPLC (gradient 
A): retention time 29.4. ESI-MS 510.3 [M+Na]+. 
 
 
(S)-2-amino-N-((R)-6-(4-hydroxy-2,6-dimethylbenzyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (182). 182 was synthesized following general 
procedure I using 174 (92 mg, 0.184 mmol, 1.0 eq) and conc. HCl (5 drops). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (80 mg). The synthesis was completed by following a modified version 
general procedure F with newly formed (R) amine intermediate (80 mg, 0.13 mmol, 1.0 eq). 
After coupling to diBoc-Dmt, instead of using TFA:DCM to deprotect, a 1M solution of BBr3 in 
DCM (0.463 mL, 5.0 eq) was slowly added to the reaction vessel to remove the boc groups and 
cleave the methyl ether. Once completely added, solution stirred for 3 h. After 3 h, solvent was 
removed under reduced pressure and residue was resuspended in MeOH, then solvent was 
moved. This process was repeated 3 x to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 182 (15 mg, 27.8%) as a TFA 
salt.  1H NMR (500 MHz, CD3OD) δ 6.95 (d, J = 1.6 Hz, 1H), 6.68 (d, J = 2.3 Hz, 2H), 6.50 – 
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6.48 (m, 4H), 4.94 (t, J = 4.6 Hz, 1H), 3.89 (dd, J = 11.5, 5.2 Hz, 1H), 3.85 (s, 2H), 3.26 (dd, J = 
13.7, 11.5 Hz, 1H), 3.09 (dt, J = 12.4, 4.3 Hz, 1H), 3.03 (dd, J = 13.7, 5.2 Hz, 1H), 2.58 (td, J = 
11.8, 2.6 Hz, 1H), 2.28 (s, 6H), 2.09 (s, 6H), 1.81 (ddt, J = 15.1, 11.2, 4.0 Hz, 1H), 1.59 (dtd, J = 
13.6, 5.1, 2.9 Hz, 1H). No 13C data acquired. HPLC (gradient A): retention time 22.6. ESI-MS 
496.2 [M+Na]+. 
 
 
4-Methoxyphenyl (E)-but-2-enoate (183). To a flame-dried round bottom flask with a stir bar 
was added anhydrous DCM via syringe. Next, 4-methoxyphenol (1 g, 8.1 mmol, 1.5 eq) was 
added to the round bottom flask, followed by crotonyl chloride (0.515 mL, 5.4 mmol, 1.0 eq), 
and Et3N (1.5 mL, 10.1 mmol, 2.0 eq). Reaction stirred at RT for 16 h. After reaction completed, 
organic layer was washed with 1 M HCl (1 x 75 mL), then with diluted 2M NaOH (1 x 75 mL), 
and finally with brine (1 x 75 mL), then organic layer was dried over MgSO4, concentrated, the 
purified using column chromatography to yield the title compound (183) as a clear, colorless oil, 
1.03 g, quant.). 1H NMR (400 MHz, CDCl3) δ 7.22 – 7.11 (m, 1H), 7.05 – 7.00 (m, 2H), 6.92 – 
6.86 (m, 2H), 6.07 – 6.00 (m, 1H), 3.79 (s, 3H), 1.95 (dd, J = 6.9, 1.6 Hz, 3H). No 13C data 
acquired. 
 
 
(R)-N-(1-phenylethyl)aniline (184). To synthesize 184 CsF was first added to a round bottom 
flask equipped with a stir bar, then flame-dried under vacuum. Acetonitrile was added to the 
reaction vessel followed by the addition of (R)-1-phenylethan-1-amine, then the aryl TMS- 
triflate. Reaction vessel was placed in an oil bath at 60C and stirred for 36 h. Once complete, 
reaction quenched with brine, then layers separated. Crude organic residue was purified using 
silica gel column chromatography to yield title compound as a solid. 1H NMR (400 MHz, 
CDCl3) δ 7.42 – 7.27 (m, 4H), 7.27 – 7.18 (m, 1H), 7.09 (dd, J = 8.9, 3.6 Hz, 2H), 6.64 (t, J = 6.3 
Hz, 1H), 6.52 (d, J = 6.7 Hz, 2H), 4.53 – 4.44 (m, 1H), 4.23 (s, 1H), 1.52 (dd, J = 5.9, 4.0 Hz, 
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3H). 13C NMR (101 MHz, CDCl3) δ 147.05, 145.04, 129.07, 128.61, 126.86, 125.84, 117.35, 
113.40, 53.58, 24.96. 
 
 
4-Methoxyphenyl (R)-3-(phenyl((R)-1-phenylethyl)amino)butanoate (185). 185 was 
synthesized by lithium conjugate addition using 183 and 184. To begin, n-BuLi was added to a 
flame-dried reaction vessel in Ar atomosphere at -78˚C that contained amine 184. After 15 min, 
183 was added to the reaction vessel via cannula. The reactions stirred at -78˚C for 2.5 h under 
Ar. Once complete, the reaction was quenched with NH4Cl solution (3 x 25). Crude residue was 
purified using column chromatography to yield the title compound as a white solid (187 mg, 
50.6%). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.34 (m, 3H), 7.34 – 7.27 (m, 3H), 7.25 – 7.17 (m, 
3H), 7.12 – 7.05 (m, 1H), 6.98 – 6.83 (m, 6H), 6.79 – 6.71 (m, 1H), 6.67 – 6.60 (m, 1H), 6.53 – 
6.47 (m, 1H), 4.75 (q, J = 6.7 Hz, 1H), 4.48 (d, J = 6.7 Hz, 1H), 4.21 (td, J = 8.5, 5.4 Hz, 1H), 
3.81 – 3.76 (m, 3H), 3.75 (s, 1H), 2.83 (ddd, J = 15.1, 5.2, 2.3 Hz, 1H), 2.53 (ddd, J = 15.2, 8.6, 
2.2 Hz, 1H), 1.53 – 1.47 (m, 5H), 1.30 – 1.26 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 171.02, 
157.13, 147.21, 146.21, 145.17, 144.45, 144.02, 129.05, 128.58, 128.40, 128.33, 127.06, 126.81, 
126.66, 125.78, 122.44, 122.15, 120.73, 117.16, 115.96, 114.72, 114.34, 113.22, 56.62, 55.71, 
55.54, 53.40, 50.59, 40.01, 25.01, 20.28, 18.58. 
 
 
(R)-2-methyl-2,3-dihydroquinolin-4(1H)-one (186). LiOH was added to a solution of 185 in 
1:1 THF: H2O. The resultant mixture was heated at 50˚C for 3 h. The mixture then cooled to 
room temp and was acidifed with 1 M HCl, then extracted with EtOAc. The combined organic 
extracts were heated at 100˚C for 16 h with PPA to form the dihydroquinolinone. Once 
completed, the reaction was cooled to room temp and basified with 10% aqueous NaOH. The 
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crude product was purified using silica gel chromatography to yield the title compound (14 mg, 
24.7 %) 1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 7.9, 1.7 Hz, 1H), 7.34 – 7.24 (m, 1H), 6.73 
(t, J = 7.5 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 4.37 – 4.25 (m, 1H), 3.78 (dqd, J = 12.9, 6.4, 3.5 
Hz, 1H), 2.64 (dd, J = 16.2, 3.6 Hz, 1H), 2.47 (dd, J = 16.1, 13.0 Hz, 1H), 1.33 (d, J = 6.2 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 194.07, 151.55, 135.17, 127.47, 118.87, 117.96, 115.68, 
49.10, 45.75, 21.35. 
 
(R)-6-bromo-2-methyl-2,3-dihydroquinolin-4(1H)-one (187). NBS (134 mg, 0.75 mmol, 1.0 
eq) was added to a solution of 186 (121 mg, 0.75 mmol, 1.0 eq) in anhydrous DCM. The mixture 
stirred at room temperature for 1.5 h. Once complete, reaction was quenched with NaHCO3, and 
the layers separated. The organic layer was washed with brine, dried over MgSO4, filtered, then 
concentrated under reduced pressure to yield the crude product which was purified via silica gel 
chromatography to yield the title compound (132 mg, 73.3%) 1H NMR (500 MHz, CDCl3) δ 
7.93 (d, J = 2.4 Hz, 1H), 7.36 (dd, J = 8.7, 2.4 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 3.77 (dqd, J = 
12.8, 6.3, 3.6 Hz, 1H), 2.64 (dd, J = 16.2, 3.6 Hz, 1H), 2.45 (dd, J = 16.2, 13.0 Hz, 1H), 1.34 (d, 
J = 6.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 192.66, 150.14, 137.68, 129.88, 120.09, 117.54, 
110.25, 49.01, 45.27, 21.20. 
 
 
Tert-butyl (R)-6-bromo-2-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (188). 188 
was synthesized following general procedure G using 187 (132 mg, 0.55 mmol, 1.0 eq), Boc2O 
(156 mg, 0.72 mmol, 1.3 eq), DMAP (7 mg, 0.007 mmol, 0.1 eq), DIPEA (0.124 mL, 0.72 
mmol, 1.3 eq). The reaction stirred at reflux for 16 h. Once enough starting material was 
converted to product, the crude yellow oil was purified using silica gel chromatography (equil in 
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100% hex, run in 2:3 EA:hex) to yield the title compound as a yellow oil (43 mg, 23%). Starting 
material was also recovered, this was not considered when calculating the yield. 1H NMR (500 
MHz, CDCl3) δ 8.09 (t, J = 3.0 Hz, 1H), 7.84 – 7.69 (m, 2H), 7.58 (dd, J = 9.0, 2.5 Hz, 0H), 7.50 
(d, J = 8.1 Hz, 1H), 7.39 – 7.31 (m, 2H), 6.78 (d, J = 3.7 Hz, 1H), 5.86 (d, J = 6.5 Hz, 1H), 5.20 
(p, J = 6.7 Hz, 1H), 3.02 (dd, J = 17.3, 5.6 Hz, 0H), 2.61 (s, 2H), 2.06 (s, 1H), 1.97 (s, 1H), 1.56 
(s, 6H), 1.55 (s, 8H), 1.52 (s, 9H), 1.36 (s, 2H), 1.24 – 1.20 (m, 1H), 1.14 (d, J = 6.7 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 186.29, 170.22, 155.85, 152.31, 150.92, 141.67, 140.52, 137.95, 
137.06, 136.89, 134.24, 130.92, 129.41, 126.20, 126.16, 126.14, 124.79, 124.00, 121.03, 121.00, 
120.89, 118.11, 116.43, 106.45, 83.98, 81.85, 49.56, 48.56, 44.12, 28.69, 28.29, 28.21, 27.63, 
20.33, 18.87, 17.68. 
 
 
Tert-butyl (R)-6-benzyl-2-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (189). 189 
was synthesized following general procedure L using 188 (43 mg, 0.13 mmol, 1.0 eq), benzyl-
Bpin (0.055 mL, 0.25 mmol, 2.0 eq), K2CO3 (52 mg, 0.38 mmol, 3.0 eq), and Pd(dppf)Cl2 (9 mg, 
0.003 mmol, 0.1 eq). The contents were placed microwave tube and reacted in microwave with 
max temp of 110°C, max power of 250 W for 30 min, with the “Powermax” option enabled. 
Once crude mixture was filtered through Celite, the solvent was removed and the residue was 
purified via silica gel chromatography (equil in 100% hex, run in 1:1 EA:hex) to yield title 
compound (35 mg, 79.5%)  as a clear colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 
2.2 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.34 – 7.25 (m, 4H), 7.20 (t, J = 7.9 Hz, 3H), 5.07 (p, J = 
6.4 Hz, 1H), 3.96 (s, 2H), 3.01 (dd, J = 17.4, 5.9 Hz, 1H), 2.53 (d, J = 17.5 Hz, 1H), 2.41 (d, J = 
11.1 Hz, 0H), 1.54 (s, 9H), 1.21 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 193.79, 
152.76, 140.39, 139.73, 136.37, 134.92, 128.83, 128.53, 126.59, 126.24, 124.51, 124.01, 81.98, 
49.50, 44.40, 41.08, 28.29, 17.77. 
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Tert-butyl(2R,4R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-2-methyl-3,4-
dihydroquinoline-1(2H)-carboxylate (190). 190 was synthesized according to general 
procedure H using 189 (35 mg, 0.095 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (24 
mg, 0.20 mmol, 2.0 eq), and Ti(OEt)4 (0.84 mL, 0.40 mmol, 4.0 eq) to form the (R)-tert-
butanesulfinyl imine intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (30 mg, 0.40 mmol, 4.0 eq) and 20 mL of THF in a xylenes dry ice bath, 
after addition, the solution was stirred at room temperature for 3 h before being quenched with 
MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography to yield the title compound as a clear, colorless oil (12 mg, 26.4 %). 1H NMR 
(400 MHz, CDCl3) δ 9.33 (s, 0H), 7.65 (d, J = 5.9 Hz, 0H), 7.49 (t, J = 8.1 Hz, 1H), 7.41 (d, J = 
8.2 Hz, 1H), 7.29 (t, J = 7.7 Hz, 3H), 7.19 (d, J = 7.1 Hz, 3H), 7.16 – 7.05 (m, 2H), 6.27 (q, J = 
5.7 Hz, 0H), 4.61 (p, J = 6.5, 5.9 Hz, 1H), 4.46 (dq, J = 15.3, 7.7 Hz, 1H), 4.35 (td, J = 11.3, 3.8 
Hz, 1H), 3.98 (s, 2H), 3.96 – 3.91 (m, 2H), 2.68 (ddd, J = 12.4, 8.0, 4.1 Hz, 1H), 2.40 (d, J = 
10.5 Hz, 1H), 2.30 (dt, J = 13.6, 6.7 Hz, 0H), 2.13 (s, 1H), 2.05 (s, 0H), 1.96 (dt, J = 12.6, 5.9 
Hz, 0H), 1.53 (s, 3H), 1.51 (s, 11H), 1.48 (s, 1H), 1.35 (s, 8H), 1.26 (s, 2H), 1.18 (d, J = 6.1 Hz, 
4H). 13C NMR (101 MHz, CDCl3) δ 153.54, 153.48, 153.44, 140.70, 140.65, 137.25, 136.97, 
134.71, 133.95, 133.76, 129.79, 129.09, 128.96, 128.55, 128.50, 128.48, 127.67, 127.49, 126.19, 
126.16, 126.12, 125.62, 122.35, 99.66, 81.10, 80.90, 60.28, 59.93, 51.64, 51.46, 50.44, 48.88, 
48.72, 47.60, 44.18, 41.49, 41.26, 38.87, 29.68, 28.34, 24.30, 24.18, 22.67, 21.62, 21.21, 19.43, 
17.41. 
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(S)-2-amino-N-((2R,4R)-6-benzyl-2-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (191). 191 was synthesized following general procedure I 
using 190 (12 mg, 0.03 mmol, 1.0 eq) and conc. HCl (4 drops). After removing solvent, residue 
was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (11 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (11 mg, 0.03 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 191 as a TFA salt. No 1H or 
13C data acquired. Product confirmed by mass spectrometry. HPLC (gradient A): retention time 
28.8. ESI-MS 466.2 [M+Na]+. 
 
 
Methyl (S)-2-methyl-3-(phenylamino)propanoate (192).  Methyl (R)-3-bromo-2-
methylpropanoate (1.0 mL, 7.86 mmol, 1.0 eq) was added to a flask containing aniline (717 mL, 
7.86 mmol, 1.0 eq) and K2CO3 (2.2 g, 15 mmol, 2.0 eq) in DMF. The resulting mixture stirred at 
80C overnight. The next day, the solvent was removed under reduced pressure and the resulting 
residue was resuspended in DCM and diH2O. The organic layer was washed with bring (2 x 25 
mL), dried over MgSO4, and concentrated toyield the title compound (212 mg, 13.9 %). No 
1H or 
13C data acquired. Instead, intermediate taken ahead to next step (formation of 193) without any 
further isolation, purification or characterization. No 1H or 13C data acquired. 
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3-Methyl-2,3-dihydroquinolin-4(1H)-one (193). 193 was added to a solution of LiOH (131 mg, 
5.5 mmol, 5.0 eq) 1:1 THF:H2O and a few drops of MeOH. Solution stirred at 50C for 3 h. The 
reactin was monitored by TLC, and once saponification was finished, solution was acidified with 
1 M HCl and the organic layer was concentrated under reduced pressure. Then PPA was added 
to the reaction flask and the solution stirred at 100C for 16 h. Reaction was monitored by TLC. 
Once the reaction was complete, reaction vessel was taken out of the oil bath and allowed to cool 
for 10 min, then ice water was poured into the reaction vessel, followed by DCM. The layers 
separated. The organic layer was washed with brine (1x25) then concentrated under reduced 
pressure to yield a crude residue which was then purified using silica gel chromatography to 
yield the pure title compound as a yellow oil (0.177, quant).  1H NMR (500 MHz, CDCl3) δ 7.84 
(dq, J = 7.3, 1.9 Hz, 1H), 7.27 (tdd, J = 7.3, 3.8, 1.7 Hz, 1H), 6.71 (qd, J = 6.6, 2.6 Hz, 1H), 6.65 
(dd, J = 8.6, 3.7 Hz, 1H), 4.52 (s, 1H), 3.53 (ddd, J = 11.2, 6.7, 4.3 Hz, 1H), 3.30 – 3.19 (m, 1H), 
2.74 – 2.61 (m, 1H), 1.23 – 1.16 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 196.45, 151.68, 
134.76, 127.79, 118.58, 117.71, 115.58, 48.62, 41.01, 12.51. 
 
 
6-Bromo-3-methyl-2,3-dihydroquinolin-4(1H)-one (194). NBS (95 mg, 0.53 mmol, 1.0 eq) 
was added to a solution of 193 (86 mg, 0.53 mmol, 1.0 eq) in anhydrous DCM. The mixture 
stirred at room temperature for 1.5 h. Once complete, reaction was quenched with NaHCO3, and 
the layers separated. The organic layer was washed with brine, dried over MgSO4, filtered, then 
concentrated under reduced pressure to yield the crude product which was purified via silica gel 
chromatography to yield the title compound as a yellow oil (108 mg, 84.4%) 1H NMR (500 
MHz, CDCl3) δ 7.85 (d, J = 2.4 Hz, 1H), 7.25 (dd, J = 8.7, 2.4 Hz, 1H), 6.50 (d, J = 8.7 Hz, 1H), 
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4.54 (s, 1H), 3.47 (dd, J = 11.9, 5.4 Hz, 1H), 3.18 (t, J = 11.7 Hz, 1H), 2.66 – 2.54 (m, 1H), 1.13 
(d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 195.17, 150.34, 139.25, 137.54, 137.28, 
130.06, 129.73, 127.30, 119.68, 117.90, 117.50, 109.87, 77.00, 48.32, 48.02, 47.79, 40.66, 40.33, 
40.07, 29.63, 12.42, 12.32, 0.97. 
 
 
Tert-butyl 6-bromo-3-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (195). 195 was 
synthesized following general procedure G using 187 (108 mg, 0.45 mmol, 1.0 eq), Boc2O (147 
mg, 0.67 mmol, 1.f eq), DMAP (5 mg, 0.05 mmol, 0.1 eq), DIPEA (0.118 mL, 0.67 mmol, 1.f 
eq). The reaction stirred at reflux for 16 h. Once enough starting material was converted to 
product, the crude yellow oil was purified using silica gel chromatography (equil in 100% hex, 
run in 2:3 EA:hex) to yield the title compound as a yellow oil (153 mg, quant.) 1H NMR (500 
MHz, CDCl3) δ 8.00 (q, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.9, 2.0 Hz, 1H), 7.47 (ddd, J = 11.2, 5.6, 
2.7 Hz, 1H), 4.30 (s, 0H), 4.23 (ddd, J = 13.4, 4.5, 2.1 Hz, 1H), 4.14 (dtdd, J = 10.9, 7.8, 5.9, 1.9 
Hz, 0H), 3.63 – 3.54 (m, 1H), 2.67 (dqdd, J = 9.0, 6.9, 5.7, 4.4, 1.8 Hz, 1H), 1.47 (d, J = 2.1 Hz, 
8H), 1.15 (dd, J = 7.1, 2.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 195.52, 167.62, 152.58, 
142.87, 136.28, 130.07, 125.19, 116.89, 82.44, 77.00, 68.03, 50.07, 42.13, 28.16, 12.52, 0.95. 
 
 
Tert-butyl (R)-6-benzyl-2-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (196). 196 
was synthesized following general procedure L using 195 (153 mg, 0.45 mmol, 1.0 eq), benzyl-
Bpin (0.147 mL, 0.675 mmol, 2.0 eq), K2CO3 (186 mg, 1.35 mmol, 3.0 eq), and Pd(dppf)Cl2 (33 
mg, 0.045 mmol, 0.1 eq). The contents were placed microwave tube and reacted in microwave 
with max temp of 110°C, max power of 250 W for 30 min, with the “Powermax” option enabled. 
Once crude mixture was filtered through Celite, the solvent was removed and the residue was 
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purified via silica gel chromatography (equil in 100% hex, run in 1:1 EA:hex) to yield title 
compound (35 mg, 79.5%)  as a clear colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 
2.0 Hz, 1H), 7.64 – 7.60 (m, 1H), 7.25 – 7.17 (m, 4H), 7.12 (dt, J = 12.4, 4.4 Hz, 3H), 4.22 (ddd, 
J = 13.4, 4.5, 1.6 Hz, 1H), 4.18 – 4.12 (m, 1H), 3.88 (s, 2H), 3.59 (ddd, J = 13.2, 9.8, 1.7 Hz, 
1H), 2.66 (dtt, J = 10.0, 7.4, 5.7 Hz, 1H), 1.47 (s, 9H), 1.15 (dd, J = 7.1, 1.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 197.08, 167.71, 153.02, 142.25, 140.44, 136.75, 134.44, 128.81, 128.54, 
127.41, 126.24, 124.03, 123.60, 82.00, 77.00, 50.29, 42.44, 41.14, 28.27, 12.74. 
 
 
Tert-butyl(3R,4R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-3-methyl-3,4-
dihydroquinoline-1(2H)-carboxylate (197). 197 and 198 were synthesized according to general 
procedure H using 196 (35 mg, 0.095 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (24 
mg, 0.20 mmol, 2.0 eq), and Ti(OEt)4 (0.84 mL, 0.40 mmol, 4.0 eq) to form the (R)-tert-
butanesulfinyl imine intermediate in situ. Once sufficient ketone was converted into imine 
intermediate (after 48 h), the reaction mixture was transferred via cannula to a round bottom 
flask containing NaBH4 (30 mg, 0.40 mmol, 4.0 eq) and 20 mL of THF in a xylenes dry ice bath, 
after addition, the solution was stirred at room temperature for 3 h before being quenched with 
MeOH. Once resultant solid was removed, crude residue was purified using silica gel 
chromatography to yield the title compound (197) and the diastereomer (198, see below) as a 
clear, colorless oils yield for 197 was 53 mg, 31.9 % of overall yield. 1H NMR (500 MHz, 
CDCl3) δ 7.71 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 2.3 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.22 – 7.15 (m, 
2H), 7.03 (dd, J = 8.7, 2.2 Hz, 1H), 4.41 (t, J = 4.6 Hz, 1H), 3.92 (s, 2H), 3.82 (dd, J = 12.9, 4.1 
Hz, 1H), 3.37 – 3.29 (m, 1H), 3.17 (d, J = 5.3 Hz, 1H), 2.14 – 2.05 (m, 1H), 1.52 (d, J = 1.5 Hz, 
9H), 1.23 (d, J = 1.4 Hz, 9H), 1.06 (dd, J = 6.8, 1.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.66, 141.09, 136.56, 135.66, 129.70, 129.19, 128.84, 128.43, 128.39, 125.96, 123.37, 81.17, 
56.51, 56.33, 46.77, 41.20, 34.01, 28.32, 22.88, 22.84, 14.60. 
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Tert-butyl(3S,4R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-3-methyl-3,4-
dihydroquinoline-1(2H)-carboxylate (198). See synthesis of 197 for details. Yield for 198 was 
27 mg, 15.7%. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.5 Hz, 1H), 7.30 – 7.25 (m, 2H), 7.21 
– 7.16 (m, 3H), 7.12 – 7.06 (m, 2H), 4.39 (dd, J = 7.3, 4.0 Hz, 1H), 3.93 (s, 2H), 3.70 (ddd, J = 
12.8, 8.5, 1.7 Hz, 1H), 3.57 (ddd, J = 12.8, 4.8, 1.5 Hz, 1H), 3.45 – 3.41 (m, 1H), 2.35 – 2.27 (m, 
1H), 1.50 (d, J = 1.6 Hz, 9H), 1.14 (d, J = 1.7 Hz, 9H), 1.07 (dd, J = 6.9, 1.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 153.77, 140.86, 135.88, 135.53, 128.95, 128.69, 128.45, 128.41, 126.04, 
123.67, 80.96, 57.51, 56.14, 47.98, 41.17, 33.48, 28.32, 28.30, 22.66, 22.64, 22.61, 22.48, 13.60. 
 
(3R,4R)-6-benzyl-3-methyl-1,2,3,4-tetrahydroquinolin-4-aminium chloride (199). Synthesis 
of 199 was achieved by treating 197 with HCl in dioxane to cleave the Ellman auxillary and to 
remove the Boc-protecting group. X-ray crystal structure of this compound showed that the C3-
methyl has R-stereochemistry. 1H NMR (500 MHz, CD3OD) δ 7.50 (d, J = 1.9 Hz, 1H), 7.42 (dd, 
J = 8.3, 2.0 Hz, 1H), 7.31 – 7.16 (m, 5H), 4.69 (d, J = 4.6 Hz, 1H), 4.05 (s, 2H), 3.60 (s, 2H), 
3.52 – 3.45 (m, 3H), 2.73 – 2.61 (m, 1H), 1.24 (d, J = 7.2 Hz, 3H), 1.20 – 1.14 (m, 3H). 13C 
NMR (126 MHz, CD3OD) δ 141.54, 139.77, 132.69, 131.68, 131.26, 129.97, 129.71, 127.53, 
126.12, 123.63, 111.41, 66.90, 64.31, 50.64, 49.00, 44.25, 42.12, 29.81, 21.47, 15.44, 13.22. 
 
 
(3S,4R)-6-benzyl-3-methyl-1,2,3,4-tetrahydroquinolin-4-aminium chloride (200) Synthesis 
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of 200 was achieved by treating 198 with HCl in dioxane to cleave the Ellman auxillary and to 
remove the Boc-protecting group. 1H NMR (500 MHz, CD3OD) δ 7.58 – 7.53 (m, 1H), 7.48 – 
7.42 (m, 2H), 7.26 (ddt, J = 33.3, 14.3, 9.3 Hz, 10H), 4.71 (d, J = 4.7 Hz, 1H), 4.06 (s, 2H), 3.60 
(s, 4H), 3.52 (dd, J = 13.0, 9.8 Hz, 1H), 2.77 – 2.65 (m, 2H), 1.25 (d, J = 7.2 Hz, 3H). 13C NMR 
(126 MHz, CD3OD) δ 144.34, 141.45, 132.70, 131.77, 130.75, 130.47, 129.98, 129.72, 127.54, 
126.73, 124.08, 122.45, 64.30, 50.48, 49.00, 44.26, 42.12, 29.73, 13.21. 
 
 
 
(S)-2-amino-N-((3R,4R)-6-benzyl-3-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (201). 201 was synthesized following general procedure F 
starting from the (R) amine intermediate 199 (25 mg, 0.076 mmol) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound as a TFA salt 
(20 mg, 41.6%).  1H NMR (500 MHz, CD3OD) δ 7.24 – 7.19 (m, 2H), 7.17 – 7.13 (m, 2H), 7.10 
(td, J = 7.2, 1.5 Hz, 1H), 6.84 (dt, J = 8.3, 1.7 Hz, 1H), 6.62 (dd, J = 8.3, 1.4 Hz, 1H), 6.52 (s, 
2H), 6.50 (d, J = 1.8 Hz, 1H), 4.99 (d, J = 4.5 Hz, 1H), 3.96 (ddd, J = 10.9, 5.0, 1.5 Hz, 1H), 3.82 
(q, J = 15.1 Hz, 2H), 3.28 – 3.19 (m, 2H), 3.03 – 2.91 (m, 2H), 2.27 (d, J = 1.4 Hz, 8H), 0.97 
(dd, J = 7.0, 1.4 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 169.65, 157.42, 143.14, 140.17, 
130.44, 130.36, 129.94, 129.29, 126.87, 123.08, 118.02, 116.67, 53.81, 51.12, 49.51, 49.34, 
49.17, 49.00, 48.83, 48.66, 48.49, 45.48, 41.85, 32.18, 31.95, 20.48, 13.67. HPLC (gradient A): 
retention time 27.6. ESI-MS 466.2 [M+Na]+. 
 
 
 
208 
 
 
(S)-2-amino-N-((3S,4R)-6-benzyl-3-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (202). 202 was synthesized following general procedure F 
starting from the (R) amine intermediate 198 (22 mg, 0.076 mmol) to yield crude product which 
was purified by semipreparative HPLC and lyophilized to yield the title compound as a TFA salt 
(12 mg, 27.3%).  No 1H or 13C data acquired. HPLC (gradient A): retention time 29.3. ESI-MS 
466.2 [M+Na]+. 
 
 
4-Methyl-3,4-dihydronaphthalen-1(2H)-one (203). Two round bottom flasks were flame-dried 
under vaccum, then flooded with Ar. Valerolactone (1.0 g, 10 mmol, 1.0 eq) was added to one 
round bottom flask via syringe followed by benzene (excess). AlCl3 (4.0 g, 30 mmol, 3 eq) was 
added to the other flask and then that flask was flooded with Ar, then 40 mL anhydrous benzene 
was added. The reaction vessel stirred at RT for 5 min and was then placed in an oil bath at 95C. 
Contents of flask containing the valerolactone were transferred to the flask containing AlCl3 via 
cannula. Reaction vessel was equipped with a condenser and stirred for 4.5 h. Once complete, 
reaction cooled to room temp then quenched with 2 M HCl and dI H2O. Organic layer was 
washed with dI H2O (1 x 25 mL), then brine (1 x 25 mL), then dried over MgSO4 and 
concentrated to yield a crude orange oil that was purified to yield the title compound  as a clear, 
yellow oil (1.60 g, quant.) 1H NMR (500 MHz, CDCl3) δ 8.03 (dd, J = 7.8, 1.9 Hz, 1H), 7.51 (t, J 
= 7.6 Hz, 1H), 7.31 (dt, J = 15.3, 7.6 Hz, 3H), 7.22 – 7.12 (m, 1H), 3.10 (td, J = 7.3, 4.7 Hz, 1H), 
2.80 (ddd, J = 17.6, 8.9, 4.6 Hz, 1H), 2.61 (ddd, J = 17.4, 8.6, 4.7 Hz, 1H), 2.25 (ddt, J = 13.5, 
9.0, 3.9 Hz, 2H), 1.91 (dtd, J = 12.8, 7.9, 3.3 Hz, 2H), 1.40 (d, J = 6.9 Hz, 4H), 1.28 (d, J = 7.1 
Hz, 1H). No 13C data acquired. 
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7-Bromo-4-methyl-3,4-dihydronaphthalen-1(2H)-one (204). To a reaction vessel already 
containing 203 (1.60 g, 10 mmol, 1.0eq) was added conc. H2SO4 and reaction vessel was heated 
in an oil bath at 60˚C. Next, NBS (2.13 g, 11.2 mmol, 1.2 eq) was added in four portions. The 
reaction stirred for 90 min and was monitored by TLC. Once complete, reaction taken off heat 
and quenched with dIH2O, layers separated. The organic layer was washed with brine (1 x 50 
mL) and dIH2O (1 x 50 mL), then dried over MgSO4 and filtered. The solvent was removed 
under reduced pressure to yield the crude product which was this purified via silica gel 
chromatography to yield the pure title compound 204 (168 mg, 27.9%) as an orange oil. 1H 
NMR (500 MHz, CDCl3) δ 8.14 (d, J = 2.2 Hz, 1H), 8.03 (dt, J = 7.9, 1.6 Hz, 0H), 7.61 (dt, J = 
8.3, 2.0 Hz, 1H), 7.52 (tt, J = 7.6, 1.7 Hz, 0H), 7.36 – 7.30 (m, 1H), 7.22 (dd, J = 8.3, 1.8 Hz, 
1H), 3.11 (dd, J = 13.1, 6.7 Hz, 1H), 3.08 – 3.01 (m, 1H), 2.79 (dddd, J = 17.5, 8.6, 4.6, 2.0 Hz, 
2H), 2.60 (dddd, J = 17.1, 9.3, 4.7, 2.2 Hz, 2H), 2.25 (dtt, J = 13.6, 6.5, 3.5 Hz, 2H), 1.90 (dddt, 
J = 17.8, 8.9, 7.0, 3.2 Hz, 2H), 1.62 (d, J = 7.0 Hz, 1H), 1.43 – 1.40 (m, 2H), 1.38 (d, J = 1.9 Hz, 
2H). No 13C data acquired. 
 
 
7-benzyl-4-methyl-3,4-dihydronaphthalen-1(2H)-one (205). 205 was synthesized following 
general procedure L using 204 (58 mg, 0.24 mmol, 1.0 eq), (2,2-dimethyl-4-
methoxyphenyl)boronic acid (0.106 mg, 0.49 mmol, 2.0 eq), K2CO3 (101 mg, 0.73 mmol, 3.0 
eq), and Pd(dppf)Cl2 (18 mg, 0.024 mmol, 0.1 eq). The contents were placed microwave tube 
and reacted in microwave with max temp of 110°C, max power of 250 W for 30 min, with the 
“Powermax” option enabled. Once crude mixture was filtered through Celite, the solvent was 
removed and the residue was purified via silica gel chromatography to yield title compound (57 
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mg, 93.4%)  as clear, colorless oil.  1H NMR (500 MHz, CDCl3) 
 
 
(R)-N-((1R)-7-benzyl-4-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)-2-methylpropane-2-
sulfinamide (206). 206 was synthesized according to general procedure H using 205 (170 mg, 
0.68 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (248 mg, 2.05 mmol, 3.0 eq), and 
Ti(OEt)4 (0.858 mL, 4.1 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (154 mg, 4.1 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
206 as a clear, colorless oil.  1H NMR (500 MHz, CDCl3) 
 
(2S)-2-amino-N-((1R)-7-benzyl-4-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (207). 207 was synthesized following general procedure I 
using 206 (55 mg, 0.16 mmol, 1.0 eq) and conc. HCl (4 drops). After removing solvent, residue 
was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (22 mg) as  a 
mixture of diastereomers. The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (22 mg, 0.076 mmol, 1.0 eq) to yield crude product as a 
mixture of diastereomers which were separated and purified by semipreparative HPLC then 
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lyophilized to yield the title compound 207 (and 208, see below) as a TFA salt. 1H NMR (500 
MHz, CD3OD) δ 7.99 (dd, J = 32.1, 8.3 Hz, 1H), 7.21 (t, J = 7.6 Hz, 2H), 7.12 (q, J = 6.9 Hz, 
4H), 7.05 (d, J = 8.2 Hz, 1H), 6.96 (t, J = 6.3 Hz, 1H), 6.49 (d, J = 3.9 Hz, 2H), 4.90 (d, J = 16.9 
Hz, 4H), 3.89 (dd, J = 15.9, 11.4 Hz, 2H), 3.26 (t, J = 12.6 Hz, 1H), 3.03 (dt, J = 13.4, 3.9 Hz, 
1H), 2.71 (dh, J = 27.7, 7.6, 6.8 Hz, 1H), 2.27 (s, 7H), 1.78 (tt, J = 11.2, 5.6 Hz, 0H), 1.70 – 1.54 
(m, 1H), 1.49 (qd, J = 11.6, 10.0, 4.8 Hz, 1H), 1.31 (dt, J = 10.3, 6.3 Hz, 1H), 1.17 (t, J = 7.4 Hz, 
3H), 1.10 – 0.99 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 168.90, 168.81, 168.78, 168.69, 
157.32, 157.27, 142.70, 142.68, 141.49, 141.47, 140.21, 140.18, 139.93, 139.91, 136.26, 136.22, 
136.04, 130.38, 130.34, 129.73, 129.67, 129.43, 129.39, 129.33, 129.05, 126.95, 123.25, 116.47, 
116.45, 53.54, 53.49, 49.51, 49.42, 49.34, 49.17, 49.05, 49.00, 48.95, 48.83, 48.66, 48.49, 42.29, 
42.27, 33.21, 32.83, 31.97, 28.86, 28.23, 28.03, 27.10, 23.10, 22.44, 20.48. HPLC (gradient A): 
retention time 43.0. ESI-MS 443.2 [M+H]+ and 465.2 [M+Na]+. 
 
 
 
(2S)-2-amino-N-((1R)-7-benzyl-4-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide (208). See synthesis of 207. No 1H or 13C data acquired. 
HPLC (gradient A): retention time 44.5. ESI-MS 443.2 [M+H]+ and 465.2 [M+Na]+. 
 
 
209 was synthesized by Tony Nastase. 
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Tert-butyl 6-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (210). 210 was 
synthesized following general procedure L using 104 (100 mg, 0.29 mmol, 1.0 eq), o-
fluoroboronic acid (82 mg, 0.59 mmol, 2.0 eq), K2CO3 (120 mg, 0.89 mmol, 3.0 eq), and 
Pd(dppf)Cl2 (22 mg, 0.030 mmol, 0.1 eq). The crude product which was purified using silica gel 
chromatography to yield the title compound 210 as a slightly yellow oil (95 mg, 91.3%)  1H 
NMR (500 MHz, CDCl3) δ 7.84 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.34 (dd, J = 8.5, 
2.2 Hz, 1H), 7.21 – 7.11 (m, 2H), 7.07 – 6.98 (m, 2H), 4.12 (t, J = 6.3 Hz, 2H), 3.96 (s, 2H), 2.73 
(t, J = 6.5 Hz, 2H), 1.54 (s, 9H).  13C NMR (126 MHz, CDCl3) δ 194.03, 161.73, 159.78, 152.63, 
142.38, 135.50, 134.41, 130.84, 130.81, 128.13, 128.06, 127.32, 127.20, 126.95, 124.71, 124.09, 
124.06, 123.78, 115.38, 115.21, 81.98, 44.14, 38.85, 34.01, 33.98, 28.17. 
 
Tert-butyl 6-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (211). 211 was 
synthesized following general procedure L using 104 (100 mg, 0.29 mmol, 1.0 eq), m-
fluoroboronic acid (82 mg, 0.59 mmol, 2.0 eq), K2CO3 (120 mg, 0.89 mmol, 3.0 eq), and 
Pd(dppf)Cl2 (22 mg, 0.030 mmol, 0.1 eq). The crude product which was purified using silica gel 
chromatography to yield the title compound 211 as a slightly yellow oil (87 mg, 83.7%) 1H NMR 
(500 MHz, CDCl3) δ 7.82 (bs, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.30 (dd, J = 8.5, 2.4 Hz, 1H), 7.27 
– 7.19 (m, 1H), 6.95 (d, J = 7.4 Hz, 1H), 6.90 – 6.83 (m, 2H), 4.13 (t, J = 6.2, 2H), 3.94 (s, 2H), 
2.75 (t, J = 6.2 Hz, 2H), 1.55 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 194.11, 163.84, 161.89, 
152.65, 142.89, 142.84, 142.53, 135.91, 134.51, 129.94, 129.87, 127.13, 124.76, 124.40, 124.38, 
123.88, 115.69, 115.52, 113.22, 113.06, 82.09, 44.20, 40.72, 38.88, 28.21. 
 
 
213 
 
 
Tert-butyl (R)-4-((( R)-tert-butylsulfinyl)amino)-6-(2-fluorobenzyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (212). 212 was synthesized according to general procedure H using 210 (95 
mg, 0.27 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (97 mg, 0.80 mmol, 3.0 eq), and 
Ti(OEt)4 (0.336 mL, 1.6 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (61 mg, 1.6 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
212 (81 mg, 65.9%) as an oil. 1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 8.6 Hz, 1H), 7.13 (d, J 
= 2.0 Hz, 1H), 7.09 (td, J = 7.6, 2.3 Hz, 2H), 7.02 (dd, J = 8.6, 2.0 Hz, 1H), 6.99 – 6.91 (m, 2H), 
4.59 (d, J = 9.8 Hz, 0H), 4.45 (d, J = 3.2 Hz, 1H), 3.89 – 3.82 (m, 3H), 3.50 (tdd, J = 11.1, 3.9, 
1.4 Hz, 1H), 3.28 – 3.24 (m, 1H), 2.16 – 2.09 (m, 1H), 1.97 (d, J = 2.0 Hz, 0H), 1.94 (d, J = 2.9 
Hz, 0H), 1.92 – 1.84 (m, 1H), 1.43 (d, J = 1.7 Hz, 10H), 1.36 (d, J = 2.5 Hz, 2H), 1.13 (d, J = 1.7 
Hz, 10H). 128.62, 128.47, 127.97, 127.91, 127.84, 127.72, 124.06, 124.03, 115.37, 115.20, 
81.09, 55.63, 50.32, 40.03, 34.08, 34.06, 29.35, 28.28, 24.14, 22.54. 
 
Tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(3-fluorobenzyl)-3,4-dihydroquinoline-
1(2H)-carboxylate (213). 213 was synthesized according to general procedure H using 211 (87 
mg, 0.25 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (89 mg, 0.73 mmol, 3.0 eq), and 
Ti(OEt)4 (0.308 mL, 1.5 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
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mixture was transferred via cannula to a round bottom flask containing NaBH4 (56 mg, 1.5 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
213 (80 mg, 700.8%) as an oil. 1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 8.5, 1.9 Hz, 1H), 
7.22 – 7.10 (m, 2H), 6.98 (dd, J = 8.6, 2.1 Hz, 1H), 6.93 – 6.87 (m, 1H), 6.80 (ddd, J = 10.9, 8.4, 
1.9 Hz, 2H), 4.62 (s, 1H), 4.46 (dd, J = 4.5, 2.5 Hz, 1H), 3.88 (ddt, J = 12.5, 6.3, 3.0 Hz, 1H), 
3.83 (d, J = 1.9 Hz, 2H), 3.51 (dddd, J = 12.9, 11.1, 3.9, 1.8 Hz, 1H), 3.26 (d, J = 2.6 Hz, 1H), 
2.15 – 2.06 (m, 1H), 1.90 (ddd, J = 14.3, 9.6, 5.0 Hz, 1H), 1.44 (d, J = 2.0 Hz, 12H), 1.36 (d, J = 
2.4 Hz, 3H), 1.13 (d, J = 2.0 Hz, 11H). 13C NMR (126 MHz, CDCl3) δ 163.84, 161.89, 153.49, 
143.45, 143.39, 136.73, 135.69, 129.84, 129.77, 129.05, 128.67, 128.55, 124.44, 124.42, 124.04, 
115.70, 115.53, 113.04, 112.87, 81.14, 77.00, 55.65, 50.46, 40.80, 40.79, 40.08, 29.48, 28.28, 
24.14, 22.53. 
 
(S)-2-amino-N-((R)-6-(2-fluorobenzyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (214). 214 was synthesized following general procedure I using 
212 (81 mg, 0.18 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (69 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (69 mg, 0.17 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 214 (51 mg, 51.5%) as a TFA 
salt. 1H NMR (500 MHz, CD3OD) δ 7.23 – 7.13 (m, 3H), 7.08 – 6.98 (m, 3H), 6.89 (d, J = 8.3 
Hz, 1H), 6.49 (s, 2H), 5.01 (t, J = 4.7 Hz, 2H), 3.95 – 3.85 (m, 3H), 3.26 (dd, J = 13.6, 11.6 Hz, 
1H), 3.17 (ddd, J = 12.5, 5.7, 3.4 Hz, 1H), 3.05 (dd, J = 13.7, 5.2 Hz, 1H), 2.68 (ddd, J = 13.0, 
11.1, 2.5 Hz, 1H), 2.27 (s, 6H), 1.88 (tt, J = 11.0, 4.1 Hz, 1H), 1.59 (dtd, J = 13.5, 5.3, 2.6 Hz, 
1H). 13C NMR (126 MHz, CD3OD) δ 168.88, 163.16, 161.22, 157.36, 140.07, 138.01, 135.83, 
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132.13, 132.10, 131.85, 130.69, 129.39, 129.32, 129.04, 128.91, 127.16, 125.35, 125.32, 123.33, 
121.11, 116.42, 116.24, 116.06, 111.39, 53.35, 45.30, 39.26, 34.87, 34.85, 31.83, 28.02, 20.44. 
HPLC (gradient A): retention time 25.7. ESI-MS 448.2 [M+H]+ and 470.2 [M+Na]+. 
 
(S)-2-amino-N-((R)-6-(3-fluorobenzyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (215). 215 was synthesized following general procedure I using 
213 (80 mg, 0.17 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (68 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (68 mg, 0.173 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 215 (21 mg, 21.6%) as a TFA 
salt. 1H NMR (500 MHz, CD3OD) δ 7.23 (td, J = 7.9, 6.0 Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 7.00 
– 6.94 (m, 2H), 6.87 (td, J = 8.6, 2.6 Hz, 1H), 6.83 (dt, J = 10.1, 2.0 Hz, 1H), 6.74 (d, J = 8.3 Hz, 
1H), 6.49 (s, 2H), 4.98 (t, J = 4.9 Hz, 1H), 3.88 (dd, J = 11.5, 5.2 Hz, 1H), 3.84 (s, 2H), 3.26 (dd, 
J = 13.6, 11.6 Hz, 1H), 3.13 – 3.06 (m, 1H), 3.03 (dd, J = 13.6, 5.1 Hz, 1H), 2.63 (td, J = 12.2, 
11.7, 2.6 Hz, 1H), 2.27 (s, 6H), 1.81 (ddt, J = 14.6, 11.0, 4.0 Hz, 1H), 1.55 (dtd, J = 13.4, 5.1, 2.8 
Hz, 1H). HPLC (gradient A): retention time 26.5. ESI-MS 470.2 [M+Na]+. 
 
 
3-Bromo-N-(4-bromo-2-fluorophenyl)propanamide (216). was synthesized according to 
general procedure C starting from the commercially available starting material 4-bromo-2-
fluoroaniline (1.0 g, 5.26 mmol, 1.0 eq), K2CO3 (1.49 g, 10.8 mmol, 2.05 eq) and 
bromopropionyl chloride (0.860 mL, 5.37 mmol, 1.02 eq) to yield the title compound as an a 
white, fluffy, shiny solid (1.71 g, quant.) with no additional purification necessary. 1H NMR (400 
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MHz, CDCl3) δ 8.18 (t, J = 8.5 Hz, 1H), 7.33 (s, 1H), 7.24 – 7.18 (m, 3H), 3.63 (t, J = 6.5 Hz, 
2H), 2.93 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 167.85, 152.96, 127.83, 127.80, 
125.13, 122.80, 118.55, 118.37, 116.22, 77.25, 77.00, 40.63, 26.36. 
 
 
1-(4-Bromo-2-fluorophenyl)azetidin-2-one (217). 217 was synthesized according to general 
procedure D starting from 216 (1.71 g, 5.26 mmol, 1.0 eq) and NaOtBu (530 mg, 5.52 mmol, 
1.05 eq) to yield the crude product which was purified using silica gel chromatography to yield 
title compound as solid (1.0 g, 78.1%). 1H NMR (400 MHz, CDCl3) δ 7.91 (t, J = 8.6 Hz, 1H), 
7.25 – 7.15 (m, 2H), 3.87 (q, J = 4.4 Hz, 2H), 3.15 (t, J = 4.6 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 165.40, 152.52, 150.53, 127.71, 127.68, 125.66, 125.58, 122.06, 122.03, 119.69, 
119.51, 115.66, 115.59, 42.07, 42.01, 38.39, 38.38. 
 
 
6-Bromo-8-fluoro-2,3-dihydroquinolin-4(1H)-one (218). 218 was synthesized according to 
general procedure E starting from 217 (1.0 g, 4.1 mmol, 1.0 eq) and using TfOH (1.09 mL, 12.3 
mmol, 3.0 eq) to yield the crude product which was purified using silica gel chromatography to 
yield the title compound as a yellow solid (508 mg, 50.8%). 1H NMR (400 MHz, CDCl3) δ 8.93 
(d, J = 4.9 Hz, 1H), 7.84 (d, J = 1.8 Hz, 1H), 7.72 (ddd, J = 6.5, 4.6, 2.7 Hz, 1H), 7.54 (ddd, J = 
9.6, 3.6, 2.0 Hz, 1H), 7.42 (dt, J = 4.7, 1.9 Hz, 1H), 7.21 (ddt, J = 10.2, 4.8, 2.8 Hz, 1H), 7.15 – 
7.11 (m, 1H), 6.65 (t, J = 8.7 Hz, 1H), 3.67 (t, J = 6.3 Hz, 2H), 3.61 (t, J = 7.0 Hz, 2H), 3.08 (dq, 
J = 6.3, 3.1 Hz, 2H), 2.70 (q, J = 5.5, 3.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 191.24, 
168.91, 151.21, 127.54, 125.29, 124.39, 122.55, 122.37, 119.92, 119.57, 118.58, 118.40, 118.16, 
114.53, 113.11, 41.67, 38.98, 37.55, 34.28. 
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Tert-butyl 6-bromo-8-fluoro-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (219). 219 was 
synthesized according to general procedure G starting from 218 (510 mg, 2.1 mmol, 1.0 eq), 
Boc2O (680 mg, 3.1 mmol, 1.5 eq), DMAP (25 mg, 0.2 mmol, 0.1 eq) and DIPEA (0.54 mL, 3.1 
mmol, 1.5 eq). Following the quench and work-up, the crude product was chromatographed on 
silica gel (equil in 100% hex, run in 2:3 EA:hex) to yield pure product as a white solid (370 mg, 
51.5%). 1H NMR (400 MHz, CDCl3) δ 7.94 – 7.83 (m, 1H), 7.43 (dd, J = 9.7, 2.3 Hz, 1H), 4.12 
(bs, 2H), 2.80 (t, J = 6.2 Hz, 2H), 1.48 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 192.15, 156.34, 
156.32, 154.29, 152.20, 132.06, 131.97, 128.46, 125.57, 125.54, 124.58, 124.38, 118.10, 118.03, 
82.69, 44.68, 39.17, 27.88. 
 
 
Tert-butyl 6-benzyl-8-fluoro-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (220). 220 was 
synthesized following general procedure L using 219 (369 mg, 1.1 mmol, 1.0 eq), benzyl boronic 
pinnacol ester (350 mL, 1.6 mmol, 2.0 eq), K2CO3 (445 mg, 3.2 mmol, 3.0 eq), and Pd(dppf)Cl2 
(78 mg, 0.10 mmol, 0.1 eq). The crude product which was purified using silica gel 
chromatography to yield the title compound 220 as a brown oil (273 mg, 71.7%). 1H NMR (500 
MHz, CDCl3) δ 7.64 (d, J = 1.9 Hz, 1H), 7.31 (t, J = 7.4 Hz, 2H), 7.28 – 7.21 (m, 1H), 7.18 (d, J 
= 7.7 Hz, 2H), 7.10 (dd, J = 11.2, 1.9 Hz, 1H), 4.11 (s, 3H), 3.97 (s, 2H), 2.78 (t, J = 6.2 Hz, 2H), 
1.49 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 193.62, 193.60, 156.25, 154.24, 152.58, 139.64, 
139.59, 139.47, 128.86, 128.81, 128.76, 128.74, 128.71, 128.68, 128.47, 128.38, 127.63, 126.55, 
122.40, 122.37, 121.89, 121.72, 82.12, 77.00, 44.78, 41.15, 39.35, 27.90. 
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6-Benzyl-8-fluoro-2,3-dihydroquinolin-4(1H)-one (221). 221 was synthesized was synthesized 
by first treating 221 (130 mg, 0.37 mmol, 1.0 eq) with 1:1 TFA:DCM for 1 h. Once complete, 
solvent was removed under reduced pressure to yield a crude yellow residue which was taken 
ahead to the next step (formation of 222) without any additional isolation, purification, or 
characterization. No 1H or 13C data acquired.  
 
1-Acetyl-6-benzyl-8-fluoro-2,3-dihydroquinolin-4(1H)-one (222). 222 The crude residue from 
221 was treated with Ac2O following general procedure K. The reaction stirred at reflux for 20 h. 
Once the reaction was complete, solvent was removed and the crude residue was purified using 
silica gel chromatography to yield title compound 222 as a clear oil (78 mg, 71.5% over two 
steps). 1H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 2.1 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.17 (dd, J = 
8.1, 6.5 Hz, 2H), 7.14 – 7.07 (m, 2H), 3.92 (s, 2H), 2.83 – 2.63 (m, 4H), 2.11 (s, 3H). No 13C 
data acquired. 
 
 
Tert-butyl (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-8-fluoro-3,4-dihydroquinoline-
1(2H)-carboxylate (223). 223 was synthesized following general procedure H using 221 (140 
mg, 0.39 mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (143 mg, 1.18 mmol, 3.0 eq), and 
Ti(OEt)4 (0.496 mL, 2.36 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
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mixture was transferred via cannula to a round bottom flask containing NaBH4 (89 mg, 2.36 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
as clear, colorless oil (65 mg, 35.9%). 1H NMR (500 MHz, CDCl3) δ 7.28 (td, J = 7.7, 2.6 Hz, 
2H), 7.23 – 7.15 (m, 3H), 7.01 (d, J = 3.0 Hz, 1H), 6.83 (dt, J = 11.4, 2.5 Hz, 1H), 4.52 (p, J = 
3.7 Hz, 1H), 3.91 (s, 2H), 3.85 – 3.72 (bs, 1H), 3.63 (bs, 1H), 3.28 (s, 1H), 2.21 (bs, 1H), 1.95 
(bs, 1H), 1.44 (d, J = 2.8 Hz, 9H), 1.19 (d, J = 2.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 
156.63, 154.63, 153.42, 139.94, 139.46, 139.40, 133.20, 128.83, 128.55, 126.33, 125.14, 125.04, 
123.36, 123.33, 116.12, 115.95, 81.12, 60.28, 55.66, 50.55, 41.20, 40.37, 30.47, 27.94, 22.51, 
22.43, 14.12. 
 
 
(R)-N-((R)-1-acetyl-6-benzyl-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide (224). 224 was synthesized following general procedure H using 222 (78 mg, 
0.26mmol, 1.0 eq), (R)-2-methylpropane-2-sulfinamide (95 mg, 0.79 mmol, 3.0 eq), and 
Ti(OEt)4 (0.330 mL, 1.57 mmol, 6.0 eq) to form the (R)-tert-butanesulfinyl imine intermediate in 
situ. Once sufficient ketone was converted into imine intermediate (after 48 h), the reaction 
mixture was transferred via cannula to a round bottom flask containing NaBH4 (60 mg, 1.57 
mmol, 6.0 eq) and 20 mL of THF in a xylenes dry ice bath, after addition, the solution was 
stirred at room temperature for 3 h before being quenched with MeOH. Once resultant solid was 
removed, crude residue was purified using silica gel chromatography to yield the title compound 
224 as clear, colorless oil (56 mg, 52.8%). No 1H or 13C data acquired. Instead, intermediate was 
taken ahead to the next step (formation of 226) without further purification, isolation, or 
characterization. 
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(S)-2-amino-N-((R)-6-benzyl-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide (225). 225 was synthesized following general I using 223 (65 
mg, 0.14 mmol, 1.0 eq) and conc. HCl (5 drops). After removing solvent, residue was re-
suspended in Et2O, and solid crashed out. After washing the solid 3 x with fresh Et2O, the 
remaining Et2O was decanted off, yielding a white solid amine hydrochloride salt (55 mg). The 
synthesis was completed by following general procedure F with newly formed (R) amine 
intermediate (55 mg, 0.140 mmol, 1.0 eq) to yield crude product which was purified by 
semipreparative HPLC and lyophilized to yield the title compound 225 (24 mg, 30.4%) as a TFA 
salt. 1H NMR (500 MHz, CD3OD) δ 7.25 – 7.19 (m, 2H), 7.11 (d, J = 7.7 Hz, 2H), 6.70 (s, 1H), 
6.63 (d, J = 12.1 Hz, 1H), 6.48 (s, 2H), 4.93 (s, 1H), 3.84 (dd, J = 11.6, 4.7 Hz, 1H), 3.75 (s, 2H), 
3.25 (t, J = 12.6 Hz, 1H), 3.01 (q, J = 11.7, 9.8 Hz, 2H), 2.46 (t, J = 11.7 Hz, 1H), 2.31 – 2.23 
(m, 7H), 1.68 (t, J = 12.6 Hz, 1H), 1.50 (d, J = 13.4 Hz, 1H). HPLC (gradient A): retention time 
35.3. ESI-MS 470.2 [M+Na]+. 
 
 
(S)-N-((R)-1-acetyl-6-benzyl-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide (226). 226 was synthesized following general 
procedure I using 224 (56 mg, 0.14 mmol, 1.0 eq) and conc. HCl (5 drops). After removing 
solvent, residue was re-suspended in Et2O, and solid crashed out. After washing the solid 3 x 
with fresh Et2O, the remaining Et2O was decanted off, yielding a white solid amine 
hydrochloride salt (47 mg). The synthesis was completed by following general procedure F with 
newly formed (R) amine intermediate (47 mg, 0.140 mmol, 1.0 eq) to yield crude product which 
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was purified by semipreparative HPLC and lyophilized to yield the title compound 226 (30 mg, 
35.3%) as a TFA salt. 1H NMR (500 MHz, CD3OD)  δ 7.26 (dd, J = 8.6, 6.6 Hz, 2H), 7.18 (dd, J 
= 8.2, 6.6 Hz, 3H), 7.04 (s, 1H), 6.89 (d, J = 11.4 Hz, 1H), 6.52 (s, 2H), 3.96 – 3.87 (m, 2H), 
3.26 (dd, J = 13.7, 11.5 Hz, 1H), 3.12 – 3.02 (m, 1H), 2.28 (s, 6H), 2.07 (bs, 3H), 1.95 – 1.83 (m, 
1H), 1.50 – 1.31 (m, 1H). HPLC (gradient A): retention time 33.8. ESI-MS 490.2 [M+H]+ 512.2 
and [M+Na]+. 
Synthesized by Dr. Kate Kojiro and Dr. Yafei Jin 
 
 
8.2 In Vitro Pharmacology 
Cell Lines and Membrane Preparations. All tissue culture reagents were purchased from 
Gibco Life Sciences (Grand Island, NY, U.S.). C6-rat glioma cells stably transfected with a rat μ 
(C6-MOR) or rat δ (C6-DOR) opioid receptor30 and Chinese hamster ovary (CHO) cells stably 
expressing a human κ (CHO-KOR) opioid receptor31 were used for all in vitro assays. Cells were 
grown to confluence at 37 °C in 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) 
containing 10% fetal bovine serum and 5% penicillin/streptomycin. Membranes were prepared 
by washing confluent cells three times with ice cold phosphate buffered saline (0.9% NaCl, 0.61 
mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells were detached from the plates by incubation in 
warm harvesting buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted 
by centrifugation at 1600 rpm for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris-
HCl buffer, pH 7.4, and homogenized with a Tissue Tearor (Biospec Products, Inc., Bartlesville, 
OK, U.S.) for 20 s. The homogenate was centrifuged at 15,000 rpm for 20 min at 4 °C. The 
pellet was rehomogenized in 50 mM Tris-HCl with a Tissue Tearor for 10 s, followed by 
recentrifugation. The final pellet was resuspended in 50 mM Tris-HCl and frozen in aliquots at 
80 °C. Protein concentration was determined via a BCA protein assay (Thermo Scientific Pierce, 
Waltham, MA, U.S.) using bovine serum albumin as the standard. 
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Radioligand Binding Assays. Radiolabeled compounds were purchased from Perkin-Elmer 
(Waltham, MA, U.S.). Opioid ligand binding assays were performed by competitive 
displacement of 0.2 nM [3H]diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic 
from membrane preparations containing opioid receptors as described above. The assay mixture, 
containing membranes (20 μg protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 
[3H]diprenorphine, and various concentrations of test peptidomimetic, was incubated at room 
temperature for 1 h to allow binding to reach equilibrium. The samples were rapidly filtered 
through Whatman GF/C filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and 
washed five times with 50 mM Tris-HCl buffer. Bound radioactivity on dried filters was 
determined by liquid scintillation counting, after saturation with EcoLume liquid scintillation 
cocktail, in a Wallac 1450 MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding 
was determined using 10 μM naloxone. The results presented are the mean ± standard error 
(S.E.M.) from at least three separate assays performed in duplicate. Ki (nM) values were 
calculated using nonlinear regression analysis to fit a logistic equation to the competition data 
using GraphPad Prism, version 6.0c, for Mac OS X (GraphPad Software Inc., La Jolla, CA).  
Stimulation of [35S]GTPγS Binding. Agonist stimulation of [35S]guanosine 5′-O-[γ-
thio]triphosphate ([355S]GTPγS, 1250 Ci, 46.2 TBq/mmol) binding to G-protein was measured 
as described previously.32 Briefly, membranes (10−20 μg of protein/tube) were incubated 1 h at 
25°C in GTPγS buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 
nM [35S]GTPγS, 30 μM guanosine diphosphate (GDP), and varying concentrations of test 
peptidomimetic. G-protein activation following receptor stimulation of [35S]GTPγS (% 
stimulation) with peptidomimetic was compared  with 10 μM of the standard compounds [D-
Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5-enkephalin (DPDPE) at DOR, 
or U69,593 at KOR. The reaction was terminated by vacuum filtration of GF/C filters that were 
washed 10 times with GTPγS buffer. Bound radioactivity was measured as described above. The 
results are presented as the mean ± standard error (S.E.M.) from at least three separate assays 
performed in duplicate; potency (EC50 (nM)) and % stimulation were determined using nonlinear 
regression analysis with GraphPad Prism, as above. 
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8.3 In Vivo Pharmacology.  
 
Animals. Adult male C57BL/6 mice weighing between 20 and 30 g at 8−16 weeks old 
purchased from Harlan (Indianapolis, IN). Mice were group-housed and had free access to food 
and water at all times. Experiments were conducted in the housing room, which was maintained 
on a 12 h light/dark cycle (with lights on at 0700). Each mouse was used only once and 
experiments were conducted between 10 a.m. and 5 p.m. Studies were performed in accordance 
with the University of Michigan Committee on the Use and Care of Animals and the Guide for 
the Care and Use of Laboratory Animals (National Research Council, 2011 publication).  
Antinociception. The antinociceptive effects of select peptidomimetics were evaluated in the 
WWTW assay using a cumulative dosing procedure.33 To determine tail withdrawal latencies, 
each mouse was placed briefly into a plastic, cylindrical restrainer and 2−3 cm of the tail tip was 
placed into a water bath maintained at 50 °C. The latency to withdraw the tail was recorded with 
a maximum cutoff time of 20 s. If the mouse did not remove its tail by the cutoff time, the 
experimenter removed its tail from the water to prevent tissue damage. Each animal received an 
injection of saline (intraperitoneal, ip) and then 30 min later, the baseline withdrawal latencies 
were recorded and ranged between 3 and 6 s. Following baseline determinations, three increasing 
doses (1, 2.2, and 6.8 mg/kg) of a final compound analogue was given at 30 min intervals to 
provide final doses of 1, 3.2, and 10 mg/kg. Thirty minutes after each injection, the tail 
withdrawal latency was measured as described above. To determine the duration of 
antinociceptive action the tail-withdrawal test was performed at varying times following 
administration of a final compound analogue (10 mg/kg, ip). To confirm that 54 produces 
antinociception via the opioid receptors, the cumulative dose response was repeated over the 
doses 3.2, 10, and 32 mg/kg following a 30 min pretreatment with 1 mg/kg naltrexone or saline 
(ip). The ED50 for mice receiving saline pretreatment is 4.73 +/- 0.08 mg/kg 54, and the ED50 for 
the mice receiving 1 mg/kg naltrexone is 15.07 +/-1.03 mg/kg 54, suggesting that the 
antinociception 54 produces is MOR-mediated.  
8.4 Computational Modeling 
Three-dimensional models of opioid receptors in inactive conformation were produced as 
previously described60 using X-ray structures of the mouse MOR (PDB ID: 4dkl)61, the human 
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DOR (PDB ID: 4n6h)62 and the human KOR (PDB ID: 4djh)63 as structural templates. The 
recently obtained crystal structure of mouse MOR in the active conformation (PDB ID: 5c1m)61  
was used as a template for homology modeling of active conformations of DOR and KOR. 
Structures of receptor loops in the active state were kept similar to those in the crystal structures 
of corresponding receptors in the inactive state. N-termini of DOR (residues 33-45), KOR 
(residues 45-57) were modeled using the structure of MOR N-terminus in the active 
conformation with a few adjustment to satisfy formation of Zn-binding centers involving D216 
(H54-D216) and H319 (H57-H319), which were previously suggested for MOR.64 Structures of 
peptidomimetic ligands were generated using 3D-Builder Application of QUANTA (Accelrys, 
Inc) followed by the Conformational Search included in the program package. Ligand 
conformations that demonstrated the best superposition of aromatic substituents of the THQ core 
with the pharmacophore elements (Tyr1 and Phe3) of receptor-bound conformations of cyclic 
tetrapeptides65,66 were selected and minimized with CHARMm implemented in QUANTA 
(Adopted-Basis Newton Raphson method, 100 steps, ε=10). Low energy conformations (within 2 
kcal/mol) were manually positioned inside the receptor binding cavity to reproduce the binding 
modes of cyclic tetrapeptides. The docking pose of each ligand was subsequently refined using 
the solid docking module of QUANTA. Models of opioid ligand-receptor complexes are 
available upon request. 
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